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Genetic analyses such as linkage and genome wide association studies (GWAS) have 
been extremely successful at identifying genomic regions that harbour genetic 
variants contributing to complex disorders. Over 90% of disease-associated variants 
from GWAS fall within non-coding regions (Maurano et al., 2012). However, 
pinpointing the causal variants has proven a major bottleneck to genetic research.  
 
To address this I have developed SuRFR, an R package for the ranked prioritisation 
of candidate causal variants by predicted function. SuRFR produces rank orderings 
of variants based upon functional genomic annotations, including DNase 
hypersensitivity signal, chromatin state, minor allele frequency, and conservation. 
The ranks for each annotation are combined into a final prioritisation rank using a 
weighting system that has been parametrised and tested through ten-fold cross-
validation.  
 
SuRFR has been tested extensively upon a combination of synthetic and real datasets 
and has been shown to perform with high sensitivity and specificity. These analyses 
have provided insight into the extent to which different classes of functional 
annotation are most useful for the identification of known regulatory variants: the 
most important factor for identifying a true variant across all classes of regulatory 
variants is position relative to genes. I have also shown that SuRFR performs at least 
as well as its nearest competitors whilst benefiting from the advantages that come 
from being part of the R environment.  
 
I have applied SuRFR to several genomics projects, particularly the study of 
psychiatric illness, including genome sequencing of a large Scottish family with 





Thesis Lay Summary 
The vast majority of our DNA sequence is identical between humans. The small 
fraction that is different reflects the differences between individuals, from how 
different you are to your siblings and parents to population level differences. Some 
of these variations in our DNA contribute to our risk of developing hereditary 
diseases. Most of the known variants that cause human disease are found in the 
regions of our DNA that encode proteins. Proteins are the building blocks of life and 
when the DNA that encodes them contains a variation or mistake, the structure of the 
protein can be altered, or the protein is not made at all, meaning it is no longer able 
to do its job, potentially leading to disease. The stretches of DNA between the 
protein coding regions, the non-coding regions, often contain molecular switches that 
control how much protein is made and when. These molecular switches are very 
important for the correct function of proteins, but our knowledge of what defines 
them is very limited. This makes it difficult to predict whether a variant is located in 
a molecular switch and if it has a functional role in human disease. However, we 
have lots of different ways of characterising and annotating DNA sequence, for 
example the extent to which a stretch of DNA is conserved between humans and 
other organisms (highly conserved DNA sequences often having important 
functions), which we can layer together to find unique patterns of annotation 
associated with different types of variants. 
The aim of my PhD was to use computational techniques to piece together some of 
the information we have on the characteristics of these molecular switches to predict 
the likelihood of a non-coding variants playing a role in human disease. To do this, I 
used a dataset of known disease-causing non-coding variants and a machine learning 
method to identify patterns associated with these variants. I used a statistical method 
called cross-validation to show that the patterns I identified are truly associated with 
the disease variants rather than being due to chance or to over-fitting of my data. I 
then used this information to build a computational tool to prioritise variants on their 
likelihood of being functional variants (and in turn likely to play a role in human 
disease). This tool is called SuRFR (SNP Ranking by Function R package) and is 
 
xxiii 
freely available as part of a widely used computer programming language. I have run 
SuRFR on a range of test datasets, where SuRFR was correctly able to prioritise the 
known disease variant(s) above the background variants in a reproducible manner. 
This shows that SuRFR is likely to work well on novel data where the disease 
causing variant is not known. As such, SuRFR can be used in the search for 
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Chapter 1: Introduction 
1.1 The study of human disease and complex traits 
Human genetics is the study of genetic variation in human genomes and the impact of 
this variation on phenotypes, including complex traits and disease. Fu et al. (2013) 
defined the genetic architecture of a trait as being “a comprehensive description of how 
genes and the environment conspire to produce phenotypes” (Fu et al., 2013). Improving 
our understanding of the genetic architecture and heritability of complex traits and 
diseases, and how our genotypes biologically connect to phenotypes, is a major goal of 
genomics projects. This is not a straightforward task, as there is a large amount of 
genetic complexity across different diseases and disorders.  
 
The simplest form of inheritance, commonly known as “Mendelian inheritance”, was 
discovered by Gregor Mendel at the end of the 19th century. Mendel’s laws describe the 
relationship between genotype and phenotype, where a single variant drives the 
expression of a particular phenotype or disease. Under this model, alleles follow either a 
dominant or recessive pattern of inheritance, further complicated by whether the variant 
is autosomal or X-linked. Mendel studied simple genetic traits where two alleles (A and 
a) generated three possible genotypes (AA, Aa, aa). When inheritance is dominant, the 
phenotypic effect of the dominant allele (A) will mask the phenotypic effect of the 
second, recessive, allele (a), so that both the dominant homozygous genotype (AA) and 
heterozygous genotype (Aa) will have the same phenotype. The phenotype of the 
recessive allele (a) will only be seen when the genotype is homozygous for the recessive 
allele (aa). If one parent carries an autosomal dominant disease allele, the probability is 
that 50% of the offspring will also receive the allele and be affected by the disease or 
phenotype. For a recessive disorder or trait, both parents will each have to carry a copy 
of the recessive allele. When both parents are heterozygous for the two alleles (Aa), 25% 
of the offspring will be homozygous for the recessive allele and be affected by the 
disease (aa), 25% will be homozygous for the dominant allele (AA) and so will not 
express the phenotype and 50% will be heterozygous (Aa) and will not express the 
phenotype (Aa), but will be carriers of the disease allele (and are therefore capable of 
passing it on to their own offspring). 
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An example of a disease that follows a Mendelian autosomal-recessive pattern of 
inheritance is cystic fibrosis, which is caused by large effect size (where effect size is 
defined as the ratio of the odds of disease manifestation in carriers vs. non-carriers 
(Zollner and Pritchard, 2007)) mutations in both copies of the CFTR gene. However, 
even this is not as simple an example as originally thought; to date, over 2,000 variants 
have been catalogued located in and around the CFTR gene that lead to cystic fibrosis 
(Drumm et al., 2012), with at least eight regulatory variants in the promoter region of 
CFTR also known to contribute to a cystic fibrosis phenotype (Giordano et al., 2013). 
Additional loci across the genome have also been identified that harbour variants that 
modify clinical outcomes of cystic fibrosis disease (Drumm et al., 2012). This suggests 
that even the architecture of ‘simple’ disorders is not particularly simple.  
 
A catalogue of known Mendelian diseases (genes, mutations and associated phenotypes) 
can be found in the online database, the ‘Online Mendelian Inheritance in Man’ (OMIM) 
(Amberger et al., 2015). It is estimated that there are ~7,000 rare monogenic human 
diseases. Over the past 25 years ~50% of the genes responsible for these diseases have 
been identified (Boycott et al., 2013, Deciphering Developmental Disorders, 2015). The 
advances of next generation sequencing (NGS), both whole genome and whole exome 
sequencing, are predicted to aid the identification of the remaining genes causing 
Mendelian diseases by 2020 (Boycott et al., 2013).  
 
At the other end of the spectrum are complex traits and disorders that do not follow 
Mendelian patterns of inheritance. These traits and disorders are caused by susceptibility 
variants with much smaller effect sizes that together (along with environmental factors) 
are associated with a phenotype. Such diseases have been the focus of genome wide 
association studies (GWAS), which assay the genotypes of hundreds of thousands of 
common markers (present in at least 1% of the population) across the genome, in 
thousands of cases and controls, to test for the association of variants with a phenotype 
of interest (Hardy and Singleton, 2009).  
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Height is an example of a complex trait that is affected by both an individual’s genotype 
at multiple loci and environmental factors. Heritability (h2, the proportion of phenotypic 
variation in a trait or disease that is due to genetic factors (Wray et al., 2013)) estimates 
for height range from ~70-90% (Silventoinen et al., 2003). To date, nearly 200 loci have 
been associated with height in GWASs, which together explain roughly 20% of the 
heritability (Berndt et al., 2013, Lango Allen et al., 2010). A complex disorder with a 
genetic architecture that is similar to height is type 2 diabetes (T2D). Heritability 
estimates for T2D range from 30 – 70% (Wellcome Trust Case Control, 2007). To date, 
over 70 loci have been identified that are associated with T2D (Replication et al., 2014), 
each of small individual effect size, together explaining roughly 10% of the heritability 
of T2D (Voight et al., 2010). 
 
NGS methods have led the discovery of millions of genetic variants identified through 
the sequencing of thousands of individuals. Comprehensive catalogues of human 
variation, such as the 1000 genomes database (Genomes Project et al., 2010), contain 
data on a range of variant classes in the human genome, including single nucleotide 
polymorphisms (SNPs), short insertions and deletions (indels) and structural variants 
(copy number variants (CNVs) and chromosomal rearrangements). These variants range 
in allele frequency from common to very rare or unique variants. The vast majority of 
human variation (90%) is common and ancient, dating back to before the out-of-Africa 
migration (at least 50,000 – 60,000 years ago) (McClellan and King, 2010a). In contrast, 
the majority of rare variants are very new, tend to be population, family or individual 
specific, and are more likely to be deleterious than older, more common variants (Henn 
et al., 2015). This is due to the actions of genetic drift and purifying selection, which 
work to remove deleterious variants from a population, preventing them from reaching 
high frequency. Variants causing Mendelian diseases tend to fall into this category of 
high effect-size rare variation. In contrast, variants associated with complex traits and 
variants of weaker deleterious effect can become common due to random drift (Figure 
1.1).  
 
Occasionally deleterious mutations of larger effect can become common in a population 
if a fast population expansion occurs (Henn et al., 2015), or if the disease has a later age 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
Chapter 1: Introduction 4 
of onset (thereby not affecting reproductive fitness). An example of such a disease is 
Huntington’s disease, which segregates in an autosomal dominant fashion and presents 
later in life (~30 -50 years of age)(Gusella et al., 1983). The Huntingtin gene was 
identified through investigation of an extremely large Venezuelan family (the pedigree 
dating back to the 1800s and containing over 3,000 members all related to a single 












Figure 1.1 Proportion of deleterious variants found in the average genome classified by their 
frequency in the population (common (in blue) versus rare (in purple)). This figure shows that 
the proportion of rare variants in an individual’s genome will be equally likely to have a 
medium or a large effect size. The vast majority of deleterious variants in an individual’s 
genome (70%) are common variants, most of which have only a small effect (‘moderate’). A 
very small fraction of common variants will also have extreme effects; however, the majority of 
these will have been purged by purifying selection. Taken from Henn et al., 2015 (Henn et al., 
2015).  
 
To summarise, deleterious variants contributing to disease occur across the full spectrum 
of allele frequencies and with a range of effect sizes (Figure 1.1). The genetic effect size 
of a variant is related to both the penetrance (the number of individuals who carry a 
particular genotype that also express the associated phenotype) and frequency of the 
variant (Zollner and Pritchard, 2007). Figure 1.2 summarises the relationship between 
effect size (penetrance), allele frequency and genetic architecture of disease variants. 
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Variants of different effect sizes and frequencies play different roles in human disease. 
Rare variants with high effect sizes generally lead to Mendelian diseases like cystic 
fibrosis, while more common variants with smaller effect sizes playing a role in 
susceptibility to more complex diseases and disorders, such as T2D. Variable 
penetrance, which can be due to the influence of genetic modifiers and environment, can 




Figure 1.2 This figure outlines potential classes of human disease, stratified by the frequency of 
underlying genetic variation on the x-axis and the penetrance of these variants on the y-axis. 
Taken from McCarthy et al. (2008) (McCarthy et al., 2008).   
 
 
1.2 Psychiatric illness 
Psychiatric disorders are debilitating clinical syndromes that are characterised by 
psychological symptoms that impact multiple life areas, creating distress for the person 
experiencing these symptoms as well as for their family and friends ((WHO, 2015) 
accessed June 2015). Although they have largely unknown aetiology and 
pathophysiology (psychiatric syndromes hence being referred to as ‘disorders’, as 
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opposed to ‘diseases’), such conditions are associated with high morbitity, accounting 
for roughly one-third of disability world wide, negatively impacting the lives of both 
sufferers and their families and causing considerable personal and societal burden 
(reviewed in (Sullivan et al., 2012)). In addition, such disorders are associated with 
increased mortality rates, from suicide and other causes (Eaton et al., 2008).  
 
To date, over 300 psychiatric disorders have been defined. Nine of these, described by 
Sullivan et al. (2012) as the ‘cardinal psychiatric disorders’, are summarised in Table 
1.1, taken from (Sullivan et al., 2012)). Of these, the Psychiatric Genomics Consortium 
(PGC) has defined autism spectrum disorder (ASD), attention deficit-hyperactivity 
disorder (ADHD), bipolar disorder (BD), major depressive disorder (MDD), and 
schizophrenia (SCZ) as being the ‘major’ psychiatric syndromes. The aim of the PGC is 
to conduct statistically rigorous and comprehensive GWAS meta-analyses on each of 
these major psychiatric illnesses, as well comparative analyses across the five disorders 
(Sullivan, 2010). 
 
Family, twin and adoption studies have shown that there is also a strong heritable 
component to psychiatric disorders (see lifetime prevalence in table 1.1). In addition, 
several environmental risk factors have been identified for many of these disorders 
(summarised in Table 1.2, taken from the review by Uher, (2014) (Uher, 2014)). The 
genetic architecture of these disorders has yet to be determined, but is likely to be 
complex. De novo mutations, structural rearrangements, rare variants, common variants 
have all been implicated in the aetiology of these disorders. Each of these, along with 
methods to identify pathogenic variants, will be described briefly in the following 
sections. More details on the potential genetic architectures of BD and MDD can be 
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Table 1.1 This table describes nine psychiatric disorders, defining their lifetime prevalence, 
heritability, essential characteristics and notable features. Taken from Sullivan et al. (2012) 
(Sullivan et al., 2012).  
 
Table 1.2. Summary of environmental risk factors for schizophrenia, bipolar disorder and 
major depressive disorder. Taken from Uher (2014) (Uher, 2014).  
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1.3 A summary of potential disease models 
1.3.1  De novo mutations  
There is growing evidence of the role of de novo variants (SNPs, indels and CNVs) in 
the genetics of psychiatric illness (Gratten et al., 2013). De novo CNVs have been 
implicated in a range of nervous system disorders (Lee and Lupski, 2006), including 
ASD (Marshall et al., 2008), SCZ ((Karayiorgou et al., 1995); (Xu et al., 2008); 
(International Schizophrenia, 2008); (Stefansson et al., 2008); (Vacic et al., 2011); 
(Bassett and Chow, 2008)) and BD (Malhotra et al., 2011). 
 
Two studies, in 2007 and 2008 respectively, showed that de novo variants were more 
commonly found in ASD cases than controls ((Marshall et al., 2008); (Sebat et al., 
2007)). Several additional studies have since shown an increase in the frequency 
(difference of 6%) of de novo variants in children with ASD compared to unaffected 
siblings ((Levy et al., 2011); (Sanders et al., 2011)). Most recently, two large exome 
sequencing studies (published in 2014) of thousands of families with a history of autism 
implicated over 400 genes with de novo loss of function variants, or likely gene-
disrupting variants, as contributing to ASD ((Iossifov et al., 2014); (De Rubeis et al., 
2014)). Many of the genes implicated in these studies were found to encode proteins 
involved in neuronal processes such as synaptic formation and voltage-gated ion 
channels, as well as transcription regulation and chromatin remodelling pathways (De 
Rubeis et al., 2014). A review by Ronemus et al. (2014) proposed that ASD is most 
commonly caused by parental germ line de novo mutations in a two-class risk model 
(Ronemus et al., 2014). The model suggests most cases (99%) are low-risk, with de novo 
mutations contributing risk of 0.5% for males and 0.15% for females; in contrast, for 
high-risk families, one parent carries a highly penetrant de novo mutation which confers 
a 50% risk of ASD in males and 12.5% risk in females (Ronemus et al., 2014).  
 
De novo mutations have also been shown to play a role in SCZ, being shown in one 
study to be eight times more common in patients with sporadic SCZ than in controls 
((McClellan and King, 2010b); (Xu et al., 2008)). This class of variation have been 
identified at specific loci across the genome, including chr22q11.2, chr15q13.3 and 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
Chapter 1: Introduction 9 
chr1q.21.1 (Purcell et al., 2014) and have been shown to converge on sets of functionally 
related proteins (including synaptic proteins and genes that have been implicated in the 
study of other psychiatric conditions). This was shown by Fromer et al. (2014), who 
performed exome sequencing in 617 schizophrenia trios and an independent set of 731 
controls (Fromer et al., 2014). This study found no increase in the rate of de novo 
mutations between probands and controls. However, it did identify an enrichment 
(corrected p = 0.0007) of de novo nonsynonymous substitutions in “SCZ genes” 
(identified by independent evidence in the literature). Similarly, this study identified an 
enrichment (corrected p = 0.0098) of mutations in synaptic genes, which were defined as 
being known associates of the N-methyl-D-aspartate (NMDA) receptor or proteins that 
interact with the activity-regulated cytoskeleton-associated protein (ARC) complex.  
 
Georgieva et al. (2014), compared the role of de novo variants in SCZ versus BD (368 
BD and 76 SCZ probands respectively and all parents) (Georgieva et al., 2014). This 
study identified a significant increase in the rate of de novo CNVs in SCZ probands vs. 
BD probands, and SCZ and controls. They also concluded that although there was a 
higher rate of de novo CNVs in BD patients versus controls, the difference was not 
significant, and therefore de novo CNVs are likely play a smaller role in the aetiology of 
BD than SCZ (Georgieva et al., 2014). 
 
1.3.2 Rare variants 
McClellan and King are advocates of the common disease rare variant hypothesis 
(McClellan et al., 2007), which proposes that complex disorders such as BD and SCZ 
are caused by rare variants of intermediate or large effect size, which segregate in 
families with incomplete penetrance (Figure 1.2).  This theory suggests that these 
variants, although individually rare (often family specific), occur at multiple loci, each 
locus explaining a fraction of cases, which collectively explain a substantial proportion 
of heritability of these disorders (McClellan and King, 2010b).  
 
Most human variation is very ancient (roughly 90%), having occurred millennia before 
humans first migrated out of Africa (McClellan and King, 2010a). The recent 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
Chapter 1: Introduction 10 
exponential growth of the human population has resulted in many rare (present in a 
specific population, sub-population or only on a family level) alleles (Keinan and Clark, 
2012). As many disease variants of intermediate and high effect confer reduced 
reproductive viability, as in SCZ (Visscher et al., 2012), these variants would be less 
likely to be transmitted down generations. Such variants could therefore be 
disproportionately rare compared to other complex traits.  
 
While Mendelian forms of AD have been identified ((Blennow et al., 2006); (Bertram 
and Tanzi, 2008)) and ASD is a co-morbid feature of over one hundred Mendelian 
diseases ((Sullivan et al., 2012); (Betancur, 2011)), no examples of Mendelian forms of 
SCZ, MDD, or BD have yet been discovered. This could be because these diseases do 
not follow that particular genetic architecture, or because limited study designs have 
prevented the discovery of this form of disease. However, examples of families multiply 
affected with psychiatric disorders have been described in the literature. Most recently, a 
study of 40 families multiply affected by BD (Ament et al., 2015) identified uncommon 
and rare variants that influence disease risk. Other examples include the study of BD in a 
large old order Amish family (Georgi et al., 2014) and a large Scottish family multiply 
affected by SCZ, MDD and BD ((Millar et al., 2000); (St Clair et al., 1990)). While the 
large Scottish family study identified a balanced translocation that segregates with 
psychiatric illness (maximum LOD = 6.0), both of the other examples require further 
work to identify the susceptibility variants. 
 
A study by Need et al. (Am J Hum Gen, 2012) analysed sequencing data (whole genome 
sequencing (WGS) and whole exome sequencing (WES) data) for 166 cases of SCZ and 
schizoaffective disorder (Need et al., 2012). 5,155 of the variants identified (restricted to 
nonsynonymous, nonsense or splice variants with MAFs < 0.05 (or <0.3 for recessive 
model)) were then genotyped in an independent cohort of 2,617 cases and 1,800 controls 
(cases and controls being of either African American or European ancestry). The first 
round association study consisted of 337,312 variants identified using sequencing in 166 
cases and 307 controls. As no SNPs passed Bonferroni correction (p < 1.5 x 10-7), the 
authors developed a two-step process: i) selecting a subset of variants (5,155) with either 
a p <0.05 or being present in >1 cases and no controls followed by ii) genotyping in 
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additional cases and controls (2,617 cases and 1,800 controls). Once again, no SNPs 
survived the Bonferroni correction; the best p-value from the combined dataset was 
0.0003, for the African American only analysis was p = 0.0006, and the best for 
European only was p = 5.9 x 10-6. However, while this study had 99% power to detect 
moderately rare (1%-5%) variants with a relative risk between 2 and 6, most very rare 
highly penetrant SCZ associated genotypes would not be expected to show a significant 
association in a dataset the size of their discovery cohort. Very rare variants will also not 
reach genome-wide significant in the expanded cohort. Need et al. concluded several 
genetic architectures for SCZ could be excluded based on their analysis: 
1. A small number of highly penetrant loci explaining the majority of cases. 
2. A moderate number (less than several hundred) of common variants with a low 
relative risk underlying most cases. 
3. Moderately rare variants that have moderate relative risk explaining most cases 
(goldilocks alleles). 
It is likely that there is a high level of locus and allele heterogeneity in SCZ. Need et al. 
suggested that the majority of SCZ associated variants will be of very low frequency and 
will be identified through common pathways and genes; however, these results could 
also imply oligogenic, polygenic or epistatic models (Need et al., 2012). 
 
Rare, family-specific variants of intermediate effect size are not identifiable using 
current GWAS methods, even with increased sample size. However, studying families, 
using techniques such as linkage analysis and WGS, can help identify the causal variants 
unique to specific families and lead to the identification of candidate genes to be studied 
in other families.  
 
1.3.3 Common variants  
The common disease, common variant model assumes that disease is caused by common 
variants of small to medium affect size (Figure 1.2). These variants are most likely to be 
identified by GWAS. A large number of psychiatric GWASs have been performed to 
date (which can be found in the NHGRI GWAS Catalogue ((Welter et al., 2014). 
Available at: www.genome.gov/gwastudies).  
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The first successful psychiatric association study was for AD. Variants in and around the 
APOE gene have been consistently identified as being significantly associated with AD, 
with a very large effect size (odds ratios 3-4) ((Strittmatter et al., 1993); (Bertram and 
Tanzi, 2008); (Jonsson et al., 2013)). To date, there are 28 AD GWAS in the NHGRI 
GWAS Catalogue (www.genome.gov/gwastudies. Accessed [14th August 2015].), 
which have identified at least 10 additional regions as being significantly associated with 
AD ((Harold et al., 2009); (Lambert et al., 2009); (Hollingworth et al., 2011); (Naj et al., 
2011); (Jonsson et al., 2013); (Perez-Palma et al., 2014)). A comprehensive database of 
AD associations can be found at www.AlzGene.org (Bertram et al., 2007). 
 
A smaller number of GWASs have been undertaken for ASD, the NHGRI GWAS 
Catalogue currently listing seven GWAS for ASD (www.genome.gov/gwastudies. 
Accessed [14th August 2015].). Of these, three identified genome-wide significant 
associations:   
1. Wang et al. (Nature, 2009) performed a GWAS on two discovery cohorts and 
two replication cohorts of European Ancestry, totalling 3,115 cases and 8,619 
controls. This study identified a genome-wide significant hit at chr5p14.1 
(combined p = 2.1 x 10-10)(Wang et al., 2009). 
2. Anney et al. (Hum Mol Genet, 2010) performed a ASD GWAS on a discovery 
cohort of 1,385 cases (from 1,369 families) and a replication cohort of 1,086 
cases (from 595 families) and 1,965 controls. A genome-wide significant 
association (p = 4 x 10-8) was found on chr20p12.1 (Anney et al., 2010). 
3. Xia et al. (Mol Psychiatry, 2014) performed a meta-analysis on two ASD 
GWASs for two Chinese cohorts (275 and 136 cases respectively, with 550 and 
984 controls respectively) and a replication cohort of European ancestry (1,299 
trios), which returned three genome-wide significantly associated variants (p 
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Figure 1.3 Manhattan plot from the largest schizophrenia GWAS to date, showing 108 genome-
wide significant loci. X-axis plots SNPs across the genome from chr1 to chrX. Y-axis plots the –
log10 p value. Bonferroni correction threshold is marked with a red line. All variants that pass 
Bonferroni correction are marked as green diamonds. All SNPs in linkage-disequilibrium with 
the significantly associated SNPs are also coloured in green. Taken from Ripke et al. 
(2014)(Schizophrenia Working Group of the Psychiatric Genomics, 2014). 
 
 
In 2014, the PGC published a SCZ GWAS, which studied 36,989 cases and 113,075 
controls, the largest psychiatric GWAS to date. This study identified 108 loci 
significantly associated with SCZ (Figure 1.3)(Schizophrenia Working Group of the 
Psychiatric Genomics, 2014). Previous to this, ~30 SCZ associated loci had been 
identified by GWAS (see references 10-23 from (Schizophrenia Working Group of the 
Psychiatric Genomics, 2014)). While still far behind the success of the SCZ GWAS, five 
genome-wide significant loci have also been identified for BD (Muhleisen et al., 2014). 
However, to date only two loci have been associated with MD (consortium, 2015), 
which have yet to be replicated. The results of GWAS studies for BD and MDD are 
discussed in detail in the Introduction to Chapter 5.  
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The lack of any replicated-associations for MDD and the potential causes for this has 
been discussed extensively in the literature ((Flint and Kendler, 2014); (Levinson et al., 
2014); (Major Depressive Disorder Working Group of the Psychiatric et al., 2013); 
(Wray et al., 2012)). These discussions focus on three main factors, which are potentially 
applicable to all psychiatric GWASs: 
 
1.3.3.1 GWAS sample sizes are too small 
GWAS are designed to capture association signals for common variants. The number of 
samples affects the ability to detect loci with different effect sizes (Flint and Kendler, 
2014). When the effect sizes are small (less than 1.2), more samples are needed to 
achieve the power to detect significantly associated loci (See Figure 1, (Flint and 
Kendler, 2014), for a description of the relationship between effect size and sample size 
for common variants). An example of this has already been seen in the literature for 
schizophrenia, where ~9,000 cases had the power to detect five genome-wide significant 
associations. This number increased to 108 when the number of cases was increased to 
~35,000 (Levinson et al., 2014). Once the number of cases passed a critical inflection 
point, as demonstrated in Figure 1.4 (in the case of schizophrenia, this number is 
~13,000-18,000 cases), ~4 new hits per 1000 additional cases were observed (Levinson 
et al., 2014). The MDD working group postulated that a sample size 2.4 times greater 
than that used for schizophrenia (prevalence 0.007) would be needed for MDD, as this 
disorder is more common (prevalence 0.15) (Major Depressive Disorder Working Group 
of the Psychiatric et al., 2013). Furthermore, as MDD has a lower heritability than 
schizophrenia (0.37 vs. 0.81), as many as 5 times the number of samples used for the 
schizophrenia GWAS might be needed. This number is debatable; the MDD working 
group suggested that at least 100,000 MDD samples (and an equal number of controls) 
would be required (Major Depressive Disorder Working Group of the Psychiatric et al., 
2013), while Flint & Kendler (2014) suggested as few as 50,000 MDD cases would be 
sufficient to detect genome-wide significant associations. Ultimately, these estimates 
will be dependent on the level of heterogeneity of MDD. 
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Figure 1.4. A graphical representation of the critical inflection point required for significant 
associations for different diseases. This figure shows how the number of discoveries is directly 
related to sample size and that this is not a fixed relationship, but specific to each genetic 
architecture. Taken from Levinson et al., 2014 (Levinson et al., 2014).  
 
 
1.3.3.2 The causal variant is not in linkage disequilibrium with any of 
the markers on the genotyping arrays 
If the causal variants are rare variants, they may not be in sufficient linkage 
disequilibrium (LD) with genotyping variants and therefore they will be below the level 
of detection of current GWAS methods ((Sullivan et al., 2012); (McClellan and King, 
2010b)). In addition, different populations having different genomic patterns of 
recombination events and haplotypes (Flint and Kendler, 2014); if multiple causal 
variants occur in the same gene, but these variants are located on different haplotypes, 
the signal would similarly not be seen in a GWAS. Therefore, population stratification 
could result in the causal variant not being in sufficient LD with a tagging SNP for the 
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1.3.3.3 Psychiatric disorders are a genetically heterogeneous disorder 
Based on the different rates of MDD between men and women (which suggests that 
although there are shared genetics between men and woman affected by MDD, there are 
also gender specific genetic determinants), there are likely to be genetically different 
forms of MDD. Similarly, sub-types of SCZ and BD, which differ in the combination of 
symptoms or severity of symptoms, are likely to exist.  If psychiatric disorders consist of 
yet to be established subclasses, studying them as a group could reduce power. 
Identifying a cohort of more phenotypically homogeneous cases could identify a more 
genetically homogeneous subset of cases and therefore reduce the sample size needed to 
detect significant associations. One such example would be to focus on hospital based 
MDD samples, as these individuals tend to represent a more extreme phenotype, with 
lower prevalence and higher heritability (Wray et al., 2012). Similarly, stratifying cases 
based on symptoms or shared environment (such as traumatic life events, environmental 
exposures such as pregnancy (cases of prenatal and post-partum MDD)) can potentially 
classify MDD cases into sub-types that are more genetically similar to each other. This 
has proven to be a strong strategy, as the only GWAS for MDD that has successfully 
identified genome-wide significant loci for MDD was for a homogeneous cohort, 
consisting of women with recurrent MDD of Han Chinese ancestry (consortium, 2015).  
This dataset only consisted of ~5,000 cases and ~5,000 controls, showing that a more 
homogeneous cohort can improve the ability to detect genome-wide significant loci. 
 
1.3.4 Polygenic model 
GWAS of complex diseases have identified large numbers of associated loci (over 70 
loci for diabetes (Replication et al., 2014) and over 100 loci for schizophrenia 
(Schizophrenia Working Group of the Psychiatric Genomics, 2014), each of small 
individual effect size ((Voight et al., 2010); Supplementary Table 2. (Schizophrenia 
Working Group of the Psychiatric Genomics, 2014)). Lee et al. (2012) analysed SCZ 
GWAS data (Schizophrenia Working Group of the Psychiatric Genomics, 2014) and 
calculated the variance explained by autosomal SNPs in a chromosome-by-chromosome 
manner (Lee et al., 2012).  These authors reported that the variance explained by 
chromosomes is linearly proportional to chromosome length. This is considered 
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consistent with a polygenic model (Lee et al., 2012). In a polygenic model the 
coinheritance of multiple common variants of individually small effect size can together 
push an individual above a particular ‘threshold’, leading, with environmental triggers, 
to disease phenotype. Individuals sharing some of these variants who fall below the 
threshold do not become ill.   
 
Wray et al. (2007) proposed that polygenic risk profiles could be generated from GWAS 
data, and this can be used to predict disease risk (Wray et al., 2007). Polygenic risk 
scores (PRS) are a measure of the association of a combination of markers with a trait 
within an individual. To generate a PRS, markers are selected in a training sample (often 
ranked on association p-value) using a cut-off (e.g. a p-value threshold). The weighted 
sum of associated alleles is used to calculate the PRS for each individual, based on the 
top ranked variants in an independent dataset (Dudbridge, 2013). This approach has been 
used to generate PRSs for a range of complex diseases including T2D (Lango Allen et 
al., 2010) and SCZ ((Schizophrenia Psychiatric Genome-Wide Association Study, 2011); 
(Ripke et al., 2013)). The polygenic component of SCZ has been predicted to be derived 
from large numbers (potentially over a thousand) variants, which together could account 
for roughly a third of the genetic liability of SCZ (Kavanagh et al., 2015). In addition, 
this polygenic component to SCZ has been shown to also contribute to the risk of BD 
(International Schizophrenia et al., 2009). As with GWAS, the power, sensitivity, and 




While most GWASs to date have focused on the identification of simple additive effects, 
the hypothesis being that SNPs exhibit additive, independent and cumulative effects on 
the trait or phenotype under investigation, there is a lot of debate over the contribution of 
epistasis to complex traits and diseases (Phillips, 2008). In contrast to the polygenic risk 
model, which suggests that multiple genes or variants of small effect contribute 
additively to trait variation, epistasis can be defined as the statistical or functional 
interaction between two or more loci, where the impact of a genotype at one locus is 
dependent on the genotype of another locus (or several other loci in the case of multi-
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locus epistasis) (Wei et al., 2014). A recent review by Wei, Hemani and Haley (Wei et 
al., 2014), discusses the likely contribution of epistasis to disease, current methods to 
detect epistasis in GWAS data, and provides some examples of epistatic interactions 
associated with disease phenotypes.   
 
The discrepancy between the sum of known genetic effects and the estimate of narrow-
sense heritability, also known as the problem of ‘missing heritability’, may in part be 
accounted for by epistasis, as regions which may individually fail to pass significance 
thresholds in GWASs studies, could be shown by their interaction term to contribute to 
the variance of a trait or disease (Wei et al., 2014).  However, caution must be advised 
before undertaking a search for epistatic interactions, as there are many confounding 
factors affecting such an analysis. Hypothesis-free methods, which search the full 
parameter space and compare all pair-wise interactions, are computationally intense and 
have the potential to suffer from both model complexity and the curse of dimensionality. 
The solution to both of these problems is very large sample sizes. Hypothesis driven 
approaches, in contrast, make use of biological priors (candidate gene analysis, pathway 
analysis, and subsets of GWAS SNPs chosen based on significance thresholds) and can 
reduce both the search space and the Bonferroni-corrected threshold (by reducing the 
number of multiple tests ((Carlborg and Haley, 2004); (Liu et al., 2011)). 
 
Wan et al. (2010), Liu et al. (2011), and Lippert et al. (2013) all performed hypothesis-
free studies, using the Wellcome Trust Case Control Consortium (WTCCC) study 
dataset ((Wellcome Trust Case Control, 2007)) to identify genome-wide interaction 
based associations across seven traits ((Wan et al., 2010); (Liu et al., 2013); (Lippert et 
al., 2013)). While the methods used by Wan et al. and Lippert et al. reported significant 
interactions, neither of these studies was able to replicate their findings in independent 
cohorts. However, the method implemented by Liu et al. identified several pair-wise 
interactions with Bonferroni corrected P < 0.05, which also replicated in independent 
datasets. In particular, they identified an interaction between C1orf106 and a novel 
locus, TEC, which was significantly associated with Crohn’s disease and which 
replicated in an independent dataset (Liu et al., 2013). The candidate loci approach has 
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also successfully been used to identify epistatic interactions influencing the risk of AD 
((Combarros et al., 2009); (Rhinn et al., 2013)). 
 
Prabhu & Pe’er (2012) performed a similar analysis on the Wellcome Trust bipolar 
cohort and were able to identify a significant interaction between SNPs within two genes 
encoding calcium channel subunits: RYR2 and CACNA2D4. Although they were not able 
to replicate the exact same SNP-pair interaction, the interaction between these two genes 
was replicated, suggesting epistasis may exist between these two genes and this 
interaction could play a role in the aetiology of bipolar disorder (Prabhu and Pe'er, 
2012). 
 
While these examples show the potential use of studying the role of epistasis in human 
disease, it is clear that such analyses suffer from background noise and are affected by 
large false positive rates. Either increased sample size or reduced candidate variant sets 
must be used to improve the ability of such methods to identify true epistatic interactions 
contributing to disease and trait variance (Wei et al., 2014).  
 
 
1.3.6 Overlap between psychiatric disorders  
It is becoming apparent that psychiatric disorders are aetiologically complex, with 
substantial genetic, locus and allelic heterogeneity ((Sullivan et al., 2012); (McClellan 
and King, 2010a); (Visscher et al., 2012)), leading to blurring between different 
diagnoses. Reasons for this are two-fold: firstly, phenotypic similarity and secondly, 
shared genetic aetiology ((Cardno and Owen, 2014); (Serretti and Fabbri, 2013)).  
 
Defining the phenotypes for each psychiatric illness is difficult. To date, no diagnostic 
tests, such as those available for many other illnesses (such as heart disease, diabetes and 
cancer), exist for psychiatric disorders. Instead, the diagnosis of psychiatric illness is 
based on clinical features. Furthermore, clinical features including psychosis, mood 
dysregulation and cognitive impairment are diagnostic for several psychiatric illnesses 
(including SCZ, BD and MDD) (discussed by (Cross-Disorder Group of the Psychiatric 
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Genomics, 2013)). Greenwood et al. (2012) suggest that the diagnostic systems currently 
used to define psychiatric phenotypes (such as the DSM-IV system (Wilson and Skodol, 
1994)) are not optimised for identifying genetic contributors to psychiatric illness 
(Greenwood et al., 2012). In addition, the diagnosis of a patient can change over time, 
based on changes to their symptoms.  
 
A meta-analysis of BD and SCZ (653 BD cases and 13,034 controls; 1,172 SCZ cases 
and 1,379 controls) identified two genomic loci (9q33.1 and 6q15) that reached genome-
wide significance (5.56 x 10-9 and 3.88 x 10-8 respectively), but were not significant for 
either individual GWAS (Wang et al., 2010). More recently, the Cross Disorder Group 
of the PGC performed a meta-analysis of the five major psychiatric illnesses (SCZ, BD, 
MDD, ASD, ADHD) in 33,332 cases and 27,888 controls. This meta-analysis identified 
four loci that passed genome-wide significance (p <5 x 10-8) at the chr3p21, 10q24, 
CACNA1C and CACNB2 gene regions (Cross-Disorder Group of the Psychiatric 
Genomics, 2013). A second analysis by the cross-disorder group of the PGC compared 
the genetic variation and the covariance between these five disorders (Cross-Disorder 
Group of the Psychiatric Genomics et al., 2013). This study made use of genome-wide 
genotype data for the GWAS meta-analysis of the five disorders previously described 
(Cross-Disorder Group of the Psychiatric Genomics, 2013) and reported a high 
correlation of common SNPs between SCZ and BD (0.68 ± 0.04 standard error), 
moderate correlation between SCZ and MDD (0.43 ± 0.04 standard error), BD and MDD 
(0.47 ± 0.04 standard error), and ADHD and MDD (0.32 ± 0.04 standard error). Only a 
low correlation was found between SCZ and ADHD (0.16 ± 0.04 standard error), while 
none was found between the remaining pair-wise combinations, or against Crohn’s 
disease (Cross-Disorder Group of the Psychiatric Genomics et al., 2013). Similar 
analyses have been attempted, using the polygenic component of these disorders to 
predict disease risk across different disorders with mixed success ((International 
Schizophrenia et al., 2009); (Schulze et al., 2014); (Wiste et al., 2014); (Maier et al., 
2015)). 
 
In addition to a high correlation of common variants between unrelated cases of 
psychiatric disorders, there is evidence that relations of probands affected with one 
disorder (such as SCZ) are more likely to suffer themselves from another psychiatric 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
Chapter 1: Introduction 21 
illness (such as BD) compared to population controls ((Lichtenstein et al., 2009); (Wray 
and Gottesman, 2012)). This further supports the possibility that these disorders share 







Figure 1.5. This figure outlines a potential shared pathogenesis and aetiology of psychiatric 
illnesses. The top section of this figure represents six genetic profiles, containing variants that 
are specific to one profile (one colour) or shared with other profiles (different colour). These 
profiles represent individuals with different genetic susceptibility to psychiatric illness. These 
genetic factors, in combination with environmental factors, can lead to disease vulnerability. 
Different combinations of genetic and environmental factors can present as different psychiatric 
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1.3.7 Complex Architecture 
As psychiatric illnesses such as SCZ are associated with increased mortality and reduced 
reproductive rates, variants with a large effect on the incidence of SCZ could be selected 
against in the population and so would remain uncommon (low allele frequency). 
However, it is more difficult to predict the allele frequency of variants with a modest 
effect on susceptibility, as these variants individually may have only a small effect on 
fitness, and could in fact have a positive effect on fitness due to their role in other traits 
(Visscher et al., 2012).  
 
Visscher et al. (2012) proposed two models that might explain the distribution of 
variants contributing to SCZ susceptibility: the neutral model and the Eyre-Walker 
model (Visscher et al., 2012). Under the first model, although most variants are rare 
(roughly 70% of variants having a MAF < 0.05), these variants only explain 10% of 
genetic variation. Therefore, the majority of variation is due to common variants of small 
effect size. In contrast, the Eyre-Walker model shows that most of the variance on fitness 
can be explained by very rare mutations of large effect size, most of which have a MAF 
< 0.05.  These two models largely encapsulate the two sides of the allelic spectrum 
argument for the genetic architecture of psychiatric illness. These two theories are not 
mutually exclusive; risk variants are likely to be both common and rare with a range of 
effect sizes. The limiting factor of current GWAS studies of psychiatric illness is sample 
size: many variants having population level effect sizes that are too small to pass 
genome-wide significance thresholds (Baker, 2014). To rectify this, the PGC has focused 
its efforts on obtaining as many cases and controls as possible. Comparing the most 
recent PGC GWAS for schizophrenia to the older GWAS study shows a marked increase 
in the number of significant loci (Schizophrenia Working Group of the Psychiatric 
Genomics, 2014), which supports the theory that additional loci will be identified for 
psychiatric disorders in the future.  
 
As can be seen from Section 1.3.3, particularly the SCZ association example, there is a 
lot of evidence suggesting that more information will be obtained from GWASs of BD 
and MDD by increasing sample sizes and/or decreasing hetergozygosity. However, the 
latest GWAS identified 108 significant loci for SCZ, the overall amount of variance 
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explained is still very small, the odds ratio of each locus being low (in the range of 1-
2)(Schizophrenia Working Group of the Psychiatric Genomics, 2014). Therefore, it is 
likely that only a fraction of the total variance for SCZ, BP and MDD will ever be 
explained by GWAS and alternative methods are needed to identify the other portion of 
variation (likely to be caused in part by rare variants of moderate or greater effect). 
Family studies will be particularly important for this. Linkage analysis can be combined 
with whole genome sequencing to improve the filtering of candidate variants (Ott et al., 
2015). It is also important to remember that variants identified by GWAS mark 
significantly associated regions and are not necessarily themselves risk variants. 
Therefore, these regions need to be followed up to identify the true causal variants at 
these loci.  
 
To summarise, it is very likely that psychiatric illnesses such as SCZ, MDD and BD will 
be shown to be caused by complex genetic architectures, comprising a range of genetic 
models. These disorders are likely genetically heterogeneous, consisting of both 
common and rare variants, both within the same gene (allelic heterogeneity) and across 
many genes (locus heterogeneity), with a range of effect sizes. It will therefore be 
important for the study of psychiatric illness not to focus too heavily on any single 
methodology. Both GWAS and NGS will be important and will play complementary 
roles in elucidating the aetiology of these disorders. 
 
1.4 Contribution of regulatory variants to disease  
The vast majority of variants associated with disease that have been identified by GWAS 
(over 90%) lie within non-coding regions (Maurano et al., 2012), Similarly, WGS 
projects (including the 1000 Genomes Project (Genomes Project et al., 2012) have 
shown that the vast majority of human variation is non-coding (Elgar and Vavouri, 
2008). The identification of the phenotypically causal fraction of variants is a major 
challenge to the study of the genetic basis of human disease. Cooper and Shendure state: 
“The primary roadblock faced by the field is increasingly one of variant interpretation, 
rather than data acquisition” (Cooper and Shendure, 2011).   
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Figure 1.6. This cartoon summarises the various functional classes of variants that can occur in 
the genome. Functional variants are represented as stars. The top sequence (A) shows an 
example of a protein-coding gene, containing a SNP within the promoter, two SNPs in exons and 
an intronic variant, which overlaps a transcription factor binding site. The second sequence (B) 
shows two genes, the first with a variant in the 5’UTR, the second, with a variant in the 3’UTR. 
Between the two genes is an insulator, which is modified by a SNP. The third sequence (C) 
shows an intergenic region, without any genes nearby. Within this sequence there are variants 
that overlap long-range enhancers, which modify the expression of genes elsewhere in the 
genome. The last sequence (D) shows variants within a non-coding RNA sequence as well as an 
intergenic variant shown to alter gene expression but acting via some unknown function. 
Modified from (Cooper and Shendure, 2011). 
 
 
By what means can a genetic variant be deleterious? A range of classes of functional 
variation is summarised in Figure 1.6. Changes to protein coding sequences can result in 
changes to amino acids, which can affect both the structure and function of a protein. 
Many tools exist that predict the deleterious consequence of protein changing variation 
(Table 1.3, taken from (Cooper and Shendure, 2011)). Furthermore, all variants within 
mRNA coding sequences (untranslated regions (UTRs) as well as protein coding 
sequence) can affect RNA structure, which in turn can affect RNA stability, localisation, 
translation efficiency and gene regulation by small RNAs ((Brest et al., 2011); 
(Mortimer et al., 2014)). However, as non-coding variants do not directly alter an amino 
acid in the mature protein, it is more difficult to identify the functional from benign 
variants. Some mechanisms by which non-coding variants may have a functional affect 
include: changes to exon/intron splicing ((Ward and Cooper, 2010)); or by disrupting 
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microRNA (miRNAs), long intergenic non-coding RNAs (lincRNAs) and other non-
coding RNAs ((Carbonell et al., 2012); (Kumar et al., 2013)). In addition, non-coding 
variants can function by modulating gene expression, by modifying regulatory elements 
such as promoter elements (De Gobbi et al., 2006), transcription factor binding sites 
(TFBSs) ((Zhang et al., 2012b); (Pomerantz et al., 2009)), insulators and enhancers 




Table 1.3 Summary table of tools that predict the deleterious impact of protein variants, 
showing the name of each tool, the type of predictive method utilised, additional information on 
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 Figure 1.7 This graph shows the proportion of the genome that is covered by biochemically 
functional elements including transcribed regions, regions bound by DNA binding proteins, and 




While there is substantial evidence that regulatory variants contribute to human disease 
(Li and Montgomery, 2013), our ability to detect the functional portion of the genome is 
limited by both our knowledge of what constitutes a functional non-coding variant and 
methods to identify those with a deleterious impact.  
 
In 2012 a paper was published that described 80% of genome as being biochemically 
functional (the ENCODE project Consortium, 2012), defining functional as participating 
in at least one RNA and/or chromatin associated event in at least one cell type. Kellis et 
al. (2014) discussed the merits and limitations of this and other definitions of 
functionality in greater depth (Kellis et al., 2014). Figure 1.7 summarises the proportion 
of the human genome that is covered by functional elements including transcripts 
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(RNA), DNA binding sites and histone modifications that mark sites of DNA regulation 
(including promoters and enhancers). If this data were taken to represent the fraction of 
the genome that is functional, then indeed, 80% would be an accurate estimation. 
However, at the other end of the functional spectrum are regions of the genome that are 
evolutionary constrained. If a region of the genome is conserved between species it is 
said to be under purifying selection, suggestion mutations at that site will be deleterious 
(Kellis et al., 2014). If only the portion of the genome that is under evolutionary 
constraint is considered as functional, only 5% of the genome would be included. 
 
The difference between the upper and lower bounds of predicted functional genomic 
elements (80% vs 5%) is substantial and highlights our limited understanding of the non-
coding portion of the genome. In addition, as so much of the genome can be assigned as 
being “functional” based on biochemically functional, the search for disease variants 
amongst these functional candidates could be compared to searching for a needle in a 
haystack, where, once the haystack has been removed, there remains a stack of needles 
(Cooper and Shendure, 2011). These needles will need to be further whittled down to 
identify the deleterious non-coding variants. The first step (removing the haystack) is 
identifying whether a variant has a functional effect and the second, is discovering if this 
functional effect is deleterious (sorting through the needles). Therefore, currently, all 
variants implicated by both NGS methods and GWASs must be functionally evaluated, 
before their role in disease can be confirmed. Experimental methods to predict the 
functional effect of a variant include in vitro investigation to determine the molecular 
consequences of a variant (for instance, whether it alters protein structure, stability, 
localisation or expression) and in vivo modelling in another organism (Cooper and 
Shendure, 2011). However, in vivo and in vitro methods are both time-consuming and 
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Figure 1.7. This image describes the variety of genomic features that are altered during the 
regulation of gene expression. Regulatory elements overlap a range of features including TFBSs, 
DNase HS, ChIP-seq peaks for a range of histone modifications. These data can be used to 
predict whether a variant overlaps a regulatory element and to predict the likelihood of that 
variant having a functional or deleterious consequence. Taken from (Qu and Fang, 2013). 
 
Bioinformatics methods can be used to filter candidate variants and reduce the number 
of variants to test in laboratory-based analyses. However, while predictive methods exist 
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for assessing the consequence of protein coding variation, tools to analyse the functional 
and potentially pathogenic consequence of non-coding variants are not as common and 
have been limited by our knowledge of the mechanisms regulating gene expression. We 
do know that transcriptional regulation is controlled by a complicated interaction of 
regulatory elements and that these elements are correlated with certain genomic features 
(Figure 1.8). Transcription factors and other DNA binding proteins bind to regions of 
open chromatin, marked by specific patterns of histone modifications, DNase HS sites 
and other genomic features. When a variant maps to a regulatory element, such as a 
TFBS, it can impact upon the binding ability of the transcription factor, thus altering 
gene expression, potentially leading to a deleterious effect. These genomic features can 
be used to help identify functional variants. This topic is discussed in more detail in the 
Introduction to Chapter 2. 
 
1.5 Thesis Aims 
At the time I undertook this PhD project, no suitable bioinformatics methods were 
available to prioritise non-coding variants from genomics projects.  
 
The first aim of my PhD was to develop a method that would prioritise candidate 
variants on the basis of their putative functional consequence. This will be covered in 
Chapters 2 and 3.  
 
Once this method was designed and tested, the second aim of my PhD was to perform a 
comparative analysis between my tool and the most comparable methods available from 
the literature. This analysis is described in Chapter 4. 
 
The final aim of my PhD was to apply this method to the study of psychiatric illness, 
which is detailed in Chapter 5. 
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Chapter 2: Design of a SNP prioritisation method and a 
spiking strategy 
2.1 Introduction 
2.1.1 The problem: identifying regulatory variants 
Linkage analysis and genome wide association studies (GWAS) have been extremely 
successful at identifying genomic regions that harbour genetic variants contributing to a 
phenotype of interest (Manolio et al., 2009). Technological advances such as next 
generation sequencing and genotyping arrays have aided this, allowing the fine mapping 
of regions of interest. Over 90% of disease-associated single nucleotide polymorphisms 
(SNPs) from GWAS fall within non-coding regions (Maurano et al., 2012), underlining 
the importance of the regulatory genome and the need for bioinformatics methods to 
identify regulatory variants. However, the ability to distinguish disease-predisposing 
non-coding variants from background variants is impeded by our incomplete 
understanding of regulatory architecture and the fact that genomic signals that 
characterise functional regulatory variants are not fully defined (Li and Montgomery, 
2013). In addition, the molecular consequences of such variants are more difficult to 
evaluate than those of variants that change the sequence of encoded proteins, leading to a 
bias in the characterisation of putative causal coding vs non-coding variants. 
Furthermore, the relatively lower cost of sequencing exomes rather than whole genomes 
has also played a part in biasing the identification and characterisation of disease variants 
towards coding SNPs. Nevertheless, recent improvements in sequencing platforms and 
methodologies are reducing the cost of whole genome sequencing (WGS) compared to 
exome sequencing, whilst also comparably improving its accuracy (Meynert et al., 
2014), leading to what will soon be a tipping point in favour of WGS and therefore the 
identification of a greater number of candidate non-coding variants. 
 
These technological advances put a growing pressure on our ability to characterise 
regulatory variants. In particular there will be an increased demand to prioritise 
candidate causal variants for their likelihood to be pathogenic via computational 
methodologies, as current experimental assays are too costly and time consuming to 
perform on large numbers of variants. One method commonly used to computationally 
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characterise variants is to annotate SNPs using pre-existing genome annotation data, 
from sources such as UCSC Genome Browser ((Kuhn et al., 2013)) and the Ensembl 
Genome Browser (Cunningham et al., 2015), and use this information to prioritise 
putative pathogenic variants.  
 
2.1.2 Publically available genomic annotation data  
A limiting factor within the field has been the lack of genomic and epigenomic 
annotation data to aid the identification of functional non-coding SNPs (Cooper and 
Shendure, 2011). This issue is currently being addressed; several large consortia have 
been established with the aim of developing techniques and producing data for the 
systematic identification and characterisation of functional elements on a genome-wide 
scale (Cooper and Shendure, 2011). By using a variety of biochemical techniques, such 
as ChIP-seq, in combination with novel computational approaches, these projects are 
producing annotation datasets for genomic and epigenomic markers including post 
translational modifications of histone proteins (including acetylation, phosphorylation 
and methylation) (Consortium, 2012); DNase hypersensitive sites (DNase HS) ((Degner 
et al., 2012); (Thurman et al., 2012)]; DNase footprints ((Hager, 2009, Hesselberth et al., 
2009)); transcription factor binding sites (TFBSs) ((Neph et al., 2012);(Wang et al., 
2012)]; chromatin states (Ernst and Kellis, 2010); enhancers (Ernst et al., 2011); 
conserved sequences (Davydov et al., 2010); as well as catalogues of SNPs, indels and 
copy number variants (CNVs) (Genomes Project et al., 2010). A fundamental aim of 
these projects is to provide the global scientific community with open-source, freely 
accessible data, promoting a vast wealth of downstream analyses. These data are 
available through genome browsers such as the Ensembl Genome Browser (Cunningham 
et al., 2015), the Epigenome Roadmap (Bernstein et al., 2010) and the UCSC Genome 
Browser (Kuhn et al., 2013).  
 
2.1.2.1 ENCODE ChIP-seq data 
The Encyclopedia of DNA elements (ENCODE) project was embarked on in 2003 with 
the aim of increasing our knowledge and understanding of human biology and disease by 
delineating all of the functional elements encoded by the human genome (Consortium, 
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2011)). This ambitious project began with a pilot phase, which took place over 4 years 
from 2003-2007. The aims of the ENCODE project pilot phase were to: i) functionally 
characterise 1% of the genome; ii) develop and advance methods for annotating the 
functionality of the genome; and iii) if successful, scale up for the whole genome, 
thereby improving our understanding of the genome (organisation, regulation and 
functionality).  
 
During the pilot phase, over 200 experimental and computational datasets were 
generated by 35 groups across the ENCODE consortia, with emphasis placed on the 
development and implementation of standards to ensure high data quality. This work 
provided a model for the next phase of the project and comprehensive annotation of the 
entire human genome, while also providing new tools and techniques to analyse the data 
efficiently, accurately and cost-effectively, in a high throughput approach. The 
ENCODE project provides genome-wide annotations of candidate functional elements to 
help better our ability to interpret the human genome ((Qu and Fang, 2013, Consortium, 
2012).  
 
Figure 2.1 describes the variety of methods used in the ENCODE project to characterise 
the genome, including ChiP-seq, which was used to generate data for histone 
modifications such as H3K27ac, H3K27me3 and H3K36me3, as well as RNA 
polymerases and certain transcription factors; and DNase-seq and FAIRE-seq, which 
were used to define regions of DNase hypersensitivity.  
 
These data can be used to identify putative functional elements and regulatory regions 
such as promoters, enhancers, repressors and insulators, by characterising the chromatin 
signatures of known elements, as changes to histone methylation and acetylation change 
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Figure 2.1: Cartoon taken from the User’s guide to ENCODE, representing the methods used 
across the ENCODE consortia to detect functional elements (Consortium, 2011). 
 
 
2.1.2.2 UCSC genome browser: 
The University of California Santa Cruz (UCSC) genome browser 
(http://genome.ucsc.edu/) provides access to a large range of genomic, epigenomic, 
conservation and sequence annotation data through a series of annotation tracks, which 
can be used to assign function to both individual nucleotide positions and larger genomic 
regions. Many different UCSC tracks are available, including information on assembly 
data, genes, predicted genes and mRNAs, expression, regulation and comparative 
genomics, and the ENCODE project data (Karolchik et al., 2011). The UCSC table 
browser allows users to query and manipulate the Genome Browser annotation tables in 
a flexible, user-oriented manner. It also provides access to the full datasets via an ftp site 
and MySQL queries. 
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Table 2.1.  The 26 populations included in the 1000 Genomes project. These populations can be 
grouped into five super populations: African (AFR), Ad Mixed American (AMR), East Asian 
(EAS), European (EUR) and South Asian (SAS). Columns 4, 5 and 6 describe whether data is 
available or not for each population (1 = data is available, 0 = data is not available). This table 
was modified from the population table provided by the 1000 Genomes project 
(http://www.1000genomes.org/faq/which-populations-are-part-your-study). 
 
2.1.2.3 1000 Genomes Project: 
The 1000 Genomes project is a catalogue of human variation. Human genetic variation 
was mapped using whole genome and exome sequencing to sequence the genomes of 
1,092 individuals from 26 populations (see Table 2.1)(Genomes Project et al., 2012). 
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This allowed a comprehensive review of the variation that exists across population 
groups to aid our understanding of how variation contributes to human phenotypes and 
disease. These data are available through a variety of sources, including a web-interface 
(http://browser.1000genomes.org/index.html) as well as downloadable bam and vcf 
format files from the 1000 Genomes FTP site (http://www.1000genomes.org/ftpsearch) 
and from Ensemble’s FTP site (ftp://ftp.ensembl.org/pub/).  
 
 
2.1.3 Lack of an appropriate method to prioritise variants 
The genomic annotation data from these public resources can be used to make informal 
and adhoc functional predictions. However, manual interrogation of such resources for 
multiple functional annotations simultaneously does not scale well for large numbers of 
SNPs spread across a broad genomic region (or genome wide), is unsystematic, lacks 
reproducibility and is difficult to benchmark (Ryan et al., 2014). 
 
A number of tools have been developed for analysing SNPs. However, the vast majority 
focus on coding variants, incorporate limited annotation data, are designed for particular 
analyses (exome data, GWAS) and require highly specific input data (such as rs 
numbers, p-values or linkage disequilibrium (LD) data). These tools implement a variety 
of strategies to identify functional SNPs, including use of comparative genomics ((Chun 
and Fay, 2009)), predicted transcription factor binding sites (Conde et al., 2006), 
positional information ((Adie et al., 2005); (Xu et al., 2005); (Calabria et al., 2010)), 
amino acid substitutions (Yandell et al., 2011), chromatin state markers ((Ernst et al., 
2011); (Barenboim and Manke, 2013)), p-values from GWAS ((Merelli et al., 2013)) and 
linkage disequilibrium (LD)((Ward and Kellis, 2012)).   
 
SNP analysis tools can be divided into five main categories: i) variant annotation 
approaches; ii) GWAS tools; iii) gene based prioritisation methods; iv) exonic variant 
tools; and v) non-coding variant tools. Here I provide a brief description of some of the 
SNP analysis methods that were available at the start of my PhD: 
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2.1.3.1 Variant annotation: 
F-SNP: a web based database, integrating information from 16 bioinformatics tools and 
databases to allow the user to predict the function of SNPs (Lee and Shatkay, 2008). 
This method does not provide a ranking measure; instead it implements a binary logic 
where SNPs are classified as being either functional or not functional. To analyse the 
output, the user must scroll through a tabular output and look at every SNP individually 
to see their predicted effect, an impractical approach for large SNP sets. 
 
AnnTools: a toolkit for annotating novel and known SNPs and indels that integrates 15 
annotation sources (Makarov et al., 2012), including dbSNP minor allele frequencies 
(MAFs), gene annotation data from UCSC, conserved TFBSs, miRNA binding sites, and 
promoter predictions. Although this method is presented as being a fast and versatile 
approach to annotate the full spectrum of coding and non-coding variants (being capable 
of annotating both SNPs and indels), it does not prioritise variants on putative 
pathogenicity.  
 
SNPnexus: an annotation tool that links functional annotation data with SNPs across a 
range of annotation categories including gene annotation (from sources such as Refseq, 
Ensembl and UCSC); gene consequences (coding, intronic, splice site, untranslated 
regions, upstream, downstream); protein consequences (synonymous, non-synonymous, 
stop-gain/loss, frameshift); HapMap population frequencies; conservation scores; and 
whether variants overlap regulatory elements (predicted TFBSs, Vista enhancers, CpG 
islands, etc.) (Dayem Ullah et al., 2013). The output table links each query SNP (one 
SNP per row) with each annotation (series of columns), allowing SNPs to be filtered on 
any single annotation or combination of annotations. While this method provides useful 
information, the number of SNPs analysed affects the efficacy of this method: the larger 
the numbers of SNPs in the input dataset, the larger, and less manageable, the output 
table. Although filtering on annotations would make the table smaller and easier to 
handle, filtering could also potentially remove borderline SNPs that may actually be 
functional. Filtering is therefore less constructive than prioritisation.   
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HaploReg: an online resource combining conservation, histone modifications, 
chromatin states and linkage disequilibrium data with regulatory motif prediction 
algorithms to predict the impact of non-coding variants (Ward and Kellis, 2012). This 
method is designed for GWAS data, to explore the potential functionality of non-coding 
variants within disease-associated loci.  
 
rSNPBase: a database of regulatory SNPs (rSNPs) supported by experimental evidence 
(Guo et al., 2014). This online resource provides annotation data ranging from 
ENCODE-generated experimental data, TFBSs, DNase hypersensitive sites (DNase HS), 
miRNA regulatory sites, to SNPs in strong LD (r2 >0.8) with the rSNPs. This data can be 
used to identify regulatory SNPs and the genes that they regulate.  This method is useful 
on a SNP by SNP level, where the SNPs of interest are already curated in human 
variation catalogues such as dbSNP (Sherry et al., 2001). However, this approach does 
not scale well for comparing multiple variants simultaneously and cannot be used for 
novel variants. 
 
RegulomeDB: an online database integrating annotation data from six main categories 
(protein binding, motifs, chromatin structure, expression quantitative trait loci (eQTLs), 
histone modifications and related data) to assign regulatory information onto any 
variants (both from sequencing projects and GWAS) (Boyle et al., 2012). As with other 
annotation methods, this is useful for assigning functional data to SNPs, however it does 
not report which SNPs are most likely to be putative functional candidates and cannot be 
used to prioritise variants. 
 
2.1.3.2 GWAS tools: 
SPOT: a web tool for the prioritisation of GWAS SNPs for replication studies. This 
method integrates data from several biological databases and uses the genomic 
information networks (GIN) prioritisation method to combine the information from these 
databases, along with GWAS p-values, to prioritise SNPs for further investigation 
(Saccone et al., 2010). This process is performed for both the original tagging SNP and 
all LD proxies. 
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SNPselector: a web tool, designed to select the most appropriate SNPs for association 
studies (Xu et al., 2005). This method prioritises SNPs across multiple categories 
including: allele frequency; whether they are the tagging SNP in an LD block; regulatory 
potential (does the SNP overlap conserved sequences, transcription factor binding sites 
or CpG islands?); and if it is located within a repetitive element. SNPs are scored on 
these categories and others and the SNPs are prioritised on this score. 
 
FunctSNP: an R package that links SNPs with functional knowledge, scoring GWAS 
SNPs based on the functional information associated with them, the total score being the 
sum of factors including SNP location, type of amino acid substitution (Goodswen et al., 
2010). This method was trained on GWAS data, which is inherently a mixed data source, 
containing many false positives, which could affect the accuracy of the method. In 
addition, when a GWAS significant SNP does not lie within a gene, FunctSNP 
automatically links the SNP to the nearest gene and the focus is shifted to the nearest 
SNP within that gene. This method assumes that the functional variant is a coding 
variant and ignores the possibility of regulatory variants having a role in disease. 
 
ChroMoS: an integrated web tool for GWAS SNP classification, prioritisation and 
functional interpretation. This method utilises a MySQL database to provide chromatin 
state annotations for SNPs from the National Human Genome Research Institute GWAS 
catalogue. SNPs can also be passed to two additional tools, sTRAP and microSNiPer, 
which predict differential transcription factor and micro-RNA binding respectively 
(Barenboim and Manke, 2013).  
 
FunciSNP: and R package designed to move beyond GWAS tagging SNPs to identify 
candidate regulatory variants (Coetzee et al., 2012). Putatively functional surrogate 
SNPs in high LD with GWAS tagging SNPs are identified by taking all SNPs in LD with 
GWAS tagging SNPs and overlapping annotation data for a range of user-defined 
“biofeatures” (including ENCODE ChIP-seq data for transcription factors; DNase HS 
sites; CFCF binding sites and annotated promoters). 
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2.1.3.3 Gene based tools 
SNPRanker:  a data-mining tool for disease associated SNPs that focuses on target 
gene prediction (ranks SNPs associated with target genes based on functional evidence) 
(Calabria et al., 2010). This tool no longer appears to be available from the source 
website. This could either be because the method is being upgraded and they have 
removed the old version until the new one is ready, or this method is now defunct. 
 
Residual Variation Intolerance Score: a gene-based score designed for the 
assessment of how well genes tolerate functional genetic variation, to aid the 
identification of pathogenic coding mutations (Petrovski et al., 2013). This method ranks 
genes on the amount of purifying selection acting against functional variation in genes, 
taking into account both gene size and total mutation rate (both the number of common 
variants and the number of protein-coding variants), to assess if genes have more or less 
functional genetic variation than expected compared to the calculated neutral variation 
rate for that gene. 
 
2.1.3.4  Exonic variant tools: 
VAAST: a probabilistic approach that combines elements of aggregative scoring 
methods and amino acid substitution (AAS) data in a unified framework (Yandell et al., 
2011). VAAST can be used to prioritise coding and non-coding variants; however, as 
non-coding variants cannot be scored using the AAS approach (as they do not encode 
amino acids), VAAST uses two different approaches to assess the deleteriousness of 
coding and non-coding variant. Instead, non-coding variants are scored using a log-
likelihood ratio combining allele frequencies in cases and controls; an estimate of the 
impact of non-coding and synonymous substitutions called Normalized Mutational 
Proportion (NMP), based on the frequency of codons in the human genome aligning with 
primate genomes and the proportion of occurrences of each of these codon pairs 
occurring across primate alignments; conservation estimates around DNase 
hypersensitive sites; and transcription factor binding sites defined by ENCODE 
regulation data, focusing on elements conserved across primate alignments.   
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EXtasy: a ranking method for the prioritisation of non-synonymous SNPs (Sifrim et al., 
2013), making use of annotation data including but not limited to: allele frequency; 
conservation; sorting tolerant from intolerant (SIFT) scores and PolyPhen scores; 
deleteriousness prediction scores from the dbSNP database; and haplo-insufficiency 
scores. This method is available both as a web interface and as a downloadable, stand-
alone program. The developers of this method have shown that it performs well 
compared to its individual component parts, suggesting that combining multiple 
annotation data can provide better sensitivity and specificity than each annotation in 
isolation. 
 
2.1.3.5 Non-coding variant tools 
RAVEN: regulatory analysis of variation in enhancers (RAVEN) is a web-based 
application that combines phylogenetic footprinting and TFBS prediction methods to aid 
the selection of candidate regulatory variants for follow-up analysis (Andersen et al., 
2008). The user selects a gene of interest and RAVEN provides a graphical view of the 
region proximal to the chosen gene, highlighting the dbSNP variants within this region, 
as well as predicted TFBSs, conservation scores (as defined by PhastCons scores) and 
any repeat sequences in the region. This method does not rank or prioritise SNPs of 
interest. Instead, it provides information on all of the potentially regulatory SNPs within 
a selected locus.  
 
Pupasuite: a web based SNP analysis tool that prioritises SNPs on factors including 
LD, MAF, validation status, variant type, and a small selection of putative functional 
properties including if the SNPs are known to be pathological (compared against a 
reference list of confirmed pathogenic variants), or occur at exon/intron boundaries 
(Conde et al., 2006). This tool uses TransFac (Wingender, 2008) to predict if non-coding 
variants overlap TFBSs, however, this feature is limited to SNPs within 10kb upstream 
of transcription start sites. This method is therefore not suitable for the analysis of 
variants further than 10kb upstream of known genes. 
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Weka: this method was trained using machine learning and a true positive dataset of 
real, biologically active regulatory variants and a background set of non-coding variants 
to train a model for predicting regulatory polymorphisms (Torkamani and Schork, 2008). 
Torkamani and Schork (2008) were among the first researchers in the field to make use 
of the ENCODE data to predict functionality. These authors compared over three 
hundred ENCODE feature sets and used machine learning to reduce this to a smaller, 
more usable set. In this study they used a good statistical framework consisting of hold 
out datasets and cross validation; however, the true positive data set was small (104 true 
variants), affecting the accuracy of the measured performance. In addition, this method is 
not formatted as a tool for predicting the functionality of regulatory polymorphisms. 
Instead the authors provide the software platform (Weka) used in their analysis and the 
input data to allow their method to be reproduced.  This prohibits this method from 
becoming a field standard approach and makes it inaccessible to the majority of 
inexperienced scientists (particularly for bench scientists with limited bioinformatics 
experience who wish to test their data).  
 
To summarise, many bioinformatics approaches have been designed to identify (or 
prioritise) tagging SNPs from GWAS studies, exonic variants, or purely to annotate 
genomic variants. However, at the start of this project, there was no effective method for 
the prioritisation of regulatory variants from NGS projects. Nor was there a gold 
standard protocol for testing and comparing methods, making a comparison between 
different strategies subjective (focusing on limited data, biased to a particular variant 
class, genomic region, or disease).  
 
Therefore, there existed a need for a simple, robust system that can combine a range of 
annotation datasets, along with other genomic functional measures, to prioritise 
candidate variants for follow up analyses. I proposed to address this by designing my 
own method. This method would be appropriate for all genomics projects, capable of 
handling both coding and non-coding variants in a single analysis, and not be limited by 
distance to the nearest transcription start site (TSS). 
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Three questions to ask when developing any new prioritisation approach are: 
1. Which annotation features should be included in the model?  
2. How should these features be combined into a single pipeline?  
3. How can this method be tested to assess its ability to prioritise functional variants? 
The following sections will deal with these points. 
 
2.1.4 Annotation features: 
2.1.4.1 Conservation 
Regions of the genome that are conserved across species are said to be under purifying 
selection, suggesting that mutations at these sites may have a deleterious impact to the 
organism (Kellis et al., 2014). Therefore, DNA elements with important functions are 
often conserved across species (Cooper and Shendure, 2011). 
 
Many algorithms have been designed to take advantage of this feature, making use of the 
availability of fully sequenced genomes of over 46 species (Cooper and Shendure, 
2011). A key decision to be made when performing a cross-species analysis is the 
phylogenetic scope one should use . If this is too broad (e.g. humans to yeast) many true 
functional sites are likely to be missed as they are unlikely to be conserved over such a 
great evolutionary distance; if too narrow (e.g. humans to primates) many non-functional 
sites will appear to be conserved as they have had insufficient time to diverge. In 
addition, a choice must be made as to which conservation methods to use. Conservation 
algorithms can be broadly divided into two groups: those that assign a conservation 
score to individual nucleotide positions and those that use a sliding window to assign a 
score to a small region. 
 
Genomic Evolutionary Rate Profiling (GERP) calculates levels of evolutionary 
constraint on a position specific level, based on an alignment of 35 mammals to the hg19 
release of the human genome (https://genome.ucsc.edu/cgi-bin/hgTables). Candidate 
constrained elements are identified by annotating regions that show a lower number of 
substitutions than expected. Each element is assigned a rejected substitution (RS) score, 
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in proportion to the magnitude of the substitution deficit obtained ((Davydov et al., 
2010); (Siepel et al., 2005)). 
 
PhastCons and PlyloP are part of the PHAST, 46way conservation package, based on 
hidden Markov algorithms. The first looks at conservation of the region containing each 
variant while the second looks at the conservation of the specific base. Both tools can be 
run on three subsets of organisms: primates, placental mammals and vertebrates (King et 
al., 2005). 
 
2.1.4.2 Chromatin States 
While the genomic signatures of each histone modification can provide a certain amount 
of data, layering them together can increase precision and specificity (Ernst et al., 
2011).However, our knowledge of how best to combine these data is limited. To 
correctly define the combinations of raw histone marker ChIP-seq data would require a 
lot of additional experimental and computational work far beyond the scope of this 
project. An alternative option was to use predefined data. One such source of data comes 
from the labs of Kellis and Berstein (Ernst et al., 2011), who systematically mapped nine 
chromatin marks across nine cell lines, and developed a multivariate hidden Markov 
model to distinguish different chromatin states, through recognition of combinatorial 
patterns of the chromatin marks. These data have been rigorously tested and confirmed 
by in vitro assays (Ernst et al., 2011). 15 chromatin states were predicted, including 
active promoter, weak promoter, strong enhancer, transcriptional elongation, polycomb 
repressed, and repetitive /copy-number-variant. 
 
2.1.4.3 DNase hypersensitivity 
DNase I hypersensitivity is a universal feature of active cis-regulatory sequence and has 
long been used to map general chromatin accessibility. The use of this method has led to 
the discovery of functional regulatory elements that include enhancers, insulators, 
promoters, locus control regions and novel elements (Thurman et al., 2012). The DNase 
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Clusters track on the UCSC Table Browser contains genome wide data assayed in 74 cell 
types, pooled together into a single value, as part of the data generated by the University 
of Washington ENCODE group (Sabo et al., 2004). 
 
2.1.4.4 Repetitive elements 
Repetitive sequences present many technical challenges for the alignment and assembly 
of next-generation sequencing data (Treangen and Salzberg, 2012). As nearly 50% of the 
human genome is derived from repeats this can be a major influence on the reliability of 
downstream analyses including SNP calling. Various tools have been designed to 
overcome this issue at the sequence alignment and assembly level and recommendations 
have been made for quality control settings to improve the accuracy of the SNP calling. 
The RepeatMasker track on the UCSC Table Browser was created using the program 
RepeatMasker, written by Arian Smit (Smit AFA, Hubley R, Green P. RepeatMasker 
Open-3.0. http://www.repeatmasker.org. 1996-2010.). This tool is used to annotate 
repetitive elements present within the query sequence. The data generated includes a 
column describing the type of repeat element identified (repClass). 
 
2.1.4.5 Mapability 
Mapability provides information on the align-ability and uniqueness of sequences based 
on the hg19 release of the human genome. Each 20bp sequence is assigned a score 
between 0 and 1: a sequence will score “1” is it is unique and “0” if it occurs four or 
more times in the genome (UCSC Table Browser Schema, (Karolchik et al., 2011)), and 
a score of 0.5 indicates the sequence occurs exactly twice, while a score of 0.33 indicates 
three times and 0.25 four times. 
 
2.1.4.6 Position 
The position of a SNP relative to that of genes is an important factor to be considered 
when scoring SNPs, as studies have shown that the position of SNPs relative to genes 
affect the likelihood of that SNP being causal: i) a regulatory site’s influence on 
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expression falls off almost linearly with distance from the TSS in a 10kb range 
(MacIsaac et al., 2010); ii) disease associated SNPs are significantly enriched within 
strong enhancers (Ernst et al., 2011); iii) non-coding disease-associated GWAS variants 
are concentrated in DNase HS sites (Maurano et al., 2012); and iv) DNase HS are known 
to overlap with regulatory elements (Vernot et al., 2012). This information can therefore 
be used to predict the probability of a variant being pathogenic.  
 
2.1.4.7 Allele frequency 
The frequency of a variant within a population or across populations can aid our 
understanding of the phenotypic impact of that SNP. For instance, a common SNP is 
unlikely to be a causal variant for a highly penetrant, Mendelian disease. Understanding 
the disease model under investigation can allow scientists to hypothesize the frequency 
of a causal variant in the population and use this information to reduce the number of 
potential variants to investigate. 
 
2.1.4.8 Chromosome region score 
Some studies, such as GWAS and linkage studies, provide information on which parts of 
the genome are most likely to contain the causal variant for a disease of interest. These 
data can be used to filter out candidate SNPs that are not located in the region of interest, 
or to give them lower priority. 
 
2.1.5 Combining features into a model framework 
Defining the features to be included in a prioritisation method is an important aspect of 
developing such a method. Equally important is the selection of a model framework to 
combine these features. Simply combining them together in a 1:1:1 ratio is not a viable 
approach, as the data are all on different scales (for instance, 0-1 versus 0-1000). The 
SNP analysis tools described in section 2.1.2 were all developed using different 
approaches and do not provide a consensus on the best way to design a variant 
prioritisation method. An aim of this chapter is to develop an appropriate model 
framework and test it. 
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2.1.6 Test datasets 
A universal challenge facing developers of new bioinformatics tools is how to test the 
performance and accuracy of their methods. Meaningful benchmarking requires test 
datasets comprising large numbers of both “true positives” and “true negatives”. For the 
development of a SNP prioritisation approach, these would be, respectively, variants that 
have been shown experimentally to be deleterious and variants that have been shown not 
to have a negative effect, both datasets containing both coding and non-coding SNPs. A 
frequent problem with designing such a dataset is that it is difficult to determine with 
absolute certainty whether a variant is a true negative.  
 
Potential sources of true positive variants for this project fall into three main categories: 
i) large-scale databases (Cooper and Shendure, 2011); ii) single locus and/or disease 
specific databases; and iii) repositories of experimentally validated variants compiled by 
single research groups. There is much debate over which type of database contains the 
best data. 
 
Many authors have argued for a focus on locus specific databases (LSDB’s) (reviewed 
by (Samuels and Rouleau, 2011)), containing variants experimentally proven to be 
associated with a specific disease. These databases are usually fully accessible to the 
public and, being primarily maintained by academic researchers, tend to be more 
comprehensive and accurate than their larger scale counterparts, which contain variants 
with mixed levels of evidence supporting their functional and pathogenic effects 
(Samuels and Rouleau, 2011). They do, nevertheless have drawbacks, most pressing 
being they tend to suffer from limited sample sizes, an unavoidable consequence of 
focusing on a single disease or locus. There is also no universal standard regulating the 
design and curation of such databases, meaning there is a lot of variability in the 
standard of these databases. As with larger databases, they are also biased towards 
coding variants. Some good examples of LSDB’s are the Cystic Fibrosis Mutation 
Database, which catalogues variants associated with the cystic fibrosis trans-membrane 
conductance regulator gene (CFTR) locus (http://www.genet.sickkids.on.ca/app); the 
HBB variants catalogued in the HbVar database of Human Haemoglobin Variants and 
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thalassaemia mutations (Giardine et al., 2007); and the Fanconi Anaemia Mutation 
database compiled by the Rockefeller University ((Samuels and Rouleau, 2011); (Cotton 
et al., 2008)).  
 
The advantages of large-scale databases such as the Online Mendelian Inheritance in 
Man (OMIM) database ((Amberger et al., 2015)) and the Human Gene Mutation 
Database (HGMD)(Stenson et al., 2003) are that they contain much larger numbers of 
variants; however a lot of variation exists between such databases, each missing some 
data (genes or variants) that the other provides. For instance, OMIM only includes select 
mutations for each gene, chosen (amongst other criteria) based on phenotypic impact, 
population frequency and historical significance. HGMD is available in two forms: a 
comprehensive, professional version, which requires a (expensive) license to access; and 
a smaller, more outdated public version. In contrast to the professional version, the 
public database cannot be downloaded as a whole from the HGMD website, most likely 
to encourage use of the professional version. Both versions report variants that are not 
necessarily disease causing, for instance GWAS SNPs and SNPs with experimental 
evidence of functionality but no known link to disease.  
 
2.1.6.1 HBB dataset 
Haemoglobinopathies, which affect the structure and function of haemoglobin 
molecules, are among the most common hereditary disorders in humans and are caused 
by mutations in the α- and β-globin gene clusters (Giardine et al., 2007). One example is 
beta-thalassaemia, a Mendelian disorder characterised by changes to the synthesis of the 
β-globin chain, causing either a structural change, affecting how it binds to α-globin, or 
by changing the quantity produced. This results in an imbalance in globin chain 
production and a reduction in the amount of mature haemoglobin A produced, leading to 
abnormal erythropoiesis (Amberger et al., 2015). Mutations at the HBB locus lead to a 
variety of phenotypes, including the Beta-thalassaemias and sickle cell anaemia.  
 
The HbVar database is a locus-specific database of human haemoglobin variants that 
underlie thalassaemias and haemoglobinopathies (Giardine et al., 2007). Developed in 
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2001, HbVar is known for being well maintained, comprehensive and simple to use 
(Samuels and Rouleau, 2011). The phenotypic heterogeneity reflects the heterogeneity of 
mutations at this locus. The variants catalogued in this database can be queried using 
several approaches including: by type of thalassaemia; gene name; globin chain; where 
the variant is located within gene (exon, intron, un-translated region (UTR); non-
coding); ethnic occurrence; or a combination of factors. Compared to other LSDBs, 
HbVar has the added advantage of allowing variants to be batch downloaded. In 
addition, the variants catalogued in HbVar are supported by extensive documentation, 
including the biochemical and phenotypic effects of each variant (including references), 
allele frequency. This database has a limited number of variants as it only focuses on a 
specific disease locus; however, as it is a highly accurate and well-maintained database, 
it is a very good candidate database for my analysis (Giardine et al., 2007).  
 
 A shortcoming of HbVar is that the majority of variants are coding variants. This is 
largely due to the genetic architecture of thalassaemias, although it is also in part due to 
acquisition bias and the greater ease in identifying coding variants. Some non-coding 
variants included within the database may have been identified concurrently with coding 
variants (i.e. being secondary or tertiary modifiers) or leading to specific functional 
effects, such as only affecting TFBSs or strong enhancers, and so may not provide a 
good representation of the global diversity of regulatory polymorphisms. 
    
2.1.6.2 RAVEN dataset 
Andersen et al. (2008) performed a literature search to identify regulatory SNPs to build 
their own training dataset to test their bioinformatics approach, RAVEN (see Section 
2.1.2)(Andersen et al., 2008). By searching for regulatory variants themselves, they were 
able to specify strict search criteria and so ensure all variants included in their dataset 
were experimentally verified (either by luciferase assay, in vitro electrophoretic shift 
assays or by showing allele-specific binding to nuclear extracts); likewise, they were 
able to restrict the variants to those within 10kb upstream of the TSS of human genes 
with available human-mouse orthologs. In this manner they identified 104 variants that 
matched their strict criteria and which could be used to train their application. In 
addition, they developed a background variant dataset, consisting of SNPs similarly 
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restricted to within the 10kb region upstream and downstream of genes with known 
mouse orthologs. All 4,000 background SNPs were common SNPs, with a MAF >0.05 
from dbSNP (Andersen et al., 2008). 
  
2.1.6.3 Spiking strategy 
The HBB and RAVEN datasets both represent very specific classes of test data. I also 
designed a strategy for building a new class of test datasets, whereby known variants 
could be spiked into an unrelated background variant set. This spiking strategy would 
allow me to assess how well the model can discriminate real functional variants against 
any arbitrary background. As I already had at my disposal two positive (known 
functional) variant datasets, I only required additional background data to spike these 
variants into.  
 
2.1.6.4 SBF2 4p background dataset 
I had access to WGS data for five individuals from a family with multiple instances of 
bipolar disorder and evidence of linkage to a locus on chromosome 4 (see Chapter 5 for 
more details): three affected carriers of the disease haplotype and two unaffected, 
married-in relations. The SBF2 linkage-region is defined as an approximately 20 Mb 
region on chromosome 4 (Le Hellard et al., 2007). Using this data as a background 
variant dataset allowed me to assess the ability of my model to prioritise the HBB and 
RAVEN variants in a novel genomic context. As this region is likely to contain at least 
one putative candidate SNP for bipolar disorder, the “known” SNPs to be spiked into 
this background set will have to compete with other functional variants. This would 
suggest that the performance of the prioritisation model on this data would be negatively 
affected and the performance measures would be lower than for the two known variant 
datasets against their own background variants.  
 
2.1.6.5 ENCODE pilot project background dataset 
The ENCODE pilot project generated annotation data across 44 genomic regions, 
covering roughly 30 Mb of DNA, 1% of the genome. These regions were chosen to 
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cover a wide range of genomic contexts. 50% were chosen around medically important 
genes (or other known sequence elements) whose biology has been well studied, while 
the other regions were selected using a stratified random-sampling strategy, based on 
two parameters: gene density and non-exonic conservation scores.  
 
I generated a background dataset consisting of all of the 1000 Genomes EUR variants 
from within the coordinate boundaries of the 44 ENCODE pilot project regions. Details 
of the 44 regions can be found in Table 2.4. Each of the 44 regions can be used 
individually as background datasets with different genomic contexts to spike true 
positive variants into. Similarly, these regions can be merged to test performance on a 
single, large, heterogeneous dataset.  
 
 
2.1.7 Summary of chapter aims 
The first aim of this chapter was to develop a method to prioritise candidate pathogenic 
variants. 
 
The second aim was to develop a performance evaluation strategy that can assess the 
prioritisation method and predict how well it will perform on novel data, across a range 
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2.2 Methods 
2.2.1 Annotation data sources and data management  
The annotation data pertaining to the HBB, RAVEN and Scottish bipolar family 2 
(SBF2) datasets were obtained and processed by Stewart Morris (SM) into spreadsheet 
format, the first column containing the SNP reference (coordinates based on the hg19 
build of the human genome) and each additional column containing the annotation data 
for each SNP for all of the collected annotation features. I developed a shell script 
combining MySQL, awk and bedtools commands to generate the data tables for each 
feature annotation (see Appendix A). 
 
These features were obtained from a variety of sources including the 1000 Genomes 
repository of human variation, the ENCODE project, and UCSC Genome Browser and 
included four conservation tools (GERP, PhastCons, 7xregpotential and PhyloP), DNase 
HS data, minor allele frequencies, chromatin states, repetitive elements, mapability and 
position relative to genes. 
  
2.2.2 Correlation analysis 
To select the best conservation tools to include in the prioritisation method, I performed 
correlation analysis using the statistical software R (version 2.14.0). Using the function 
cor() and the method “spearman”, I calculated Spearman’s rank correlation coefficients, 
rho scores. In addition to producing rho values for this correlation analysis, this method 
also reports p-values on the significance of the relationship. 
 
2.2.3 Data preparation 
2.2.3.1 HBB 
I searched the HbVar database (accessed: November 2011) for variants specific to the 
HBB gene using the command:  
>“name like ‘HBB’ AND any substitution”  
This returned 767 variants, which I downloaded as a tab-separated text file and 
converted into an excel spreadsheet. Of the 767 disease-associated variants available for 
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this region, I excluded roughly half because they were not SNPs (either small indels or 
other mutations), leaving 363 disease SNPs. An additional 141 background SNPs were 
identified within this region using the dbSNP archive of genetic variation, giving a total 
benchmarking dataset of 504 SNPs. Functional annotation data for these variants were 
collected and processed by SM.  
 
2.2.3.2 RAVEN 
The RAVEN dataset was made available as part of the supplementary material for the 
paper by Andersen et al. (2008), in the format described in Table 2.2. From this file, I 
extracted the “chromosome position in Hg17” column, which I separated into a 
chromosome column and a coordinate column for conversion into Hg19. Conversion 
from Hg17 to Hg19 was performed by SM. Due to changes between Human Genome 












Table 2.2. This table represents an example of the RAVEN SNP file format. Column 1 lists the 
gene names associated with each variant; columns 2 shows the PubMed IDs for the analyses 
where each SNP was functionally assessed; column 3 lists the dbSNP IDs for each SNP; columns 
4 and 5 describe the two alleles and the proximal sequence for each SNP; and column 6 relates 
the reference source for each SNP.  
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Table 2.3.Table of information on the ENCODE pilot regions, including information on non 
exonic conservation score (NEC), % gene density (GD), pick method, number of genes in each 
region and the number of SNPs (MAF<5% from the 1000 genomes EUR database). The 
ENCODE pilot regions cover 30Mb of the genome (~1%) and were picked either manually 
(based around well studied genes or other well-known sequence elements, in regions where a 
high amount of comparative sequence data had been collected) or according to a stratified 
random-sampling strategy so as to include representative regions varying in the number of 
genes and functional elements based on gene density score (percentage of bases covered by 
exons ) and non-exonic conservation score (sharing at least 80% base alignment with the mouse 
genome). 
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2.2.3.3 ENCODE pilot project background dataset 
To build the ENCODE datasets I extracted SNPs from the 1000 Genomes European 
(EUR) subpopulation. Table 2.3 describes each of the ENCODE pilot regions. I 
assembled the SNP functional annotations using a shell script that made use of tools such 
as mySQL, bedtools, bedops, and awk commands (The full shell script can be found in 
Appendix A). I spiked several subsets of HBB and RAVEN into the 44 ENCODE 
background datasets. 
 
2.2.3.4 SBF2 4p linkage region 
Chapter 5 describes the analysis of sequencing data from a large Scottish family (SBF2) 
with multiple cases of bipolar disorder. SM extracted variants located on the SBF2 
chr4p15-16 disease-linked haplotype (see Chapter 5 for more details). The annotations 
for the roughly 5,000 SNPs were collected and formatted into a spreadsheet as described 
in section 2.3.1. These data were used as a background spiking dataset to test the 
prioritisation model. 
 
2.2.4 Model implementation  
2.2.4.1 Perl 
The models were initially implemented in procedural Perl language (version 5.10) and 
designed to run as UNIX command-line applications. All bioinformatics work was run 
using the server “Ironhide”, which has an Intel quad core (2 threads per core) i7 
Processor running at 2.67 GHz per core, 12Gb of RAM and 5Tb of RAID storage, with a 
64 bit Fedora Linux operating system. 
 
2.2.4.2 R    
I re-implemented my prototype Perl codes in R as a series of functions. Over the course 
of this analysis, the version of R was updated from 2.14 to 2.15. 
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2.2.5 Performance measures: ROC Curves and AUCs 
The performance measures I used to assess my method were Receiver Operating 
Characteristic (ROC) curves and their corresponding Area Under the Curve. Originally 
the ROC curves and AUCs were produced using SPSS (Figures 2.3 – 2.6). However, 
later ROC curves and AUCs were produced using the R package ROCR using the 
commands: 
 
AUCs were calculated using the following R function: 
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2.3 Results 
2.3.1 Summary 
The aim of this chapter was to design a method, combining multiple types of functional 
annotation data into a single measure, to prioritise candidate causal SNPs for further 
investigation. Central to the development of this method was the selection of appropriate 
functional annotations; the choice of model structure; and lastly, development of a 
stringent model assessment protocol to gauge model performance.  
 
2.3.2 Feature Selection 
The functional annotations I chose to assess for inclusion in the SNP prioritisation 
pipeline were: minor allele frequency (MAF); SNP position relative to gene features; 
conservation; DNase HSs; repetitive elements; mapability; and chromatin states. For 
background on each of these features see section 2.1.3.2. These annotations were chosen 
based on: i) data availability and ease of access; ii) evidence from the literature showing 
that these annotations overlap functional elements; iii) data quality (genome coverage 
and accuracy); and iv) redundancy, as there are many annotations that perfectly correlate 
with each other. 
Several conservation annotations were available from the UCSC genome browser. 
Before deciding how to combine the various annotations into an integrated pipeline, I 
first compared the different conservation annotations to identify the most informative 
data to include in the model. 
 
2.3.2.1 Correlation analysis of conservation tools 
I compared the utility of four conservation tools available from the UCSC table browser: 
GERP, PhastCons, PhyloP and 7xRegPotential ((Cooper et al., 2005); (Siepel et al., 
2005); (Kolbe et al., 2004)). As PhyloP and GERP have been shown to have similar 
performances, incorporation of both tools in the method would be redundant. As GERP 
was shown to perform marginally better (Pollard et al., 2010), I chose to only include 
GERP in the next step of my analysis. I then calculated pair-wise correlation coefficients 
for the remaining conservation tools in an all-against-all approach. The aim of this 
analysis was to identify the combination of tools with the highest individual predictive 
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value, whilst controlling for redundancy. Using R, I calculated Spearman’s rank 
correlation coefficient, rho, and the associated p-values for each of the SNPs within the 
SBF2 linkage region (see section 2.2.5.1). Table 2.4 shows the rho scores and p-values 
for each of these combinations.  
The three variations of PhastCons (Primate, Placental and Vertebrate) had medium to 
high correlation with each other, ranging from ~0.68 – 0.92, with very low p-values. As 
these tools are so similar, differing only in the phylogenetic scope of their training data, 
it would be redundant to use more than one in the pipeline. PhastCons placental has the 
best phylogenetic scope of the three PhastCons methods, as it has good power (more so 
than PhastCons primate) but also captures non-coding conservation which is often 















Table 2.4. Correlation coefficients (rho) and associated p-values for the pair wise comparison of 
all the conservation tools I included in my analysis, ranked highest to lowest rho score. 
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GERP and PhastCons placental produced the next highest score (0.19), the remaining 
pair-wise correlations performing with rho’s ranging from 0.13 to -0.02 (Table 2.). The 
correlations of 7xRegPotential with all of the other tools (PhastCons Placental (D), 
PhastCons Primate (G), PhastCons Vertebrate (H) and GERP (I)) produced very high p-
values, making these combinations untrustworthy. This appears to be due to the low 
number of SNPs with a 7xRegPotential score and the even lower number of SNPs with 
both a 7xRegPotential score and another conservation score. 
 
Of these four tools, the two most commonly used methods are PhastCons and GERP 
(Pollard et al., 2010). As they do not correlate perfectly, I chose to include both GERP 
and PhastCons in my method. As PhastCons placental had the best correlation with 
GERP (without being redundant) and had the best phylogenetic scope of the three 
PhastCons models, I chose to use this version in my pipeline. 
 
2.3.3 Comparison of model frameworks 
I considered several models for combining functional annotation data to best prioritise 
putative functional over non-functional variants. The simplest method would have been 
to add the raw scores together in a 1:1:1 ratio. However, this method relies on the 
assumptions that all features are perfectly correlated with functionality, they are all 
equally important to the discrimination of functional vs. non-functional variants, and 
they are all independent features. This is not to the case for annotations such as the 
chromatin states, where studies have shown different combinations of histone acetylation 
and methylation mark different types of regulatory elements (Ernst et al., 2011). 
Furthermore, scoring variants on their raw scores across multiple functional categories is 
problematic, as different annotations are scored on different scales. 
 
The second method I considered was a ranking system: i.e. each SNP would be ranked 
on their score from each functional annotation and these ranks would be combined into a 
single measure, re-ranking SNPs on this score. This method avoids the use of arbitrary 
weightings and would make it easy to add new annotation data in the future. As with any 
system, there are also disadvantages to this method. By prioritising SNPs based on a 
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rank of ranks, each individual score is “smoothed” and any interesting features (such as 
uneven distribution of scores) is lost. For instance, if an annotation contains a sudden 
shift from high scores to much lower scores, the SNPs on the boundary of this shift will 
appear more closely related in a ranked system then if the actual score was included. 
Like the first method, a pure rank-of-ranks would also fail to take into account the 
relative ability of each annotation to discriminate between functional and non-functional 
variants.   
 
The third model I considered involved weighting the different features against each 
other, based on the premise that different annotation sets have different levels of 
predictive value and should therefore be weighted with respect to each other to produce a 
final prioritisation score. This is favourable compared to the blind additive method; 
however caution must be taken as to how to define weightings, as this method could be 
considered arbitrary and biased.  In addition, weighting the “raw” scores, all on different 
scales, is also problematic. 
 
I chose to implement a fourth, hybrid, model, combining the best aspects of both the 
feature weighting and ranking models. This model would rank continuous features, score 
categorical features and weight the annotations against each other and combined them 
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Figure 2.2. Graphical representation of the model described and tested in this chapter. This 
model combines a ranking system for the functional annotation features conservation, 
chromatin states and DNase HS, whilst scoring SNPs on a number of other categories including 
position, frequency, chromosome region and repetitive. All these factors are then combined into 
a cumulative “rank-of-ranks” to prioritise SNPs from most to least likely to be functional. 
 
 
2.3.4 Feature scores 
In this model framework, SNPs were ranked on their scores for the features DNase HS 
and the two conservation features, GERP and PhastCons. For the other features, 
including MAF and Position, SNPs were stratified into subclasses and scored according 
to which subclass they fell into (a more detailed description of each annotation can be 
found in sections 2.3.3.3.1-5). The feature ranks and scores were then weighted against 
each other and combined into a final collective score, which was used to generate a 
“rank-of-ranks” to prioritise SNPs on the likelihood of functionality. Figure 2.2 provides 
an overview of the variant prioritisation pipeline, including the scores used for 
categorical features and the values used to weight the annotation categories. The results 
were saved to a tab-delimited output file. This process was originally performed by a 
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Perl script, but was later re-implemented in R. Model performance was assessed using a 
selection of test datasets and ROC curve analysis. 
 
2.3.4.1 MAF 
MAFs were divided into 4 bins (unique, not unique but less than 1%, greater than 1% but 
less than 3% and greater than 3%), each bin corresponding to a different score. I 
implemented a 4,2,1,0 scoring system, arbitrarily chosen based on doubling in 
importance and so doubling in score from bin to bin: anything >3% scores 0, >1% and 
<3% scores 1, <0% and <1% scores 2 and anything unique (= 0%) scores 4 (see figure 
2.3). This method was based on the assumption that unique variants (not present in the 
1000 Genomes database) are most likely to be pathogenic, and the more common a SNP 












Figure 2.3. Graph illustrating the scores assigned by the model to SNPs with different MAFs. 
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2.3.4.2 Position 
For the position score, SNPs were binned into distinct position classes: exonic, splice 
site, promoter, 10kb upstream or down stream of a gene, within a CpG island or CpG 
shore or beyond 10kb from any gene (i.e. intergenic). These classes were assigned 
different scores based on the relative importance of each positional class and the 
likelihood of SNPs in that class being causal variants, over SNPs in other classes (see 
Table 2.5 for more details). The scores were chosen based on knowledge from the 
literature ((MacIsaac et al., 2010); (Ernst et al., 2011); (Maurano et al., 2012)) and the 
example set by other existing methods (SNPselector: (Xu et al., 2005); SNPRanker: 











Table 2.5. Position scores. Each SNP is assessed using data from RefSeq and UCSC to define the 
position category it belongs to. If a SNP belongs to multiple categories (exonic variant for one 
transcript but an intronic variant for a second gene transcript), it is assigned to the highest 
scoring category (ie exonic over intronic). 
 
 
2.3.4.3 UCSC genome browser annotation data 
The conservation and DNase HS site annotations from UCSC were all ranked on the 
total number of SNPs in the dataset, the ranks normalised to a 0-1 scale, ensuring each 
analysis is comparable, irrespective of the number of SNPs in the dataset. 
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Ernst et al. showed that chromatin state classes are correlated across cell lines and that a 
region that is predicted to be a strong enhancer (or promoter) in one cell line tended to be 
an enhancer in other cell lines (although in the other cell lines, it might only be a weak 
enhancer or promoter) (Ernst et al., 2011). The Ernst-defined chromatin states were 
converted to a binary classifier: all marks of active regulation being converted to “1” and 
the marks of closed chromatin (no regulation) being scored “0”. This was done for all 
nine Ernst cell lines and the 9 binary scores were added together and used to rank SNPs 
(SNPs having active scores across all nine cell lines ranking highest and those with none 
ranking lowest). 
 
2.3.4.4 Repetitive elements 
 I included two methods in my pipeline as posterior WGS quality control settings: 
mapability and RepeatMasker data.  
Mapability: SNPs were scored on mapability, a score of “1” indicating the sequence is 
unique, a score of less than 1 indicating an increasing numbers of occurrences in the 
genome, and a score of “0” suggesting it occurs four or more times in the genome.  
RepeatMasker: SNPs were separated into two classes based on their RepeatMasker 
annotation: SNPs overlapping any repetitive element or not overlapping any repetitive 
element. SNPs not in repetitive elements were scored above those overlapping repetitive 
elements. 
 
2.3.4.5 Chromosome region score 
For studies where linkage data is available (such as from a pedigree analysis) or where 
significantly associated regions are known, I wanted to allow SNPs within the 
linkage/associated loci to be prioritised above SNPs outside of these regions, as such a 
priori information can reduce the search space for putative causal variants. Therefore, 
SNPs within known linkage regions were boosted with an additional score. However, as 
none of the test datasets provided this type of annotation, none of the studies outlined in 
later sections of this chapter benefited from this score. 
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2.3.5 Assessment of model framework 
Validation of the prioritisation method required the use of test datasets to assess model 
performance. A good benchmarking dataset is characterised by being validated, 
accessible and containing a good number of variants. I have compiled multiple test 
datasets, each of which fulfils these criteria. 
 
2.3.5.1 HBB dataset 
The first benchmarking dataset I used consisted of HBB gene mutations associated with 
Beta thalassemia (variants from the HbVar database: see section 3.2.5.2). This dataset 
contained 363 disease associated SNPs and a further 141 SNPs control SNPs (benign). 
As I was particularly interested in prioritising non-coding variants, I filtered out all 
coding variants from this dataset. This left me with 39 non-coding disease variants and 
141 background variants. I tested the prioritisation method on this data and drew ROC 
curves and calculated the AUC, shown in Figure 2.4. This result (AUC of 0.988) showed 
that my method was able to correctly prioritise the non-coding disease variants over the 
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Figure 2.4. ROC curve and AUC for the model run on the HBB non-coding disease variants 
against the control set of SNPs from the same HBB locus. ROC curve (blue) shows the true 
positive rate plotted against the false positive rate, the green line representing the result 
expected by chance. Both the AUC and the ROC curve show that the model is able to prioritise 
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Figure 2.5 ROC curve and AUC for the model run on the RAVEN experimentally validated 
regulatory variants against the control set of SNPs matched to the true variants to within 10kb 
of human genes with mouse homologs. ROC curve shows the true positive rate plotted against 
the false positive rate, the green line representing the result expected by chance. Both the AUC 
and the ROC curve show that the model is able to prioritise the regulatory variants over 
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2.3.5.2 The RAVEN dataset 
As functional characterisation of non-coding SNPs is particularly challenging, it was 
important that I identify an additional dataset that contained such SNPs. My second test 
dataset was constructed by Anderson et al. (2008) to assess the performance of their 
method RAVEN, and which I named the RAVEN dataset. The dataset contained 95 
experimentally validated regulatory SNPs and 3990 control (background) SNPs 
(Andersen et al., 2008). 
 
My model achieved an AUC of 0.823 on this dataset (Figure 2.4). This lower 
performance compared to the HBB dataset is to be expected for several reasons. Firstly, 
the RAVEN dataset contains a much higher proportion of control SNPs to case SNPs. 
Secondly, as the control SNPs have not been proven to be non-functional, it is possible 
that some are in fact functional. As I could not control for such false negatives, it could 
be assumed that the specificity and sensitivity achieved by the scoring methods were the 
minimum the model will achieve on these data.  
 
 
2.3.6 Spiking analysis 
2.3.6.1 SBF2 background dataset 
The first spiking background set chosen consisted of variants on a 20Mb region of 
chromosome 4p16 locus that has been shown to be linked to BP disorder in a large 
Scottish family (SBF2) (see Chapter 5). The spiking approach was first used to spike the 
39 regulatory SNPs from the HBB dataset into the SBF2 SNP file. I hypothesised that 
this would provide a greater measure of the pipeline’s performance than comparing the 
known HBB variants against the HBB background variants. My reasons were: i) the 
SBF2 background dataset consists of a much larger number of SNPs; ii) these SNPs have 
already been filtered on MAF and consist of only SNPs with a MAF < 5%, decreasing 
the advantage of the HBB variants  (which are all rare) over the background set; iii) this 
region is much larger than the HBB locus, including over 100 genes producing proteins 
and non-coding RNAs with a broad range of cellular functions and therefore likely to 
have diverse forms of regulation (and features); and iv) the pipeline would have to be 
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able to prioritise the known HBB variants over variants that may also be causal but have 
yet to be identified, thus providing competition for the highest ranking positions.  
 
As with the RAVEN dataset, this background set contained true positives that would be 
classed as false positives, which would be predicted to lower the performance of any 
tested pipeline. However, an advantage of this method was that any background SNPs 
that performed better then the true HBB SNPs could be considered excellent candidates 
for my analysis of variants segregating with illness. In addition, as the HBB regulatory 
SNPs were taken out of context, there would be no question of linkage between the case 
and control SNPs. 
 
Despite the added level of stringency and complexity, the model was still able to 
prioritise the HBB variants over the majority of the SBF2 variants, with an AUC of 
0.993 (Figure 2.6). I also spiked the RAVEN regulatory variants into the SBF2 
background set. This proved more of a challenge for the model and the performance 
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Figure 2.6 ROC curve and AUC for the model run on the HBB non-coding disease variants 
against the control set of SNPs from the F22 chr4p16 locus. ROC curve shows the true positive 
rate plotted against the false positive rate, the green line representing the result expected by 
chance. Both the AUC and the ROC curve show that despite being spiked against a novel 
unrelated background set, the model is able to prioritise the disease variants over background 
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Figure 2.7 ROC curve and AUC for the model run on the RAVEN non-coding disease variants 
against the control set of SNPs from the F22 chr4p16 locus. ROC curve shows the true positive 
rate plotted against the false positive rate, the green line representing the result expected by 
chance. Both the AUC and the ROC curve show that the model is able to prioritise the disease 
variants over background variants with high specificity and sensitivity and this result is not 
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2.3.6.2 The ENCODE pilot project background dataset 
I also spiked various subsets of HBB and RAVEN into the 44 ENCODE background 
datasets in order to assess the impact that varying the genomic context of the background 
set would have on the model’s performance. Table 2.6 shows the full results for this 


















Table 2.6. Table of AUCs and Average AUCs for each spiking analysis. Each ENCODE pilot 
region dataset consists of SNPs within each region with a MAF <5% based on the 1000 Genomes 
Eur subpopulation database. Bottom row (highlighted in green) shows the average AUCs for 
each spiking analysis. Across all analyses, decreasing AUCs correlate with increasing gene 
density and number of genes corrected for region size. AUC is not affected by the size of the 
pilot regions, the NEC or the number of SNPs. 
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I first used the non-coding, true positive HBB SNPs used for the initial analysis 
described in Figures 2.4 and 2.6 (see section 2.3.5.1 and 2.3.5.2). Table 2.6 shows a very 
narrow range of AUCs for this spiking set across the 44 regions, ranging from 0.950 – 
1.000, with an average AUC of 0.983. 
 
I next ran the pipeline on the full true positive HBB dataset (including coding variants) 
and tested the method’s ability to rank coding as well as non-coding true positives above 
background variants. As expected, the average AUC was higher than for the non-coding 
true variants alone, increasing to 0.996. 
 
The third spiking analysis I ran was a spiking set consisting of the 141 control, non-
disease causing, HBB SNPs (All control HBB SNPs). The average AUC produced was 
0.416, much lower than for the non-coding true positive HBB dataset and the “ALL’ 
(coding and non-coding variant dataset) spiked into the ENCODE background SNP sets. 
This result shows that disease SNPs are more likely to rank above control SNPs. An 
average AUC of less than 0.5 also implies that the control variants have ranked lower 
than expected by chance. This result may be explained by the fact that although we are 
treating while the ENCODE datasets as “control” sets, they will likely contain true 
functional variants which could be prioritised above the non-functional (non-disease 
causing) HBB SNPs. This is another indication of the method’s ability to distinguish 
functional from non-functional variants 
 
I then ran the Full RAVEN true positive set against the ENCODE background variants. 
These SNPs were used for the initial analysis described in Figure 2.5. The average AUC 
for this dataset was 0.745.  
 
One drawback of the RAVEN dataset is the proportion of ‘true’ SNPs that have a MAF 
greater than 5%. These will perform worse than the ENCODE background SNPs, which 
were selected to have a MAF less than 5%. I therefore tested a final RAVEN set 
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consisting of only true SNPs with a MAF of less than 5%. This dramatically improved 














Table 2.7. This table summarizes the average allele frequencies (Average DAF.G1K.EUR) and 
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2.4 Summary and Discussion   
2.4.1 Summary of chapter 
To prioritise candidate pathogenic variants I have designed a pipeline, which utilises a 
combination of functional annotation, frequency, and positional information for each 
variant, and combines them into a single rank score.  
 
The aims of this chapter were: i) to assess the different model designs that could be used 
for my prioritisation method, identify the most appropriate one and test how well this 
model works on a variety of test datasets; ii) to explore the wide range of functional data 
that is available and select those features which would be most informative in our model; 
and iii) discuss the availability of test datasets and different methods of constructing new 
ones. 
 
2.4.2 Comparison of different features: 
I compared functional annotation data from a variety of sources to identify those features 
that would best aid the discrimination of functional from non-functional variants. 
Features selected for this model included MAF, conservation (GERP and PhastCons 
scores), position relative to genic elements, DNase HS, chromatin states (Ernst data), 
repetitive elements, mapability and a weighting for being located within a chromosome 
region of interest.  
 
2.4.2.1 The advantages of using chromatin states versus raw histone 
data 
As described in the Introduction to this chapter, the acetylation and methylation of 
different combinations of histone markers have been shown to correlate with different 
regulatory elements. These data can be used to aid the prioritisation of functional SNPs 
by providing information on any overlaps with putative regulatory elements. Ernst et al. 
looked at the specific relationship between these markers and applied this data to predict 
whether a variant overlaps regulatory elements. This data has been made publically 
available in the form of chromatin states (Ernst et al., 2011). An advantage of this data is 
that the complex job of combining individual histone modification data has already been 
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performed, tested, peer reviewed and shown to be accurate. A disadvantage is that this 
data currently relates to a very small set of cell lines, whereas the equivalent raw data 
from the ENCODE project can be obtained for a much wider range of cell lines.   
 
As part of the prioritisation model, the chromatin state data was averaged across the nine 
cell lines to get an idea of the regulatory effect of each variant under investigation across 
all available cell lines. However, this method puts greatest emphasis on SNPs that 
overlap high scoring chromatin states across all nine cell-lines. This quantitative 
approach might not best represent nature, as a SNP that overlaps a high scoring 
chromatin state in one cell line still provides valuable information. Similarly, the 
chromatin states were divided into two bins and ranked accordingly, a method that does 
not take into account differences between the chromatin states within the two bins. I 
therefore consider in the next chapter a more justifiable method of scoring SNPs based 
on their chromatin state data.  
 
2.4.2.2 Cross-species conservation  
Conservation has historically been the most commonly used feature for identifying 
regulatory elements ((Boffelli et al., 2003); (Brugger et al., 2004); (Ghanem et al., 2003); 
(Gottgens et al., 2002); (Pennacchio and Rubin, 2001)). I used a combination of 
correlation analysis and experimental evidence from the literature to focus in on two of 
the four methods tested: GERP and PhastCons (placental). GERP calculates 
conservation at the nucleotide level, whereas PhastCons calculates a conservation score 
on a region-by-region basis, using a sliding window approach. By combining two 
contrasting approaches I hoped to identify conserved regulatory elements with even 
greater accuracy, the premise being that variants scoring highly in both approaches are 
more likely to be real than variants predicted to be conserved by only one method 
(Cooper and Shendure, 2011). 
 
A caveat in this assumption is that we know from our correlation analysis that GERP and 
PhastCons placental only correlate with a Spearman’s coefficient value of 0.18772. That 
is to say, they are only weakly correlated. This begs the question, how much is the 
method benefiting from using a combined conservation score based on both of these 
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approaches? Would it in fact perform better using only one or other of these two? In the 
next chapter, I will address this issue and look at the performance of each method 
individually. 
 
2.4.3 Model design 
The hybrid model I chose to test in this chapter combines ranking and weighting. Model 
performance was tested using a variety of datasets and ROC curve and AUC statistics. 
 
2.4.3.1 Conclusions on model performance 
My model performed very well on the HBB dataset, with an AUC of 0.998 and to a 
similar level on the HBB data spiked into the SBF2 locus (AUC of 0.993). One reason 
why the model may identify these HBB variants with almost perfect sensitivity and 
specificity, even with the change of genomic context, could be related to the type of 
variants within this dataset. Thalassemia is a highly penetrant, Mendelian disorder, 
which could be expected to be caused by variants with a high effect size and a highly 
deleterious effect on phenotype. These variants could be hypothesised to either affect 
annotation features to a greater extent than weaker variants (i.e. regulatory variants with 
no link to disease, or less penetrant, low effect, complex trait variants) and therefore 
could be more easy to identify by studying changes to annotation features.  
 
In contrast, the RAVEN variants are experimentally verified regulatory variants. As 
such, these variants may be harder to distinguish from background variants, thus 
accounting for the lower AUCs obtained in comparison to the HBB variant analyses. In 
addition, this could explain the decreased ability of the method to prioritise RAVEN 
variants over background when spiked into the SBF2 dataset, as this dataset is likely to 
contain functional variants that are competing with the RAVEN variants and have more 
distinct feature annotations than the RAVEN variants. 
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2.4.3.2 Caveats of feature and model selection method 
Although I was able to show that my model was able to prioritise the regulatory variants 
from the HBB and RAVEN datasets with high specificity and sensitivity, therefore 
showing its application to real data, questions can be raised as to the method used to 
select both the features and the model for the prioritisation method. Features were 
chosen on a relatively ad hoc basis, without formal comparison of the relationship 
between different features. Similarly, the scores (instead of ranks) assigned to the 
features MAF, Position, chromosome region score and repetitive element score, were 
chosen on how important each sub-class is relative to the others (for instance, promoter 
variants were considered more important than intergenic variants and scored 
appropriately). This was not an uninformed process as it was strongly influenced by 
evidence from the literature and general opinion in the scientific community. 
Nevertheless, this approach could have benefited from more formal model training. This 
will be the subject of the next chapter. 
 
2.4.4 Test datasets 
The development of algorithms to identify functional regulatory SNPs has been impeded 
by the lack of data on regulatory SNPs (Torkamani and Schork, 2008). The better the 
data, the more accurate the assessment; good benchmarking data can be used across 
multiple different methods, allowing a fair comparison between methods. However, very 
few sources of verified regulatory variants exist, and those that are available are mostly 
limited in number and are not available to download in bulk format.  
Time and effort are required to construct useful datasets, but the information we can get 
from these data can be limited and biased. Finding a dataset that is applicable across the 
genome and across variant classes is, therefore, very difficult. 
 
This lack of a gold standard dataset is a major issue hindering the construction and 
testing of prioritisation methods.  To overcome this, I assembled my own repertoire of 
datasets, consisting of two true positive datasets (HBB and RAVEN) and four 
background sets (HBB, RAVEN, SBF2 and ENCODE spiking background sets).  
Although each has its own caveats, they each have fundamental facets of a hypothetical 
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gold standard dataset: the HBB dataset contains SNPs from the human haemoglobin beta 
gene (coding and non-coding), the true positive SNPs being disease causing for beta 
thalassemia; the RAVEN dataset contains non-coding SNPs, all within 10kb of genes 
with mouse homologs, the true positive SNPs consisting of experimentally verified 
regulatory SNPs; the SBF2 background set provides a large number of unrelated, low 
MAF variants (all with a  MAF <5%); and the ENCODE background datasets provide an 
opportunity to test model performance across a range of genomic contexts. The 
individual aspects of a gold standard dataset presented by this collection of data, make 
these datasets, when used in combination, a good substitute for a single benchmarking 
dataset.  
   
2.4.4.1 Pros and cons of the HBB dataset  
Using these data I was able to test how well the model performs on different classes of 
regulatory variants under different genomic contexts. When the pipeline was run on 
these data it successfully ranked the known SNPs above the background (control) SNPs, 
as illustrated by the ROC curves in Figures 2.4, 2.5, 2.6 and 2.7 and the AUCs (ranging 
from 0.797 to 0.998). This showed our model was able to correctly prioritise known 
disease or functional variants over background variants with un-known function. 
 
The main caveat of the HBB dataset that it is not an unbiased dataset, as the SNPs all 
map to a very small region of the genome. Because of this, the inheritance of the disease 
SNPs and control SNPs may be under some level of linkage and not independent. It 
should also be noted that the “disease” variants are all associated with a Mendelian 
disorder, ß thalassemia, which is a very specific disease model and most likely has a 
very different genetic architecture to complex diseases. As I wanted to design a model 
that can be used for a variety of genomic projects, this dataset only provides limited 
information and needs to be supported by additional data.  
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2.4.4.2 Pros and cons of the RAVEN dataset  
The RAVEN dataset is roughly 2.5 times larger than the HBB non-coding dataset, 
thereby increasing the power of my analysis. In addition to the experimentally validated 
true positive variants, Andersen et al (2008) also compiled a dataset of ~4,000 
background variants matched to the true positive variants to within 10kb upstream of the 
transcription start site of human genes with available human-mouse orthologs. The 
advantage of this RAVEN background dataset over the HBB background variants is that 
the variants come from a range of locations across the genome. By combining know 
regulatory variants with unrelated background variants we remove the evolutionary 
context of the known variants and locus effects. This was the source of inspiration to 
extend the analysis further by developing even larger, unrelated background sets, which 
the known variants could be spiked into, thus providing more information on how well 
my method can prioritise known regulatory variants.  
 
The RAVEN dataset provides has attributes that the HBB dataset lacks; however, this 
dataset suffers from its own limitations. A disadvantage of the RAVEN dataset is that all 
the control non-coding SNPs have a MAF greater then 5%. Therefore, by ranking SNPs 
on MAF, I have biased the prioritisation against the common background variants and 
towards the much less frequent regulatory SNPs.  
 
2.4.4.3 Pros and cons of the SBF2 4p background dataset  
As both the HBB and RAVEN datasets on their own are limited, I performed an 
additional spiking analysis, whereby both true positive sets were spiked into a 
background dataset consisting of the SBF2 linkage-region dataset. As this is both an 
unrelated locus and made up of SNPs with a MAF <5%, it overcomes the drawbacks of 
testing each dataset in its native background by removing the positional (and possible 
linkage) bias between disease SNPs and control SNPs; focusing on regulatory SNPs; and 
providing a background SNP dataset consisting entirely of SNPs with a MAF <5%.  
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A drawback to this dataset is that it is likely to contain true functional SNPs that are 
categorised as control SNPs. These SNPs could potentially out perform the spiked-in 
regulatory SNPs, lowering the perceived performance of the methods tested on this 
dataset. This background spiking set describes a single genomic locus and there is no 
way of telling if it is predictive or representative of the entire genome or if it contains 
some structural or regional bias I have not accounted for.  
 
2.4.4.4 Advantages of the ENCODE background dataset 
Using the 44 regions that make up the ENCODE pilot project as spiking sets has many 
advantages, one of which is it allowed me to assess how well any prioritisation model 
can differentiate true regulatory variants from control variants over a range of genomic 
contexts. A second advantage is the size of the ENCODE dataset: as of June 2012, over 
170,000 SNPs from the 1000 Genomes EUR (release 72) dataset were annotated within 
the 30Mb across the 44 ENCODE pilot regions, potentially including a variety of SNP 
classes including coding variants and non-coding variants, some of which could be 
regulatory variants (promoters, long range enhancers; repressors, insulators, etc). 
 
As 14 of these regions were selected because they contain very well studied genes (with 
known biological and disease functions/roles), it can be assumed that these regions will 
contain annotated and characterised disease causing protein-coding and regulatory 
variants. All the regions would be expected to contain functional (non-pathogenic) 
regulatory variants in addition to non-functional background variants. The ENCODE 
pilot region dataset is therefore a stringent background dataset, as the protein-coding 
variants and regulatory variants present will compete against the spiked-in known 
regulatory variants, affecting the model’s ability to prioritise the known variants above 
the background variants.  
 
By incorporating different genomic loci with a range of non-exonic conservation scores 
and gene densities, I was able to challenge the model in two additional ways:  
1. If the background variants are highly conserved, this would challenge the 
model’s ability to discriminate variants based on conservation. In this scenario, 
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would the model be able to prioritise the spiked-in variants over the background 
variants via the other features?  
 
2. As gene-dense regions contain large numbers of background variants that are 
either exonic, splice or promoter variants, the power of the position score will be 
affected. Can the model still correctly prioritise the known functional variants 
above background variants when there are a large number of background 
variants competing for the position score? 
 
This is a very novel approach. By using these regions as an additional spiking control set 




2.4.5 Conclusions from the ENCODE spiking analysis  
The spiking of HBB and RAVEN variants into the ENCODE pilot project regions can 
tell a lot about both the performance and functionality of the model. In particular, sub-
setting the HBB and RAVEN variants into different categories allowed me to compare 
how well the model distinguishes different variant classes and to postulate what features 
might be affecting its performance. 
In particular I would like to focus attention on three particular comparisons: the HBB 
non-coding true positive variants vs. the RAVEN true positive variants; the HBB non-
functional variants set as true positives vs. the RAVEN regulatory dataset; and the Full 
RAVEN dataset vs. the rare RAVEN dataset. 
 
2.4.5.1 Disease causing vs. regulatory SNPs (HBB TP non-coding vs. 
Full RAVEN regulatory) 
Comparing the performance of the model on the HBB non-coding SNPs spiked into the 
ENCODE background datasets vs. the RAVEN non-coding regulatory variants, we see 
very similar results to the earlier analyses (HBB and RAVEN in their own background 
sets and the HBB and RAVEN spiked into SBF2), with AUCs of 0.983 and 0.745 on the 
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HBB and RAVEN data respectively. This is further validation that my method is 
performing consistently across different datasets.  
 
2.4.5.2  Functional vs. non-functional SNPs (HBB All False vs. Full 
RAVEN set)  
I next questioned how well the pipeline would perform if I used background SNPs as my 
true positive SNPs, which are presumably non functional. By comparing the 
performance of the model on the HBB background variants (all False) vs. the RAVEN 
variants (full), treating the HBB background variants as true positives, we can assess the 
models ability to discriminate true positives from false positives. The HBB false positive 
dataset was compared against the RAVEN variant set as they contain similar numbers of 
variants (141 vs. 95), with a comparable average MAF of roughly 0.27. This removes 
any bias caused by number of variants or MAF. Therefore, the difference in AUC (HBB 
FP: 0.4155 vs. RAVEN: 0.745) can be attributed to the models ability to discriminate 
between functional non-coding variants and non-functional non-coding variants. It is 
interesting to note the model actually prioritised the HBB false positive variants worse 
than you would expect by chance. This could be due to the fact that the ENCODE 
background datasets all contain real, experimentally verified disease variants 
(particularly around medically important genes) as well as potentially many regulatory 
variants we know nothing about, thus a large number of false negatives which the model 
is correctly prioritising as true positives above the false positive HBB variants. 
 
2.4.5.3 Rare vs. common (Full RAVEN vs. less than 5% RAVEN sets) 
As discussed in 2.2.2.1, the AUCs from Table 2.4 show that the model is prioritising the 
HBB and RAVEN known variants consistently well across different background 
datasets. However, the question of why the model is prioritising the HBB variants better 
than the RAVEN variants remains unanswered. My final question on these data was, 
therefore, how much impact is MAF having on the ability to prioritise functional variants 
over non-functional variants? I have already shown that when MAF is removed (by 
correcting the average MAF across variants) the method can still correctly distinguish to 
a very high degree the functional from non-functional variants. However, how much 
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would the performance of the method change on the RAVEN data if only rare variants 
were considered? 
 
To address this, I generated a smaller RAVEN dataset consisting of only those variants 
that have a MAF of <5%. The average MAF of this dataset was 0.009, much more 
comparable to the HBB true positive non-coding dataset. Interestingly, when the model 
was used to prioritise these variants against the ENCODE background datasets the AUC 
(0.925) was more similar to the HBB non-coding set (0.983) than the full RAVEN 
dataset (0.745), indicating that the HBB variants are most likely being prioritised better 
than the RAVEN variants because they are rare, rather than because of some underlying 
difference in their architecture. 
 
2.4.5.4 Implications 
We can therefore conclude from these analyses that true functional variants are 
prioritised better by my model than non-functional control variants; control variants are 
prioritised worse than expected by chance; and this effect is not a by-product of 
weighting of allele frequencies (RAVEN and HBB control av. AF ~0.27). Spiking 
various subsets of the HBB and RAVEN SNPs into the ENCODE pilot regions has also 
highlighted the ability of my method to identify true functional variants over background 
variants. 
 
2.4.6 The difference between implementing in Perl vs. R 
For the sake of transparency, simplicity, portability, “market penetration” and 
adaptability, I re-implemented my prototype Perl codes in R as a series of R functions. 
Working in R has many advantages over Perl for genomic data. Firstly, R is a software 
environment as well as a programming language, structured around data frames and 
capable of dealing with large amounts of data, which can be read in and analysed 
without the need to compile and run any code. This allows complex operations to be 
performed on large datasets with speed and efficiency. R is also specifically designed for 
statistical and data-mining analyses, and has many built-in tools to perform with ease 
operations that would be quite complicated to do in Perl. As the ranking and scoring of 
SNPs in my model are all very simple to do in R, it made sense to re-implement in this 
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environment. The resulting code is shorter and simpler in R, providing a level of 
transparency beyond anything that can be achieved in Perl. Being part of the R 
environment, my code can also be linked with other functions and packages, such as 
ROCR, reducing the time wasted moving from one statistical environment to another. 
Lastly, having my code written as a series of R functions, there is the potential to 
reformat the code for it to be wrapped into an R package. This would further simplify the 
code into a single command, while still providing flexibility and allowing easy 
modification. 
 
2.4.7 Things to improve 
2.4.7.1 Datasets 
The HBB and RAVEN true positive datasets are good examples of different classes of 
regulatory variants (one a Mendelian disease set, the other a purely regulatory set), 
however the background variants they are compared against have their disadvantages: 
the HBB background set is a single locus – could have some unique feature we know 
nothing about; the RAVEN background set contains SNPs that all have a MAF > 0.5%, 
so are immediately biased against for MAF score; the SBF2 background dataset provides 
a large number of rare (MAF <0.05%) variants, but this is a locus linked to a specific 
disorder (BD) and so is likely to contain real causal variants for BD that are competing 
with our known functional variants. In addition, the SBF2 dataset is concentrated around 
a single chromosome locus, which may suffer from some unique chromosomal structural 
organisation I have not taken into account. I therefore needed an improved spiking set 
that would allow me to study the ability of my method to correctly prioritise know 
regulatory variants over background variants from a variety of different genomic 
contexts. For this reason, I developed the ENCODE background dataset. 
 
An additional problem faced when analysing and predicting the functionality of non-
coding variants is the breadth of classes of regulatory elements. This is often not taken 
into account; regulatory variants are all tarred with the same brush under the general 
descriptor “non-coding variants” or at most “regulatory variants”, when in fact 
regulatory elements can be divided into subclasses such as non-protein-coding RNAs, 
promoters, enhancers, repressors and insulators.  Similarly, variants can be subdivided 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
Chapter 2: Design of a SNP prioritisation method and a spiking strategy 85 
by their biological effect: whether they lead to a “strong” effect (highly penetrant, 
mendelian diseases); account for a small amount of variance for a complex disorder; or 
have a functional role, affecting gene expression, but not manifesting as a disease 
phenotype. 
 
The list of classes that we can use to discriminate different regulatory variants is small 
but by no means exhaustive: improvements in our understanding of the regulatory 
architecture of the genome will no doubt add additional classes to this list as we identify 
more types of regulatory elements.  
I therefore need a more comprehensive true positive variant dataset, consisting of large 
numbers of verified regulatory variants. This will be dealt with in the following chapter. 
 
2.4.7.2 Feature weightings and feature scores 
The method by which features and weightings were chosen, though based on logical 
assumptions, was arbitrary, unsystematic and potentially biased. This therefore needs to 
be addressed. The first step to correct this imbalance is to convert the various scores used 
in the model to ranks (so all features are ranked). Once this has been done, I should also 




I have developed a prioritisation method that makes use of a range of functional 
annotation data to rank SNPs on the likelihood of having a functional effect. This 
method makes use of a model framework that combines aspects of both a scoring model 
and a ranking model. Specific features, scores and weightings have been chosen based 
on multiple pieces of information and tested on a variety of datasets to gauge the 
model’s performance. The performance evaluation showed this method was able to 
prioritise regulatory variants above background variants with high specificity and 
sensitivity (AUCs ranging from 0.721 to 0.989). In addition, I have established a spiking 
strategy to evaluate tool performance. This in itself is a novel approach with great 
potential. However, in this context the spiking strategy could potentially lead to over-
fitting and an over estimation of model performance. Improved performance evaluation 
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methodology and additional testing is required on more diverse datasets to provide a 
better picture on how the method is performing and how I can improve it. 
 
The method used for the feature selection and assessment was adhoc and arbitrary. A 
more systematic, reproducible, unbiased evaluation method is required with: 
  1. Better training and testing data. 
  2. More statistically rigorous performance evaluation. 
  3. A more inclusive feature set.  
 
I will address these three points in the next chapter.
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Chapter 3: Model testing using cross-validation and 
development of an R-package  
3.1 Introduction  
3.1.1 Summary of Chapter 2 
At the start of my PhD, there was a need in the field of genomics for a method to 
prioritise SNPs (particularly non-coding SNPs) on the basis of putative functionality, 
making use of the wealth of genomic and epigenomic annotation data available from 
projects such as the ENCODE project (Consortium, 2012), Functional Annotation of the 
Mammalian Genome (FANTOM5) project (Consortium et al., 2014) and the 1000 
Genomes project (Genomes Project et al., 2010). I chose to develop a method to fill this 
gap. Crucially, this method would support the interpretation of data from a range of 
genomics projects including variants from genome-wide association studies (GWASs) 
and next generation sequencing (NGS) projects. The steps I undertook to construct and 
test an initial model are described in Chapter 2.   
Evaluation of this preliminary model on test data showed that it was able to prioritise 
positive variants (known disease or regulatory variants) over background variants with 
high specificity and sensitivity. However, the model building approach I used was 
unsystematic and the model relied on adhoc thresholds for some of the annotation 
measures. In addition, the model assessment made use of limited datasets and therefore 
ran the risk of being over fitted to the test data. It was important, therefore, to develop a 
more formalised approach, combining: i) systematic model selection; ii) a more rigorous 
statistical framework for stringent evaluation of model performance and prevention of 
over fitting; and iii) larger datasets, to increase power. In this chapter I describe the steps 
taken to address these issues. 
 
3.1.2 Systematic model training and validation 
Prediction methods are used across diverse fields ranging from the biosciences to 
insurance, marketing, meteorology and beyond. More pertinently, in the fields of 
epidemiology and clinical diagnostics, complex biological data are used to predict 
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phenotypes and diagnosis. For example, biomarkers are used to predict disease status 
((Liu and Albert, 2014); (Rowe et al., 2013)) and microarray data are used to forecast 
clinical cancer outcomes (Dupuy and Simon, 2007). Similarly, predictive methods are 
being used across a range of genomic data-mining projects attempting to link genes and 
proteins to pathogenicity. Although the data used in each of these scenarios differs, the 
methodologies and data requirements are similar. Two factors are critical to successfully 
build and evaluate any predictive model. The first is high quality benchmarking data; the 
second is appropriate training and evaluation methodology (Vihinen, 2012). Both of 
these factors will be discussed in the following sections. 
 
3.1.3 Defining benchmarking datasets 
Development and assessment of predictive methods is often hindered by the use of 
small, often private, datasets and limited performance evaluation measures (Vihinen, 
2012). Such model evaluation is neither comprehensive nor generalisable. A model’s 
performance assessed under these conditions cannot be fairly compared against 
predictive methods trained on other data. A better approach is to use established 
benchmarking data in a systematic, impartial analysis. This ensures that the evaluation of 
performance is consistent across all methods.  
 
Vihinen (2012) suggests that a dataset should meet a minimum set of criteria before it 
can be considered a definitive benchmarking dataset. It should be: relevant; 
representative; non-redundant; scalable; simple; reusable; consist of experimentally 
determined classes; and should contain equal numbers of positive and negative variants. 
In addition, a benchmarking dataset should be large enough to provide sufficient 
statistical power (Vihinen, 2012). This demanding set of conditions is difficult to meet in 
any single dataset. In particular, finding a dataset that contains large numbers of 
functionally validated positive and negative variants is challenging, verging on 
impossible. In the Methods and Results sections of this chapter (3.2 and 3.3 
respectively), I will describe how I constructed a benchmarking dataset by combining 
two independent datasets: experimentally verified positive variants from the Human 
Gene Mutation Database (HGMD) and the ENCODE pilot project background spiking 
variant dataset introduced in Chapter 2. 
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3.1.3.1 HGMD variants 
The HGMD database is a large scale, comprehensive archive of germline mutations that 
are implicated or are associated with human disease (Stenson et al., 2003). It contains 
over 141,000 mutations, including SNPs, indels and rearrangements, which are available 
via two databases: a public version freely accessible for all registered users from 
academic institutions and non-profit organisations; and a subscription version, HGMD 
Professional, available through the purchase of a license. A disadvantage of the public 
version is it is several years out-of-date in comparison to the professional version. It also 
cannot be batch-downloaded and the variant annotations are more limited than the 
professional version.  For these reasons, I chose to focus on the professional version and 
obtained the appropriate license. 
 
The HGMD professional database is subdivided into multiple annotation tables 
including: MUTATION (single base-pair substitutions; missense/nonsense); DELETION 
(deletions of 20 bp or less); INSERTION (insertions of 20 bp or less); INDEL (indels of 
20 bp or less); DELINS (a combined table for data on deletions, insertions and indels); 
GROSDEL (for large deletions); GROSINS (for large insertions); COMPLEX (for 
complex rearrangements); AMPLET (for repeat variations); and PROM (variants 
causing regulatory abnormalities). I focused on the PROM table, which contains non-
protein-coding variants with reported phenotypic impacts. These can be further 
categorised into the following variant subclasses: 
 
DM and DM? (Disease-causing Mutations): These variants have been reported in 
the literature to be pathogenic mutations. The ‘DM?’ subclass are variants where there is 
doubt regarding the degree of pathogenicity. Diseases represented by the DM group of 
mutations include Parkinson’s disease, glaucoma, cystic fibrosis, aplastic anaemia, 
Hirschsprung’s disease, Cowden’s disease, beta thalassaemia, Wilson’s disease, 
retinoblastoma, retinitis pigmentosa and haemophilia. 
 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
Chapter 3: Model testing using cross-validation and development of an R-package 90 
DP (Disease-associated Polymorphisms): These variants have been reported to be 
significantly associated with disease; however, are not supported by experimental 
evidence of functionality. 
 
DFP (Disease-associated Polymorphisms with additional supporting evidence of 
Functionality): Like the DP class of variants, these variants have been reported to be 
significantly associated with disease; the difference being they are supported by 
experimental evidence to be directly functional. Variants in this class are associated with 
diseases and disorders such as type 2 diabetes, asthma, LDL-cholesterol levels, 
hypertension, schizophrenia, coronary heart disease, myocardial infarction, rheumatoid 
arthritis, increased risk of lung cancer, neonatal respiratory distress syndrome, Crohn’s 
disease, polycystic ovary syndrome, macular degeneration, Alzheimer’s disease and 
Graves’s disease. 
 
FP (in vitro/laboratory or in vivo Functional Polymorphisms): These variants 
have been reported to have a functional consequence, but have yet to been associated 
with a disease phenotype. 
 
FTV: Polymorphic, or rare nonsense, or frame shift variants that have been predicted to 
alter the gene product (i.e. to result in the production of a truncated product), but as of 
yet with no reported disease association. 
 
The organisation of the HGMD Professional database into these classes and subclasses 
allows specific subsets of SNPs to be easily extracted. 
 
3.1.3.2 ENCODE variants 
In addition to the HGMD functional variants, a control dataset was required to assess the 
model’s ability to distinguish positive (functional) variants from negative (non-
functional) variants. An ideal control dataset would match the positive set in size, for 
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accurate model assessment (Vihinen, 2012). To my knowledge, no such large, 
experimentally verified non-functional dataset existed. I therefore chose to use the 
ENCODE pilot project spiking dataset I developed in Chapter 2 for the evaluation of the 
preliminary model’s performance. This dataset contains variants from the 1000 Genomes 
European population, restricted to within the boundaries of the 44 ENCODE pilot 
project regions. 
 
3.1.4 Training methodology  
The quality of a predictor depends largely on how the model training has been 
performed. The most common mistake, as observed by Smialowski et al. (2010), made 
during model building is the incorrect partitioning of data into training and test datasets. 
It is important to ensure the training and test data are kept separate, as leakage between 
these datasets can lead to over fitting and an over optimistic estimate of model 
performance. Furthermore, construction and evaluation of predictive models require the 
use of well-established validation methods such as cross-validation, which assesses both 
a model’s performance and its ability to generalise to independent data (Smialowski et 
al., 2010). 
 
3.1.4.1 Cross-validation  
Cross-validation is a statistical method used to assess the performance of a model and to 
predict how well it will perform on novel data. The cross-validation protocol involves 
splitting data into multiple training and validation sets and first training the model on the 
training dataset and then testing it on the validation dataset. Different forms of cross-
validation are characterised by different methods of data splitting; for example, leave-
one-out cross-validation (LOOCV), repeated random sub-sampling, and k-fold cross-
validation ((Arlot, 2010); (Hastie, 2009)). In k-fold cross-validation the dataset is split 
into k equal sub-samples. For each round of cross-validation, 1 to k, one of the k sub-
samples is used as the validation data, while the other k-1 sub-samples are combined into 
a training dataset. This is repeated until all k sub-samples have been used as the 
validation dataset (see Figure 3.1). k can be represented by any positive integer; 
however, it is most commonly set to ten, as ten-fold cross-validation is a generally 
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accepted compromise between computational complexity (running time and required 
CPU’s) and statistical power.  
Cross-validation can be used for model selection (estimating the performance of 
different models in order to choose the best one) and model assessment (having chosen a 
final model, estimating its generalisation error on new data). To perform both model 
selection and model assessment, the data is best partitioned into three parts (tripartite 
division): training, validation and test datasets. However, when an analysis is ‘data 
poor’, only a limited number of samples being available for training, validation and 
testing, the power of the cross-validation can be maximised by drawing the training and 
validation data from a single, larger dataset that is partitioned into folds (for instance, ten 
folds for ten-fold cross-validation). During each round of ten-fold cross validation, one 
fold is held out as the validation dataset and the other nine combined into the training 
dataset (Figure 3.1). Performance error is calculated as the difference in performance on 
the training and validation datasets across each fold. The best model chosen from the 
cross-validation is then tested on the hold out test dataset. The generalisation error is 
calculated as the difference in model performance on the test dataset versus the model 
training and validation performance. Crucially, the data used for training and validation 
cannot be used for the final model testing as this would lead to an over estimation of 
model performance. Similarly, once a model has been run on the test data, it cannot be 
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Figure 3.1 Cartoon outlining 10-fold cross-validation using a tripartite data split. The full 
dataset is divided into two sections: training and validation dataset and a hold out test dataset. 
The training and validation dataset is partitioned into ten folds. During each round of cross-
validation, one fold is set as the validation set and the other nine folds are joined together into 
the training fold. Each weighting model is run on the training and validation sets in each of the 
ten folds and the training and validation AUCs for each fold are calculated and recorded. 
Performance error is calculated as the difference between the training and validation AUCs 
across all ten folds. The best model from cross-validation (the highest AUC with lowest 
performance error) is then selected and run on the hold out test dataset. The difference between 
the test AUC and the average training/validation AUC for that weighting model is used to 
calculate the generalisation error. 
 
 
3.1.5 Development of an R package 
R, which was created by Ross Ihaka and Robert Gentleman (Ihaka, 1996), is both a free 
programming language and an environment for statistical computing and graphics 
(http://www.r-project.org/about.html). The advantages of this system are extensive. R is 
a flexible, modular language, which allows for effective and simple data handling. As 
the R language is simple and intuitive, it is easy to learn and is therefore used 
extensively for the analysis of genomic and epigenomic data. R is highly extendable and, 
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through the efforts of the Comprehensive R Archive Network (CRAN) and other, newer, 
distributors and repositories (such as Bioconductor), it is constantly evolving through the 
inclusion of new packages. Importantly, new R packages have to pass a peer-review 
process before being accepted by CRAN and Bioconductor, providing confidence in 
their design and functionality. The modularity of R means that R packages and functions 
can be used individually or combined into larger R codes. In addition, R allows data to 
be stored as a range of objects, each of which can be manipulated in different ways. 
Lastly, R compiles and runs on a range of platforms and systems including UNIX, 
Linux, Mac OS and Windows, making it universally accessible. 
I decided to restructure my list of R functions into an R package. An R package has the 
following advantages over a series of R functions: it is simpler and faster to run, as the 
number of commands required to achieve the same output is reduced; and it can be 
submitted to an R repository, making it easier to distribute and more widely accessible. 
Once the decision was made to restructure my R code and functions into an R package, it 
was necessary to select a package name. I chose to call the R package “SNP Ranking by 
Function R package” (SuRFR). For the rest of this chapter and this thesis I will refer to 
the prioritisation R package I have developed as SuRFR 
 
 
3.1.6 Summary of chapter aims 
The aim of this chapter was to improve the SNP prioritisation method described in 
Chapter 2. This was achieved by i) redesigning the model framework to make it more 
reproducible; ii) updating the annotation data; iii) expanding the test datasets to increase 
the power of the analysis; iv) formalising the model testing to prevent over-fitting; and 
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3.2 Materials and Methods 
3.2.1 Simplified model framework 
The model framework was restructured around the concept of a straight forward rank-of-
ranks. For each annotation category, SNPs were ranked from least likely to be functional 
through to most likely; the ranks across all of the annotation categories were combined 
using a weighting model to generate an aggregate rank (the rank-of-ranks). Equation 1 
describes this model framework: 
R = ranki  ( ∑ ( rij . wj )) 
Equation 1. 
rij is the rank of the ith variant in the jth annotation category, and wj is the weight for the 
jth annotation category (Ryan et al., 2014). 
 
A central aspect of this method is the weighting term (𝑤j) a vector of multipliers (one 
multiplier for each annotation category), which quantifies the importance attributed to 
each annotation category in the prioritisation of putative functional variants. I developed 
three different weighting models for SuRFR, for three different categories of regulatory 
variants: a model designed to be generally applicable to any analysis (“ALL”); a model 
designed specifically for the prioritisation of rare, highly penetrant disease variants 
(“DM”); and a model designed for complex trait variants (“DFP”). 
 
3.2.2 New annotation data sources 
The annotation data classes and sources used in SuRFR are summarised in Table 3.1 and 
detailed in the following paragraphs: 
 
MAF: I used an updated minor allele frequency (MAF) table for the 1000 Genomes 
EUR population (release 72). For this annotation, SNPs with the lowest MAF (i.e. rarest 
SNPs) were ranked highest. 
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Table 3.1 This table describes the annotations used in the R package, SuRFR, as well as the 
sources they were obtained from and the dates they were downloaded (Ryan et al., 2014). 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
Chapter 3: Model testing using cross-validation and development of an R-package 97 
DNase HS: SNPs were ranked on normalised peak score, taking the maximum signal 
strength across any cell line. 
 
DNase footprints: SNPs were ranked on the number of cell-lines where DNase 
footprints were observed. 
 
Position: The position score used for the model in Chapter 2 was modified to include 
annotation data for gene names, exons, introns, splice sites, CpG islands, and CpG 
shores. Data from the FANTOM5 project, characterising novel transcription start sites 
(TSSs), was used to annotate previously undocumented promoters (defined as being 
1000 bp upstream of FANTOM5 TSSs) and regions 10kb upstream of transcripts. The 
rank orders of this annotation feature were redefined based on evidence from the 
literature (see section 3.3.3.3); the new rank order of position categories can be seen in 
Table 3.2. 
 
Transcribed Enhancers: I collated CAGE-defined transcribed enhancers, identified 
using data from the FANTOM5 project (Andersson et al., 2014), into a new feature 
annotation dataset. SNPs were ranked by a binary classification, based on whether or not 











Table 3.2 Updated rank orders of position categories. This data is based on enrichment data 
presented by Hindorff et al. (Hindorff et al., 2009), and Schork et al. (Schork et al., 2013). 
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Table 3.3 Table from the UCSC Genome Browser showing the nine cell lines used as the source 
of the experimental data produced by Ernst et al. used to define chromatin states.	  
	  
 
Transcription Factor Binding Sites: I identified an updated transcription factor 
binding site (TFBS) table from the UCSC Genome Browser. SNPs were ranked on the 
highest peak signal for any of the transcription factors across all of the cell lines. 
 
Conservation: SuRFR’s conservation score was based on GERP rejection substitution 
(RS) scores. SNPs were ranked from highest to lowest RS; prior to ranking, all negative 
RS scores were converted to zero. 
 
Chromatin States: The chromatin state data across nine cell lines (Table 3.3) presented 
by Ernst et al. (2011) was reassessed using multivariable regression. The new chromatin 
state rankings can be seen in Table 3.4. 
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Chromatin state classes Rank 
Promoter 10 
Strong Enhancer 9 




Transcription Transition 4 
Transcription Elongation 3 
Weak Transcription 2 
Heterochromatin 1 
 
Table 3.4 Rankings of each of the 10 chromatin state classes (best rank: 10, worst rank: 1) 
defined by the regression analysis described in Results section: Multivariable regression. Each 
chromatin class is colour coded to reflect the individual chromatin states they represent (shown 
in full in Table 3.6.) 
 
 
3.2.3 Construction of test datasets 
3.2.3.1 HGMD variants 
The HGMD Professional data is available via MySQL.  I accessed the database via the 
command line, using the command format: 
mysql –A –h host –u username –p password 
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The data I required for each variant from the HGMD mySQL database included: 
chromosome, position, ID (HGMD Accession number), Ref base, Alt base, disease, 
gene, tag and dbSNP id. 
This information was not available from any single table; therefore I used JOIN to pull 
out the appropriate data from multiple tables into a single output. I did this in two steps: 
i) SNPs present in dbSNP; and ii) SNPs not in dbSNP. I also only extracted variants of 
the subclasses DM, DFP and FP. The command formats for each step are: 
 
1. SNPs in dbSNP: 
Select “chrom”, “pos”, “dbSNP_id”, “ref”, “alt”, “tag”, “id”, “gene”, “disease” from 
hgmd_vcf INNER JOIN prom ON (id = acc_num) LEFT JOIN dbSNP ON (id = 
hgmd_acc) where hgmd_acc IS NULL and (tag = “DM” or tag = “DFP” or tag = 
“FP”); 
 
2. SNPs not in dbSNP: 
Select “chrom”, “pos”, “dbSNP_id”, “ref”, “alt”, “tag”, “id”, “gene”, “disease” from 
hgmd_vcf INNER JOIN prom ON (id  = acc_num) INNER JOIN dbSNP ON (id = 
hgmd_acc) where (tag = “DM” or tag = “DFP” or tag = “FP”); 
 
These commands provided me with the columns I needed for a total of 1,959 SNPs 
(1,332 in dbSNP, 627 not in dbSNP). After removing 62 duplicates, this dataset 
contained 1,897 variants. 
 
A subset of these SNPs overlapped with my RAVEN variants (70 variants). I therefore 
removed these variants from the HGMD dataset before using it. This left 1,827 variants 
in the positive dataset (644 DM variants, 686 DFP variants and 497 FP variants). This 
dataset will be referred to as the ‘ALL’ dataset from this point onward. 
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The ALL SNPs were partitioned into a training/validation set (1,440 variants) and a hold 
out test dataset (387 variants). I constructed two additional training/validation/test 
datasets by further subdividing the HGMD dataset by variant subclass. These two 
datasets consisted of i) DM variants only (the DM dataset) and ii) DFP variants only (the 
DFP dataset). The DM and DFP datasets were split into tripartite subsets as for the ALL 
HGMD dataset; the DM training/validation set containing 512 SNPs; and the DFP 
training/validation set containing 534 SNPs. 
 
3.2.3.2 ENCODE variants 
The 44 ENCODE pilot project regions contain between them 170,892 variants from the 
1000 Genomes EUR population (see Chapter 2 for more details). These variants were 
divided into two sets: a training/validation set, equal in size to the positive SNP set (i.e. 
1,440 SNPs for the ALL dataset; 512 for the DM dataset; and 534 for the DFP dataset) 
and a background hold out test dataset (169,452 SNPs). All of the SNPs present in the 
training/validation datasets were excluded from the test dataset.   
 
3.2.3.3 HBB dataset 
The HBB variants described in Chapter 2 were used as an additional positive spiking set. 
The HBB non-coding variants were compared to the HGMD dataset and any SNPs 
present in both datasets were removed from the HBB dataset. This left me with a HBB 
non-coding dataset of 27 variants. 
 
3.2.3.4 RAVEN dataset 
The RAVEN variants from Chapter 2 were also used to assess the ability of the new 
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3.2.4 Multivariable regression 
Multivariable regression was used for three separate tasks:  
i) To correlate the 15 chromatin states with the training data to identify the most 
informative chromatin state ranking to include in the model.  
ii) To compare the predictive power of the old versions of the annotation features 
(used in Chapter 2) versus the new versions (see Methods 3.2.2).  
iii) To guide the parameter boundaries for the grid search algorithm used for 
parameter optimisation. 
All three tasks were performed using the R function glm(). The following commands 
were used to prepare the data for the glm function: 
Loading the test datasets: 
HGMD_training_1440 <- read.table("HGMD_1440_training.18.12.13.txt", header=T, 
sep = "\t", stringsAsFactors = FALSE, na = "NA") 
Cross_Val_1440_Null <- read.table("cross_val_encode_1440_Training.18.12.13.txt", 
header=T, sep = "\t", stringsAsFactors = FALSE, na = "NA") 
 
Merging the positive and negative variants into one dataset: 
HGMD_All_T_F <- merge(HGMD_training_1440, Cross_Val_1440_Null,  all= TRUE) 
 
Setting the binary classifier (functional/non-functional): 
TrPos_File <- "4.12.13_hgmd_prom.final.bed" 
TrPos<-read.table(TrPos_File,header=T, sep = "\t", stringsAsFactors = FALSE, na = 
".") 
positives <- TrPos$Pos 
HGMD_All_T_F$Score <- 0 
HGMD_All_T_F$Score[HGMD_All_T_F$Pos %in% positives] = 1 
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3.2.4.1 Regression of the chromatin states on the full 
training/validation dataset 
Multivariable regression was performed on the chromatin states for all nine of the Ernst 
cell lines: GM12878, H1-hESC, K562, HepG2, HUVEC, HMEC, HSMM, NHEK, and 
NHLF (Table 3.3). 
 
HGMD_ALL_E_Gm12878 <- glm (y~ 
HGMD_All_T_F$wgEncodeBroadHmmGm12878HMM+0, family = binomial(link = 
"logit")) 
summary(HGMD_ALL_E_Gm12878) 
HGMD_ALL_E_Gm12878_summary <- summary(HGMD_ALL_E_Gm12878)$coef 
write.table(HGMD_ALL_E_Gm12878_summary, file = 
"Multivariable_regression_HGMD_ALL_Ernst_Gm12878.12.3.14.txt", append = 
FALSE, quote = TRUE, sep = "\t",eol = "\n", na = "NA", dec = ".", row.names = TRUE, 
col.names = TRUE, qmethod = c("escape", "double"),fileEncoding = "") 
 
3.2.4.2 Regression of the new and old versions of the annotation 
features on the full training/validation dataset 
Regression was performed on the normalised ranks of each individual feature using a 
command such as this one used for MAF: 
 
HGMD_ALL_MAF <- glm (y~ HGMD_All_T_F$MAF.rank_normalised, family = 
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3.2.4.3 Regression of feature annotations on the full training/validation 
dataset to guide parameter boundaries for grid search algorithm 
A multivariable regression analysis was performed on the combined feature set to aid the 
choice of upper and lower weighting limits for parameter optimisation, using the 
following commands: 
 
#  Position + MAF + DNAse f + Cons + DNase c + Ernst + enhancers + TFBSs: 
y <- HGMD_All_T_F$Score 
HGMD_all_new_rank_tfbs <- glm (y~  HGMD_All_T_F$F_Position.rank + 
HGMD_All_T_F$MAF.rank_normalised + HGMD_All_T_F$DNase.foot.av.rank + 
HGMD_All_T_F$Conservation.rank +  HGMD_All_T_F$E.DNase.av.rank + 
HGMD_All_T_F$Ernst.Av.new.rank + HGMD_All_T_F$Enhancers.rank + 
HGMD_All_T_F$TFBSs.rank,  family = binomial(link = "logit")) 
summary(HGMD_all_new_rank_tfbs) 
HGMD_all_new_rank_tfbs_summary <- summary(HGMD_all_new_rank_tfbs)$coef 
write.table(HGMD_all_new_rank_tfbs_summary, file = 
"Multivariable_regression_HGMD_all_new_rank_TFBSs_summary.5.5.14.txt", append 
= FALSE, quote = TRUE, sep = "\t",eol = "\n", na = "NA", dec = ".", row.names = 
TRUE, col.names = TRUE, qmethod = c("escape", "double"),fileEncoding = "") 
 
 
3.2.5 Ten-fold cross-validation 
The known functional and pathogenic variants from the HGMD database (ALL dataset) 
were combined with the background ENCODE variants into a single training/validation 
dataset of 2,880 SNPs and a test dataset consisting of 169,839 SNPs. 
 
The training/validation dataset was further randomly subdivided into ten folds for cross-
validation. Pseudo-code for the R code that was implemented for parameter optimisation 
and ten-fold cross-validation can be seen in Figure 3.2. Parameter optimisation was 
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performed using a modified grid search algorithm. This method incorporated 
multivariable regression on the full training/validation dataset to guide the parameter 
boundaries of the grid search algorithm. This was similarly performed for the DM and 
DFP datasets.   
 
Parameter weightings were permuted using brute force permutation of all possible 
positive integer parameter values. In total over the three datasets, almost half a million 
permutations of weighting models were assessed using ten-fold cross-validation (n = 
450,000). 
 
Performance was measured using ROC curves and AUCs using the R package ROCR 
(Sing et al., 2005). The objective parameter optimised for weighting parameter selection 
was maximum AUC, with a threshold acceptable performance error of <0.005 
(calculated as the difference between the mean training and validation AUCs: ΔAUC). 
Three models were developed from this analysis, one for each dataset: ‘ALL’, ‘DM’ and 
‘DFP’. For each of these three datasets, the best model was applied to the hold out test 
dataset (similarly divided by variant class into ALL, DM and DFP test datasets). 
Generalisation errors were calculated as the difference between the test AUC and the 
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3.2.6 Building the R code into an R package 
3.2.6.1 package-skeleton 
To build a new R package I performed the following actions in R: 
1. I cleared workspace so as to have a clean R session:  
rm(list = ls()) 
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2. I loaded each of the package functions and data objects one by one.  
 
3. To build the package, I ran the command:  
package.skeleton (“package_name”)  
 
4. I edited the package files as follows: 
i) I filled in the DESCRIPTION file and manual pages (~/package/man) 
ii) I edited the NAMESPACE file to contain look-up information for 
functions and objects within the package. 
iii) I wrote a user manual explaining how each part of the R package works, 
containing real working examples (see Appendix B). 
 
5. Lastly, I built, installed and checked the package using the commands: 
R CMD build package_name 
R CMD install package_name.0.99.tar.gz 




3.2.6.2 Sweave vignette  
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3.3 Results 
3.3.1 Construction of training, validation and test datasets 
I selected functional non-coding variants with experimentally verified phenotypic 
impacts from the HGMD PROM database of regulatory variants implicated in disease. 
This data was then divided into three datasets: DM (known disease causing SNPs: 644 
SNPs); DFP (disease-associated variants with functional evidence: 686 SNPs); and ALL 
(all DM, DFP and FP HGMD PROM SNPs: 1,827 SNPs). For each of these three 
datasets, an equal number of background variants was obtained by randomly sampling 
the 1000 Genomes EUR variants located within the ENCODE pilot project regions. Each 
dataset was divided into a training/validation dataset (ALL: 1,440 known functional 
variants and 1,440 background variants; DM: 512 known and 512 background variants; 
and DFP: 534 known and 534 background variants) and a hold out test dataset (387, 132, 
152 known variants (ALL, DM and DFP respectively); and 169,452 background 
variants).  
 
3.3.2 Changes to the feature annotations included in SuRFR  
The ENCODE project and other genomics projects are not static data sources, but are 
constantly being improved (due to technological advances and updated protocols) and 
expanded to contain new and extended data (e.g. additional cell lines). It was, therefore, 
important to continue checking these resources regularly to keep abreast of new 
developments and update the annotation data used by SuRFR. Several updates of 
features used by SuRFR, as well as some additional annotation features, came to my 
attention during my second year. This chapter describes the evaluation of the impact of 
these features on model performance. In addition, this chapter outlines the testing and 
optimisation of the prioritisation model using cross-validation and reports the 
performance of SuRFR on a variety of independent datasets. 
 
Some of the features described in Chapter 2 were not incorporated in the model in the 
most objective or systematic manner. In particular, the chromatin states from Ernst et al. 
(2011) were integrated into the model without taking into account differences in 
predictive power for the different chromatin states. For example, the promoter, enhancer, 
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insulator and transcription chromatin state classes and subclasses were all treated 
equally, whereas the literature suggests that certain chromatin states are more likely to 
overlap some regulatory elements more often than others (Ernst et al, 2011). In addition, 
the rank orders of the Position ranking had been chosen using out-dated data. 
Furthermore, the conservation score had not been tested systematically to measure the 
contribution of GERP and PhastCons individually. I, therefore, also re-evaluated the 
impact of these features on model performance. 
 
3.3.2.1 Updated annotation sources 
Minor Allele Frequency (MAF): A new release of the 1000 Genomes MAFs, based 
on data from 2,504 individuals (compared to 1,092 in the last release), became available.  
This data was used to rank SNPs, on the basis of MAF, from most rare to most common. 
 
DNase HS clusters: This data contains information on DNase HSs assayed across 125 
cell lines, a large increase on the previous version, which was based on 74 cell lines. I 
performed multivariable regression on the full training and validation dataset, comparing 
these data and the DNase HS data from the original model (Chapter 2). Table 3.5 shows 
that the updated DNase HS data has a higher ß coefficient than the old data, therefore 
incorporation of this data would better enable SuRFR to discriminate between functional 
and background variants. 
 
3.3.2.2 New annotation data sources 
DNase Footprints: Genomic DNase I footprinting data demarcate sequence-specific 
transcription factors binding sites within regulatory regions, at nucleotide resolution. 
This data, collected as part of the ENCODE project, consists of high confidence DNase I 
footprints from 41 cell types (45.1 million footprints in total) (Neph et al., 2012). By 
combining this data, in addition to data on DNase HS clusters, I anticipated improving 
the ability of SuRFR to better prioritise regulatory variants by identifying those that 
overlap DNA elements bound by regulatory factors. Regression of this data on the full 
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training and validation dataset showed that the DNase footprints dataset is an 
informative annotation for differentiating between regulatory and background variants in 
this dataset (with a β coefficient of 2.62; see Table 3.5). 
 
FANTOM5 CAGE data: The FANTOM5 consortium published new data early in 
2014, comprehensively mapping TSS and their promoters across 975 human samples 
(573 primary cells, 152 tissues and 250 cell lines)(Consortium et al., 2014). I 
hypothesised that inclusion of this data would lead to more accurate promoter 
identification, thereby improving the accuracy of my position ranking.  
 
Transcribed Enhancers: A by-product of the FANTOM5 project was the 
identification of CAGE defined transcribed enhancers (Andersson et al., 2014). These 
were shown to be more accurate predictors of real enhancers than ENCODE data. I 
therefore tested this feature’s ability to predict variant functionality.  
 
TFBSs: I included the wgEncodeRegTfbsClusteredV3 dataset from the UCSC Genome 
Browser in the parameter optimisation. The highest peak signal for any transcription 
factor (TF) across all cell lines was used to rank SNPs.  
 
3.3.2.3 Optimisation of the remaining annotation features 
In addition to updating the feature annotation data for MAF and DNase HS and 
incorporating several new features into the model, I also re-evaluated how the remaining 
features (position, chromatin states and conservation) contributed to the performance of 
SuRFR. 
 
Position rank:  
Hindorff et al. (2009) and Schork at al. (2013) suggested that disease associated 
variants are more likely to occur in particular position categories, such as enhancer 
elements and promoters, more often than others ((Hindorff et al., 2009); (Schork et 
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al., 2013)). Using the genomic enrichment results for disease variants from both 
these sources, I re-ordered the ranking of the position categories (see Table 3.2). I 
further modified this annotation feature by incorporating the FANTOM5 TSS data. 
 
Old data β coeff p-value  New data β coeff p-value 
Ernst 2.3776 <2e-16  New Ernst 4.458 <2e-16 
 DNase_c V2 2.406 <2e-16 DNase-c V1 2.2516 <2e-16 
 DNase_F 2.6197 <2e-16 
Position 7.888 <2e-16  New Position  11.6197 <2e-16 
Table 3.5 Comparison of the old versus new feature annotations for the Chromatin states 
(Ernst), DNase HS data (DNase HS clusters: DNase_c; and DNase footprints: DNase_F). 
Regression was performed on the normalised ranks of each annotation feature, allowing the β 
coefficients to be directly compared. 
 
Chromatin states: 
Multivariable logistic regression on the full training/validation dataset was used to assess 
the relationship between each of the 15 chromatin states and variant class; the ß 
coefficients indicating the relative correlation of each annotation category to the 
classifier (i.e. positive or background variant).  Table 3.6 shows the average ß 
coefficients for each chromatin state across the nine cell lines GM12878; H1-hESC; 
K562; HepG2; HUVEC; HMEC; HSMM; NHEK; and NHLF. 
 
The average β coefficients showed pronounced grouping of “like” categories (promoter 
with promoter, weak enhancer with weak enhancer, etc.) of chromatin states with similar 
β coefficients. Using this information I collapsed these similar categories into 10 classes 
of chromatin states. The two ‘Repetitive/CNV’ categories had high standard error rates 
and noise in the data. This class was positioned in the middle of the ranking, between 
classes that correlated positively with the data classes and those that had a negative 
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correlation. Using these data I defined the rank order for the chromatin state classes, 






nine cell lines Std. Error Pr(>|z|) 
15_Repetitive/CNV 13.399 322.129 0.966 
1_Active_Promoter 3.551 0.353 0.000 
2_Weak_Promoter 2.127 0.338 0.000 
3_Poised_Promoter 2.565 0.558 0.006 
6_Weak_Enhancer 1.099 0.278 0.008 
4_Strong_Enhancer 1.500 0.389 0.025 
12_Repressed 0.404 0.142 0.029 
9_Txn_Transition -0.051 0.401 0.729 
8_Insulator 0.030 0.412 0.585 
10_Txn_Elongation -0.363 0.191 0.140 
7_Weak_Enhancer -0.072 0.244 0.541 
11_Weak_Txn -0.532 0.110 0.000 
13_Heterochrom/lo -0.659 0.057 0.000 
5_Strong_Enhancer 0.010 0.410 0.280 
14_Repetitive/CNV -4.811 246.088 0.867 
 
Table 3.6 Multivariable regression ß coefficients (column 2), standard error rates (column 3) 
and p value (column 4) for each of the 15 chromatin states averaged across nine cell lines. 
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Conservation: 
I next compared the relative contribution of each of the two conservation methods, 
GERP and PhastCons, and their combined contribution, to the model’s ability to 
prioritise functional over non-functional variants. I did this by performing multivariable 
regression on the full HGMD/ENCODE training/validation dataset, to see how well each 
predictor could differentiate SNPs on the binary classifier (functional/non-functional). 
Table 3.7 shows the ß coefficient for the combined conservation rank (GERP + 
PhastCons) and Table 3.8 shows the ß coefficients for each tool individually. The 
combined conservation score does not correlate well with the classification of functional 
versus non-functional (p>0.5). However, GERP is positively correlated with the 
classifier, with a ß coefficient of 0.5709 (p-value < 2.78e-15), while PhastCons has a 
strong negative correlation with the classifier, with a ß coefficient of -1.6903 (p value < 
2.38e-9). This indicated that using GERP on its own would have more power than 
combining GERP and PhastCons together, and that PhastCons is a poor predictor of 
single SNP function. 
 
 
 Estimate Std. Error z value Pr(>|z|) 
(intercept) -0.05663 0.04784 -1.184 0.2365 
HGMD_ALL$Conservation.rank 0.20567 0.10895 1.888 0.0591 
Table 3.7 Multivariable regression output for the combined conservation rank (GERP + 
PhastCons) on the full training/validation dataset. 
 
 
 Estimate Std. Error z value Pr(>|z|)  
(intercept) -6.16035 0.27235 -22.619 < 2e-16  *** 
HGMD_ALL$GERP 0.57093 0.07227 7.900 2.78E-15  *** 
HGMD_ALL$PhastCons -1.69035 0.28320 -5.969 2.39E-09  *** 
Table 3.8 Multivariable regression ß coefficients on the full training/validation for the two 
conservation methods individually: GERP and PhastCons. 
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3.3.2.4 Multivariable regression to select parameter boundaries 
Multivariable regression on the training/validation dataset was used to define the upper 
and lower parameter boundaries for the modified grid search algorithm used for the 
parameter optimisation step. This was performed for each of the three training/validation 
datasets: ALL, DM and DFP (Tables 3.9, 3.10 and 3.11 respectively). Using these ß 
coefficients I chose positive, whole integer parameter ranges for each of the annotation 
categories for the parameter optimisation of SuRFR. The parameter boundaries used for 




ALL training/validation dataset β coefficient 
Std. 
Error z value Pr(>|z|) 
(Intercept) -4.7960 0.2198 -21.8243 0.0000 
HGMD_ALL$F_Position.rank 6.3699 0.2763 23.0509 0.0000 
HGMD_ALL$DAF.rank_normalised -1.3615 0.1732 -7.8610 0.0000 
HGMD_ALL$DNase.foot.av.rank 0.7172 0.2431 2.9504 0.0032 
HGMD_ALL$Conservation.rank 0.6396 0.1648 3.8804 0.0001 
HGMD_ALL$E.DNase.av.rank -0.0496 0.2066 -0.2402 0.8102 
HGMD_ALL$Ernst.Av.new.rank 1.9758 0.2798 7.0606 0.0000 
HGMD_ALL$Enhancers.rank -0.1061 0.6572 -0.1614 0.8718 
HGMD_ALL$TFBSs.rank 1.1599 0.2031 5.7115 0.0000 
Table 3.9 Multivariable regression ß coefficients, standard errors, z values and p-values for the 
ALL training/validation data.  
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DM training/validation dataset 
β 
coefficient Std. Error z value Pr(>|z|) 
(Intercept) -11.8927 1.2509 -9.5074 0.0000 
HGMD_DM$F_Position.rank 7.5632 0.7236 10.4527 0.0000 
HGMD_DM$DAF.rank_normalised 5.0458 0.6299 8.0101 0.0000 
HGMD_DM$DNase.foot.av.rank 0.1967 0.6003 0.3277 0.7431 
HGMD_DM$Conservation.rank 2.4449 0.4928 4.9612 0.0000 
HGMD_DM$E.DNase.av.rank -0.3372 0.5647 -0.5971 0.5504 
HGMD_DM$Ernst.Av.new.rank 2.7075 0.7680 3.5253 0.0004 
HGMD_DM$Enhancers.rank -12.5078 738.4351 -0.0169 0.9865 
HGMD_DM$TFBSs.rank 2.0049 0.5556 3.6083 0.0003 
Table 3.10 Multivariable regression ß coefficients, standard errors, z values and p-values for the 
DM training/validation data.  
 
 
DFP training/validation dataset β coefficient Std. Error z value Pr(>|z|) 
(Intercept) -2.9183 0.3479 -8.3891 0.0000 
HGMD_DFP$F_Position.rank 5.6870 0.4372 13.0080 0.0000 
HGMD_DFP$DAF.rank_normalised -3.5053 0.3330 -10.5260 0.0000 
HGMD_DFP$DNase.foot.av.rank 1.1763 0.3951 2.9772 0.0029 
HGMD_DFP$Conservation.rank 0.0569 0.2530 0.2249 0.8220 
HGMD_DFP$E.DNase.av.rank 0.2229 0.3306 0.6743 0.5001 
HGMD_DFP$Ernst.Av.new.rank 1.6903 0.4512 3.7462 0.0002 
HGMD_DFP$Enhancers.rank 1.4698 1.3626 1.0787 0.2807 
HGMD_DFP$TFBSs.rank 0.5706 0.3302 1.7279 0.0840 
Table 3.11 Multivariable regression ß coefficients, standard errors, z values and p-values for the 
DFP training/validation data. 
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Footprints Enhancers TFBSs 
ALL 0-2 0-3 0-8 0-1 0-16 0-3 0-1 0-5 
DM 0-13 0-7 0-8 0-1 0-18 0-2 0-1 0-6 
DFP 0-1 0-1 0-6 0-1 0-15 0-6 0-6 0-3 
Table 3.12 The upper and lower boundaries of the weighting parameters chosen to be tested 
using the grid search algorithm. Column one describes the three models (ALL, DM and DFP) 




3.3.3 Ten-fold cross-validation 
The ALL, DM and DFP training/validation sets were further partitioned into ten equal 
folds for ten-fold cross-validation, ensuring no overlap existed between any of the 
training/validation datasets and the hold out test datasets. I performed weighting model 
parameter optimisation and ten-fold cross-validation on each of these three datasets and 
assessed the performance and generalisability of SuRFR using ROC curves and AUC 
statistics. 
 
3.3.3.1 Training and validation (AUCs, errors, specificity and 
sensitivity) 
The optimum weighting model for each dataset was chosen based on the highest average 
training/validation AUC with a performance error of less than 0.005. The AUCs for the 
top 1% of weighting models were very similar, differing by less than 0.003 (∆AUC 
ALL: 0.0026; ∆AUC DM: 0.0021; ∆AUC DFP: 0.0011), suggesting a smooth parameter 
space with few fine-grained local optima. Performance errors for each model (ALL, DM 
and DFP) were calculated as the difference between the average training and validation 
AUCs. The AUCs and error rates for each model are shown in Table 3.13. Each model 
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performed well on the training/validation data, with AUCs ranging from 0.908 to 0.976 
and performance errors of less than 0.004, indicating that each model can successfully 














ALL 0.944 0.944 0.909 0.000 0.035 
DM 0.976 0.976 0.956 0.000 0.020 
DFP 0.912 0.908 0.897 0.004 0.013 
Table 3.13 Average training, validation and test AUCs for the three SuRFR models run on the 
cross-validation datasets. 
 
3.3.3.2 Hold out test dataset 
The top weighting models for each of the three data classes ALL, DM and DFP, were 
next run on the hold out test dataset to establish SuRFR’s generalisation error. These 
data are shown in Table 3.13 and Figure 3.3. Again, each of the three models performed 
with high specificity and sensitivity, producing AUCs of 0.897 to 0.956 and 
generalisation errors less than 0.035. This suggests that all models are likely to perform 
equally well on novel data. 
 
 
3.3.4 Characterisation of regulatory variant classes 
The best weighting models for each of the three variant classes are shown in Table 3.14. 
This data shows that each of the three variant classes is best prioritised by a different 
combination of genomic annotations. The most informative annotation category across 
all three variant classes was position (SNP position relative to genes). MAF was a very 
useful annotation for the prioritisation of DM variants over background, but was not at 
all useful for prioritising the ALL or DFP classes of regulatory variants. In contrast, 
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Figure 3.3 ROC curves and AUCs for the three SuRFR models (ALL: green; DM: blue; and 
DFP: gold) run on the hold-out test dataset. Y-axis represents the average true positive rate; the 
x-axis represents the average false positive rate and the grey dotted line represents random 
chance. 
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conservation was a relatively uninformative annotation: it provided only a minor 
contribution to SuRFR’s ability to prioritise the DM variants, played an even smaller 
role in the prioritisation of the ALL variants and had no role in the prioritisation of the 
DFP variants. 
 
The redefined chromatin states had a variable impact on the ability of SuRFR to 
distinguish functional from non-functional variants, most effectively prioritising the DM 
variants, closely followed by DFP and being least effective at prioritising the ALL 
category of variant. In contrast, the TFBS annotation consistently added to the correct 
ranking of true variants in all three variant classes. 
Multivariable regression suggested that DNase HS and DNase footprints are highly 
correlated features, which may suggest that they provide similar input to the 
prioritisation of known regulatory variants (Table 3.5). However, when these two 
features were incorporated in the same model, the DNase footprints were more highly 
correlated with correct prioritisation of known variants than the DNase HS clusters 
(Tables 3.9, 3.10 and 3.11). This was reflected in the subsequent weightings assigned to 
the two annotation categories.  
 
 
Table 3.14 Parameter weightings for best performing weighting model for each variant class 
from the ten-fold cross-validation analysis. The first column lists the three weighting models 
(ALL, DM and DFP). Each subsequent column represents a different annotation class. The 
values represent the weightings of each annotation class defined in each weighting model. 
 






Footprints Enhancers TFBSs 
ALL 0 1 1 0 8 0 1 3 
DM 12 2 6 1 15 1 0 5 
DFP 0 0 3 1 15 3 5 2 
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3.3.5 Additional test datasets: HBB and RAVEN 
As a further test of the generalisability of SuRFR, I tested the three models on the HBB 
and RAVEN datasets presented in Chapter 2. The HBB (27 non-coding SNPs not present 
in the HGMD dataset) and RAVEN (95 regulatory variants not in the HGMD dataset) 
true positive SNPs were spiked into the 44 ENCODE pilot regions (minus the 
training/validation SNPs). Figure 3.4 shows the ROC curves and AUCs for these two 
analyses.  
 
All three models prioritised the non-coding HBB variants with very high specificity and 
sensitivity; the DM model performed the best, with an AUC of 0.989, followed by the 
ALL (0.981) and DFP models (0.956). More variation existed in the ability of SuRFR to 
prioritise the RAVEN variants over the background ENCODE variants; the ALL and 
DFP classes generated AUCs of 0.921 and 0.937 respectively, while the DM model 
achieved an AUC of 0.797. 
 
 
3.3.6 Background variants as known functional variants 
The RAVEN background variant dataset contains 3,856 variants all located within 10kb 
of genes conserved between mice and humans (Andersen et al., 2008). As a negative 
control I performed a bootstrapping analysis, running SuRFR on 100 randomly sampled 
subsets of the RAVEN background variants against the remaining background variants. 
Each subset contained 95 variants, each of which was defined as a “known” (positive) 
variant; the remaining 3,761 background variants being classed as background (control) 
variants. The average AUC calculated across the 100 bootstrapping sets was 0.50 (Figure 
3.5), indicating that the background variants were not prioritised any better than would 
be expected by chance. In contrast, the 95 “real” true positive RAVEN variants spiked 
into the same background dataset produced AUCs of 0.83, 0.845 and 0.842 for the ALL, 
DM and DFP models respectively. This demonstrates that SuRFR is capable of 
prioritising functional variants better than non-functional variants. 
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Figure 3.4 Mean ROC curves (y-axis: True positive rate; x-axis: False positive rate) and AUCs 
for the three SuRFR models (ALL (green) DM (blue) and DFP (gold)) run on: a) HBB non-
coding pathogenic and b) RAVEN non-coding regulatory datasets spiked into the ENCODE 
pilot projact background dataset. The dotted grey line indicates random chance. 
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Figure 3.5 ROC curves and AUCs for the three SuRFR models (ALL, DM and DFP) run on i) 
100 background datasets classed as functional and ii) the true functional variants run against 
the background dataset. These results show that SuRFR does not rank the background variants 
any better than expected by chance, supporting earlier results that showed SuRFR can 
prioritise functional over background variants.   
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3.3.7 R package details 
Using the R function package.skeleton, I converted my R code into an R package, 
SuRFR. The SuRFR R package is available from: http://www.cgem.ed.ac.uk/resources/ 
 
In addition, I wrote a user manual and a sweave vignette for this R package. The user 
manual can be found in Appendix B while the sweave vignette can be found in 
Appendix C. 
 
The data presented in this chapter (and Chapter 4) were published by Genome Medicine 
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3.4 Summary and Discussion 
3.4.1 Summary of Results 
The aim of this chapter was to improve the model I developed in Chapter 2. This was 
achieved by implementing both a modified model framework and a more structured 
model assessment protocol. The new model framework was based on a rank-of-ranks, 
removing the need for arbitrary thresholds and treating each annotation category equally, 
thereby removing any bias and providing consistency across the annotations. The 
improved model assessment protocol combined a modified grid search algorithm and 
ten-fold cross validation. This protocol made use of a benchmarking dataset consisting 
of regulatory variants from HGMD and background variants from the 1000 Genomes 
EUR population located within the ENCODE pilot project regions. Performance was 
measured using ROC curves and AUCs. Three models were developed from this 
analysis: the ALL, DM and DFP models. The results of the cross-validation showed that 
each model was able to prioritise their corresponding class of regulatory variants above 
the background variants with high sensitivity and specificity (AUCs between 0.897 and 
0.976: see Table 3.12 and Figure 3.4) and low performance and generalisation errors 
(Table 3.12). These results suggest that SuRFR does not suffer from over-fitting and is 
likely to perform equally well on novel data.  
 
3.4.2 Changes to feature annotation data 
Projects such as ENCODE are continuing to provide the scientific community with 
genomic annotation data, from TFBSs, to RNA assays and a range of DNA and histone 
modifications, across an ever increasing number of cell lines. Genomic annotation data is 
therefore not static but constantly being updated and expanded. As such it was important 
to update and expand the annotations used by SuRFR to prioritise putative functional 
variants.  
 
Table 3.1 lists the annotation features used in this modified version of SuRFR. These 
features can be divided into three classes: i) annotation features from the original model 
for which new releases have become available (making use of larger numbers of cell 
lines and modified experimental design); ii) new annotation features (features that had 
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not been released at the time of the initial build of SuRFR); and iii) annotations from the 
original model of SuRFR but incorporated differently (optimised integration of related 
classes). 
 
By including updated versions of the annotations MAF and DNase HS clusters, I 
expected to improve the accuracy of my method, as the updated annotation data should 
be more accurate. Similarly, I hoped to improve accuracy by including additional 
features that I hypothesised would improve the prioritisation of functional variants over 
background variants. The new annotations I chose to include were DNase footprints, 
FANTOM5 CAGE defined promoters, FANTOM CAGE defined transcribed enhancers 
and TFBSs. Lastly, by changing the way both the position rank and chromatin state rank 
were calculated, using a more formalised approach (multivariable regression), I intended 




Figure 3.6 DNase HS versus DNase footprint. Figure from (Vernot et al., 2012). 
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DNase HS data (clusters and footprints): While DNase HSs indicate regions of open 
chromatin, DNase footprints more specifically reveal single protein-binding events 
(Madrigal and Krajewski, 2012), as illustrated by Figure 3.6. I hoped, by combining 
DNase footprinting data with DNase HS data, to improve the specificity of SuRFR, as 
regions where the two features overlap are potentially more likely to mark true binding 
events than either feature on its own (Figure 3.6). 
 
I hypothesised two scenarios for these data: i) that there would be a combinatorial effect, 
each feature aiding the other and adding specificity to the prioritisation of regulatory 
variants; or ii) that the footprints, being more specific elements, demarking sequences of 
regulatory factor occupancy on a nucleotide level (in comparison to DNase HS clusters, 
which mark regions of open chromatin), would provide greater accuracy than the DNase 
HS clusters and would therefore remove the need for the DNase HS cluster feature. The 
results from the cross validation analysis surprised me. Although scenario i) appears to 
be in effect for the DM class of regulatory variants and scenario ii) is true for the DFP 
class, neither explained why the ALL class of variants required neither DNase HS cluster 
data or the DNase footprinting data. An explanation for this could be that the ALL model 
placed greater emphasis on the TFBS annotation data than any other feature, bar 
position. As the TFBS annotation and DNase HS features all provide information on the 
likelihood of a variant overlapping a protein binding domain, there is a certain amount of 
redundancy between these features, thus explaining the lack of DNase HS features in the 
ALL model. In summary, although these two features provide largely overlapping data, 
the different variant models required different weightings of these features: for the DM 
class of variants, each of these features contributes equally to the correct prioritisation of 
functional variants; while the DFP model relies more heavily on the DNase footprint 
data; and the ALL model required neither feature.  
 
Transcribed enhancers: the FANTOM5 project produced an atlas of active, 
transcribed, enhancer regions. These regions were defined by bidirectional CAGE tags, 
assayed across a range of samples, including 432 primary cells, 135 tissues, and 241 cell 
lines (Andersson et al., 2014). Using in vitro enhancer assays in HeLa cells, Andersson 
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et al. (2014) were able to show that bidirectional capped RNAs were a more accurate 
signature of active enhancers than enhancers predicted by DNase HSs or ‘strong 
enhancer’ chromatin states. This database of over 43,000 enhancer candidates was 
therefore as good a candidate annotation to test as the DNase HSs and the chromatin 
states. The cross validation analysis supported the inclusion of this feature in both the 
ALL and, particularly, the DFP model. This was in contrast to the results of the 
multivariable regression analysis (Tables 3.9, 3.10 and 3.11), which were inconclusive. 
However, I suggest that this issue derives from the fact that both the enhancer dataset 
and training/validation dataset are small. I propose this issue is one of data acquisition 
rather than a lack of correlation between this feature and regulatory effect. Larger 
numbers of known true positives are required to improve this analysis. In particular, 
there is an acquisition bias in most known regulatory variant datasets towards variants 
proximal to genes, specifically within promoter regions. This bias further reduces the 
likelihood of training data containing sufficient numbers of enhancer variants for us to 
expect a high correlation between regulatory variants and enhancer features. This feature 
is therefore an important one to retain in the SuRFR models, allowing us to detect more 
enhancer variants and reduce the bias away from promoter variants in any future 
validated regulatory datasets. 
 
TFBSs: TFBSs tend to be short (4-10 bp) DNA sequences that occur repeatedly across 
the genome. TFBSs are important components of the human regulatory network and 
changes to these binding sites can affect the ability of transcription factors to bind to 
them, thus having an effect on function and potentially leading to a disease phenotype. 
However, only a fraction of predicted sites are real, active regions of transcription factor 
occupancy that play a role in gene regulation (Cuellar-Partida et al., 2012). Predictive 
methods, therefore, that use pattern recognition to identify putative novel TFBSs tend to 
identify a large number of false positives, and so are inherently error prone. In contrast, 
experimental methods such as chromatin immunoprecipitation and high-throughput 
sequencing (ChIP-seq) have been used to identify regions of (true) transcription factors 
occupancy genome-wide. The ENCODE consortia performed an integrative analysis on 
161 transcription factors across 91 cell types to comprehensively map the human 
regulatory network ((Wang et al., 2012); (Gerstein et al., 2012)). These data are 
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catalogued and annotated by the Factorbook repository (Wang et al., 2013) and have 
been used to generate the annotation dataset wgEncodeRegTfbsClusteredV3. Based on 
this knowledge, I hypothesised that this dataset of ChIP-seq identified TFBSs would be 
an important feature to integrate into my prioritisation model. As expected, this 
annotation played an important role in prioritising functional regulatory variants over 
background variants, and this role was not variant class specific. In fact, after the 
position feature, this was the second most universally informative feature (tied with 
chromatin states). This result reinforces the rule that, wherever possible, experimental 
data should be used over predicted data, which is inherently error prone.  
 
Chromatin states: In Chapter 2, I split the chromatin states into a binary classification 
(1/0), either active states with the potential to affect regulation, or inactive states (such as 
heterochromatin). These scores were summed across the nine cell lines included in the 
analysis, with possible scores ranging from 0 - 9. However, this did not take into account 
differences in predictive power between the chromatin states within each class. This also 
assumed that a SNP overlapping an informative feature in nine cell lines was nine times 
as informative as a SNP overlapping an informative feature in a single cell line. This is 
very unlikely to be the case, particularly as Ernst et al. (2011), showed that regulatory 
regions vary in activity levels across cell types and enhancers show very high tissue 
specificity (Ernst et al., 2011).  
 
Subsequently, I used multivariable regression on the chromatin states to more accurately 
determine the correlation between the rankings of the chromatin states and the correct 
prioritisation of causal variants over background variants. This analysis highlighted a 
marked grouping of ‘like’ chromatin states (regulatory element classes: promoters, weak 
enhancers, strong enhancers, repetitive sequences, etc). This supported results from Ernst 
et al., showing that ‘like’ chromatin states correlated across cell lines: genomic regions 
annotated as enhancer states (strong or weak) and promoter states (active, weak and 
poised) in one cell line often remained the same class of state (enhancer or promoter) 
across the other cell lines (Ernst et al., 2011). I therefore used these results to group the 
chromatin states into ‘classes’ and ranked the SNPs on these classes (Table 3.3). The 
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updated chromatin class ranks showed a marked improvement in their correlation with 
regulatory status in the multivariable regression, with β coefficients increasing from 2.38 
for the original ranks to 4.46 for the new rank order. In addition, the new chromatin state 
feature was the second most universally informative feature (tied with the TFBS data) in 
the cross-validation analysis, further supporting the data of Ernst and Kellis. 
 
Position: Hindorff (2009) and Schork (2013) independently demonstrated enrichment of 
disease-associated variants in specific genomic locations more often than others. I, 
therefore, re-ranked the position categories to reflect the results of their analyses. 
Similarly, data from the FANTOM5 project provided more accurate data on TSSs across 
the genome, allowing more accurate mapping of SNPs to promoter and 10 kb upstream 
regions. These changes improved the accuracy of the position rank, as shown by the 
multivariable regression analysis performed on the old and new position ranks (ß 
coefficients changing from 7.89 to 11.62). Although position score had always been the 
most effective annotation in the prioritisation of functional regulatory variants over 
background, I anticipated that these changes would also improve the specificity and 
sensitivity of my model. This was indeed the case, as shown by the results of the three 
models run on the HBB and RAVEN datasets, both of which produced higher AUCs 
than the original analyses on these datasets (See section 3.4.5 for more details). 
 
Conservation: Multivariable regression was performed on the two conservation 
methods, GERP and PhastCons, and their cumulative conservation score. This allowed 
me to assess the ability of each tool, individually and combined, to predict the 
functionality of the training/validation SNPs. Surprisingly, I found that the low 
correlation of the conservation score used in the original model (from Chapter 2) was 
due to a negative correlation of the PhastCons data to the SNP functional classification, 
masking the positive correlation of GERP to this classification. Both GERP and 
PhastCons are recommended in the literature as useful tools for nucleotide sequence 
based prediction and have been shown to perform to a similar extent (Pollard et al., 
2010). This information is difficult to reconcile to the results of the regression analysis in 
section 3.3.2.3. While this incongruity is difficult to explain, the GERP regression result 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
Chapter 3: Model testing using cross-validation and development of an R-package 130 
appears to reflect previous reports of GERP’s performance while the PhastCons does 
not. This might reflect the difference in resolution of the measures used by both tools 
(GERP provides a nucleotide level measure, while PhastCons provides a multi-
nucleotide region measure). This could also suggest that the PhastCons result is an 
anomaly in the data. Additional information is needed to clarify this issue. Pending 
further investigation, I therefore chose to leave out the PhastCons annotation from all 
future analyses. 
 
Annotation weightings: The SNP rankings for each of the annotation categories were 
combined into a cumulative rank-of-ranks. Rather than arbitrarily weighting each 
annotation parameter against the others, I used a model training and assessment protocol 
to identify the most informative combination of annotation weightings, optimising their 
relative contribution to the final ranking of SNPs. Using cross-validation and a 
benchmarking dataset of non-coding disease and regulatory variants and background 
variants of unknown function provided me with the statistical framework needed for 
rigorous model assessment as well as an estimation of how well SuRFR would perform 
on novel data. 
 
 
3.4.3 Conclusions from cross-validation 
The grid search algorithm is an exhaustive search of a manually selected subset of a 
defined parameter space. This method is commonly used for hyperparameter 
optimisation, model selection, and to prevent over-fitting. In this context, a 
hyperparameter is defined as a parameter of a prior distribution, in this case, the 
weighting of an annotation ranking.  Two requirements of the grid search algorithm are: 
i) the user must manually define the search space; and ii) it must be guided by cross-
validation (Hsu, 2010). This method is designed to maximise generalisation by 
exhaustively searching for the optimum hyperparameter set (in this case, the best 
combination of annotation weightings) across the parameter space. 
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There are many practical advantage of the grid search algorithm including: i) speed, as it 
is highly parallelisable (as the parameter evaluations are independent of each other); ii) 
simple set-up, as the grid search space can be constructed by brute force permutation; iii) 
flexibility, as the parameter boundaries can be changed; and most importantly, iv) ease 
of integration into the widely used cross-validation analysis framework. This method is 
therefore well suited to the task of model selection and assessment. 
 
A disadvantage of this method is the computational cost of an exhaustive search, which 
can be outperformed by randomly chosen subsets of the parameter space (Bergstra, 
2012). To improve the performance of this method, I adapted it in two ways. Firstly, I 
performed multivariable regression on the full training/validation set to guide the 
weighting parameter boundaries, thereby reducing the grid search space. Secondly, I 
restricted the parameter values to positive integers, further reducing the number of 
weighting models to be permuted. This reduced the computational intensity of the 
analysis (the final number of permutations permuted being just under half a million; n = 
450,000). Furthermore, the performance of the modified grid search algorithm could be 
assessed by analysing the distribution of the AUCs produced during cross-validation. 
These data enabled me to evaluate how well the grid search algorithm worked in 
comparison to other machine learning approaches. 
 
The AUCs of the top 1% of weightings models (ranked on maximum AUC with a 
performance error < 0.005) were closely clustered, suggesting the models represented by 
the group all scored very similarly, arguing for smooth parameter space with few fine-
grained local optima. This suggested that the boundaries of the grid search algorithm 
were well chosen and the most informative subset of the parameter space was 
interrogated by this analysis. The low performance errors and generalisation errors from 
the ten-fold cross-validation provided additional evidence of the efficiency and success 
of this analysis, suggesting that SuRFR is able to prioritise real, functional variants over 
background variants and it will work equally well on novel data. 
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Studies have shown that no single machine learning algorithm outperforms all other 
methods on all data types and the most important factor affecting the performance and 
reliability of any machine learning algorithm is the training data used ((Tan and Gilbert, 
2003); (Vanneschi et al., 2011); (Caruana, 2006)). I am therefore confident that the 
approach I have used is as effective as any other approach and this is in large-part due to 
the rigorous benchmarking data I have used. 
 
3.4.4 Implications from characterisation of different regulatory variant 
classes 
The ten-fold cross-validation and subsequent model testing using the hold out test 
dataset showed that the three classes of functional variants (ALL, DM and DFP) were 
each best prioritised by different combinations of annotation weightings. Whether this is 
because different classes of variants are caused by combinatorial changes to genomic 
features, or because these different variant classes lead to specific combinatorial patterns 
of genomic features (i.e. cause or effect), cannot be explained by this data alone. 
However, some of these patterns intuitively make sense. For instance, the DM class of 
variants were best prioritised by parameter models that included a strong weighting for 
MAF (rare SNPs ranked higher than common SNPs). This class of variant tends to give 
rise to rare, high penetrance, Mendelian disorders, with severe phenotypes. It is therefore 
not surprising that this class are enriched for rare variants and that MAF is a good feature 
to differentiate them from background variants. Interestingly, these DM variants were 
also consistently ranked higher than the background variants for a large range of 
annotation weighting models, suggesting that these variants are associated with changes 
across many functional annotation categories and are thus identifiable by a range of 
annotation weighting models.   
 
In contrast, the DFP variants (GWAS significant SNPs with functional evidence) were 
more difficult to identify, with only a very specific subset of weighting models 
prioritising them over the background variants. This dataset consists of common SNPs 
with small effect sizes, likely to result in subtler changes to function (than the DM 
variants), which, as a result, could be more difficult to detect. This could explain why 
such a specific-combination of annotation weightings is required to correctly prioritise 
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them above the background variants. As these SNPs are from association studies, they 
are also likely to be common variants associated with lower penetrance, complex traits. 
It is unsurprising, therefore, that the DFP model does not find the prioritisation of rare 
variants to be a useful predictor. 
 
Across all three variant classes, position was found to be the most informative annotation 
feature. This is in keeping with the literature, where it has been shown that the influence 
of a regulatory site on expression drops off almost linearly with distance from the TSS in 
a 10 kb range (Manolio et al., 2009) and that disease variants are enriched in certain 
genomic positions, such as coding and promoter regions, over intronic and intergenic 
regions (Schork et al., 2013). 
 
The ranking of chromatin states (Table 3.3) was chosen based on multivariable 
regression on the full training and validation dataset, the promoter and enhancer 
chromatin state classes ranking higher than the other chromatin states. After the position 
feature, this was the second most informative annotation across all three variant classes. 
This is in keeping with the literature where it has been shown, for example, that disease 
variants are over-represented in strong enhancers (Ernst et al., 2011). 
 
The next most informative feature across the three classes was TFBSs. This is not 
surprising, as changes to TFBSs may alter the binding ability of transcription factors, 
thereby having an impacting on function and regulation. 
 
Non-coding disease associated variants are enriched in DNase HS and thus putative 
regulatory sites (Maurano et al., 2012). DNase HS clusters and DNase footprints are 
highly correlated and provide overlapping information; DNase HSs mark regions of 
open chromatin while the DNase footprints mark regions of transcription factor 
occupancy within these broader regions. Despite this, using both features in the same 
weighting model provides more information than using either feature on its own. This 
study showed both DNase HS clusters and DNase footprints to be informative markers 
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of functionality, though neither feature was weighted as strongly as I would have 
expected. An explanation for this is that DNase HSs and DNase footprints co-localise 
with many other features including enhancers, TFBSs and promoter regions, and their 
effectiveness is therefore masked by the inclusion of these other features.  
 
The remaining features had more variant-class-specific roles, being informative in the 
prioritisation of one class but not necessarily the others (as shown for MAF above). For 
instance, the transcribed enhancer class of annotation does not correlate with the DM 
variants and is only modestly informative for prioritising the ALL class above 
background. In contrast, the transcribed enhancers are highly informative for prioritising 
the DFP variant class. It is difficult to draw any conclusive hypothesis from this result, 
as the transcribed enhancer dataset is very limited (roughly 40,000 enhancers across the 
entire genome) and the p-values from the multivariable regression (Tables 3.8, 3.9, 3.10) 
were non-significant, indicating there is a lot of variability in the data. More data is 
therefore needed to validate this result. 
 
Historically, many of the tools used for discriminating functional from non-functional 
variants made use of evolution as a measure of deleteriousness (Cooper and Shendure, 
2011). Phylogenetic and constraint based approaches are designed on the premise that 
genomic sequence elements that are conserved across species, or in excess of neutral 
expectation, are likely to have important functions. Therefore, when variation is 
identified within one of these highly conserved elements, it is predicted to have an 
impact on function, potentially leading to a disease phenotype. In contrast to this view 
from the literature, this study suggests conservation is not a particularly informative 
annotation, playing a minor role in the prioritisation of DM variants, an even smaller 
contribution to the prioritisation of ALL variants and not contributing at all to the 
discrimination of DFP variants above background. This could be due to redundancy 
amongst the annotations (other annotations masking the true information content of this 
feature), or it could be highlighting the fact that these features are not as enriched in 
conserved regions as previously assumed. Indeed, some studies have shown that 
conservation is in fact a poor predictor of regulatory function (Ritchie et al., 2014) and 
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there is extensive regulatory gain and loss between lineages, indicating that regulatory 
element positions fluctuate across evolution (Meader et al., 2010). 
These data suggest that many annotation categories are correlated and specific subsets of 
annotations are required to best discriminate the different functional variant classes from 
the background variants. 
 
 
3.4.5 Generalisability: performance on HBB and RAVEN 
As a further test of the generalisability of the three SuRFR models, I ran them on two 
additional datasets: the HBB non-coding dataset and the RAVEN dataset, both spiked 
into the 44 ENCODE regions. All three models performed extremely well on the HBB 
dataset, with average AUCs ranging from 0.95 to 0.989; the DM model performing the 
best. The DM model’s performance on these data is very similar to its performance on 
the cross-validation hold out test dataset, where it achieved an AUC of 0.956. This was 
not due to leakage between datasets, as SNPs present in the HGMD dataset were 
removed from the HBB dataset prior to testing. This result is unsurprising, as the HBB 
non-coding dataset contains variants that are very similar to the DM class of HGMD 
variants (disease mutations for a high penetrance Mendelian disease (beta thalassaemia)). 
The performance of the DM model is also comparable (AUCs: 0.989 vs 0.983), to the 
performance of the old model on the same data (Chapter 2, Table 2.4). This result was 
quite surprising, considering the old model was designed in an unsystematic, ad-hoc 
manner, and showed that my general premise in Chapter 2, though unjustified, was still 
good. 
 
More variation could be seen in the performances of the three models on the RAVEN 
dataset; the ALL and DFP models performing roughly equally well (with AUCs of 0.921 
and 0.937 respectively) and the DM model performing with a much lower AUC of 
0.797. These results were not unexpected as the RAVEN dataset contains variants that 
are known to be regulatory, without necessarily a disease phenotype. Therefore, these 
variants are most similar to the DFP class of variants. As such, I would not expect the 
DM model to prioritise them as well as the ALL or DFP models. All three models 
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perform much better than the old model (Chapter 2 Table 2.4, AUC: 0.745) on this 
dataset.  
 
The comparison of SuRFR’s performance on the bootstrapping RAVEN background 
dataset provided a negative control, complementing the earlier tests of SuRFR’s 
generalisability. These results showed that the positive (functional) variant datasets are 
not being ranked above background variants due to some artefact in the data, but are 
instead being truly ranked on their putative functionality.  
 
Taken together, these results suggest that the old version of the prioritisation approach 
was more similar to the DM model of SuRFR and that the parameter optimisation 
procedure and cross-validation did improve the performance and generalisability of my 
prioritisation method. Not only have I made my analysis more robust, I have improved 
the accuracy and performance of SuRFR during the process. 
 
 
3.4.6 Benefits of R package and Bioconductor 
Implementation of SuRFR as an R package has many advantages, including speed, ease 
of use and increased market penetration. Integration of SuRFR into the widely used R 
environment provides flexibility, modularity, adaptability, ease of installation and 
updates. This facilitates the incorporation of additional modules, functions and 
annotations in the future and allows it to be combined with other R packages. 
 
I have constructed the SuRFR R package in a way that allows the user to modify the 
features and parameters to suit their own requirements by specifying a custom model 
instead of the ALL, DM or DFP models. In addition, the MAF function makes use of a 
Gamma distribution to allow the optimal MAF range to be modified to suit each 
analysis. This is particularly useful for the analysis of GWAS data, which, generally 
consist of common variants, do not benefit from the default MAF setting (which 
prioritises unique and rare variants over common variants). Figure 3.7 shows three 
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examples of MAF settings: 3.7.A shows the prioritisation of unique variants above all 
others; B represents a scenario where SNPs with a MAF of 5% are prioritised highest; 
and C represents the prioritisation of variants optimised around a 20% MAF. 
 
 
Figure 3.7. Example gamma distributions for three optimum MAFs: A. 0% (unique); B. 5%; 
and C. 20%. SNPs that are ranked based on their positions on the curve. 
 
3.5 Conclusions 
Robust performance assessment requires good benchmarking data and good performance 
evaluation methodology. I have used both to build upon the work initiated in Chapter 2 
to develop a new variant prioritisation R package. I have shown that the final models and 
weightings chosen from the model assessment and parameter optimisation were able to 
prioritise known functional variants very well (with high AUCs) and also generalised 
well to novel data. This analysis also provided interesting biological insights into the 
functional annotations that correlate with different regulatory variant classes. SuRFR has 
many advantages over other methods. However, to confirm it is better than other 
comparable approaches I must do a formal comparative analysis. This will be the topic 
of Chapter 4. 
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Chapter 4: Comparison against competing approaches 
4.1 Introduction 
4.1.1 Review of SuRFR evaluation and performance  
In Chapter 3 I described how I designed and tested a new R package, SuRFR, which 
prioritises genomic variants on the basis of functional annotation. This system makes use 
of data from multiple annotation categories, ranking SNPs in each category and using a 
weighting model to combine the individual ranks into a rank-of-ranks. Three weighting 
models were trained and validated using ten-fold cross-validation: a general model 
broadly applicable to any genomics analysis (ALL); a model designed for the 
prioritisation of rare disease variants (DM); and a model for the prioritisation of complex 
disease variants (DFP). The performance of each of these models has been assessed 
using a hold out test dataset and two additional, unrelated datasets (the HBB and the 
RAVEN datasets). All three models were shown to perform with high specificity, 
sensitivity, and generalisability on the data classes for which they were designed, 
suggesting that SuRFR will accurately prioritise putative functional variants for further 
investigation. However, the usefulness of this method cannot be fully established until it 
has been compared against other related tools.  
 
During the first half of my PhD, no sufficiently comparable approach existed (see 
Chapter 2 for a summary of the tools that were available during that time); however, 
from late 2013 onwards, several new methods were published: GWAS3D (May, 2013); 
FunSeq (October, 2013); CADD (February, 2014); and GWAVA (February, 2014). In 
this chapter I will describe each of these methods; discuss their pros and cons; and 
question how well they perform against SuRFR in a comparative analysis. 
 
 
4.1.2 Update on SNP prioritisation approaches 
4.1.2.1 GWAS3D 
GWAS3D is a method designed for the interpretation of genomic variants from GWAS 
studies, but it can also be used for the prioritisation of regulatory variants independent of 
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GWAS signals (Li et al., 2013). This method was developed as a web-based tool, 
implemented with a Perl-based web framework, ‘Catalyst’, using a MySQL database to 
store the annotation data. The workflow for GWAS3D is shown in Figure 4.1. 
 Given a set of GWAS data, GWAS3D performs a preliminary filter on the data to filter 
out less significant SNPs, removing query SNPs that fall above a user defined p-value 
cut-off. If the input data is not presented in VCF format (and so lacks reference and 
alternative alleles for each SNP), any SNPs that do not map to HapMap or 1000 
Genomes are also filtered out. GWAS3D next identifies all SNPs in linkage 
disequilibrium (LD) (based on a user-defined LD standard) with each of the lead (query) 
SNPs. These SNPs are then annotated for a range of features (Figure 4.1, blue coloured 
block entitled ‘GWAS3D Signals Mapping’) including distal interactions, active histone 
marks, conservation, and user-defined data. Any SNP overlapping at least one signal is 
brought on to the next stage of the pipeline, while any SNP that does not overlap any 
signal is removed. Next, the binding affinity significance of each SNP for each of the 
transcription factor (TF) motifs from the ENCODE project is measured using position 
weight matrices of the transcription factor binding site (TFBS) motifs. The log-odds 
(LOD) of probabilities of binding for each of these motifs is then compared against the 
null distribution of binding affinity difference (calculated by permuting each ENCODE 





Figure 4.1. This diagram outlines the GWAS3D workflow, and has been taken from Li et al., 
2013. See the description of the pipeline (Section 4.1.2.1) for full details (Li et al., 2013). 
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GWAS3D uses three measurements (GWAS, binding affinity and conservation) and 
their associated p-values to perform Fisher’s combined probability test to calculate a 
combined p-value (CP) for each variant. The most significant p-value for any SNP in LD 
with the original lead variant is taken as the CP for that lead variant. All of the original 
input variants are then ranked on their CP values. 
 
In contrast to the analysis of GWAS data, when a variant list without association data is 
used, the data cannot be filtered on association significance, nor can a final GWAS 
measurement be calculated and included in the CP value. In addition, during the LD 
filtering step of GWAS3Ds protocol, some of the input SNPs are likely to be replaced by 
alternative SNPs within the same LD block (as the query SNP may not be the lead SNP 
for that LD block).  Therefore, although in theory this method can be used to assess non-
GWAS data, in practice, this method is not well suited to such data. For this reason, I 
chose not to compare SuRFR against GWAS3D. 
 
4.1.2.2 FunSeq  
Function based prioritisation of sequence variants (FunSeq) is a variant prioritisation 
workflow developed to prioritise candidate non-coding cancer drivers (somatic 
mutations) based on patterns of selection, but which can also be used for personal 
genomics (germ-line mutations) (Khurana et al., 2013). Figure 4.2 describes how 
FunSeq scores variants on their predicted deleterious impact. The input SNPs are filtered 
at each level of the prioritisation workflow; only those SNPs that meet a level’s criteria 
being retained. As a SNP passes each level, it achieves a higher score; scores range from 
0 (no levels passed) to 6 (six levels passed). 
 
Khurana et al. (2013) used population-variation data across 1,092 individuals from the 
1000 Genomes (Phase 1) project to identify signatures of purifying selection. Using the 
full range of polymorphisms (SNPs, indels and structural variations) from these 
individuals, they studied patterns of purifying selection in different functional categories, 
defined by data from ENCODE. In particular, they looked at non-coding regions. The 
non-coding regions were first divided into broad categories based on their overlap with 
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functional data from ENCODE (such as TFBSs, DNase hypersensitive (DNase HS) 
regions, enhancers and non-coding RNAs). These broad categories were then further 
subdivided into 677 high-resolution categories (for instance, into different families of 
TFs). These categories were analysed to see if any were enriched for rare variants under 
very strong selection. In this way they identified 102 categories (of the 677) that showed 
statistically significant selective constraints, and specific genomic regions where variants 
are more likely to have strong phenotypic impact. Using these data, they defined the 
regions that contained a high fraction of rare variants (covering ~0.02% and ~0.4% of 
the genome) as “sensitive” and “ultra-sensitive” regions. Within these regions they found 
~40 and ~400 fold enrichment respectively of disease-causing mutations from HGMD, 
therefore providing independent validation that these sensitive and ultra-sensitive 
regions are functionally important. 
 
 The authors next examined somatic variants (cancer variants) and found that 99% of 
somatic variants occur in non-coding regions, including TFBSs, non-coding RNAs and 
pseudogenes. Analysis of somatic variants from tumour and normal tissue from the same 
individual showed an enrichment for missense (~5x), loss-of-function (~14x), sensitive 
(~1.2x) and ultrasensitive (~2x) variants. Khurana et al. showed that somatic cancer 
variants are enriched for functionally deleterious mutations and somatic variants in the 
non-coding elements under strongest selection are the most likely to be cancer drivers. 
 
Although the authors recommend that FunSeq would be best used for tumour genomics, 
they also suggest that it can be used for the identification of potentially deleterious 
variants in personal genomics. In this latter capacity, FunSeq is a comparable method to 
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Figure 4.2. This figure presents a graphical overview of the FunSeq workflow, showing the 
filtering of SNPs to identify candidate non-coding cancer drivers based on patterns of selection. 
In the first step, the somatic variants are filtered to exclude 1000 Genomes polymorphisms. In 
the second step, only variants which overlap at least one of the non-coding annotations are 
retained. In step 3, variants that are located in “sensitive” regions are retained. In step 4, 
variants are prioritised on whether they disrupt a transcription-factor binding motif, while in 
step 5, variants are filtered based on whether they reside near the centre of a biological network. 
Lastly, variants are prioritised based on whether they are located in a region that contains 
mutations found in other (or multiple) cancer samples. This figure is taken from (Khurana et 
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4.1.2.3 CADD 
Combined Annotation-Dependent Depletion (CADD) is a framework for integrating 
diverse genome annotation data, designed to score all possible SNPs and indels on 
deleteriousness (Kircher et al., 2014). This method was trained on a combination of 
observed and simulated variation. The observed data consisted of 14.9 million SNPs 
across the human genome with a derived allele frequency (DAF) ≥ 95% (1000 Genomes 
project), and, as such, are fixed or almost fixed in the population. In contrast, the 
simulated data consisted of 14.9 simulated de novo mutations derived using a custom 
empirical model of sequence evolution (motivated by parameters of the General Time 
Reversible (GTR) model (Tavaré, 1986)). The authors claimed an advantage of this 
training data was that it did not rely on catalogues of known pathogenic variants and 
therefore was not affected by the acquisition bias from which such data collections 
suffer.  
 
CADD was built on the premise that selective constraint can be used as a measure of 
deleteriousness. Linear models were used to correlate 63 genomic annotation features 
with the observed and simulated datasets. This analysis showed that nearly all of the 
annotations could be used to discriminate observed from simulated variants. The 
strongest individual annotation metrics were found to be the conservation features. Using 
features derived from these 63 genomic annotations, Kircher et al. trained a Support 
Vector Machine (SVM) with a linear Kernel. From this, ten models (each independently 
trained on observed variants and different subsets of simulated variants) were developed. 
Spearman’s rank correlations showed that these ten models were highly correlated (rho > 
0.99). These ten models were averaged into a single model, which was used to score all 
(8.6 billion) possible SNVs in the genome (each position being a potential SNP or indel 
location (Figure 4.3)). The scoring system developed was called the C score. To simplify 
the C scores, Kircher et al. computed scaled C scores, which represent a variant’s rank 
compared to the previously computed C scores for the 8.6 billion possible variants in the 
genome. Scaled C scores range in value from 0 – 99, higher scores suggesting greater 
deleteriousness than lower scores. Figure 4.3 shows that disease variants have on 
average higher scaled C scores than non-disease variants (see Table 4.3.c: “Olfactory”) 
or random background variants (see Table 4.3.c: “Other”) 
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Figure 4.3 Relationships of the CADD scaled C scores (ranging from 0 to 99) to genome-wide 
variant consequence categories: a) ratio of variants within each variant consequence category 
for each C score bin (0-1; 1-2; 2-3; … 50-51; ≥51); b) ratio of variants within each variant 
consequence category, normalised by the number of SNPs with in each category, for each C 
score bin; the legend for each variant category includes, in brackets, the median and range of 
scaled C scores for that category; c) violin plots showing the median C scores of potential 
nonsense variants for 6 classes of genes (genes with at least 5 known pathogenic variants 
(Disease); genes predicted to be essential (Essential); Genes from GWAS studies harbouring 
significantly associated variants (GWAS); genes recorded by the 1000 Genomes project as 
harbouring at least two loss-of-function mutations (LoF); genes encoding olfactory receptor 
proteins (Olfactory) and a random selection of 500 genes (Other)), showing disease and 
functional nonsense variants are more likely to have higher C scores than non-disease 
(Olfactory) or random background nonsense variants (Other). Taken from Kircher et al. (2014) 
(Kircher et al., 2014). 
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The authors used this method to prioritise pathogenic and benign variants from the 
ClinVar database of clinical variation, and showed that CADD could prioritise the 
pathogenic SNPs above the benign SNPs better than the missense and conservation 
metrics SIFT, PolyPhen, GERP, PhastCons and PhyloP (Kircher et al., 2014). I therefore 
considered this method to be an appropriate comparative tool to test against SuRFR. 
 
4.1.2.4 GWAVA 
Genome-wide Annotation of Variants (GWAVA) was developed by Ritchie et al. (2014) 
to prioritise non-coding variants on the likelihood of functionality and, therefore, 
pathogenicity (Ritchie et al., 2014). This method combines multiple annotations to 
identify variants that are likely to be functional. These annotations include: regulatory 
features (such as DNase HS, TFBSs and RNA polymerase binding); genic context 
(position of variants relative to genomic features such as exons, introns, distance to the 
nearest TSS, etc.); human variation; conservation; and sequence context (such as G+C 
content, CpGs and repetitive elements). A modified random forest algorithm was used to 
train a classifier that integrates these individual annotations into a single metric to 
discriminate functional variants from background. The classifier was trained on data 
consisting of 1,614 known disease-implicated, regulatory variants from HGMD 
(downloaded from Ensembl), and three different background datasets. These background 
datasets consisted of randomly selected variants from the 1000 Genomes project (with 
minor allele frequencies ≥ 1%): i) 161,400 variants from across the genome; ii) 16,140 
variants matched (to the HGMD regulatory variants) for distance to the nearest TSS; and 
iii) all variants within a 1 kb window of each of the HGMD variants (5,027 variants). 
From these three training datasets, three distinct classifiers were developed. Model 
training and validation was performed using ten-fold cross-validation and performance 
was measured using ROC curves and AUCs, which showed that the relative performance 
of the three models improved as the background variant datasets became less stringently 
matched to the known HGMD variants (Figure 4.4). Independent validation, using 
pathogenic variants from the ClinVar clinical variant database against non-pathogenic 
ClinVar variants and 1000 genomes background variants matched by distance to the 
nearest TSS, showed GWAVA was successfully capable of prioritising pathogenic 
variants above background variants. 
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Due to the similarities in the feature sets and model training methods used by both 




Figure 4.4 Mean ROC curves and AUCs from the ten-fold cross-validation experiments of 
GWAVA on the three training datasets. Taken from Ritchie et al., 2014 (Ritchie et al., 2014). 
 
 
4.1.3 Additional datasets 
As GWAVA was trained on HGMD data that contained variants that overlap variants 
from my hold out test dataset, the HBB non-coding dataset and the RAVEN dataset, 
GWAVA’s performance on these three datasets would be inflated due to over-fitting. 
This meant that none of these datasets could be used for the comparison of SuRFR, 
CADD, FunSeq and GWAVA. Therefore, an additional, unbiased, dataset was required. 
The most obvious data to use were the two ClinVar datasets used by Ritchie et al. (2014) 
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to evaluate GWAVA’s performance on novel data, as they had not been used to train any 
of these four models.  
 
4.1.3.1 ClinVar 
The ClinVar database is a public archive of medically important variants and 
phenotypes, officially launched in April 2013 (Landrum et al., 2014). This resource is 
funded and curated by the US National Institute of Health (NIH). An advantage of this 
database is that all submissions are categorised both by data source (whether from 
clinical tests, literature review or research) and review status (the extent of variant 
verification: single submission; multiple submissions; or reviewed by an expert panel). 
In addition, many of these variants have been functionally validated. Using these and 
other filters, users can select subsets of data that meet specific, user-defined criteria. As 
this resource is still quite new, it is more limited in size than other resources, such as 
HGMD. However, it also contains variants that are not yet present in HGMD, making it 
an excellent independent data source. 
 
4.1.3.2 1000 Genomes variants matched for distance to the TSS 
An interesting aspect of the datasets generated by Ritchie et al. (2014) for the training 
and validation of GWAVA is that the background datasets were matched to the positive 
variants by distance to the nearest TSS. This, importantly, allowed them to assess the 
performance of their method, excluding the effect of position. This allowed them to 
correct for the acquisition bias that exists in databases of regulatory variants (which tend 
to contain more variants proximal to the TSS than more distal variants). Using a similar 
method, I generated my own matched background dataset for the RAVEN regulatory 
dataset, consisting of variants from the 1000 Genomes European (EUR) dataset. 
 
4.1.3.3 Complex trait related datasets 
Projects that start with an association signal or a linkage region followed by sequencing 
or fine mapping of the region, and end with an experimentally, functionally validated 
regulatory disease variant form an important class of test dataset. It was important to 
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identify studies like these, to allow me to test the performance of each of the four 
prioritisation-methods in a less synthetic manner. The following sections describe three 
complex trait analyses that fit this criterion, which I then used to compare the 
performances of the prioritisation methods. 
 
SORT1: 
Musunuru et al. (2010) investigated a locus on chromosome 1p13 known to be strongly 
associated with low-density lipoprotein cholesterol levels (LDL-C) and cardiovascular 
disease (Musunuru et al., 2010). Fine-mapping in the genomic region responsible for 
LDL-C association, using SNPs genotyped from ~20,000 individuals of European 
descent (Kathiresan et al., 2009) identified 22 variants. Of these, the six SNPs with the 
highest association were clustered in a 6.1 kb non-coding region. Luciferase assays and 
electrophoretic shift assays (EMSA) demonstrated that one of the six, rs12740374, 
creates a binding site for the transcription factor C/EBP and alters liver-specific 
expression of the SORT1 gene.  
 
EGR2: 
A good candidate for systemic lupus erythematosus susceptibility (SLE) is the early 
growth response 2 gene (EGR2). Myouzen et al. (2010) performed a case–control 
association study for SLE, of the 80kb region around the EGR2 gene (Myouzen et al., 
2010). This study identified a single non-coding SNP with a significant p-value. 
Functional characterisation (EMSA) of the SNPs in complete LD (R2 = 1.0) with this 
tagging SNP showed that two SNPs had allelic differences in binding ability. Moreover, 
luciferase assays performed on these two SNPs showed that one (rs1412554) increased 
expression by 1.2 fold while the second, (rs1509957) repressed transcriptional activity.  
 
TCF7L2: 
In a search for variants associated with type-2 diabetes (T2D), Gaulton et al. (2010) 
identified a GWAS significant SNP (rs7903146) at the TCF7L2 locus (Gaulton et al., 
2010). This variant and five others in high LD with it were investigated using luciferase 
assays. Allelic differences in enhancer activity were observed for the tagging SNP, 
rs7903146.  
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4.1.4 Summary of chapter aims 
The aim of this chapter was to compare the performance of SuRFR against three similar 
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4.2 Methods 
4.2.1 Running GWAVA 
GWAVA can be used either as a web based tool that provides pre-computed scores for 
all known human variants, or run locally as a python script. I chose to use the 
downloadable command-line version as some of the variants in the test datasets are not 
included in the 1000 Genomes and so could not be annotated by the online version. 
The GWAVA software requires the following python libraries (and their dependencies) 
to operate: 
- numpy (1.7.0)    
- scikit-learn (0.14.1)  
- scipy (0.11.0)    
- pybedtools (0.6.4)  
- pandas (0.12.0)    
- tabix (0.2.5)  
 
Stewart Morris (SM) installed GWAVA and its environment variables on the server 
Wheeljack. GWAVA operates via a two-step process: first building a variant annotation 




Step 1: SNP annotation 
The input data format is a four-column bed file containing the tab-delimited columns: 
chromosome; start coordinate; end coordinate; and a unique identification number. For 
example:  
chr1    123455  123456  rs123 
 
Variants in the input were first sorted using the command format:  
sort -k1,1 -k2,2n ClinVAR_path_non_path.bed -o ClinVAR_path_non_path.sorted.bed 
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The sorted data was run through the annotation script using the command format ‘python 
annotation_script sorted_variant_file annotated_variant_file’: 
 




Step 2: SNP classification 
The annotated variant file was then run through the classifier script using the command 
format ‘python GWAVA_classifier model_type annotated_variants scored_variants’, 
model types being ‘unmatched’, ‘tss’, or ‘region’. E.g. 
 
python gwava.py tss annotated_variants.csv variant_scores.bed  
 
 
4.2.2 Running FunSeq 
FunSeq is a PERL- and Linux/UNIX-based tool that is available either as a web tool or a 
downloadable command line program. The command line version of FunSeq requires the 
files listed in Figure 4.5 and has the following dependencies: 
- Bedtools  
- Tabix  
- VAT (snpMapper Module) 
- Perl 5 or higher 
- Perl package Parallel::ForkManager 
 
SM installed FunSeq and its dependencies on the server Wheeljack. The input for 
FunSeq is a bed file containing the following tab-delimited columns: chromosome; start 
coordinate; end coordinate; reference allele; and alternative allele. The general usage 
commands for FunSeq are shown in Figure 4.6 
 
For my analysis, FunSeq was run using the –m 2 option (germline mutation). 
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I ran a test comparing different MAF thresholds (0-1 in 0.1 steps) and found ‘0.1’ to be 
the best compromise between specificity and sensitivity. I therefore set the MAF 




























Figure 4.5 Required data files for FunSeq, taken from the Funseq manual web page: 
http://info.gersteinlab.org/FunSeq 
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4.2.3 Running CADD 
CADD is available as a web tool. The input data must be in the form of the first five 
rows of a VCF file without a header row (e.g. chromosome; coordinate (+1); ID; 
reference allele; and alterative allele).     
 
4.2.4 ClinVar datasets 
I made use of multiple datasets from ClinVar in this analysis: a pathogenic dataset, a 
non-pathogenic dataset and a non-coding pathogenic dataset. The pathogenic dataset and 
non-pathogenic dataset were both downloaded from the GWAVA support website 
(ftp://ftp.sanger.ac.uk/pub/resources/software/gwava/v1.0/annotated/ accessed March 
2014). These two datasets consisted of a true positive set of 194 pathogenic variants and 
a background set of 150 non-pathogenic variants. However, the pathogenic dataset 
contained a large number of mitochondrial variants. Removing the mitochondrial 
variants reduced this dataset to 128 pathogenic variants. An additional 58 non-exonic, 
non-coding SNPs were obtained directly from the ClinVar database. 
 
 
4.2.5 1000 Genomes background variants 
A dataset of 19,400 1000 Genomes background variants matched (by distance to the 
nearest TSS) to the pathogenic ClinVar variants was downloaded from the GWAVA 
support website. SM wrote a Perl script to allow us to generate additional background 
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datasets consisting of 1000 Genomes EUR variants matched by distance to the nearest 
TSS for each positive variant dataset. The function of this script was to bin all the 
variants from the 1000 Genomes EUR database into bins of different distances to the 
nearest TSS. Using this program he was able to randomly sample the 1000 Genomes 
database for SNPs matched to a list of distances to the nearest TSS, pulling out as many 
SNPs at each distance as required for each analysis. SM used this method to construct a 
matched background set of variants for the ClinVar non-coding dataset. This dataset 
contains 5,800 variants. He repeated this for the RAVEN regulatory dataset, producing a 
matched background dataset of 9,500 variants. 
 
 
4.2.6 Complex trait related datasets 
The SNPs from both the SORT1 analysis and TCF7L2 analysis were used by Ritchie et 
al. to test the performance of GWAVA and so were available from the GWAVA support 
website. I constructed annotation tables for both of these SNP sets; the SORT1 
annotation table contained 22 variants and the TCF7L2 annotation table containing six 
SNPs. 
 
I ran the lead SNP (rs10761670) from the EGR2 analysis performed by Myouzen et al. 
(2010) through the online tool SNAP 
(https://www.broadinstitute.org/mpg/snap/ldsearch.php accessed May 2014) to identify 
all the SNPs proxy to this tagging SNP (R2 ≥ 1.0). This program returned a list of 35 
proxy SNPs (including the tagging SNP). I constructed an annotation table for these 35 
SNPs, using the 1000 Genomes Asian (ASN) population to define MAFs. In addition, I 
also generated a SNP dataset for the 80kb region surrounding the EGR2 gene. This 
larger dataset contained all the SNPs from this region present in the 1000 Genomes ASN 
database (n = 237). 
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4.3 Results 
I compared SuRFR’s ability to prioritise known pathogenic variants against three 
additional variant prioritisation approaches: FunSeq, CADD and GWAVA.  Independent 
data that had not been used for the training of any of these methods was required to 
compare their performances. This restricted the data sources at my disposal, as the tools 
were trained on different datasets. Despite this, I was able to identify data not used to 
train any of these tools (the ClinVar datasets) and used this to compare all of the 
methods against each other.  
 
 
4.3.1 Performance of SuRFR versus GWAVA, CADD and FunSeq  
4.3.1.1 ClinVar 
To compare the performances of SuRFR, GWAVA, FunSeq and CADD, I used an 
independent dataset of clinical variants from the ClinVar archive of disease variants 
(Landrum et al., 2014) (see Section 4.1). This dataset consisted of 128 pathogenic 
variants, extracted from the ClinVar archive by Ritchie et al. (2014) to test the 
generalisability of GWAVA. I had modified this dataset by removing all mitochondrial 
variants (reducing the number from 194 to 128 variants). The reasons for this were two-
fold: firstly, SuRFR has been trained on nuclear (and not mitochondrial) variants and 
therefore it cannot be assumed that SuRFR can correctly prioritise functional 
mitochondrial variants; and secondly, SuRFR relies heavily on genomic annotations that 
pertain exclusively to nuclear, and not mitochondrial, variants (in particular, histone 
modifications). As none of the other datasets used in this analysis contained 
mitochondrial variants, this task did not need to be repeated. 
 
The 128 (nuclear) pathogenic variants were compared against two background datasets: 
a background dataset of 150 “non-pathogenic” variants (also from the ClinVar archive) 
and 19,400 variants identified as part of the 1000 Genomes project, distributed across the 
genome and matched with the pathogenic variants for distance to the nearest TSS. As for 
the pathogenic variants, these background datasets were selected by Ritchie et al. for 
their analysis of GWAVA’s generalisability.  
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Closer examination of the pathogenic ClinVar dataset showed that it contained several 
synonymous, non-synonymous and UTR exonic variants. I therefore also extracted an 
additional pathogenic dataset directly from the ClinVar archive, consisting of purely 
non-exonic, non-coding variants (58 non-exonic, non-coding, clinical variants). For this 
second pathogenic dataset, I generated a background dataset matched by distance to the 
nearest TSS, 100 times the size of the pathogenic dataset (100 background SNPs 
matched to each pathogenic SNP).  
 
None of these datasets had been used to train SuRFR, GWAVA, CADD or Funseq, 
allowing these data to be used for rigorous comparison of tool performance. For the 
parameters used for each of these tools, see Section 4.2. 
 
Pathogenic ClinVar variants: 
I ran SuRFR, GWAVA, CADD and FunSeq on the 128 pathogenic variants in 
combination with i) the 150 non-pathogenic variants test dataset and ii) the 19,400 
matched 1000 Genomes variants. On these data, SuRFR was able to discriminate the 
pathogenic variants above background with AUCs of 0.80 and 0.85 respectively. On the 
same data, AUCs of 0.71 and 0.80 were achieved by GWAVA, 0.76 and 0.83 by CADD 
and 0.54 and 0.48 by FunSeq (Figure 4.8 A & B). These results show that SuRFR 
outperforms all the other methods on these data. FunSeq’s performance on both of these 
datasets was roughly what you would expect by chance. Based on this result, I chose not 
to include FunSeq in any of the downstream analyses. 
 
Non-coding versus matched 1000 Genomes background variants: 
In contrast, when the performance of SuRFR, GWAVA and CADD on the non-exonic, 
non-coding pathogenic dataset was compared, all three methods performed at a very 
similar level, with CADD just outperforming SuRFR (Figure 4.9). The AUCs measured 
in this analysis were 0.671 (SuRFR), 0.629 (GWAVA) and 0.692 (CADD), all much 
lower than for the other pathogenic ClinVar dataset (Figure 4.8 A & B). 
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Figure 4.8. Comparison of SuRFR, GWAVA, CADD and FunSeq on A. ClinVar pathogenic vs 
non-pathogenic variants and B. ClinVar pathogenic vs 19,400 matched 1000 Genomes variants. 
This plot shows the performance if these four methods via ROC curves (true positive rate on the 
y-axis, versus false positive rate on the x-axis) and AUCs against the performance expected by 
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chance (grey dotted line). SuRFR (blue line) outperforms all three models, GWAVA (red line), 





Figure 4.9 ROC curves and AUCs for SuRFR (blue), GWAVA (red) and CADD (green) run on 





The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
Chapter 4: Comparison against competing approaches  159 
4.3.1.2 HBB coding 
Of the four tools I have compared, GWAVA is the most similar tool to SuRFR, making 
use of largely overlapping annotation data to prioritise non-coding variants on predicted 
functionality. To test and compare the ability of these two methods to prioritise 
pathogenic coding variants, I ran both tools on a test dataset consisting of coding disease 
variants for the disease ß thalassemia, located within the HBB gene. Both of these 
methods were extremely successful at prioritising the coding pathogenic variants above 
background 1000 Genomes variants, with AUCs of 0.996 and 0.975 for SuRFR  (DM 




4.3.1.3 RAVEN versus background matched by distance to the nearest 
TSS 
As the RAVEN regulatory variants were used as part of the training and validation data 
for the development of GWAVA, this data could not be used to fairly compare 
GWAVA’s performance against the other tools (as it would give an inflated estimate of 
GWAVA’s performance). However, this data could be used to compare the performance 
of SuRFR and CADD. I generated a new background variant dataset consisting of 100 
matched variants for every RAVEN variant. This background dataset contained 9,500 
variants matched for distance to the nearest TSS. SuRFR did not perform as well on this 
dataset as it had done on the original RAVEN dataset (where the control SNPs were not 
matched by distance to the nearest TSS), achieving an AUC of 0.702 compared to the 
previous AUC of 0.94 (both for the DFP model). However, despite this large decrease in 
performance, SuRFR still performs better than CADD, which achieved an AUC of 0.608 
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Figure 4.10 ROC curve and AUCs showing the performance of SuRFR (blue line) and GWAVA 
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Figure 4.11 ROC curves and AUCs for SuRFR (blue line) and CADD (green line) run on the 
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4.3.1.4 Complex trait datasets 
I next compared the ability of SuRFR, GWAVA and CADD to prioritise known, 
functional, pathogenic variants identified by others during the study of complex traits. In 
each of these three examples, the projects started with an association signal or a 
candidate gene region. These candidate loci were then analysed in more detail. The 
outcome of each study was the identification of variants that altered gene expression or 
protein-DNA interactions, through the use of reporter assays or electrophoretic shift 
assays (EMSAs).  
 
SORT1: 
Musurunu et al. (2010) investigated a region of chromosome 1p13 associated with LDL-
C levels.  Subsequent fine mapping of this region, genotyping roughly 20,000 
individuals of European descent, identified 22 SNPs within the minimal genomic region 
associated with LDL-C in these individuals. Of these 22 SNPs, the six with the highest 
association were clustered in a 6.1kb region. Functional investigation of these SNPs 
confirmed that one of the six, rs12740374, creates a binding site for the transcription 
factor C/EBP, and functional assays indicated it altered expression of the SORT1 gene. I 
ran the 22 SNPs in high LD (R2 = 1.0) with the tagging SNP (rs10761670) through 
SuRFR, GWAVA and CADD. SuRFR prioritised the functionally validated SNP 
(rs12740374) first out of 22, while GWAVA ranked it sixth and CADD ranked it 
twentieth (Table 4.1).  
 
EGR2: 
The chr10q21 candidate locus for SLE is roughly 80kb in size and contains 237 variants 
from the 1KG Asian population database with a MAF >0.10 (as of June 2014). 
Assessment of all 237 by GWAVA and SuRFR failed to rank the functionally validated 
variant, rs1509957, in the top 10% of prioritised SNPs. However, restricting the dataset 
to the 35 proxy SNPs in high LD (R2 >= 1.0) with the most significantly associated SNP 
for SLE (Myouzen et al., 2010), the functional variant ranked very highly for both 
SuRFR and GWAVA (first and second respectively). In contrast, CADD ranked this 
variant eighteenth (Table 4.1). 
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TCF7L2:  
The last complex trait example I used to compare the performances of SuRFR, GWAVA 
and CADD was the TCF7L2 locus associated with T2D. This locus contains six variants 
that were functionally assessed, of which one was shown to significantly increase 
enhancer activity (rs7903146). Prioritisation of these six variants using SuRFR, 






Total number of 
variants 
SuRFR ranking of 
functional variant 
GWAVA ranking of 
functional variant 
CADD ranking of 
functional variant 
SORT1 22 1st out of 22 6th out of 22 20th out of 22 
EGR2  35 1st out of 35 2nd out of 35 18th out of 35 
TCF7L2 6 2nd out of 6 2nd out of 6 2nd out of 6 
 




In conclusion, SuRFR was best able to prioritise known, functionally verified complex 
trait variants above background variants better than both GWAVA and CADD. In 
addition, this analysis showed that although CADD may be as good a method for 
identifying some classes of functional variants, it is not as good as either SuRFR or 
GWAVA at prioritising validated functional variants for complex traits. 
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4.4 Summary and Discussion 
4.4.1 Pros and Cons of GWAVA, CADD and FunSeq 
I compared SuRFR’s ability to prioritise pathogenic variants against three tools 
(GWAVA, FunSeq and CADD) which were also designed to prioritise non-coding 
variants and all of which were published near the end of my PhD. Although they are all 
designed to perform the same task, they were developed based on different frameworks: 
GWAVA being written in Python and making use of a modified random forest algorithm 
(Ritchie et al., 2014); CADD providing a single measure (C score), based on the 
integration of a range of annotations, pre-computed for the entire genome (Kircher et al., 
2014); and FunSeq scoring variants on the pattern of functional annotations they overlap 
(Khurana et al., 2013). 
 
4.4.1.1 GWAVA 
Of these three, the method that most closely resembles SuRFR is GWAVA. There are 
two aspects of GWAVA that make it very similar to SuRFR: the feature set incorporated 
into its prioritisation model; and the training methodology implemented during its 
development. Like SuRFR, GWAVA was designed to make use of the annotation 
features conservation, histone marker data, and allele frequency, amongst others. 
Although the black box nature of GWAVA prevents us from making a proper 
comparison of the features used by GWAVA versus SuRFR, or the weighting of the 
features within GWAVA’s model, several conclusions can be drawn based on the data 
presented in the GWAVA paper. While not identical, the functional annotations used by 
these two methods are similar enough to explain why both methods perform to a similar 
level on several datasets: the HBB coding dataset (Figure 4.11) and the EGR2 and 
TCF7L2 complex trait datasets (Table 4.1). However, in this chapter I have also shown 
that SuRFR performs better than GWAVA on several other datasets, including the three 
ClinVar datasets (Figure 4.9 A. & B. and Figure 4.10), as well as the SORT1 complex 
trait dataset. This could potentially either be due to the differences in the functional 
annotation used by each method (for instance, GWAVA includes GC content and 
SuRFR uses FANTOM CAGE data and transcribed enhancer data) or due to the way 
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each method combines the annotation data into a unified model (ranking versus random 
forest approach).  
 
Another possible explanation for the difference in performance between the two 
approaches could be training methods used for each tool. GWAVA was trained and 
validated using a bipartite split of the training data (into training and validation folds for 
cross-validation). In contrast, SuRFR was trained using a tripartite data split: training, 
validation and hold out test datasets. Tripartite splitting of the training data allows both 
performance and generalisation errors to be calculated, quantifying the level of over-
fitting to the training data and providing a measure of the generalisability of the method. 
Bipartite splitting, in contrast, does not allow the amount of over-fitting to be assessed. 
GWAVA could, therefore, be over-fitted to the training data, explaining why it performs 
worse on independent datasets.  
 
A final explanation for the difference in performance between SuRFR and GWAVA 
could be the differences in training data. Although both methods make use of data from 
HGMD, the data used to train GWAVA is an older release of HGMD, from 2012. This 
data was not obtained directly from HGMD, but instead from Ensembl, and was less 
well annotated than the same data obtained directly from HGMD. In contrast, to train 
SuRFR I used a more recent, professional release of HGMD (2014), which was well 
annotated and sub-categorised into variant classes (DM, DFP, etc. see Chapter 3 for 
more details). Using this additional classification data, I was able to filter the PROM 
table to remove any ambiguous SNPs (removing SNPs that were not verified as disease 
mutations (the DM? variants) and removing SNPs that had been identified from GWAS 
but had not been followed up with functional validation (the DP variants)). By only 
using SNPs that had a proven disease or functional role, I was able to train SuRFR on a 
much cleaner dataset than the full HGMD regulatory dataset, potentially improving the 
signal to noise ratio in my data and fitting my weighting model more accurately to 
disease (and functional) variants.  
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4.4.1.2 CADD 
CADD was developed using a support vector machine learning approach, trained on 14.7 
million high-frequency human-derived alleles and an equal number of simulated variants 
(Kircher et al., 2014). This framework combines a range of 63 annotations 
(Supplementary Tables 1 and 2 (Kircher et al., 2014)) into a single measure, known as a 
C score, for each variant. This measure can be viewed as an estimate of deleteriousness 
and can be used to rank variants on their deleterious effect.  
 
In my comparative analysis of CADD and SuRFR’s performances, SuRFR either out-
matched or performed as well as CADD on all of my test datasets. This may be because 
CADD has been trained to differentiate high-frequency alleles from simulated variants 
of equal frequencies, whereas the datasets I have used contain variants with a range of 
allele frequencies. This may also be due to biases in the data used to train CADD. For 
instance, the authors claim the best features were conservation metrics; however, the 
training data contains positive variants that are fixed or almost fixed in the human 
population (DAF > 95%), whereas the simulated variants are de novo variants (therefore 
unique variants) that are likely to overlap many unconstrained regions of the genome, 
biasing towards conservation metrics.  
 
4.4.1.3 FunSeq  
FunSeq’s model framework is built on the enrichment of rare variants in particular 
annotation categories to estimate levels of purifying selection. Although this approach 
can be used for personal genomics, the authors make a point of highlighting that it is 
most useful and effective for cancer genomics. This is particularly apparent from my 
analysis of its performance on the ClinVar datasets, where it was not able to distinguish 
pathogenic variants from background variants any better than would be expected by 
chance (Figure 4.8). FunSeq’s poor performance on these data is likely to be explained 
by the manner in which it filters SNPs. In its default mode (for the identification of 
cancer drivers), FunSeq filters out all variants that occur in the 1000 genomes project, as 
any variant that is not unique is unlikely to be a cancer driver. For the analysis of 
germline mutations, FunSeq instead allows the user to define a cut-off MAF; all SNPs 
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with MAFs above this threshold being discarded. When no threshold was used (setting 
the MAF cut-off to 1.0), FunSeq could not distinguish the background variants from 
pathogenic variants, leading to a very high false positive rate. I went on to test a range of 
potential MAF cut-offs (0.1 to 1.0 in 0.1 steps) and found the best cut-off (producing the 
best AUC) to be a MAF of 0.1. Using this cut-off, however, many variants within my 
test datasets were discarded (as they had MAF’s greater than 0.1), increasing the false 
negative rate. In conclusion, although using a MAF cut-off of 0.1 maximised the 
specificity and sensitivity of this tool, both measures were still very low. 
 
4.4.2 Importance of the ClinVar dataset 
As each method was trained on different datasets, it was crucial to find a dataset that had 
not been used to train any of the models under comparison, as this would lead to an 
unrealistically exaggerated estimate of that method’s performance (due to over-fitting). 
The ClinVar database, which was not used to train any of the methods, was therefore 
essential to the fair assessment of each model’s performance. Similarly, creating 
multiple test datasets from this data source allowed me to draw different conclusions 
from the analysis. 
 
4.4.2.1 Pathogenic versus non-pathogenic 
Combining the pathogenic variants with the non-pathogenic variants from ClinVar 
allowed me to assess how well each method could prioritise known-functional variants 
against a background set of truly null variants. This was a very rare opportunity, as very 
few datasets of functionally assessed non-functional, non-disease causing variants exist. 
However, these variants might yet prove to be functional as they could have a functional 
role we don’t yet have a test for. 
 
The results of this analysis (Figure 4.9A.) showed that SuRFR can prioritise functional 
versus non-functional variants at least as well as (and marginally better than) CADD and 
GWAVA and all three greatly outperform FunSeq, which does not perform much better 
than random chance. 
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4.4.2.2 Pathogenic versus matched Thousand Genomes background 
variants 
In Chapter 3 I showed that a SNP’s position relative to genes (Position annotation) is the 
most important feature for prioritising functional variants over background variants. A 
background variant dataset matched to the functional variants with respect to position to 
the nearest TSS removes positional bias. The prioritisation of variants in such a dataset 
would be based on their rankings and scores for other features. As SuRFR relies heavily 
on positional information, such a background dataset would therefore put SuRFR at a 
disadvantage. In contrast, this type of background dataset is most advantageous to 
GWAVA, as the TSS model was trained on variants matched by distance to the nearest 
TSS, and therefore relies more on the other features in its model. This type of data 
neither positively nor negatively affected CADD’s performance, as it was trained on 
genome-wide data, unlimited by position relative to genes  
 
Although this dataset was in many ways more stringent than the first ClinVar dataset, the 
results are very similar: SuRFR performs at least as well as GWAVA and CADD and all 
three tools greatly outperform FunSeq. As FunSeq performed so poorly on both of these 
datasets I excluded it from all future comparisons. 
 
4.4.2.3 Non-coding, matched background 
As discussed in Section 4.4.2.2, background datasets matched by distance to the nearest 
TSS are specifically designed to be the toughest dataset for SuRFR, as they remove the 
advantage of the position score (SuRFR’s best performing feature). Combining this style 
of background data with a positive dataset consisting of only non-coding (disease 
causing / functional) variants creates the most stringent dataset of all, as all three 
methods prioritise exonic and coding variants above all other variants. Therefore, this 
dataset truly tests how well each method can prioritise non-exonic, non-coding 
functional variants. 
 
Although this dataset handicaps SuRFR compared to the other two methods, SuRFR still 
performs as well as CADD and GWAVA (Figure 4.10), and this result is likely to be a 
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lower estimate of SuRFR’s performance. It is highly unlikely that any real-world 
scenario would exist where the causal variant (within a region of interest) is matched, by 
exactly the same distance to the nearest TSS, by such a large number of control variants. 
Therefore, in any real-world scenario we would expect the position score to have more 
of an effect and improve the ranking of the causal variant versus background. This 
observation is justified by the performance of SuRFR on the data from the three complex 
trait studies outlined in section 4.3.1.4. 
 
 
4.4.3 Ability to prioritise coding variants: HBB coding 
Although GWAVA and SuRFR were designed for the prioritisation of non-coding 
variants, I chose to test how well these two methods perform when prioritising coding 
variants in additional to non-coding variants. This analysis verified the fact that while 
both methods have been trained on non-coding datasets, they can both correctly 
prioritise coding pathogenic variants over background variants (Figure 4.11). This 
information is useful, as it is an important advantage over other methods to be able to 
prioritise coding and non-coding variants simultaneously. Currently one drawback to 
SuRFR is that is not capable of distinguishing between different classes of coding 
variants (3’UTR, 5’UTR, synonymous, and non-synonymous substitutions), as it does 
not make use of annotations that could prioritise these variant sub-classes.  
 
 
4.4.4 Matching by distance to TSS 
Rerunning SuRFR on the RAVEN functional variants and a new background dataset, 
matched by distance to the nearest TSS, allowed me to once again assess the lower limit 
of SuRFR’s performance, as well as to determine how well CADD performs on the same 
data. Although SuRFR is at a greater disadvantage on this data than CADD, it still 
outperforms it (Figure 4.12, AUCs of 0.702 and 0.608 for SuRFR and CADD 
respectively).  This suggests that SuRFR is better suited to the prioritisation of functional 
non-coding variants (not necessarily with a role in disease) than CADD. The difference 
in SuRFR’s performance on this data versus the first RAVEN dataset (Figure 3.5.) once 
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again highlights the importance of the Position weighting to SuRFR’s ability to prioritise 
functional variants. 
 
4.4.5 Complex trait datasets 
Developing datasets composed of large numbers of real, experimentally verified, 
functional and/or disease-causing variants is crucial to establishing the performance of a 
prioritisation approach.  Such datasets provide the power required to predict with a 
reasonable amount of certainty how well a predictive approach will perform on novel 
data. However, such datasets are also highly synthetic and not representative of the 
numbers and types of variants likely to be present in a “real world” analysis. For 
instance, these datasets are enriched for large numbers of pathogenic variants that would 
not normally be seen in a single disease analysis. In addition, the genomic background 
that these variants would normally be found in has been altered, loosing the genomic 
context, local structural information, LD, and the array of allele frequencies, replacing 
them with random variants. The genomic background for disease variants could have 
both epistatic and polygenic effects, which would not be seen in curated databases of 
disease variants.  
 
Experimental approaches to identifying the causal variant(s) for a disease or complex 
trait often start with either an association signal or linkage data from a family analysis. 
This information allows investigators to focus on a specific region of interest. Follow-up 
analysis such as fine-mapping, sequencing, genotyping etc., can then be used to prioritise 
a subset of variants for functional investigation (using luciferase assays, EMSA shift 
assays etc.), which can lead to the discovery of variant(s) that alter gene expression and 
can result in a pathogenic phenotype. 
 
4.4.5.1 Positive attributes 
The three complex trait studies used in section 4.3.1.4 provided an opportunity to test 
how well the three tools SuRFR, GWAVA and CADD perform on single 
phenotype/single locus datasets. These three different examples of complex trait 
analyses each represent a different type of study: i) each of these datasets represents a 
different complex traits (LDL_C) and diseases (SLE and diabetes); ii) the causal variants 
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have different functional roles (the LDL-C variant creates a binding site for the 
transcription factor C/EBP while the diabetes variant affects enhancer activity); and iii) 
the regions under investigation range in size from a 6 kb to 80 kb. 
 
4.4.5.2 Negative attributes 
These are only three examples representing the search for causal variants associated with 
complex disease; I have no examples of Mendelian diseases. This means I can test the 
performance of the ALL and DFP models of SuRFR, but do not have appropriate data to 
test the DM model. In addition, the regions under investigation are all less than 100 kb; 
therefore, the number of SNPs included in each study is limited. When the full region 
around the SLE locus was investigated, the number of SNPs increased from 35 to 237. 
When this larger SNP set was run through GWAVA and SuRFR, neither method 
prioritised the causal variant in the top 10% (GWAVA ranked this variant 162nd and 
SuRFR ranked it 118th out of 237). This suggests that this region therefore contained 
many variants, which, in addition to the causal variant, have functional roles identifiable 
from the annotation data (active enhancers, regulatory variants etc.) but not associated 
with SLE.  
 
Caution should therefore be taken when searching for candidate causal variants, as many 
variants in the genome will also have regulatory functions and will be identifiable by the 
functional annotation data used to prioritise disease variants. This highlights the 
importance of reducing the list of candidate variants to be prioritised using any available 
a priori information, such as linkage and association signals.  
 
4.4.6 Conclusions 
In this chapter I have compared the performance of SuRFR, GWAVA, CADD and 
FunSeq on a variety of test datasets. I have shown that SuRFR performs at least as well 
as its nearest competitors, and in some instances out performs them.  
 
The differences in performance between these four methods are likely to be due to a 
combination of differences in model design as well as differences in the training data 
used. Furthermore, differences in performance for some of these methods can be 
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accounted for by the fact that they are designed with a different main purpose (FunSeq is 
designed for the cancer genomics; CADD is a measure of deleteriousness rather than 
functionality).  
 
In addition to SuRFR performing better on these data than the other three methods, 
SuRFR also has the advantage of being implemented as an R package and being part of 
the R environment. This is an advantage over CADD, which is a web-based method, as it 
does not limit the number of variants that can be analysed at one time (and is also better 
than the downloadable version of CADD which requires a large amount of free memory: 
79 Gb). This is also an advantage over GWAVA, which is written in Python, as R is a 
statistical framework, allowing downstream analysis without exporting to another 
software. At every point during the running of the R package, users can understand the 
extent to which the various annotations contribute to the variant rankings, allowing 
construction of hypotheses based on the data obtained.  
 
The most important advantage SuRFR has over these other methods is its flexibility, 
allowing the user to change the weighting vector used to suit their own hypotheses and 
also allowing additional annotation sources to be included in its framework. For these 
reasons, SuRFR is an excellent addition to ranks of variant prioritisation methods and I 
am confident it will hold its own against its competitors. Plans for future developments 
will be discussed in Chapter 6 (Discussion). 
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Chapter 5: Application of SuRFR to the study of 
psychiatric illness 
5.1 Introduction 
There has been considerable success in the search for genetic determinants of Mendelian 
diseases. In contrast, it has proven very difficult to identify the genetic variants 
contributing to complex diseases and disorders. Factors that might contribute to this are 
the differences in genetic architecture and the greater environmental contribution to 
complex disease (see Chapter 1: section 1.4). The genetics of psychiatric illness have 
proven particularly difficult to unravel; it is only within the last two years that the first 
major successes in the field of psychiatric genomics have been achieved, with the 
Psychiatric Genomics Consortium (PGC) identifying 108 loci associated with 
schizophrenia (Schizophrenia Working Group of the Psychiatric Genomics, 2014). 
Similarly, in 2014 a genome-wide association study (GWAS) combining PGC bipolar 
disorder samples (Psychiatric, 2011) and samples derived from the MooDS (Systematic 
Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia) 
consortium identified five loci that showed genome wide significant association with 
bipolar disorder (Muhleisen et al., 2014). Three of these loci had been previously 
reported ((Ferreira et al., 2008); (Psychiatric, 2011); (Chen et al., 2013)) and two were 
novel loci.  The smaller number of loci identified in the bipolar disorder GWAS 
compared to the schizophrenia GWAS is likely to reflect, in part, the difference in 
sample sizes of these two GWASs (Chapter 1: Section 1.5).  
 
Although these successes are important and pave the way for similar discoveries for 
other psychiatric illnesses, GWASs are only the first step in identifying variants, genes 
and pathways that contribute to illness. Further investigation of these findings, such as 
functional investigation of candidate variants (Muhleisen et al., 2014) and pathway 
analysis (Nurnberger et al., 2014) are needed to link association data to the underlying 
biology (Shinozaki and Potash, 2014).  
 
Some disorders are unlikely ever to be aided by GWAS, mainly due to an insufficient 
number of affected individuals (as limited numbers means insufficient power for true 
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associations to reach genome-wide significance). In such cases, methods such as whole 
genome sequencing (WGS), family studies and linkage analysis, will be important in 
identifying risk variants and elucidating candidate genes. On the other hand, genomics 
projects (GWAS, WGS, etc.), which function on a genome-wide scale, are implicating 
an ever-increasing number of variants. The experimental assays currently available to 
characterise putative susceptibility variants are too costly and time consuming to 
perform on large numbers of SNPs. Bioinformatic prioritisation of candidate variants is 
an essential aid to the analysis of these data, as it allows experimental follow-up to be 
focused on those SNPs with the highest likelihood of being functional based on the 
currently available evidence.  In this chapter, I will describe the application of SuRFR to 
two family-based psychiatric illness analyses, investigating the genetics of bipolar 
disorder and major depressive disorder.  
 
5.1.1 Bipolar disorder 
Bipolar disorder (BD) is a major psychiatric condition with a lifetime prevalence of 1% 
(Mülheisen et al., 2014). It is characterised by an episodic, recurrent change in mood that 
ranges from severe depression to elation (mania) (Craddock and Sklar, 2009).  The 
World Health Organisation (WHO) has classified BD as one of the top ten leading 
causes of global disease burden for the 15-44 year old age group (Muhleisen et al., 
2014). Family, twin and adoption studies have shown that there is a strong heritable 
component to this disorder, with studies suggesting between 60-85% of risk variance 
being attributable to genetic factors ((Smoller and Finn, 2003); (Nothen et al., 2010)). 
The aetiology of BD is complex: multiple genetic and environmental factors contribute 
to disease risk ((Lichtenstein et al., 2009); (Shinozaki and Potash, 2014)). Although, 
traditionally, BD and other psychiatric disorders were considered to be clinically 
distinct, there is growing evidence for shared phenotypes across many psychiatric 
disorders, in particular BD, schizophrenia, schizoaffective disorder and major depressive 
disorder ((Lichtenstein et al., 2009); (Shinozaki and Potash, 2014)). This overlap in 
clinical features may reflect overlapping genetic causes ((Barnett and Smoller, 2009); 
(Cross-Disorder Group of the Psychiatric Genomics et al., 2013)). Similarly, it is 
recognised that several clinical subtypes of BD exist, including bipolar disorder type I, 
bipolar disorder type II, and bipolar type schizoaffective disorder (Craddock and Sklar, 
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2009). Taken together, these factors make studying the genetics of BD complicated. 
Despite the large amount of effort that has gone into linkage, sequencing and association 
studies of BD, there are no confirmed, functionally validated susceptibility variants for 
BD. In addition, the handful of loci that have been implicated in GWAS as being 
significantly associated with BD only explain a small proportion of the heritability. A 
number of next generation sequencing (NGS) projects have been undertaken to identify 
rare variants that contribute to disease susceptibility ((Chen et al., 2013); (Georgi et al., 
2014);(Ament et al., 2015)); however, as with GWAS, additional validation and 
functional investigation of these data are required to confirm the role of these variants in 
disease aetiology. Table 5.1 outlines some of the largest BD studies that have been 
performed over the last decade (GWAS with ~1,000 or more cases; sequencing of over 
200 individuals).  
There are a number of strategies that together should result in the discovery of 
susceptibility variants for BD. These include analysis of larger GWAS cohorts and 
whole genome sequencing. A complementary strategy is to reduce heterogeneity. This 
can be achieved by sub-typing diagnoses ((Lee et al., 2011); (Greenwood et al., 2012)), 
stratifying illness by co-morbid conditions (Kerner et al., 2013) and/or using family 
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Study	   Details	  of	  project	  design	   Results	  
(Baum	  et	  al.,	  
2008)	  
GWAS	  of	  BD	  in	  two	  independent	  case-­‐controls	  sets	  of	  
European	  ancestry,	  with	  461	  cases	  and	  563	  controls;	  and	  
772	  cases	  and	  876	  controls	  respectively.	  Roughly	  550,000	  
SNPs	  within	  genes	  were	  genotyped	  in	  these	  samples.	  
No	  variant	  reached	  genome-­‐wide	  significance	  in	  
the	  individual	  studies;	  however	  the	  combined	  
study	  returned	  one	  significantly	  associated	  
variant	  (p=	  1.5	  x	  10-­‐8),	  located	  in	  an	  intron	  of	  
the	  gene	  DGKH.	  The	  authors	  considered	  this	  a	  
good	  candidate	  gene,	  as	  it	  plays	  a	  role	  in	  the	  




GWAS	  of	  seven	  common	  diseases,	  including	  BD,	  in	  a	  
British	  case-­‐control	  set.	  The	  BD	  GWAS	  was	  performed	  on	  
1,868	  cases	  and	  3,000	  controls,	  using	  the	  Affymetrix	  
GeneChip	  500K	  Mapping	  Array	  Set.	  
No	  genome-­‐wide	  significant	  association	  was	  
observed	  for	  BD.	  However,	  KCNC2,	  GABRB1,	  
GRM7	  and	  SYN3	  all	  showed	  association	  at	  P<	  5	  
×	  10-­‐7.	  	  
(Sklar	  et	  al.,	  
2008)	  
GWAS	  of	  samples	  from	  the	  Systematic	  Treatment	  
Enhancement	  Program	  for	  Bipolar	  Disorder	  (STEP-­‐BD)	  
study	  (1,461	  cases	  and	  2,008	  controls).	  
No	  variant	  reached	  genome-­‐wide	  significance;	  
however,	  the	  strongest	  association	  was	  seen	  for	  
a	  variant	  in	  MYO5B	  (P=1.66	  x	  10-­‐7).	  In	  addition,	  
comparison	  of	  top	  associated	  SNPs	  from	  this	  
study	  and	  the	  WTCCC	  showed	  that	  there	  was	  a	  
concordance	  of	  signals	  for	  SNPs	  in	  the	  gene	  
CACNA1C.	  	  	  
(Ferreira	  et	  al.,	  
2008)	  
GWAS	  of	  BD	  in	  a	  dataset	  referred	  to	  as	  the	  ED-­‐DUB-­‐
STEP2	  dataset,	  consisting	  of	  cases	  and	  controls	  from	  the	  
University	  of	  Edinburgh,	  Trinity	  College	  Dublin	  and	  the	  
STEP-­‐BD	  study.	  In	  total,	  this	  dataset	  consisted	  of	  4,387	  
cases	  and	  6,209	  controls.	  	  
This	  analysis	  identified	  two	  strongly	  associated	  
regions.	  The	  first,	  rs10994336	  (P=	  9.1	  x	  10-­‐9)	  
was	  in	  the	  gene	  ANK3	  and	  the	  second,	  
rs1006737	  (P	  =	  7.1	  x	  10-­‐8),	  was	  in	  the	  previously	  
reported	  gene	  CACNA1C.	  	  	  
(Ollila	  et	  al.,	  
2009)	  
GWAS	  replication	  study.	  The	  authors	  took	  the	  strongest	  
associated	  SNPs	  from	  two	  GWAS	  studies	  (WTCCC,	  2007;	  
and	  Baum	  et	  al,	  2008)	  and	  genotyped	  these	  26	  variants	  in	  
a	  Finnish	  BD	  family	  cohort	  (723	  individuals	  from	  180	  
families).	  
Confirmed	  six	  associations:	  DFNB31	  
(rs10982256),	  SORCS2	  (rs4411993,	  rs7683874,	  
rs10937823),	  SCL39A3	  (rs4806874),	  and	  DGKH	  
(rs9315885).	  
(Smith	  et	  al.,	  
2009)	  
The	  authors	  conducted	  two	  GWAS,	  one	  on	  samples	  of	  
European	  ancestry	  (EA:	  1,001	  cases	  and	  1,033	  controls)	  
and	  one	  of	  African	  ancestry	  (AA:	  345	  cases	  and	  670	  
controls).	  	  
No	  signal	  reached	  genome-­‐wide	  significance;	  
however	  the	  top	  two	  variants	  from	  each	  study	  
(EA	  and	  AA)	  were:	  an	  intergenic	  region	  of	  Xq27	  
and	  NAP1	  (EA);	  and	  DPY19L3	  and	  NTRK2	  (AA).	  
(Wang	  et	  al.,	  
2010)	  
Performed	  a	  genome-­‐wide	  meta-­‐analysis	  of	  two	  cohorts	  
of	  combined	  BD	  and	  SCZ	  cases	  (653,	  1172	  cases	  and	  
1034,	  1379	  controls	  respectively).	  
Identified	  five	  loci	  associated	  with	  both	  BD	  and	  
SCZ:	  NAP5,	  chr6q15	  (near	  GABRR1),	  CNTNAP2,	  
chr9q33.1	  (near	  ASTN2)	  and	  NALCN.	  
(Howrigan	  et	  
al.,	  2011)	  
Used	  prior	  findings	  from	  genome-­‐wide	  linkage	  analysis	  to	  
re-­‐analyse	  the	  GWAS	  data	  from	  the	  STEP-­‐BD.	  Using	  this	  
linkage	  data,	  they	  implemented	  a	  weighted	  FDR	  
approach.	  
No	  SNPs	  reached	  genome-­‐wide	  significance.	  
(Psychiatric,	  
2011)	  	  
GWAS	  of	  7,481	  BD	  cases	  and	  9,250	  controls	  and	  a	  
replication	  cohort	  of	  4,496	  BD	  cases	  and	  42,422	  controls.	  
Confirmed	  the	  previously	  identified	  association	  
for	  CACNA1C	  and	  identified	  a	  new	  association	  
with	  an	  intronic	  variant	  in	  ODZ4.	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Study	   Details	  of	  project	  design	   Results	  
(Smith	  et	  al.,	  
2011)	  
GWAS	  of	  BD	  on	  samples	  from	  the	  Bipolar	  Genome	  Study	  
(BiGS),	  consisting	  of	  2,191	  cases	  and	  1,434	  controls.	  
No	  variants	  reached	  genome-­‐wide	  significance;	  
however,	  the	  authors	  noted	  that	  the	  variant	  
rs2367911,	  near	  the	  gene	  CACNA2D1	  had	  
suggestive	  association	  (P = 5.9	  ×	  10-­‐6).	  This	  gene	  
is	  related	  to	  the	  previously	  reported	  gene	  
CACNA1C.	  
(Cichon	  et	  al.,	  
2011)	  
GWAS	  of	  BD	  in	  a	  German	  cohort	  (MooDS).	  Discovery	  
cohort	  consisted	  of	  682	  cases	  and	  1,300	  controls;	  total	  
number	  of	  samples	  between	  the	  discovery	  cohort	  and	  
two	  replication	  cohorts	  were	  6,030	  cases	  and	  31,749	  
controls.	  	  
This	  study	  identified	  rs1064395	  as	  a	  risk	  factor	  
for	  BD.	  This	  variant	  is	  located	  in	  the	  3’UTR	  of	  
the	  gene	  NCAN,	  encoding	  an	  extracellular	  
matrix	  glycoprotein,	  thought	  to	  play	  a	  role	  in	  
migration	  and	  cell	  adhesion.	  	  	  
(Lee	  et	  al.,	  
2011)	  
GWAS	  of	  a	  sub-­‐set	  of	  BD	  (bipolar	  I)	  in	  a	  Han	  Chinese	  
cohort.	  The	  discovery	  cohort	  consisted	  of	  1,000	  cases	  and	  
1,000	  controls;	  the	  replication	  cohort	  contained	  409	  
cases	  and	  1,000	  controls.	  
Although	  no	  genome-­‐wide	  associated	  regions	  
were	  identified,	  several	  suggestive	  loci	  were	  




The	  authors	  attempted	  to	  counteract	  the	  genetic	  
heterogeneity	  of	  BD	  by	  using	  temperament	  as	  a	  
quantitative	  trait	  to	  define	  subtypes	  of	  BD.	  Genotyping	  
was	  performed	  on	  1,263	  BD	  cases	  and	  1,434	  controls.	  
Using	  five	  subscales	  of	  temperament	  
(hyperthymic,	  dysthymic,	  cyclothymic,	  irritable	  
and	  anxious),	  the	  authors	  identified	  three	  
significantly	  associated	  regions:	  chr1	  (INTS7	  
gene),	  chr12	  (MDM1)	  and	  chr22	  (FBLN1).	  	  	  
(Kerner	  et	  al.,	  
2013)	  
Exome	  sequencing	  study	  of	  individuals	  from	  a	  family	  with	  
BD	  and	  co-­‐morbid	  anxiety	  spectrum	  disorders.	  This	  study	  
compared	  the	  exomes	  of	  three	  affected	  sisters	  against	  
one	  unaffected	  brother	  and	  200	  population	  controls.	  
Exome	  sequencing	  identified	  very	  rare,	  
heterozygous	  variants	  in	  eight	  brain	  expressed	  
genes:	  IQUB,	  JMJD1C,	  GADD45A,	  GOLGB1,	  
PLSCR5,	  VRK2,	  MESDC2	  and	  FGGY.	  Predicted	  by	  
at	  least	  one	  functional	  predictive	  algorithm	  (out	  
of	  three:	  SIFT,	  PolyPhen	  and	  Mutation	  Taster)	  
to	  be	  potentially	  protein	  damaging.	  
(Chen	  et	  al.,	  
2013)	  
Meta-­‐analysis	  of	  a	  cohort	  consisting	  of	  cases	  and	  controls	  
of	  European	  and	  Asian	  ancestry.	  This	  analysis	  combines	  
two	  GWAS;	  the	  first	  (phase	  I)	  based	  on	  6,658	  cases	  and	  
8,187	  controls,	  the	  second	  (phase	  II)	  tested	  in	  a	  sample	  of	  
484	  cases	  and	  1,823	  controls.	  Together,	  this	  combined	  
dataset	  comprised	  	  ~17,000	  samples.	  
The	  discovery	  phase	  of	  this	  study	  identified	  one	  
genome-­‐wide	  significant	  result	  near	  TRANK1	  
(rs9834970,	  P=	  2.4	  x	  10-­‐11).	  In	  addition,	  there	  
was	  suggestive	  evidence	  of	  association	  for	  a	  
variant	  near	  ANK3	  (P	  <	  10-­‐6).	  These	  associations	  
were	  replicated	  in	  the	  phase	  II	  data.	  
(Muhleisen	  et	  
al.,	  2014)	  
In	  the	  largest	  BD	  GWAS	  to	  date,	  the	  authors	  genotyped	  
2.3	  million	  SNPs	  in	  a	  cohort	  of	  24,025	  patients	  and	  
controls.	  These	  samples	  were	  a	  combination	  of	  samples	  
from	  the	  BGC-­‐BD	  and	  MooDS	  consortia	  (9,747	  cases	  and	  
14,278	  controls).	  
This	  analysis	  identified	  five	  genome-­‐wide	  
significantly	  associated	  loci:	  ANK3,	  ODZ4,	  
TRANK1,	  DCY2	  and	  an	  intergenic	  region	  on	  
6q16.1.	  Three	  of	  these	  regions	  had	  previously	  
been	  reported,	  while	  the	  other	  two	  were	  novel.	  	  	  
(Xu	  et	  al.,	  
2014)	  
GWAS	  performed	  on	  Canadian	  and	  UK	  population	  
cohorts,	  consisting	  of	  950	  BD	  cases	  and	  950	  controls.	  
No	  genome-­‐wide	  significant	  results.	  However,	  
this	  study	  identified	  several	  suggestive	  
associations	  with	  variants	  in	  regions	  previously	  
implicated	  in	  other	  GWAS	  studies	  (including	  
SYNE1	  on	  chr6q25,	  PPP2R2C	  on	  chr4p16.1,	  
ZNF659	  on	  chr3p24.3,	  CNTNAP5	  on	  chr2q14.5	  
and	  CDH13	  on	  chr16q23.3).	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   Details	  of	  project	  design	   Results	  
(Georgi	   et	   al.,	  
2014)	  
WGS	  analysis	  of	  a	  genetic	   isolate	   (large	  old	  order	  Amish	  
pedigree)	  with	   BD.	  Of	   the	   497	   individuals	   in	   this	   family,	  
the	   genomes	   of	   50	   	   (consisting	   of	   18	   parent-­‐child	   trios)	  
were	  sequenced	  and	  a	  further	  388	  family	  members	  were	  
genotyped.	  
Using	  a	  combination	  of	  linkage,	  association	  and	  
WGS	   analysis,	   this	   study	   identified	   five	  
nominally	   significant	   linkage	   regions:	  
chr2p25.3-­‐p25.1,	   chr4p16.3,	   chr7q21.11-­‐
q31.33,	   chr16p13.3-­‐13.12	   and	   chr18p11.22-­‐
q13.1.	   Analysis	   of	   the	   variants	   located	   under	  
these	   peaks	   identified	   several	   amish-­‐specific	  
putative	   damaging	   exonic	   missense	   variants;	  
however,	   no	   evidence	   strongly	   implicated	   any	  
one	  locus	  or	  a	  common	  pathway.	  
(Nurnberger	  et	  
al.,	  2014)	  
Meta-­‐analysis	   of	   four	   published	   GWAS	   to	   identify	  
biological	   pathways	   that	   contribute	   to	   BD.	   966	   genes	  
with	  two	  or	  more	  variants	  associated	  with	  BD	  (P	  <	  0.5)	  in	  
three	  of	  four	  GWAS	  were	  included	  in	  this	  analysis.	  	  
17	  pathways	  were	  implicated	  in	  this	  analysis,	  of	  
which	   6	   were	   associated	   with	   BD	   in	   both	   the	  
initial	  and	  replication	  samples.	  These	  pathways	  
included:	   hormonal	   regulation,	   calcium	  
channels,	   second	   messenger	   systems	   and	  
glutamate	  signalling.	  
(Ament	   et	   al.,	  
2015)	  
Whole	   genome	   sequencing	   of	   200	   individuals	   from	   41	  
families	  multiply	  affected	  with	  BD.	  This	  study	  focused	  on	  
3,087	  genes	  with	  i.	  evidence	  of	  association	  from	  GWAS	  or	  
ii.	  with	  know	  synaptic	   functions.	  Targeted	  sequencing	  of	  
a	  subset	  of	  these	  candidate	  genes	  (26)	  was	  performed	  in	  
an	  additional	  3,014	  cases	  and	  1,717	  controls.	  
The	   aim	   of	   this	   study	   was	   to	   identify	  
uncommon	   and	   rare	   variants	   that	   might	  
influence	  risk	  for	  bipolar	  disorder.	  This	  analysis	  
focused	   on	   genes	   with	   a	   priori	   functional	   or	  
GWAS	  association	  evidence.	  BD	  pedigrees	  were	  
shown	   to	   have	   an	   increased	   burden	   of	   rare	  
variants	   in	   genes	   and	   pathways	   that	   regulate	  
neuronal	  excitability,	  particularly	  in	  ion	  channel	  
genes.	  Most	  of	  the	  risk	  variants	  identified	  were	  
non-­‐coding	   variants	   predicted	   to	   have	  
regulatory	   functions,	   suggesting	   an	   important	  
role	  for	  the	  regulation	  of	  gene	  expression	  in	  BD.	  	  	  
 
Table 5.1. Summary of large-scale analyses of BD performed over the last decade.  
	  
5.1.2 Major depressive disorder 
Major depressive disorder (MDD), also known as major depression and unipolar 
depression, is a debilitating psychiatric disorder, characterised by a persistent depressive 
mood, loss of interest or pleasure in normally enjoyable activities and changes to sleep 
and appetite (Verbeek et al., 2013). MDD is one of the most common psychiatric 
disorders, with a lifetime prevalence of ~15% (Kessler et al., 2005). In 1996 the World 
Health Organisation predicted MDD would be the second leading cause of disability 
worldwide by 2020 (after ischemic heart disease) (Murray and Lopez, 1996). Almost 
twenty years later, this prediction is on track; MDD is the third leading cause of 
disability in Europe and in the US is reported as being the greatest cause of disability of 
any biomedical disease (Flint and Kendler, 2014). 
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Family studies have shown there is a genetic component to MDD, with heritability 
estimated to be 0.37 (95% confidence intervals 31-42%)(Sullivan et al., 2000). Both 
early onset and recurrence of depression are associated with higher familial aggregation 
((Wray et al., 2012); (Sullivan et al., 2000); (Kendler et al., 2005)). This disorder is twice 
as common in women as men ((Wray et al., 2012); (Wilhelm et al., 2003)). 
 
To date, ten GWASs have been published (see Table 5.2). Only two of these have 
returned genome-wide significant associations ((Kohli et al., 2011); (consortium, 2015)). 
The first, by Kohli et al. (2011) identified a ~450kb region associated with MDD. Two 
tagging SNPs within this region were found to be associated with altered expression of 
SLC6A15. The second, by the CONVERGE consortium (2015), attempted to reduce 
genetic heterogeneity by focusing on women with recurrent MDD, of Han Chinese 
ancestry (all four grandparents were Han Chinese). This study used low-coverage whole 
genome sequencing of 5,303 cases and 5,337 controls (also Han Chinese women). After 
quality control, the SNP set for GWAS consisted of 6,242,619 SNPs. This study 
identified, and later independently replicated, two genome-wide significantly associated 
regions for MDD. The first variant, rs12415800 (P = 2.53 x 10-10), is located near the 
SIRT1 gene on chromosome 10; the second variant, rs126244970 (P = 6.45 x 10-12), is 
also on chromosome 10, in an intron of the LHPP gene. 
 
	  
Study	   Details	  of	  project	  design	   Results	  
(Sullivan	  et	  al.,	  2009)	   GWAS	  of	  435,291	  SNPs	  genotyped	  in	  1,738	  
MDD	  cases	  and	  1,802	  controls	  from	  a	  
Dutch	  cohort.	  	  
No	  SNP	  reached	  genome-­‐wide	  significance.	  However,	  of	  
the	  top	  200	  ranked	  SNPs,	  11	  localised	  to	  a	  167	  kb	  region,	  
which	  overlaps	  the	  gene	  PCLO.	  The	  protein	  encoded	  by	  
this	  gene	  is	  known	  to	  be	  involved	  in	  neurotransmission.	  
(Lewis	  et	  al.,	  2010)	   GWAS	  of	  471,747	  SNPs	  genotyped	  in	  a	  UK	  
cohort	  of	  1,636	  MDD	  cases	  and	  1,594	  
controls.	  
No	  genome-­‐wide	  significant	  results	  were	  identified	  in	  this	  
study.	  A	  SNP	  in	  BICC1	  achieved	  suggestive	  evidence	  of	  
association	  (P	  <	  10-­‐6),	  but	  this	  finding	  has	  not	  been	  
replicated.	  
(Muglia	  et	  al.,	  2010)	   The	  authors	  performed	  GWAS	  on	  two	  
independent	  European	  cohorts:	  first	  1,022	  
cases	  of	  MDD	  and	  1000	  controls	  
(genotyped	  using	  the	  Illumina	  550	  
platform);	  and	  second	  492	  MDD	  cases	  and	  
1052	  controls	  (genotyped	  using	  the	  
Neither	  of	  the	  two	  separate	  GWASs,	  nor	  the	  meta-­‐
analysis,	  identified	  any	  genome-­‐wide	  significant	  
associations.	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Affymetrix	  5.0	  platform).	  These	  
independent	  datasets	  were	  also	  studied	  
together	  in	  a	  meta-­‐analysis.	  
(Rietschel	  et	  al.,	  2010)	   GWAS	  of	  604	  patients	  with	  MDD	  and	  1,364	  
controls	  from	  a	  German	  cohort.	  
No	  SNPs	  reached	  genome-­‐wide	  significance.	  Two	  SNPs	  
showed	  nominally	  significant	  association,	  one	  of	  which	  is	  
located	  in	  a	  putative	  regulatory	  element	  for	  HOMER1.	  
Evidence	  from	  animal	  studies	  and	  human	  imaging	  studies	  
support	  the	  hypothesis	  that	  HOMER1	  may	  play	  a	  role	  in	  
the	  aetiology	  of	  MDD	  through	  a	  dysregulation	  of	  
cognitive	  and	  motivational	  processes.	  
(Shyn	  et	  al.,	  2011)	   GWAS	  of	  1,221	  cases	  and	  1,636	  controls	  
from	  a	  US	  cohort.	  The	  authors	  also	  
conducted	  a	  meta-­‐analysis	  of	  three	  
European-­‐ancestry	  GWAS	  datasets	  totalling	  
3,957	  cases	  and	  3,428	  controls.	  
This	  study	  failed	  to	  identify	  any	  variants	  that	  reached	  
genome-­‐wide	  significance.	  The	  strongest	  evidence	  for	  
association	  in	  this	  analysis	  was	  observed	  for	  three	  
intronic	  SNPs	  in	  SP4,	  ATP6V1B2	  and	  GRM7.	  Prior	  
biological	  evidence	  suggested	  GRM7	  to	  be	  a	  strong	  
candidate	  gene	  for	  MDD.	  However,	  this	  has	  yet	  to	  be	  
replicated	  in	  any	  other	  GWAS	  study.	  	  
(Shi	  et	  al.,	  2011)	   GWAS	  on	  a	  US	  cohort	  consisting	  of	  1,020	  
MDD	  cases	  and	  1,636	  controls.	  
No	  genome-­‐wide	  significant	  results	  were	  identified	  in	  this	  
study.	  The	  strongest	  evidence	  of	  association	  was	  
observed	  on	  chr18q22.1.	  
(Kohli	  et	  al.,	  2011)	   Discovery	  set	  consisted	  of	  353	  MDD	  cases	  
and	  366	  controls	  from	  a	  clinic	  in	  Munich	  
Germany.	  The	  replication	  set	  consisted	  of	  
3,738	  cases	  and	  10,635	  controls	  from	  six	  
independent	  cohorts	  of	  German,	  Dutch,	  UK	  
and	  African	  American	  origin.	  
This	  study	  identified	  a	  single	  genome-­‐wide	  significant	  
association	  with	  a	  variant	  on	  chr12q21.31.	  This	  variant	  
appears	  to	  be	  part	  of	  a	  haplotype	  containing	  seven	  
additional	  common	  variants	  in	  LD	  with	  the	  tagging	  SNP,	  
covering	  a	  region	  of	  ~450kb.	  This	  region	  is	  a	  gene	  desert,	  
the	  closest	  gene	  to	  which	  is	  SLC6A15	  (a	  further	  287kb	  
distal	  to	  the	  associated	  region).	  Gene	  expression	  showed	  
that	  two	  of	  the	  common	  variants	  in	  the	  associated	  region	  
altered	  the	  expression	  of	  SLC6A15	  in	  the	  hippocampus.	  
(Wray	  et	  al.,	  2012)	   GWAS	  of	  the	  MDD2000+	  cohort,	  consisting	  
of	  2,431	  cases	  and	  3,673	  controls.	  In	  
addition,	  the	  authors	  performed	  a	  meta-­‐
analysis	  including	  two	  additional	  datasets	  
(totalling	  5,763	  cases	  and	  6,901	  controls).	  
No	  SNPs	  in	  either	  the	  MDD2000+	  study	  nor	  in	  the	  meta-­‐
analysis	  reached	  genome-­‐wide	  significance.	  
(Major	  Depressive	  
Disorder	  Working	  
Group	  of	  the	  
Psychiatric	  et	  al.,	  2013)	  
This	  is	  the	  largest	  GWAS	  for	  MDD	  to	  date,	  
consisting	  of	  9,240	  cases	  and	  9,519	  
controls	  of	  recent	  European	  ancestry.	  In	  
addition	  to	  a	  large	  replication	  cohort	  
(6,783	  cases	  and	  50,695	  controls),	  this	  
study	  stratified	  cases	  by	  phenotypes	  
including	  sex,	  recurrence	  and	  age	  of	  onset	  
amongst	  others.	  
No	  SNP	  reached	  genome-­‐wide	  significance.	  
(consortium,	  2015)	   This	  study	  focused	  on	  a	  cohort	  of	  Han	  
Chinese	  women,	  5,303	  with	  recurrent	  MDD	  
and	  5,337	  controls.	  Low-­‐coverage	  whole-­‐
genome	  sequencing	  was	  used	  to	  genotype	  
the	  cohort;	  6,242,629	  SNPs	  were	  used	  for	  
the	  GWAS.	  	  
Two	  genome-­‐wide	  significant	  loci	  were	  identified:	  
rs12415800	  (P	  =	  2.53	  x	  10-­‐10),	  located	  near	  the	  SIRT1	  gene	  
on	  chromosome	  10;	  and	  rs126244970	  (P	  =	  6.45	  x	  10-­‐12),	  
in	  an	  intron	  of	  the	  LHPP	  gene.	  	  Neither	  of	  these	  
significantly	  associated	  variants	  were	  replicated	  in	  a	  
comparison	  against	  the	  PGC	  MDD	  GWAS	  data	  (2013).	  
Table 5.2 Summary of the ten MDD GWAS studies performed to date.  
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So far, candidate gene approaches have analysed almost 200 genes in the search for 
genes and pathways that might function in the aetiology of MDD. So far, these studies 
have had limited success, and many groups working on the same gene report contrary 
and conflicting findings. A meta-analysis of 26 genes yielded significant results for 7 
genes (Flint and Kendler, 2014). However, the mean effect size across these studies was 
shown to be 1.35, and the variants tested were shown to be common. These two facts 
together suggest that these associations, if real, should have been identified by at least 
one of the ten MDD GWASs published to date. As they have not, it is possible that these 
are false positive findings (Flint and Kendler, 2014). However, increased genetic 
heterogeneity of GWAS samples might have masked the association with a subtype of 
illness. Similarly, rare variants or variants with a lower effect size, which would also be 
missed by GWAS, may still contribute to MDD (Flint and Kendler, 2014). 
 
Although GWASs have yet to identify replicated variants associated with MDD, we 
have still learnt something from these analyses, as the lack of results provide clues to the 
genetic architecture of MDD: 
1. Large numbers of common variants of small effect sizes (odds ratios of less than 
1.2) could account for a large portion of the genetics of MDD.  If this is the case, 
increased sample sizes will be needed to identify these variants, as increasing the 
number of cases of MDD used for GWAS will improve the power to detect 
common variants of small effect sizes (<1.2) (Levinson et al., 2014). 
 
2. The limited success of GWAS could also point to the role of individually rare 
variants with higher effect sizes in causing complex traits such as MDD 
(McCellan and King, 2010). Although each of these variants might only occur in 
a small subset of cases, collectively they could contribute a significant portion of 
the genetics of MDD. These rare variants are unlikely to be indentified by 
current GWAS approaches (Flint and Kendler, 2014). 
 
3. The environmental component for MDD is quite substantial. Sullivan et al. 
(2000) showed that variance in liability to MD is mostly due to individual 
specific environmental effects (95% confidence interval 58%-67%)(Sullivan et 
al., 2000). Focusing analyses on cases of MDD with more homogenous 
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environmental backgrounds could be a way of reducing heterogeneity in the 
data; for instance, studying women with perinatal and post-partum MDD (Wray 
et al., 2012).   
 
4. Genetic heterogeneity, coupled with phenotypic homogeneity, could reduce the 
power of association studies. In their 2014 paper, Flint and Kendler (Flint and 
Kendler, 2014) described the following scenario: if two unrelated pathways lead 
to MDD and 50 variants contribute to disease aetiology through one pathway and 
another 50 contribute through the second pathway (both sub-types of MDD 
presenting with the same phenotypes), the power to detect either pathway is 
reduced by half. They suggested that without prior knowledge of these two 
pathways, the results of such an analysis would be difficult to decipher. 
 
Sub-setting cases based on additional phenotypes (for instance, by sex, co-morbid 
psychiatric traits, severity of symptoms, combination of symptoms, biomarkers (e.g., 
MRI data), early-onset, or other co-morbid illnesses) could provide more homogenous 
datasets. Similarly, family studies of psychiatric illness provide a level of genetic 
homogeneity, as cases share genetic factors contributing to disease susceptibility. 
 
 
5.1.3 Collaborative efforts with Cold Spring Harbour Laboratories 
Our group has been working in collaboration with Prof. Dick McCombie’s group at Cold 
Spring Harbour Laboratories (CSHLs) to investigate the genetic causes of several 
psychiatric illnesses using family studies. I have worked on two of these projects as part 
of my PhD project:  the Scottish BD family project; and a second Scottish family, 
presenting with both MDD and idiopathic oedema. 
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5.1.4 The Scottish bipolar family project 
5.1.4.1  Background 
In 1996 a linkage analysis was performed on twelve Scottish mood disorder families 
(Blackwood et al., 1996). One of these families, from now on referred to as “SBF2” 
(Figure 5.1), with multiple cases of BD and MDD, generated a significant two-point 
LOD score (LOD >= 3.3; (Lander and Kruglyak, 1995)) of 4.1 (at recombination 
fraction θ = 0) with the marker D4S394 on chromosome 4p, under the narrow diagnostic 
model (BD cases only; MDD coded as ‘unknown’). Little change was seen in the linkage 
to this marker when the broad model (BD and MDD) was used (LOD 3.95, θ = 0), 
showing evidence of linkage to BD and MDD in this region (Blackwood et al., 1996). 
Re-analysis of this family, using an extended pedigree and additional microsatellite 
markers, increased the LOD score to 4.41 at marker D4S394 (under the narrow 
diagnostic model) (Le Hellard et al., 2007). Additional investigation of this region using 
a robust variant components analysis method (Visscher et al., 1999), showed very strong 
evidence for a quantitative trait locus in this region affecting both bipolar disorder and 
MDD, achieving a maximum LOD of 5.9 and explaining roughly 25% of variance for 
these traits in this pedigree. This region has failed to be identified as significantly 
associated to BD by GWAS; however, a variant at the centromeric end of this linkage 
region (rs215411) was significantly associated with SCZ in a recent GWAS 
(Schizophrenia Working Group of the Psychiatric Genomics, 2014). In addition, there is 
tentative association evidence suggesting chr4p15-16 is a putative locus for 
susceptibility for BD  ((Christoforou et al., 2007); (Baum et al., 2008); (Ollila et al., 
2009)), as well as tentative linkage evidence (Georgi et al., 2014). These, together with 
the linkage analysis, suggest that the region may contain a rare genetic risk variant for 
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5.1.4.2 Collaboration with CSHLs on the SBF2 project 
Based on the linkage analyses (which showed strong evidence of linkage to this region 
under a dominant model ((Blackwood et al., 1996); (Le Hellard et al., 2007))) and the 
variance components analysis (which suggested the association is unlikely to be due to a 
polygenic component (Visscher et al., 1999)), we hypothesised that the genetic risk 
variant for BD and MDD in SBF2 would be a rare variant, segregating with incomplete 
penetrance, located within the linkage region on chromosome 4.  
 
Our collaborator at CSHLs, Prof. Dick McCombie, set out to generate sequencing data 
from the 4p locus in this family. At the time this project was initiated (2009), several 
sequencing options were available. Whole genome sequencing was chosen as the most 
effective method to achieve sufficient coverage at lowest cost.  
CSHLs sequenced the whole genomes of five individuals from SBF2, three affected-
carriers of the disease-linked haplotype on chromosome 4p15-16 (ID 17 (MDD), ID 21 
(BD) and ID 29 (BD)) and two unaffected, married in individuals (ID 33 and ID 39). 
Samples were sequenced on the Illumina GAIIx platform. The mean sequencing depth 
across the five individuals ranged from 36x to 58x. These data were processed using the 
Illumina pipeline v1.5/v1.6 for base calling. Sequence alignment was performed using 
BWA (Li and Durbin, 2009), and the Genome Analysis ToolKit (GATK)(McKenna et 
al., 2010) was used to analyse the sequencing data. SNPs were filtered using the 
following GATK filtering thresholds: 
• Filter out SNPs which have a phred-scaled Qscore >= 30 
• Filter out SNPs within clusters (3 SNPs within 10bp of each other) 
• Filter out SNPs which have <10X coverage 
• Include SNPs which are found in chrM and chrRandom 
• Include SNPs in repeat regions 
 
This analysis focused on the SBF2 disease-linked haplotype, defined as an 
approximately 20Mb region on chromosome 4p (Le Hellard et al., 2007).  CSHLs 
transferred files containing the SNPs from the linkage region as VCF files. The 
downstream analysis of this data is described in more detail in section 5.3.1. 
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Prior to my PhD project, the Evan’s group had performed an initial investigation of the 
SNP data from the disease-linked chromosome, focusing on the coding SNPs. No 
unique, putatively functional, non-synonymous or missense SNPs were identified in the 
cases, suggesting that the causal variant might be a non-coding variant. It was therefore 
important to be able to functionally interpret and compare non-coding variants 
(regulatory variants in untranslated regions (UTRs), introns, promoters and intergenic 
regions; splice variants, etc). I therefore aimed to use SuRFR to prioritise these variants 
on the likelihood of functionality. 
 
5.1.5 Co-morbid major depressive disorder and idiopathic oedema  
5.1.5.1 Idiopathic Oedema 
Idiopathic oedema (IO) is also known as cyclical oedema, periodic oedema, the fluid-
retention syndrome, and, less formally, unexplained swelling (Denning et al., 1990). 
This disorder is characterised by intermittent swelling symptoms, often occurring at two 
or more sites simultaneously, including the face, hands, fingers, feet, breasts, abdomen 
and limbs. These symptoms also include fluid retention and an increase in body weight 
from the morning to the evening (diurnal weight variation). The amount of weight 
change considered clinically significant is still under debate. Thorn’s operational 
criterion (Thorn, 1968), suggests a diurnal weight variation exceeding 1.4 Kg to be 
diagnostic for IO. This is still commonly used for the diagnosis of this disorder; 
however, a study of ‘normal’ fluid retention versus that experienced by women with IO 
did not find this diagnostic measure capable of discriminating between cases and 
controls (Denning et al., 1990). This is supported by the most recent assessment of the 
community prevalence of swelling symptoms (Dunnigan et al., 2004), which reported a 
median self-recorded daily weight gain for patients with severe IO to be 0.89 Kg. This 
study also found that the severity of discomfort experienced by individuals with IO is 
disproportionate to the amount of swelling observed by clinicians, and changes in 
swelling are often more obvious to those suffering from IO and their close relatives 
(Dunnigan et al., 2004). 
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In recent years, it has become more commonly accepted that symptoms of IO often form 
a clinical triad consisting of swelling symptoms, functional-autonomic symptoms 
(irritable bowel syndrome, urge frequency, and incontinence of micturition, vasomotor 
symptoms with pallor, faintness and syncope) and affective disturbances (anxiety and 
life-event stress)(Dunnigan and Pelosi, 1993). IO is also associated with obesity, 
diabetes and hypothyroidism (Pelosi et al., 1986). Many patients also suffer from 
psychological symptoms including depression; patients with IO were shown to be 
significantly more likely to have MDD than a cohort of female hospital outpatients 
(Pelosi et al., 1986). Despite increased knowledge of the symptoms and clinical 
manifestation, IO remains a poorly understood condition. 
 
5.1.5.2 F224: a family multiply affected my idiopathic oedema 
This condition mostly affects women, although a few cases have been reported in men 
(Hoffman et al., 1998). Until 1993 this disorder had not been seen in adolescents or 
children. At that time a study published by Dunnigan and Pelosi (1993) reported 18 
cases of pre-pubescent idiopathic oedema, 15 girls and 3 boys, from 13 families. Apart 
from the usual triad of symptoms (swelling, autonomic and affective disturbances), all 
18 children in the study by Dunnigan and Pelosi appeared healthy; laboratory tests 
excluded allergic, obstructive, cardio-vascular, and hypoproteinaemic causes of oedema. 
Treatment with drugs, such as chlorpropamide and spironolactone, ephedrine, captopril 
and bromocriptine produced no consistent improvement. However, all but one of the 
eighteen children showed a marked improvement in symptoms on administration of a 
carbohydrate-limited diet (120-140g carbohydrates per day). Relapses in diet were 
associated with a return of IO symptoms, which were also brought on and exacerbated 
by stressful life events (Dunnigan and Pelosi, 1993).  
 
Five of these children were related through their mothers, four sisters, all of whom also 
suffered from IO, as did their mother (see pedigree for F224, Figure 5.2). These five 
children showed symptoms of IO as early as three months of age. The early onset of the 
disorder in these individuals and the family history of IO suggest this to be a case of 
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Figure 5.2 Pedigree of family F224, multiply affected by idiopathic oedema (IO). Individuals 
affected with IO are drawn in purple, unaffected individuals are coloured grey. The five 
affected offspring (47,48,49,50 and 51) were all included in the study of IO by Dunnigan and 
Pelosi, 1993. 
 
5.1.5.3 Linkage analysis of four families with IO and MDD 
In 2008, an extended pedigree of F224 was reported with multiple cases of IO and MDD 
(Anderson et al., 2008). Of the 28 affected individuals in this family, 18 had both MDD 
and IO, 7 were affected with MDD only and the remaining 3 suffered from IO only.  
F224, along with three additional, smaller families (F225, F226 and F364), were used in 
a genome-wide linkage analysis to identify regions of the genome associated with both 
MDD and IO. The primary aim of this analysis was to use the co-occurrence of IO and 
MDD in these cases to delineate a sub-phenotype, to identify regions of the genome 
harbouring causative variants for MDD. 
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Two disease definitions were used in this analysis: a narrow (individuals affected with 
MDD) and a broad (individuals with MDD and IO) definition. Parametric linkage and 
non-parametric multipoint variance component analysis were performed using 371 
microsatellite markers in the four families. Four parametric linkage models were run, 
autosomal dominant and autosomal recessive models (with corresponding disease allele 
frequencies of 0.012 and 0.300 respectively) being fitted to both the narrow and broad 
disease definitions. Table 5.3 shows the markers with the maximum LOD scores for 













F224 LOD: 0.91 0.92 0.85 ? 
Total LOD: 1.73 1.55 2.2 1.2 
Marker: D14S275 D14S275 D8S260 D7S516 
Chromosome: Chr14q Chr14q Chr8q Chr7q 
 
Table 5.3. Markers with the highest LOD scores from the marker specific analysis performed by 
Anderson et al. (2008) on the four families with co-morbid IO and MDD.  
 
 
Although this analysis failed to identify any regions of the genome significantly linked 
to MDD and IO (LOD >= 3.3; (Lander and Kruglyak, 1995)), several regions were 
identified with suggestive evidence of linkage (LOD >= 1.9; Lander and Kruglyak, 
1995): 
Chr8q: the marker D8S260 achieved the highest marker specific LOD across all four 
families. This LOD was with the narrow recessive model, suggesting this locus to be 
linked to MDD and not IO.  
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Chr14q: the marker D14S275 achieved the second highest LOD (1.73) with the narrow 
dominant model, as well as the highest LOD (1.55) for the broad dominant model. Both 
of these models are based on autosomal dominant form of inheritance, implicating a 
single, high penetrance variant in this region. This marker also had the highest family 
specific (F224) LOD (0.92) for the broad dominant model, suggesting a risk variant for 
both IO and MDD in this region. 
 
Chr7q: the best result for the broad recessive model was a LOD of 1.2 with marker 
D7S516 on chr7q.  
 
The linkage results for the two disease definitions used (narrow (MDD only) and broad 
(MDD and IO)), suggest that although there might be a common locus contributing to 
both disorders, MDD and IO might also be caused by variants on different loci. 
Specifically, chr8q is the most likely locus for a susceptibility variant for MDD, while 
chr7p and chr14q may contribute to both disorders.  
 
5.1.5.4 F224 as a family case study for idiopathic oedema and 
depression 
The relationship between these two conditions in this family is not clear, but intriguing.  
What is clear is that there is a high burden of IO in this family and a large number of 
individuals suffering from depression, many in the form of MDD. As this family appears 
to suffer from an early onset, familial form of IO, with more severe swelling symptoms 
and functional-autonomic symptoms (Dunnigan and Pelosi, 1993), these individuals 
might also suffer from more severe affective disturbances than more common forms of 
IO, which could be diagnostically similar to MDD. Therefore, the psychiatric symptoms 
used to diagnose MDD in these co-morbid individuals might be part of the depressive 
symptoms known to contribute to IO aetiology. In addition, the cases of MDD without 
IO in this family might be sporadic, or the IO symptoms may be very minor in nature. 
Based on a lifetime prevalence of ~15% for MDD (Kessler et al., 2005), the number of 
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expected cases in a family of 61 individuals would be ~ 9 cases; the number of cases of 
MDD without IO in this family (7) falls within this expected range.  
MDD and IO in this family might be two separate phenotypes with a common (or 
overlapping) cause, or MDD in individuals with IO might be a component part of the 
(severe) IO phenotype. Either way, this indicates the presence of a variant or variants 
that can predispose to MDD. The IO and MDD phenotype in this family can therefore be 
used to select a phenotypic subtype of MDD in a genetically homogeneous background. 
It can be hypothesised that under such circumstances of reduced phenotypic and genetic 
heterogeneity, it might be easier to identify a functional variant than looking for common 
variants within a genetically and phenotypically diverse group of individuals. 
Furthermore, any genetic risk factors for depression identified from this study might be 
generalisable in the population. 
 
5.1.5.5 Potential mechanisms of action for IO and MDD 
Although the biological mechanisms underlying IO and MDD are not yet known, several 
theories have been put forward based on the phenotypes and aetiology of IO: 
 
Immune response:  
In a study of four cases of adult IO, serum levels of cytokines were shown to be 
abnormal; an increased serum concentration of SIL-2R was observed and TNF-alpha, 
IFN-gamma and IL-2 were found to be transiently elevated (Hoffman et al., 1993). The 
authors suggested that in these individuals, the formation of oedema could be a 
consequence of activation of T cells, resulting in the production of cytokines, and a 
cytokine induced alteration of the function of endothelial cells. However, they could not 
postulate the source of the stimulus leading to T cell activation. There is also a potential 
role for an activated immune system, and by extension autoimmunity, in the 
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Abnormal neurotransmitter function:  
Abnormal neurotransmitter function could cause both the functional-autonomic 
symptoms of IO (via the autonomic nervous system) and the affective disturbances 
associated with both IO and MDD (Dunnigan and Pelosi, 1993). 
 
Insulin:  
IO shares common symptoms with diabetic oedema. The high co-occurrence of a 
diabetic family history, obesity and weight gain with IO suggests a potential link 
between IO and an insulin-mediated abnormality of carbohydrate metabolism (Dunnigan 
and Pelosi, 1993). This is supported by the positive effect of a carbohydrate-restricted 
diet. Similarly, this link suggests a potential role for insulin in the aetiology of this 
disorder. More specifically, as insulin levels have been shown to be normal in many 
incidences of IO, there might be a variation in the function of insulin receptors in 
individuals with this condition (Dunnigan and Pelosi, 1993). In addition, acute, sub-
acute and chronic diabetic oedema, are clinically similar to IO, suggesting a common 
cause (Dunnigan and Pelosi, 1993). This could suggest a pathogenic role of insulin, or a 
variation in the function of insulin receptors.  
Furthermore, there is a very strong link between diabetes and MDD (Vancampfort et al., 
2015b), BD (Vancampfort et al., 2015a) and schizophrenia (Foley et al., 2015). 
Insulin has also been reported to multiply effect the transport of water and electrolytes 
(Dunnigan and Pelosi, 1993) including but not limited to stimulating the sympathetic 
nervous system (Landsberg and Young, 1985) and by regulating membrane ion 
transport, modifying calcium exchange and thereby modulating arteriolar tone 
(Blaustein, 1977). 
 
Ion channels:  
Changes to the structure and function of ion channels could be responsible both for the 
fluid retention symptoms of IO (as described by the potential effect of insulin in the 
previous section) and depression (ion channels being consistently implicated in 
psychiatric illness)((Ament et al., 2015); (Schizophrenia Working Group of the 
Psychiatric Genomics, 2014)).  
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Vasculature leakage: 
There is some evidence for the role of capillary leakage, leading to an increased 
diffusion of fluid into the extra vascular space, in the aetiology of IO (Dunnigan et al., 
2004). It has also been shown that when an individual suffers from emotional stress, 
neurological vasodilator pathways are activated, leading to increased blood flow to the 
skin and muscles (Greenfield, 1966). Variation in vasculature could provide a link 
between the fluid retention symptoms of IO and stress. Similarly, it has been 
hypothesised that increased permeability in the blood-brain barrier can lead to 
psychiatric illness through an inflammation response ((Maes et al., 2008); (Shalev et al., 
2009)). Vascular degeneration in the brain, leading to changes in the blood brain barrier 
and impaired amyloid beta-peptide clearance, has also been implicated in the 
pathogenesis of Alzheimer’s disease (Bell and Zlokovic, Acta Neuropathol, 2009 (Bell 
and Zlokovic, 2009)).  
 
Stress and environmental factors:  
The impact of stress on the symptoms of both IO and MDD adds to the evidence that 
there is a strong environmental component to both of these disorders. Genes and variants 
that interact with environmental factors could play important roles in the pathogenicity 
of both IO and MDD. 
 
5.1.5.6 Collaboration with CSHLs  on the F224 project 
We have also collaborated with Prof. Dick McCombie’s CSHLs group to study the co-
occurrence of MDD with IO in F224 (Figure 5.3). Five individuals from this family were 
sequenced; a parent-offspring triad (IDs 25, 26 and 50 from the pedigree shown in 
Figure 5.3), the child being one of the children from the original early-onset IO analysis 
described in section 5.1.4, and two additional affected individuals, a mother and 
daughter pair (IDs 31 and 53). All four affected individuals suffer from both MDD and 
IO. The whole genomes of these five individuals were sequenced with an average depth 
of 31-40X, 90% of the genome being covered by a read depth of at least 20X. The 
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After quality filtering each genome was represented by roughly ~3.4 million SNPs. 
These data were sent to us by CSHLs as VCF files. Stewart Morris (SM) identified all 
heterozygous SNPs common to the affected individuals but not present in the control 
individual. This filtered dataset contained 142,374 SNPs. 
 
The aim of this project was to perform prioritisation analysis of the variants identified. A 
plausible model for the genetic risk variant in this family would be a rare variant of 
moderate effect, lying within one of the linkage regions. This is however by no means 
the only potential model; risk variant(s) of any minor allele frequency could exist 
anywhere in the genome, functioning on their own or in combination, affecting gene-
gene interactions. I therefore chose a two pronged approach for this analysis: i) focusing 
on the three genomic loci with suggestive evidence of linkage to MDD and IO and ii) a 
whole genome analysis.  
 
5.1.6 Summary of chapter aims 
The aim of this chapter was to use SuRFR to prioritise variants from two projects 
studying psychiatric illness in families: bipolar disorder and MDD in family SBF2 and 
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5.2 Methods 
5.2.1 SuRFR Annotation: 
Using the coordinates of the Family SBF2 and F224 variant datasets (based on the 
GRCh37/hg19 assembly of the human genome), I annotated these variants using the 
annotation function, “Denovo_anno_table”, from the R package SuRFR, using the 
following command format:  
 
ann_table <- Denovo_anno_table(file, pop="EUR", threads=1) 
 
I used this annotation data to rank the variants on the basis of predicted function. I also 
used these annotation tables to identify all of the exonic variants in the SBF2 and F224 
datasets, which I extracted and saved as VCF files.  
 
5.2.2 SuRFR prioritisation: 
I ran the annotation data through SuRFR’s prioritisation function, 
”SuRFR_analysis_tab_file”, to prioritise the full variant sets for SBF2 and F224 (using 
SuRFR’s DM model): 
 
SBF2_DM <- SuRFR_analysis_tab_file(filename, DM, unique) 
 
F224_DM <- SuRFR_analysis_tab_file(filename, DM, unique) 
 
5.2.3 Ensembl’s Variant Effect Predictor: 
I ran the exonic datasets for SBF2 and F224 through the online version of Ensembl’s 
Variant EffectPredictor (http://www.ensembl.org/Homo_sapiens/Tools/VEP, accessed 
15/6/15) (McLaren et al., Bioinformatics, 2010). For this, I used the following options: 
 
Assembly: GRCh37.p13  
Species: Human (Homo sapiens) 
Data format: Ensembl default:  
          chr end end disease allele/ref allele (e.g., 1 818046 818046 T/C ) 
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5.3  Results 
5.3.1 Whole genome sequencing study of SBF2  
As previously described, linkage analysis performed on SBF2 identified a region of 
chromosome 4 that co-segregated with disease status, making this a good candidate 
region to search for a putative susceptibility variant for BD and MDD. The population 
frequency of a variant with a large effect size would be expected to be very low, as BD is 
rare (~1%) and no variants on chromosome 4p reach genome-wide significance in 
GWAS. I therefore hypothesised that the disease predisposing variant for BD and MDD 
in SBF2 to be either a rare or unique variant. 
  
Our collaborators at CSHLs provided us with whole genome sequencing data for five 
members of SBF2, three affected (two with BD and one with MDD) and two unaffected 
married-in individuals. SM processed the GATK SNP file and extracted SNP position, 
reference base and alternative allele. He then identified the SNPs that were unique to the 
disease-linked chromosome (within the five individuals) by identifying those SNPs that 
were heterozygous in all the cases and homozygous in the two controls. The script 
written by SM also allowed for sequence failure of one affected and one unaffected 
individual at any position that would otherwise qualify as a disease-chromosome-linked 
SNP. In this way SM extracted all the SNPs present on the disease-linked haplotype 
(defined as chr4: 6,534,951 – 26,495,592).  
 
Once the list of variants on the disease-linked chromosome was generated, SM identified 
the variant frequencies using data from the thousand genomes project (1KG) and 
HapMap. Only SNPs with a Minor Allele Frequency (MAF) below 5% in the 1KG 
European population were included in the next step as the goal was to search for a 
dominant rare variant (one that is present on the disease-linked chromosome of family 
SBF2 and only found rarely, if at all, in public databases). This dataset consisted of 739 
variants. 
 
I annotated the 739 variants using the annotation function of my R package SuRFR. 
Table 5.4 shows the distribution of these variants across the genomic position categories 
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used by SuRFR. This table shows that the majority of variants in this dataset are 
intergenic (i.e. at least 10kb away from a gene). Only nine variants were found to be 
located in exons or splice sites.  
 
Score Genomic Feature 
Number of 
variants 
0 intergenic 467 
1 intron 190 
2 CpG islands and CpG shores 1 
3 10 kb upstream and downstream of genes 67 
4 promoter 5 
5 exon, splice site 9 
Table 5.4 Location of variants relative to genomic features. Column 1 contains the scores used 
by SuRFR; column 2 describes the type of position category associated with that score; and 
column 3 shows the number of variants mapping to each genomic feature. 
 
5.3.1.1 SuRFR analysis 
I ranked these variants on the basis of their estimated functional potential using the 
“DM” model of SuRFR.  Table 5.5 shows the results for the top 37 variants (top 5%) 
from this analysis (full dataset can be found in Appendix E). Of these 37 variants, 2 are 
exonic (position score 5) and two are located in putative promoter regions (1kb upstream 
of the TSS). In addition, 29 of these variants have not been observed in the 1KG EUR 
dataset, suggesting they might be unique to this family. 12 variants overlap high DNase 
HS peak signals (>500) and 10 overlap high TFBS peak signals. 13 variants overlap 
DNase footprints in at least one cell line. The SNPs in this list are within or nearby 
several interesting candidate genes, which are either associated with or functional 
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5.3.1.2 VEP analysis of exonic and splice variants 
I next analysed all the exonic and splice variants within the full set of 739 SNPs. As 
SuRFR has not been designed to discriminate between different types of exonic variants, 
I used Ensembl’s Variant Effect Predictor (VEP) to analyse these variants. VEP predicts 
the effect of a variant on gene transcripts (McLaren et al., 2010).  
 
The VEP output comes in two forms: i) a summary panel and pie chart (Figures 5.4 and 
5.6) giving a brief overview of the VEP job (including the number of variants included, 
whether they overlap genes or regulatory features (transcription factor binding sites), and 
the proportion of types of consequences VEP predicts the variants to cause, based on the 
total number of transcripts affected) and ii) a table, detailing the effect of each variant on 
each transcript. This table contains details on the location of the genomic locations of the 
variants, any genes they overlap, whether they are existing variations (known from 
dbSNP or 1000 Genomes), what their predicted consequence is and the predicted impact 
of this consequence (Modifier, Low, Moderate, or High. See the description on the VEP 
website: 
http://www.ensembl.org/info/genome/variation/predicted_data.html#consequences), and 
whether SIFT and PolyPhen predict them to have a deleterious effect on protein structure 
and function.  
 
Figure 5.4 and Table 5.6 summarise these data. All nine variants are found in variant 
databases such as the 1000 Genomes project, dbSNP and the HapMap project. Two 
variants are coding and one lies within a splice site. Only one variant was shown to be a 
non-synonymous substitution, changing a glutamic acid residue (E) to a lysine residue 
(K) in the protein CC2D2A. VEP predicted this variant to have a moderate impact on 
protein function. In addition, SIFT and PolyPhen respectively predicted this variant to be 
deleterious and possibly damaging. The other coding variant, in MRFAP1, is a 
synonymous substitution, predicted by VEP to have a low likelihood of pathogenic 
consequence and by SIFT and PolyPhen to be benign. Variant rs3733510 overlaps a 
splice site; however, VEP did not predict it to have a pathogenic consequence. The 
remaining six exonic variants were found to overlap 5’ and 3’UTRs.  Re-sequencing of a 
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subset of the 739 variants by J.C. Yao et al. at CSHLs validated five of the nine exonic 










Figure 5.4 Summary statistics from VEP for the nine exonic / splice site variants from the SBF2 
disease-linked haplotype. The summary table reports the number of variants included in the 
VEP job, how many of these were known variants, and whether any of these overlapped genes, 
transcripts or regulatory features (TFBSs). The two pie charts summarise the proportion of 
consequences for all of the transcripts these variants overlap; the pie chart on the left reported 





Table 5.6. Summary of VEP results for the eight exonic and single splice site variant in the SBF2 
dataset. This table shows the gene the variant overlaps (column 1), the genomic position of the 
variant  (column 2), the disease and reference alleles (columns 3 and 4 respectively), the rs 
number associated with that genomic position (column 5), the minor allele frequency (MAF) of 
the variants (column 6), the main consequence type VEP predicts the variant to have across all 
transcripts (column 7) and the predicted impact of this consequence (Low, Modifier, Moderate, 
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5.3.1.3 Investigation of variants in LD with the schizophrenia GWAS 
variant rs215411 
A recent GWAS identified a variant within the chr4p15 locus as being significantly 
associated with schizophrenia. This variant is located in an intergenic region (the nearest 
gene is ~35kb away), suggesting it might function as an enhancer or other long range 
regulatory element. I identified the linkage disequilibrium block (D’ = 0.8) around this 
variant using HaploView (HapMap V2, Release 24, population CEU, solid spine of 
LD)((Barrett et al., 2005)). This region spans the chr4 region from 23,323,427 to 
23,446,949 bp. The SBF2 sequencing data (MAF <0.5) contains six variants that lie 
within this region (Figure 5.5). Any of these six variants could be hypothesised to 
function as long-range enhancers. The highest ranking of these SNPs ranked 366th out of 
the SBF2 SuRFR ranking data. Excluding all variants with a position score > 0 (i.e. only 
ranking intergenic variants), reduced this dataset to 467 intergenic variants. The highest 





Figure 5.5. Screen shot of the UCSC genome browser showing the linkage block (D’ = 0.8) 
around the SZC GWAS variant rs215411. The top track, “SBF2 WGS variants”, is a custom 
track, showing the locations of the six SBF2 rare variants (MAF <0.5) that are located in this 
region. The GWAS variants rs215411 is coloured green and can be seen to the right hand side of 
the region. 
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5.3.2 Whole genome sequencing study of F224  
Our collaborators at CSHLs generated WGS data for a family with rMDD and co-
occurring IO (F224). From these data, SM extracted the heterozygous variants that were 
present in the four cases and absent from the married-in control. I annotated the 142,374 
SNPs in this dataset using the annotation function of SuRFR. I did not use a MAF cut-
off for this dataset as it was unclear what minor allele frequency to expect for the risk 
variant. I used the DM model to prioritise the rare variants over common variants as I 
hypothesised the susceptibility variant(s) to be of moderate to high effect size (best 
identified by the DM model), potentially uncommon or rare in the general population. 
 
5.3.2.1 SuRFR analysis 
I ranked all 142,374 variants using the DM model of SuRFR. The top 30 variants from 
this analysis are shown in Table 5.7, along with the nearest gene and their MAFs. In 
addition, I extracted subsets of this ranked data for each of the three loci implicated by 
linkage analysis: chr7p (chr7: 1-59,000,000), chr8q (chr8: 47,000,000-147,000,000) and 
chr14q (chr14: 19,000,000-68,000,000). The top 30 variants from each of these regions 
are shown in Table 5.9 A, B and C, along with the nearest gene and their MAF. Only one 
of the top 30 whole genome variants lies in a linkage region: the SNP at chr8: 82754557 
ranks 7th. The highest ranked variant from the chr7q locus ranks 243rd and the best 
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Table 5.7. The top 30 ranked variants from the full F224 dataset (142,374 SNPs). Column 1: the 
DM rank of each variant; column 2: the coordinates of the variants; column 3: the gene 
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Table 5.8. The top 30 DM ranked variants from the three F224 linkage regions: chr7q (A), 
chr8q (B) and chr14q (C). For each table, column 1 shows the rankings of these SNPs against 
the full F224 dataset, column 2 shows their position (coordinates in Hg19 format), column 3 
contains the gene associated with the variant (if blank, this variant is intergenic) and column 4 
contains the variant MAFs. 
C. 
A. B. 
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5.3.2.2 Analysis of exonic variants using VEP 
Using the annotation data from SuRFR, I was able to identify all of the variants in the 
WGS dataset that overlapped exons. I extracted this subset of 2,912 variants from the 
full dataset and ran it through the Variant Effect Predictor (VEP) to identify any variants 
with deleterious effects (missense, stop loss, stop gain and frameshift mutations). The 
summary statistics from VEP on this dataset can be seen in Figure 5.6. Of these 2,912 











Figure 5.6. Summary statistics from VEP for the full exonic F224 dataset. 
  WGS 7q 8q 14q 
Total variants 142,374 3,817 4,692 1,775 
exonic 2,912 163 78 81 
missense 477 27 8 11 
stop lost 3 0 0 0 
stop gain 4 0 0 0 
frameshift 2 0 0 0 
 
Table 5.9 Breakdown of the types of deleterious exonic variants present in the full F224 dataset 
(across the whole genome (WGS)), and within each of the three linkage regions (chr7q, chr8q 
and chr14q). 
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Of these 2,912 variants, 477 were missense mutations, 3 were stop lost mutations, 4 were 
stop gain mutations and 2 were frameshift mutations (Table 5.9). None of these were 
located in the linkage regions. All nine of the stop-loss, stop-gain and frameshift 
mutations were predicted by VEP to have a high impact on protein structure (Table 
5.10). Six of these variants are not found in the 1000 Genomes database or other human 
variation databases, suggesting they are unique to F224. 
 
The other 2,903 variants were predicted to have either a moderate or low risk of 
pathogenicity. However, 141 of these variants were predicted by either SIFT or 
PolyPhen (or both) to be potentially deleterious, (See Appendix F for a summary of the 
VEP output table for these 141 variants). Of these 141 variants, 46 had a MAF <= 0.05, 
of which 44 had a MAF <= 0.01. Only one of the 141 variants (rs351855) was annotated 
by VEP as having clinical significance (highlighted in the table in Appendix F).  
 
Using the annotation data generated by SuRFR I extracted the subset of exonic variants 
within the three linkage regions (chr7p, chr8q and chr14q)(Figure 5.7, Table 5.9).  All 
322 variants were missense variants or synonymous variants. 39 of these missense 
variants were predicted by VEP to have a moderate impact on protein structure and 
function (Table 5.11), of which 11 were predicted by SIFT and/or PolyPhen to be 




Table 5.10 Summary data from VEP for the nine exonic variants predicted to have high impact 
on protein structure and function (IMPACT column). Six of these variants have not been seen in 
the 1000 Genomes EUR database, suggesting they are unique to family F224. 
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Figure 5.7 Summary statistics from VEP for the subset of exonic variants that overlap the three 
linkage regions (chr7q, chr8q and chr14q). All the protein coding variants were identified by 
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5.4 Discussion 
5.4.1 Summary 
SuRFR was designed to aid in the analysis of variants from a range of genomics projects, 
including WGS data. To that effect, I have used SuRFR to prioritise variants from two 
WGS projects: the Scottish BD family (SBF2) project and the F224 project, a family 
with major depressive disorder and idiopathic oedema. The goal was to prioritise the 
putative functional variants for further investigation.  This analysis focused on single 
nucleotide polymorphisms, as SuRFR has not been trained to prioritise indels or CNVs.  
 
I have trained three different SuRFR models, each designed for specific analysis types, 
for prioritising causal variants for diseases with different genetic architectures. I 
previously showed that the ALL model is capable of prioritising known disease variants 
from a range of disease architectures above background variants. However, when the 
mode of inheritance is known to be Mendelian-like (rare variants of large effect), using 
the DM model improves the likelihood of correctly prioritising the causal variants above 
background variants. It is therefore important to correctly identify the disease model of 
the variants under investigation. For both SBF2 and F224 I hypothesised the 
susceptibility variants to be variants of large effect with medium to high penetrance, that 
are either rarely seen in the general population, or are unique to these families. I 
therefore used the DM model of SuRFR for both of these analyses. However, as the 
linkage results for F224 were less informative that for SBF2, I did not pre-filter the F224 




5.4.2 SBF2  
5.4.2.1 Candidate genes: 
Amongst the top ranking SuRFR output variants from the ~20Mb disease-linked 
haplotype, there were several that were within or nearby interesting candidate genes:  
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C1QTNF7:  
Conduct disorder (CD) is one of the most prevalent childhood psychiatric disorders, 
characterised by aggressive behaviour, persistent rule breaking, and associated with 
alcohol problems (Dick et al., 2011). The C1q and tumour necrosis factor-related protein 
7, C1QTNF7, is an extracellular protein of unknown function. Two variants in this gene 
showed genome-wide significant associations (P<5 x 10-8) with CD in a study of 872 
cases of CD and 3,091 controls (Dick et al., 2011). As CD is a psychiatric condition that 
can co-morbidly occur in youth with BD (Joshi and Wilens, 2009) and there is evidence 
of genetic overlap between psychiatric disorders (see Chapter 1: 1.4), this gene is an 
interesting candidate for BD.  
 
The top two ranking C1QTNF7 variants (ranking 3rd and 4th overall) are unique variants, 
not seen in the 1000 genomes database. These two SNPs are located one base pair apart 
and overlap both a DNase HS cluster and three TFBSs, including c-FOS (Figure 5.7). c-
FOS is known to be expressed in the brain (Herrera and Robertson, 1996) and to play an 
important role in regulation of synaptic plasticity (Cohen and Greenberg, 2008). Variants 
associated with both schizophrenia risk and protection, have been identified in the c-FOS 
gene (Boyajyan et al., 2015). GABAB receptors, which have been implicated in 
psychiatric disorders (de Bartolomeis and Tomasetti, 2012), have also been shown to be 











Figure 5.7 Image from the UCSC genome browser, showing the location of the two intronic 
C1QTNF7 variants and their overlap with a binding site for the brain-expressed transcription 
factor c-FOS.  
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Two additional C1QTNF7 variants are in the top 5% table (Table 5.4). These variants, 
both with MAFs of 0.03 in the 1000 genomes EUR dataset, are located 3 base pairs apart 
from each other ~7kb upstream of the C1QTNF7 transcription start site. These two 
variants also overlap a DNase HS cluster and several TFBSs (POLR2A, BCL11A, 
PAX5, YY1 and EP300).  
 
KCNIP4:  
The protein encoded by this gene is a member of the family of voltage-gated (Kv) 
channel-interacting proteins (KCNIPs). Members of this protein family are small 
calcium binding proteins and interaction partners of the voltage-gated potassium channel 
subunit Kv4 family (Weissflog et al., 2013). A candidate gene based association study 
(594 adult attention-deficit/hyperactivity disorder (ADHD) cases, 630 BD cases and 974 
controls) showed KCNIP4 to be associated with both ADHD (best p = 0.0079) and BD 
(best p = 0.0043) (Weissflog et al., 2013). However, the power of this study was limited 
due to the small number of samples.  
 
Voltage-gated calcium channels and their binding partners have been implicated 
consistently in GWAS of psychiatric illness (Lee et al., 2012). In particular, the 
potassium voltage gated protein KCNC2, along with its interaction partner ANK3 (Judy 
et al., 2013)(which helps to regulate the localisation of voltage-gated ion channels 
(Garrido et al., 2003)) have both been implicated in multiple GWASs of BD ((Wellcome 
Trust Case Control, 2007); (Ferreira et al., 2008); (Muhleisen et al., 2014)). These 
calcium-binding proteins, including KCNIP4, are therefore excellent biological 
candidates for conferring risk of BD and depression. Together, these results suggest 
KCNIP4 may play a role in conferring risk for BD and psychiatric illness. Two intronic 




SORCS2 is a member of the sortilin family of mammalian type-I transmembrane 
receptors containing a Vsp10p domain ((Hermey, 2009); (Willnow et al., 2008)). The 
sortilins are fundamental for development and maintenance of neuronal synaptic 
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properties, signalling characteristics, morphology and growth ((Jansen et al., 2007); 
(Hermey, 2009); (Lane et al., 2012)). Five members of the sortilins are found in 
vertebrates (SORL1, SORT1, SORCS1, SORCS2 and SORCS), all of which are 
expressed in the brain (Willnow et al., 2008). There is growing evidence that this family 
of receptors are potential neuronal disease genes, SORL1 and SORCS1 being implicated 
in Alzheimer disease (Reitz et al., 2013). 
 
SORCS2 is a neuronal receptor involved in protein trafficking. This gene was implicated 
by a GWAS (best p value = 0.000014) ((Wellcome Trust Case Control, 2007); (Baum et 
al., 2008); (Ollila et al., 2009)) and an association study comparing 576 schizophrenia 
patients and 506 BD patients with 607 controls from the Scottish population (p = 
0.0003)(Christoforou et al., 2007). However, despite these early suggestive findings, 
associations with this gene have failed to reach genome-wide significance in the largest 
BD GWAS to date by Mülheisen et al. (2014) (Table 5.1). This does not mean that rare 
variants within this gene are not associated with BD. Nor does it preclude the possibility 
of Scottish specific variation playing a role in the aetiology of BD in SBF2, as has been 
suggested for variants in Neuregulin and DISC1 ((Walker et al., 2010); (Hennah et al., 
2009)). 
 
The top 5% of ranked variants from family SBF2 included 8 non-coding variants around 
this gene and within its introns. In addition, two variants within the 3’UTR of SORCS2 
were found. VEP classifies all 3’ and 5’ UTR variants as “modifiers”, implying they may 
function through a regulatory function affecting gene expression, or mRNA stability or 
localisation (Duan et al., Hum Mol Genetics, 2003).  
 
DRD5:  
This gene encodes a dopamine receptor. There exists a lot of evidence implicating 
dopamine receptors in the aetiology of psychiatric conditions, in particular schizophrenia 
((Brisch et al., 2014); (Hoenicka et al., 2007)). Most recently, the 2014 PGC 
schizophrenia GWAS identified the locus containing the DRD2 gene as a genome-wide 
significantly associated region with schizophrenia (Schizophrenia Working Group of the 
Psychiatric Genomics, 2014). However, the mechanisms by which dopamine receptors 
might contribute to psychiatric disorders are still being investigated ((Laruelle, 2014); 
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(Grace, 2012); (Lodge and Grace, 2011)).  We do know that neurotransmitter systems 
are closely linked, with interactions occurring between dopamine, glutamate (de 
Bartolomeis and Tomasetti, 2012) and serotonin (de Bartolomeis et al., 2013). In 
addition, all effective antipsychotic drugs (both classical and current drugs) for 
schizophrenia function through mechanisms that include dopamine and related 
neurochemical pathways (Brisch et al., 2014).  A variant 5’ to the DRD5 gene ranked 
27th in the DM rankings. This variant appears to be unique to family SBF2.  
  
SLIT2:  
The SLIT2 protein acts as a molecular guidance cue in neuronal migration. The 
Drosophila homolog of this protein was shown to be a neuronally expressed protein that 
plays a role in axon guidance (Itoh et al., 1998). Although this gene has not been shown 
to be associated with any of the major psychiatric illnesses, this gene was identified in an 
association with anger in suicide attempts (Sokolowski et al., 2010). This, along with its 
function as an axon guidance molecule, important for neuronal wiring, makes it an 
interesting candidate gene for BD. 
 
The 24th best ranking variant from the family SBF2 was a unique, intronic SLIT2 variant, 
located 7 base pairs from an intron-exon boundary and predicted by VEP to be located in 
a splice site, though not to affect splicing.  
 
CC2D2A:  
This gene encodes a coil-coil domain protein. Mutations in CC2D2A have known to 
cause Joubert syndrome and Meckel syndrome, two forms of ciliopathies, which 
encompass a range of symptoms including mental retardation (Bachmann-Gagescu et al., 
2012). This protein interacts with CEP290 (Gorden et al., 2008), which in turn has been 
shown to interact with DISC1 (Millar et al., 2003). CEP290 has been implicated as an 
autism candidate gene (Cukier et al., 2014), while DISC1 (disrupted in schizophrenia 1) 
has been implicated in several psychiatric illnesses ((Bradshaw and Porteous, 2012); 
(Brandon and Sawa, 2011); (Millar et al., 2001)), suggesting CC2D2A may be part of a 
larger network of proteins involved in psychiatric illness.  
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This gene harbours the only non-synonymous substitution (rs144439937) in the set of 
rare (MAF <0.05) variants from the SBF2 disease-linked chromosome. This variation 
results in a lysine residue (K) being replaced by a glutamate (E) at amino acid position 
507. VEP reported this variant to be moderately likely to have a negative consequence to 
protein function. This variant changes a basic amino acid (K) to an acidic amino acid 
(E), which might alter the electrostatics of the surface of the protein, affecting how it 
interacts with other proteins. The population frequency of rs144439937 (MAF 0.008) 
meant it was excluded from the initial analysis of coding variants described in section 
5.1.4.2 (as it was not unique to family SBF2). However, it is possible that this variant 
confers risk of illness via an interaction with other variants.  
 
Intergenic variants within the rs215411 linkage region: 
Six variants from SBF2 were found to be in LD with a genome-wide significant variant 
for schizophrenia, rs215411. On its own, the rank of the highest ranking variant (94th out 
of the 467 intergenic SBF2 variants) may not be sufficient to include this SNP in any 
follow-on experimental analysis; however, the independent evidence from the 
schizophrenia GWAS, suggesting a susceptibility variant for psychiatric illness may be 
located in this region, adds additional weight. 
 
 
5.4.2.2 Potential future work on the SBF2 project  
Experimental follow up: 
SuRFR is a predictive method, designed to be an aid to genomics projects, prioritising 
variants from most likely to be functional (and therefore the best starting point for 
follow-up analysis), to least likely to be functional. Experimental analysis is needed to 
verify the functionality of high-ranking variants. Methods to functionally validate 
variants in the lab include luciferase assays and EMSA shift assays or other related 
approaches, which can be used to show changes in gene expression or in the binding 
ability of transcription factors. Several reviews discussing the various options available 
to experimentally establish the functional consequence of regulatory variants have been 
recently published ((MacArthur et al., 2014); (Li et al., 2015); (Knight, 2014)). 
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Validation of sequencing: 
No sequencing platform has been shown to be 100% accurate (Lam et al., 2012). Based 
on cross-platform comparative analysis and our own sequencing validation experiments, 
it appears that rare or unique variants have the lowest validation rates and are most likely 
contain erroneous variants (Lam et al., 2012). Several courses of action are available to 
deal with this: i) The GATK SNP filtering steps chould be re-evaluated (more stringent 
thresholds should be used); ii) All high-ranking SNPs chould be re-sequenced in these 
individuals to show they are real variants.  
 
Confirm association of causal variants with illness in additional cases/controls: 
Candidate SNPs identified in the affected individuals should be followed up in additional 
family members to confirm that these variants segregate with illness. High-ranking 
common SNPs chould also be genotyped across a large number of individuals from the 
Scottish population (including other individuals with BP) to see if they are associated 
with BP on a population level. This is particularly relevant for the K507E variant in 
CC2D2A.    
 
Consider additional disease model hypothesis: 
I have hypothesised a dominant disease model, and have predicted the chr4p locus 
identified through linkage analysis to harbour a highly penetrant, rare susceptibility 
variant. However, the LOD generated by the linkage analysis (LOD = 4.1) does not 
negate the possibility of risk variants occurring elsewhere in the genome. Therefore, 
there could be other interpretations for genetic risk of BD in this family. For instance, 
the chr4p locus might harbour several variants that interact and together lead to illness. 
Similarly there might be a number of variants across the genome that could each 
individually have a small effect but together concert a polygenic risk.  
 
5.4.2.3 Active projects on the Family SBF2 data 
Our collaborators at CSHLs are sequencing the genomes of additional individuals from 
family SBF2. Another collaborator, Prof. Andrew McIntosh and his group, have 
genotyped over 50 individuals from family SBF2 and are calculating a polygenic risk 
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score for the family members. In addition, Andrew McIntosh’s group is re-assessing the 
linkage in SBF2 using additional individuals and genotyping data. These data should be 




Early onset cases of any disorder tend to be more severe than late-onset versions and are 
more likely to have a strong genetic component ((Gogtay et al., 2011); (Agopian et al., 
2012); (Childs and Scriver, 1986)). Familial, highly penetrant disorders are therefore 
good candidates for gene identification. The related individuals with IO identified by 
Dunnigan and Pelosi, shown to also be affected by depressive symptoms, frequently 
diagnosed as MDD, are therefore potentially useful in the discovery of the genetic 
factors linked to IO and MDD. 
 
The disease model for MDD and IO in F224 is less clear than for BD and MDD in 
family SBF2. The linkage analysis, although suggestive, did not point to any region of 
the genome with sufficient significance to focus the search on any one locus. This could 
be due to: heterogeneity across the four families; a multi-locus interaction model; a more 
polygenic model; and/or a large environmental component to illness. I used SuRFR to 
rank all 142,374 variants on the basis of predicted function. I then used VEP to identify 
proteins predicted to have a deleterious impact on protein structure and function.  
 
5.4.3.1 Candidate genes from the SuRFR ranking analysis 
Due to the lack of clarity from the linkage data, I have analysed the variants identified by 
whole genome sequencing in four datasets: the whole genome data; the chr7q linkage 
region; the chr8q linkage region; and the chr14q linkage region. The following section 
summarises the best candidate genes from these datasets. 
 
QRICH1:  
Little is known about the glutamate rich protein 1 (QRICH1) gene or its encoded protein. 
However, this protein is predicted to contain a caspase activation recruitment domain 
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(CARD) (from UniprotKB, 27th July 2015). The CARD family of proteins play an 
important role in regulating apoptosis, inflammation signalling and NF-kB signalling 
(Kao et al., 2015).  
 
A non-coding variant in the promoter region of QRICH1 ranked second out of the 
whole-genome SuRFR ranking data. This variant overlaps a range of strong regulatory 
features including the chromatin state active promoter, DNase HS in 125 cell lines; 37 
TFBSs; and has a high conservation score. Due to the potential role of inflammation in 




The islet cell auto antigen (ICA1) gene has been associated with type I diabetes and 
plays a role in glucose regulation (Arvan et al., 2012). ICA1 has also been implicated as 
an autoimmune gene (Johar et al., 2015). The link between IO and diabetic oedema 
implicates genes such as ICA1. This gene would therefore be an interesting gene to 
investigate further.  
 
Two intronic ICA1 variants were in the top 30 chr7q linkage region variants, ranking 2nd 
and 9th (311th and 891st out of the whole-genome data).  
 
AQP1: 
Aquaporin 1 plays a critical role in water transport across the peritoneal membrane, 
which forms the lining of the abdominal cavity, containing the blood vessels, lymph 
vessels and nerves (Morelle and Devuyst, 2015). Increased expression of AQP1 in 
peritoneal capillaries leads to increased water permeability (Devuyst and Ni, 2006).  
 
An intronic variant of this gene ranked 5th of the variants in the chr7q linkage region and 
624th out of the whole genome data. This variant is an excellent candidate for the 
capillary leakage phenotype seen in IO, which might also confer risk to psychiatric 
illness via inflammatory response due to abnormal blood-brain barrier communication 
((Maes et al., 2008); (Shalev et al., 2009)). In addition, Aquaporin 4 (AQP4) is known to 
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be expressed in the brain (Amiry-Moghaddam et al., 2004) and has been proposed to 
function in concert with the potassium channel Kir4.1 (Nagelhus et al., 2004), suggesting 
a functional link between aquaporins, and potassium gated ion channels and a novel 
pathway involved in the aetiology of psychiatric illness. 
 
CAMK2B: 
Increased expression of the Calcium/calmodulin-dependent protein kinase II B 
(CAMK2B) protein in the frontal cortex has been shown in patients with schizophrenia 
and depression (Novak et al., 2006). Furthermore, increased expression of this protein 
was reported in the prefrontal cortex of suicide victims (Choi et al., 2011). This gene is 
therefore a good candidate for both the psychological symptoms of IO and MDD. 
 
An intronic CAMK2B variant ranked 20th out of the chr7 linkage region variants (1360th 
overall). This variant overlaps the binding sites of over 20 transcription factors (by ChIP-




The Dopa Decarboxylase (DDC) gene is also known as Aromatic L-Amino Acid 
Decarboxylase (AADC). AADC is a key component of the serotonin and dopamine 
synthesis pathways ((Deneris and Wyler, 2012); (Cenci, 2014)). This protein is also 
expressed in blood vessel associated cells (Bertler et al., 1966). Mutations of this gene 
(homozygous and compound heterozygous mutations) lead to AADC deficiency, which 
negatively affects neurotransmitter metabolism, which in turn leads to a deficiency of 
both serotonin and dopamine (Brun et al., 2010)) clinically characterised this disorder as 
consisting of vegetative symptoms, oculogyric crises (a prolonged involuntary upward 
eye movement), dysteria (uncontrollable repetitive muscle movements) and severe 
neurological dysfunction which usually begins in infancy or early childhood. Other 
symptoms reported by Swoboda et al. (2003) include emotional lability and irritability, 
as well as gastrointestinal problems such as reflux disease, constipation and diarrhoea 
(Swoboda et al., 2003).  
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Some of these symptoms appear related to IO (motional lability, irratibility, 
gastrointestinal problems), although the overall aetiology is much more extreme. A 
regulatory variant could be hypothesised to lead to a less severe disorder than AADC, 
such as the intronic DDC variant which ranks 22nd out of the chr7q variants and 1492th 
out of the whole-genome ranked data.  
 
KCNS2: 
This gene encodes a potassium voltage gated channel. As described earlier in this 
discussion (5.4.2.1), potassium voltage gated channels are widely expressed in both the 
central and peripheral nervous system, mediate neuronal excitability ((Yellen, 2002); 
(McKeown et al., 2008)), and have been implicated via multiple lines of evidence to play 
a role in the pathology of psychiatric illness (Brisch et al., 2014).  
 
A variant less than 1.5kb upstream of the KCNS2 gene ranked 5th out of the chr8 linkage 
region variants and 246th out of the whole-genome ranked data.  
 
NCALD: 
A variant in the NCALD gene on chromosome 8 has been reported to be a risk variant for 
coeliac disease (Monten et al., 2015). In the same report, the authors suggest a link 
between NCALD, coeliac disease and nutrient signalling.  
 
An intronic NCALD variant ranked 18th in the chr8q linkage region and 957th out of the 
whole genome ranking. This variant overlaps binding sites for nine transcription factors 
(UCSC genome browser, ENCODE ChIP-Seq track, accessed 27th July 2015): POLR2A, 
ATF2, FOXM1, EZH2, WRNIP1, STAT1, RELA, CHD1 and IKZF1. Of these, ATF2 
responds to stress-related stimuli and plays a role in inflammation (Yu et al., 2014). Both 
IO and this transcription factor has been linked with obesity ((Pelosi et al., 1986); 
(Miyata et al., 2013)). In addition, the most successful treatment of IO is a reduced 
carbohydrate diet, which would include a reduction in gluten containing foods. Taken 
together these data suggest a potential overlap in function for NCALD in celiac disease 
and IO and a link between IO, obesity, ATF2 and NCALD. 
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SSTR1: 
This gene encodes the somatostatin receptor 1, which Egerod et al. (2015) showed plays 
a role in somatostatin secretion in gastric somatostatin cells (Egerod et al., 2015). They 
also showed that this action is regulated by a combination of hormones, 
neurotransmitters, neuropeptides and metabolites (Egerod et al., 2015). A closely related 
protein, SSTR2, has also been implicated in the pathogenicity of Alzeihmer’s disease 
(Adori et al., 2015). 
 
Two variants for this gene were included in the top ranking variants for the chr14 
linkage region. The first, which ranked 2nd (291st in the whole-genome data) lies within 
the 3’ UTR of SSTR1; the second, ranking 28th (4270th in the whole-genome data) is 
located downstream of this gene. 
 
5.4.3.2 Analysis of coding variants using VEP: 
As with the SBF2 data, I also focused on the variants that overlapped exons. Because 
SuRFR cannot discriminate between different classes of exonic variants (synonymous, 
non-synonymous, UTR, etc), I used VEP to search this list of variants for ones that 
potentially have a deleterious effect on protein structure and function. 
 
Nine variants were predicted by VEP to have a high impact, located in the genes: 
MORN4, ZNF214, TRIM48, OR812, OR5M11, LEPREL2, ZNF717 and CER1. Of these, 
the most interesting candidate genes are CER1 and MORN4. The CER1 gene encodes a 
cytokine that may play a role in anterior neural induction and somite formation during 
embryogenesis (Uniprot, 27th July, 2015). MORN4 has been shown through Drosophila 
and Mouse models to have a role in axon degeneration (Bhattacharya et al., 2012). Little 
is known in the literature about ZNF717 (a pseudogene), ZNF214 (a zinc finger protein), 
OR812 and OR5M11 (two olfactory receptor genes), TRIM48 (a RING finger protein) or 
LEPREL2 (a collagen prolyl hydroxylase). 
 
Only one variant from this dataset was reported by VEP to have a clinical significance 
(although only predicted by VEP to have a moderate impact). This variant, rs351855 is a 
missense variant of the Fibroblast Growth Factor Receptor 4 (FGFR4) gene. This SNP is 
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associated with susceptibility to ischemic stroke ((Zhang et al., 2012a); (Yin et al., 
2014)) and has been shown to modulate the association of a variant in the Klotho Beta 
(KLB) protein (expressed in the digestive system, regulates bile acid production and 
associated with diarrhoea (Camilleri et al., 2014)) with colonic transit in irritable bowl 
syndrome with diarrhoea (IBS) (Wong et al., 2011). According to UniProt 
(http://www.uniprot.org/uniprot/P22455#section_comments, accessed 12th August 
2015), GO terms associated with FGFR4 include cell migration, signalling pathways 
(including insulin receptor signalling and nerotrophin TRK receptor signalling pathway), 
and glucose homeostasis (see Figure 5.8 for the full list of GO terms reported by 
UniProt). Many of these terms support a potential biological link between this gene and 




Figure 5.8 Screen shot from the UniProt webpage for the FGFR4 protein, showing the gene 
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5.4.3.3 Summary of implicated mechanisms 
The strongest hypothesis for IO in the literature is vascular leakage in the capillary bed. 
The capillary bed and vasculature system work in tandem with the lymphatic system, 
both being integral parts of vasculature structure, regulating fluid release and uptake 
from the blood into the interstitial fluid and back into the blood 
(http://anatomyandphysiologyi.com/lymphatic-system/ accessed July 2015). Furthermore 
there is evidence in the literature of shared swelling symptoms between IO and lymph 
vessel diseases (characterised by lymphedema, swelling of the limbs due to a build up of 
lymph fluid in soft tissue), such as Elephantiasis ((Babu and Nutman, 2014). See also the 
WHO report on elephantiasis: http://www.who.int/mediacentre/factsheets/fs102/en/).  
The dysregulation of either part of this vascular mechanism could explain the swelling 
symptoms observed in IO. In addition, the neurovasculature is an important component 
of the brain; defects in the mechanism of the blood-brain barrier and lymphatic 
vasculature have been implicated in neurological disorders ((Shalev et al., 2009); (Bell 
and Zlokovic, 2009)). The lymphatic system is also an important element of the immune 
system (Liao and von der Weid, 2015), which has recently been implicated as a common 
pathway for schizophrenia, BD and MDD (Network and Pathway Analysis Subgroup of 
Psychiatric Genomics, 2015). Taken together, these results suggest there might exist a 
common mechanism contributing to the range of phenotypes (swelling symptoms, 
functional-autonomic and affective disturbances) associated with IO and depression in 
F224. This hypothesis is supported in this analysis by the high-ranking variant identified 
in AQP1, which suggests a mechanism combining vasculature, lymphatic system and a 
potential immune/inflammatory response in the aetiology of IO and MDD.  
 
There could also be a neurological cause for both IO and MDD in this family. The 
evidence that stress worsens both the swelling and affective symptoms of IO also 
supports the theory of a neurological component. Among some of the highest-ranking 
variants from SuRFR were variants involved in neuronal processes. These included the 
potassium channel protein KCNS2, the calcium/calmodulin dependent protein CAMK2B 
and the serotonin/dopamine synthesis protein DDC (which, being expressed in the 
blood-brain barrier, points back to the first hypothesis). 
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Interestingly, although drugs had very little effect, a change in diet from a normal diet to 
low carbohydrate diet has been shown to have greatest effect on IO swelling symptoms 
(Dunnigan and Pelosi, 1993). In cases with successful treatment, symptoms only 
returned when the diet restrictions were not followed or stressful life events occurred.  
This suggests that both diet and stress are important factors in the pathophysiology of 
IO, potentially implicating a carbohydrate metabolism/ insulin related cause to this 
disorder. The variant in the NCALD gene, which has been linked to coeliac disease, as 
well as a SNP in ICA1, which plays a role in glucose metabolism, are good candidates to 
follow-up this particular theory. 
 
This analysis has highlighted several mechanisms that might play a role in the aetiology 
of IO and depression. It should be noted that none of these three mechanisms are 
mutually exclusive and some of the genes impacted may be involved in more than one 
pathway/mechanism.  
 
5.4.3.4 Future work on the Idiopathic oedema data 
One major drawback to my analysis of the IO data was its size, as the raw WGS data 
contained over 12 million variants, a number of which are likely to be sequencing errors. 
Before further analysis is done on these data, variants should be filtered as follows: 
 
1. As with the SBF2 data, the GATK quality control step could be repeated using more 
stringent thresholds to improve the signal to noise ratio and increase our chances of 
identifying the true causal variants. 
 
2. WGS of additional individuals from F224 would allow additional variants not present 
in all cases to be excluded, further reducing the number of SNPs to be analysed. 
 
3. The linkage analysis performed by Anderson et al. (2008) included three other 
families. Analysing sequencing data from these families could allow us to filter variants 
further. Across these families there could be genes and/or pathways that harbour 
different variants, all contributing to disease risk.  
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Once a filtered set of SNPs has been produced and re-analysed (using the methods 
described in this chapter), candidate variants should be validated by Sanger sequencing.  
Many experimental methods are available to functionally characterise these variants. 
Some examples include: i) obtain gene expression data in appropriate cell lines and test 
whether these variants are eQTLs; ii) perform luciferase assays and EMSA shift assays 
to test if variants are regulatory variants and if they directly alter TFBSs; iii) use genome 
editing techniques such as CRISPR to recreate these variants in cell lines and use these 
cultured cells to test if variants alter the stability or localisation of mRNA or proteins.  
 
   
5.5 Conclusion 
I have used SuRFR to prioritise putative causal variants associated with two different 
psychiatric illnesses in two different projects. These two prioritised lists of variants will 
be used to guide the selection of variants for experimental and genetic investigation as 
part of a major international collaboration. 
 
I have also discussed several drawbacks to the project design, and ways of improving the 
quality of the data to be analysed using SuRFR. I showed in Chapter 4 that the more 
refined the variant data, the better SuRFR performs. These points will be discussed 
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Chapter 6: Discussion 
6.1 Summary of thesis 
Whole genome and whole exome sequencing methods have generated large amounts 
of data on human genetic variation. As these methods become more affordable they 
are likely to become routine tools in the investigation of the genetic basis of human 
disease (Wang et al., 2015). As “Big Data” continues to get bigger, we need tools to 
identify the signal of true pathogenic variation over the background noise generated 
by benign variation. This task is particularly challenging for non-coding variants, as 
our knowledge of what defines functional and pathogenic non-coding variation is 
limited. In this chapter I will summarise the aims of my PhD and my progress 
towards achieving them. I will also discuss limitations of this project and suggest 
directions this project could be taken in the future. 
 
6.1.1 Aim 1 
The first aim of my PhD was to develop a bioinformatics tool to prioritise variants on the 
basis of their putative functional and pathogenic roles. I have addressed this aim in 
Chapter 2 and Chapter 3, where I outlined the development and testing of my method, 
SuRFR, an R package for the ranked prioritisation of candidate causal variants. The 
modular design and tuneable parameterisation of SuRFR allows for simple and efficient 
incorporation of publically available data and prior biological knowledge into the 
ranking scheme. In Chapter 2, I introduced: i) the annotations used to prioritise known 
functional and pathogenic variants over background variants; ii) the training datasets I 
constructed for this analysis and iii) the principles behind the initial model I 
implemented. In Chapter 3, I expanded on the topics introduced in Chapter 2 and 
presented the formalised model training protocol used to develop SuRFR. 
 
SuRFR produces rank orderings of variants for each of a wide diversity of functional 
genomic measures and annotations. These include: minor allele frequency (MAF); 
position of SNPs relative to genic elements (exons, introns, promoters, etc.); DNase 
hypersensitivity sites (DNase HS); chromatin states; transcription factor binding sites 
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(TFBSs); enhancers; and conservation. These individual ranks are then combined into a 
final rank using a weighting system parameterised and tested through ten-fold cross-
validation. Central to the success of the parameterisation and testing of this approach is 
the quality of the training data. Known regulatory variants were obtained from the 
Human Gene Mutation Database (HGMD), while background variants were obtained by 
randomly sampling SNPs from the 1000 Genomes project located within the ENCODE 
pilot regions. Known and background variants were randomly assigned to 
training/validation sets and a hold out test set. Performance was measured using 
Receiver Operating Characteristic (ROC) curves and Area Under the Curve (AUCs) 
statistics. Performance and generalisation errors were calculated to estimate the 
generalisability of the method and to predict its performance on novel data. 
 
In Chapter 3 I showed that the AUCs from the optimum combination of weightings run 
on the hold out test dataset were very high (0.90-0.95), indicating that the method works 
well to prioritise known regulatory variants over background variants on an independent 
dataset. In addition, the performance and generalisation errors were low (0.004-0.030), 
indicating the likelihood of the pipeline performing equally well on novel data.  
 
This analysis has provided insight into the extent to which different classes of functional 
annotation are most useful for the identification of known regulatory variants. I have 
shown that known regulatory variants tend to overlap some functional categories more 
than others: the most important factor for identifying a true variant across all regulatory 
classes of regulatory variant is position relative to genes (upstream proximity to the 
transcription start site (TSS) strongly affects the likelihood of a SNP being functional). 
However, this could reflect the acquisition bias that exists in all databases of known 
pathogenic variants, which are enriched for variants proximal to genes. Additional 
training data, for variants with a known disease role located in all genomic regions, is 
needed to rectify this imbalance. Unfortunately, such data is not currently available in 
the numbers needed to provide sufficient power.  
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6.1.2 Aim 2 
The second aim of my PhD was to perform a comparative analysis between SuRFR and 
other prioritisation tools. In Chapter 4 I compared the performance of SuRFR against 
three related tools which were all published near the end of my PhD: GWAVA, CADD 
and FunSeq. In this chapter I showed that SuRFR performs equally well when applied to 
novel data (data that had not been used to train any of these methods). These data 
included variants from the ClinVAR database of clinical variation, a novel non-coding 
dataset (the RAVEN dataset), and coding variants from the HbVar database. In addition, 
when GWAVA, CADD and SuRFR were run on three datasets consisting of SNPs 
identified from the investigation complex traits ((Musunuru et al., 2010); (Myouzen et 
al., 2010); (Gaulton et al., 2010)), SuRFR outperformed both GWAVA and CADD. 
Whilst SuRFR performs as well as these other methods, it also has several additional 
advantages in its design and implementation. These are detailed below: 
 
6.1.2.1 Integration  
Being an R package, SuRFR is a component of the R environment and can be used in 
combination with other R packages without the need for additional data formatting. R is 
becoming an increasingly important tool in genomics, mainly due to the advances and 
improvements being made to the R software project Bioconductor. The aim of this 
project is to provide a comprehensive suite of tools for the analysis of high throughput 
genomics data (Huber et al., 2015). The R packages provided and maintained by 
Bioconductor are individually useful, but collectively have even greater merit as they 
allow the analysis and interpretation of genomics data in a unified framework. In 
addition, any other R packages (either private or from other repositories such as CRAN) 
can be used in conjunction with those curated by Bioconductor.  
 
6.1.2.2 Modularity  
SuRFR has been constructed in such a way as to allow the user to incorporate additional 
data in the future. One example would be to include expression data generated in a 
specific cell line to add greater discriminatory power to the ranked list of variants. 
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6.1.2.3 Flexibility  
Although I have trained three models (ALL, DM and DFP), SuRFR can also be run 
using custom models defined by the user, based on the weightings they feel most 
appropriate to their data. For instance, MAF can not only be up-weighted or down-
weighted according to the user’s preferences, but also the optimal MAF (in the default 
mode, set to unique, “0”) can be specified by the user (for example, if the best associated 
SNP from a GWAS has a MAF of 0.3, the user may wish to set the optimum MAF to 
0.3). 
 
6.1.3 Aim 3 
The third aim of my PhD was to apply SuRFR to the study of psychiatric illness. In 
Chapter 5, I analysed whole genome sequencing data from a large Scottish family with 
bipolar disorder (SBF2) and a second family with major depressive disorder (MDD) and 
idiopathic oedema (IO)(F224). Using SuRFR to prioritise these data I have highlighted 
several plausible candidate genes and variants for follow-up analysis. These include 
variants in pathways previously implicated in psychiatric illness including calcium 
channels and synaptic proteins, as well as high ranking variants from novel genes and 
pathways. One of the advantages of SuRFR is that the features that contribute to the 
rankings are easy to identify and investigate further. For instance, two high ranking 
variants from the SBF2 analysis (ranking 3rd and 4th overall), which lie within an intron 
of C1QTNF7 (itself a candidate psychiatric gene – see section 5.4.2 for further 
information), appear to have ranked highly because they were: unique to the family; had 
high DNase HS scores; overlapped DNase footprints in a large number of cell lines (16 
and 11 respectively); had high chromatin state scores (Chromatin state score of 9, 
suggesting strong enhancers); and overlapped  several TFBSs (including a binding site 
for c-Fos , a brain expressed transcription factor known to play a role in synaptic 
plasticity (Cohen and Greenberg, 2008)). These data together support the potential 
pathogenicity of these variants whilst also suggesting a potential mechanism of action.   
 
These two family projects, involving international collaborations, are on-going. More 
information is currently being gathered on the variation present within these families and 
the segregation of variation with illness (additional linkage data, inclusion of additional 
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individuals, etc), which should become available in the near future. This will allow us 
the opportunity to finalise the subset of high ranking variants to be taken forward for 
follow-on experimental investigation. 
 
6.2 Project limitations 
6.2.1 Acquisition bias of training data 
Methods that rely on catalogues of know pathogenic variants, including GWAVA and 
SuRFR, are limited by the number of variants within these catalogues. These datasets 
also suffer from acquisition bias, and tend to over represent variants near to or within 
genes. This issue particularly affects our ability to identify signals associated with long-
range enhancers.  
 
A new computational method was published in August 2015 which attempted to 
overcome this issue by implementing a sequence-based approach (Lee et al., 2015). This 
method predicts the functional effects of regulatory variants by training a gapped k-mer 
support vector machine (gkm-SVM) using cell-type specific sequence features of 
regulatory elements, including DNase HSs and putative TFBSs. The premise for this 
method is that cell-type specific regulatory elements can be identified using cell-type 
specific genomic features and that these data can be used to predict the effect of SNPs on 
these features in their native genomic contexts. The gkm-SVM produces a regulatory 
sequence vocabulary by generating scores for all unique 10-mer sequences, which it 
compares against the known regulatory sequences. The difference in gkm-SVM score 
between the wild-type variant and the SNP, termed deltaSVM, is used to predict how big 
a functional effect the SNP has. The larger the score (either positive or negative), the 
greater the SNP effect.  
 
The authors trained the gkm-SVM using DNase HS data from specific cell types to 
identify genomic sequences that are likely to also have regulatory activity within those 
specific cell types and therefore predict the likelihood of novel variants affecting 
regulatory activity, thus identifying DNase quantitative trait loci (dsQTLs) (SNPs that 
are highly correlated with DNase-seq read depth (Degner et al., 2012)). This method was 
compared against GWAVA, CADD and GERP (Lee et al., 2015) using a dataset of 
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known dsQTL SNPs and non-dsQTL SNPs with comparable levels of DNase HS. The 
gkm-SVM was shown to predict SNPs associated with dsQTLs more accurately than the 
other methods (AUCs of 0.75, 0.63, 0.69 and 0.56 for gkm-SVM, CADD, GWAVA and 
GERP respectively).  
 
An additional experiment reported in this paper to support gkm-SVM’s performance 
(Lee et al., 2015) made use of the analysis of SORT1 by Musurunu et al. (Musunuru et 
al., 2010). This analysis investigated a region of chromosome 1p13 associated with 
LDL-C levels and identified a single SNP, rs12740374, as altering the hepatic expression 
of the SORT1 gene. I also used the data from this analysis to compare the performances 
of SuRFR, CADD and GWAVA in Chapter 4 (Section 4.3.1.4). In their study, Lee et al. 
showed that the deltaSVM for the functional SNP rs12740374 was only higher than for 
the surrounding SNPs when the gkm-SVM was trained on data from an appropriate cell-
type (HepG2). When other cell-types were used (MEL and LNCaP) the gkm-SVM could 
not prioritise rs12740374 better than the background SNPs. This highlights that the 
performance of this method is very sensitive to the training data used and if the 
appropriate cell-type specific data is unavailable, its performance suffers. In contrast, 
SuRFR identified this variant 1st out of 22 SNPs, without requiring cell-type specific 
data, suggesting SuRFR may compare favourably with the gkm-SVM method on other 
data. 
 
6.2.2 Limitations of family-based sequencing projects 
There are many advantages to using next generation sequencing (NGS) methods to study 
variation contributing to the full spectrum of human disease types and associated genetic 
architectures.  One of the greatest advantages of whole genome sequencing is that it 
detects common and rare variants, both within protein coding sequences and non-coding 
sequences, in the same assay. In addition, it is not limited to the study of single 
nucleotide polymorphisms, also being capable of identifying indels, CNVs and 
translocation events. However, there are several challenges facing the application of 
NGS.  
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The first relates to sequencing accuracy and sensitivity. Lam et al. (2012) compared the 
performances of the two leading sequencing platforms (Illumina and Complete 
Genomics) (Lam et al., 2012). This study showed that while there was an 88% 
concordance between platforms (with a sensitivity of 99.34%), there existed platform 
specific variation (2.7% for Complete Genomics and 9.2% for Illumina). The platform 
specific variation was also shown to be enriched for novel variants and was shown to 
have a false positive rate of at least 35%, suggesting many of these variants are likely to 
be errors. The concordance of indels was even lower between platforms, only 26.5% 
being common to both Complete Genomics and Illumina. The platform specific indels 
were also more difficult to validate as they were found to be more likely to overlap 
repeats, making them difficult to amplify by PCR for Sanger sequencing. These results 
suggest that care should be taken when using NGS methods to identify putative disease 
variants, as real variants will be missed and false positives will be included. Lam et al. 
further suggested that comprehensive variation detection could be better achieved by 
using at least two platforms. However, they also recognise that this would not always be 
possible due to the added expense.  
 
The second challenge to be faced is base-calling and sequence alignment, which can also 
affect the sensitivity and specificity of sequencing data. Failure to accurately align 
sequence data to a reference genome can lead to large portions of the sequencing data 
being missed. Similarly, the quality control thresholds used by base-calling algorithms 
can leading to large error rates: too lax and they can lead to the inclusion of false 
positives; too severe and true SNPs can be left out as false negatives)(Nielsen et al., 
2011). These should also therefore be considered carefully before sequence data is 
analysed.  
 
While issues concerning the accuracy of sequencing data can affect whether a true 
variant is identifiable, there are other reasons why a causal variant may not be found in a 
family study. One reason is that the proposed genetic architecture is wrong, leading to 
incorrect filtering of pathogenic variants. In the analysis of the SBF2 disease-linked 
haplotype, I used a MAF threshold of 0.05, so only the uncommon, rare and unique 
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variants were included in my analysis. However, if my hypothesised disease model is 
incorrect, I might have missed susceptibility variants.  
 
A second reason why a causal variant may not be identified could be within-family locus 
heterogeneity, where multiple variants are responsible for disease, but in different 
branches of the family. Bilineal inheritance would confound traditional methods, such as 
focusing on variants shared in cases but absent in controls, and linkage analysis. This has 
been shown by Rehman et al. (2015), who studied the effect of familial locus 
heterogeneity in a large number of families with various forms of hereditary hearing 
impairment (Rehman et al., 2015). In this analysis, the authors identified a large 
difference between the expected maximum LOD (mLOD) (calculated based on a fully 
penetrant, autosomal recessive marker) and the genome-wide LOD scores, suggesting 
that multiple loci are contributing to this disease in different parts of the family. To 
overcome this, Rehman et al. proposed splitting a heterogeneous family into smaller 
units, calculating new mLODs for each unit, and comparing this to the LODs generated 
for each unit. In addition, affection status of individuals within each unit can also be 
modified (cases alternately set to unknown) to compensate for heterogeneity within each 
family sub-unit, thereby identifying the affected individuals that are likely to segregate 
the same causal variants (for the full workflow, see Figure 4 from (Rehman et al., 
2015)). Rehman et al. identified linkage regions using this approach and performed 
exome sequencing to confirm segregation of causal variants with the phenotype of 
interest.  
 
The low LOD scores generated for F224 might indicate that this family is an example of 
familial heterogeneity. The linkage analysis could therefore be repeated, splitting the 
family into sub-units and comparing the mLOD for each sub-unit against the actual 
LODs achieved to identify individuals that segregate the same causal variant. In 
addition, this analysis could be performed for different phenotypes (idiopathic oedema 
only, major depressive disorder only and both diagnoses) to identify causal variants that 
segregate with one diagnoses but not the other. 
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6.3 Potential improvements to SuRFR 
While I have shown SuRFR is capable of prioritising candidate SNPs with high 
specificity and sensitivity, there are several ways that I could improve SuRFR’s 
functionality and usefulness in the future: 
 
6.3.1 Coding variants 
Many methods are available that are capable of differentiating between different classes 
of coding variants (UTR vs. protein coding; synonymous, non-synonymous, missense, 
splice variants, etc.), including Ensembl’s Variant Effect Predictor (McLaren et al., 
2010), SIFT (Ng and Henikoff, 2001), polyPhen (Adzhubei et al., 2010), SNAP 
(Bromberg and Rost, 2007), FATHMM (Shihab et al., 2013) and PANTHER (Thomas et 
al., 2003). Any one of these methods can be used separately to predict the 
deleteriousness of the coding variants identified during SuRFR’s annotation step. 
However, it would be useful to have a unified framework that incorporates all the 
relevant data to prioritise different classes of coding variants and non-coding variants in 
a single pipeline. One method to do this would be to include the output of one or several 
of these protein-coding prediction methods into SuRFR’s annotation table. This would 
allow SuRFR to discriminate between non-synonymous, synonymous, frame-shift, UTR, 
etc, while still incorporating all the previous genomic features.  
 
Earlier this year, Dong et al. published a comparison of 18 deleterious-scoring methods, 
including three conservation scores, eleven functional prediction scores and four 
ensemble methods (combining multiple methods in a single output) (Dong et al., 2015). 
Using three independent datasets, this study found that the novel ensemble method being 
presented in this paper outperformed all the other methods. FATHMM was found to be 
the best performing individual tool, while the next best performing ensemble method 
(combining SIFT, PolyPhen-2, LRT, MutationTaster and PhyloP scores) was KGGSeq 
(Li et al., 2012). One of the main conclusions from this analysis was that ensemble 
methods can perform better than their individual component scores and that ensemble 
methods that included protein-specific features only perform better than methods that 
utilise general genomic annotation data (Dong et al., 2015). 
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This analysis suggests that the best way to incorporate a protein-level deleteriousness 
measure into SuRFR would be to incorporate an ensemble method into SuRFR’s 
annotation data and train an additional model using protein-coding data from HGMD. 
 
6.3.2 Indels 
SNPs represent a large proportion of human variation, but are not the only class of 
variant that has been implicated in human disease. Indels are also known to have 
pathogenic roles ((Mullaney et al., 2010)). However, few prioritisation methods are 
designed to functionally interpret the deleteriousness of indels. One exception is the 
gkm-SVM method described in section 6.1.2 (Lee et al., 2015). This method allows 
indels to be analysed by summing the deltaSVM score across all affected nucleotides.  
 
Although SuRFR is not currently trained to analyse indels, gkm-SVM suggests a 
framework that could be used to modify SuRFR’s SNP functionality: by summing scores 
across all affected base positions.  This, however, fails to take indel length into account, 
biasing the method in favour of longer indels. There is currently insufficient evidence 
suggesting that longer indels are more likely to be deleterious than short indels. 
 
Deletions could alternatively be scored by summing and averaging the scores across all 
deleted bases (thus taking into account indel length). However, a deletion that overlaps 
both a single highly functional variant and many non-functional variants would not be 
prioritised by this method, as the average signal would be low. Instead, indels could be 
prioritised based on the highest functional score of any base affected by the indel. 
Possible approaches to scoring insertions is less obvious. One option would be to 
combine the scores of the bases either side of the insertion.  
 
As with designing a SNP prioritisation method, the best way to resolve these options 
would be to use known pathogenic indels and background indels as a model training set. 
The HGMD database contains a catalogue of pathogenic indel data, while the 1000 
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genomes project also contains large numbers of indels. These data could be used to train 
an indel-specific version of SuRFR. 
 
6.3.3 Variant interactions 
As discussed in Chapter 1, there is a lot of evidence suggesting that some diseases are 
caused by multiple interacting variants. When two or more variants affect disease 
susceptibility, the performance of the predictive method can be increased by allowing for 
interactions between variants (Krzywinski and Altman, 2014). It would be interesting to 
look into the possibility of generating a two-point or multi-point version of SuRFR, 
which could take into account multiple interacting variants. However, the development 
of such a method would be limited by the availability of appropriate training data, as few 
validated epistatic interactions are catalogued. 
 
6.3.4 Expression and methylation data  
Disease risk variants are known to be enriched in expression quantitative trait loci 
(eQTLs) and methylation quantitative trait loci (meQTLs) ((Nicolae et al., 2010); 
(Gamazon et al., 2013); (Richards et al., 2012); (Westra et al., 2013)). See Albert and 
Kruglyal (2015) for a review of recent human eQTL datasets and the disease/trait studied 
(Albert and Kruglyak, 2015). Furthermore, there is evidence of cross-talk between DNA 
and histone methylation, gene expression being controlled by both forms of methylation, 
both together or independently (Du et al., 2015). Similarly, DNA methylation regions 
have been shown to overlap promoter regions and to be enriched for disease variants 
(Ma et al., 2015). 
 
While DNA methylation data may be prioritised by SuRFR (by substituting the 
coordinates of SNPS in the input file with the coordinates of differentially methylated 
CpGs), it would be a useful extension to SuRFR’s remit if it could be modified to 
function as a formal add-on to methylation packages to prioritise differentially 
methylated probes with similar p-values. In addition, databases of eQTL data, such as 
the Genotype-Tissue Expression (GTEx) project (Consortium, 2013), and meQTLs 
(Lemire et al., 2015) could be tested as additional prioritisation features. 
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6.3.5 Increased flexibility  
SuRFR has been designed to make use of locally stored annotation data, constructing an 
annotation table from these data. In addition to R, this process relies on methods 
including bedtools and vcftools. The resulting annotation table is a simple dataframe, 
which is then used by the ranking function to create a second output table containing the 
individual ranks for each feature as well as the overall rank of these ranks, combined 
using user-specified weighting parameters. 
 
I hope to submit SuRFR to the Bioconductor project for integration into their database of 
R packages. To this end, I have been in contact with the Bioconductor package 
development support team to discuss the restructuring that is needed before they can 
accept SuRFR. Earlier this year, the Bioconductor team published a paper outlining their 
future plans for genomic analyses projects (Huber et al., 2015). Their main aim for the 
future is to have a single universal system to store and manipulate genomic data. As part 
of this, Bioconductor have developed a new R object class called GRanges, a 
standardised format for storing all data pertaining to genomic coordinates and annotation 
data. For SuRFR to be accepted by Bioconductor I will have to reformat the data into a 
GRange object. An advantage of restructuring SuRFR into a GRange object is that all 
GRanges are compatible with other GRange objects, therefore increasing the flexibility 
of SuRFR further.  
 
An additional requirement for SuRFR to be accepted is that all of the annotation data 
used by SuRFR (currently stored locally) must be added to AnnotationHub, a centralised 
annotation database that is updated and controlled by Bioconductor. 
 
6.3.6 Tissue/cell type specificity  
SNPs associated with complex traits have been shown to have tissue dependent effects 
on gene expression (Fu et al., 2012), suggesting that tissue specificity plays an important 
role in disease.  Similarly, eQTLs are largely context dependent, being active in specific 
cell types at specific time points ((Nica et al., 2011); (Grundberg et al., 2012)).  
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
Chapter 6: Discussion  238 
 
Although tissue and cell-type specific annotation data is available for many features 
(including histone modifications, DNase HS, DNase footprints, enhancers, tissue 
specific promoters), the development of tissue/ cell-type specific versions of SuRFR is 
limited by the lack of sufficient cell-type specific and disease specific training data (the 
data that is available for single traits/diseases being limited in size). Despite this caveat, 
it could still be useful to incorporate cell-type or tissue specific data into the output of 
SuRFR. These data can be used in addition to the weighted rank of ranks for users to 
discriminate between variants. For instance, it would be interesting to identify brain-
specific features that overlap variants of interest for psychiatric illness. 
 
6.4 Conclusions 
In this thesis I have described the development, testing and application of a novel 
computational approach for the functional investigation of putatively deleterious 
variants. This method filled a niche that was not covered by other tools. Since then, other 
tools have been developed that perform the same role; however, I have also shown that 
SuRFR compares favourably with these other approaches, confirming its continued 
relevance (Ryan et al., 2014)(Appendix D).  
 
All prioritisation approaches are stepping-stones on the path to identifying true risk and 
causal disease variants. As such, their usefulness is in directing future research efforts 
towards a subset of variants to be followed up further, rather than being the end point of 
an analysis. In this context, the potential future plans of this project can be divided in 
two directions: the first, following up the candidate variants identified in Chapter 5; the 
second, expanding SuRFR’s remit to allow the investigation of additional variant types 
in an improved model. These two directions are equally exciting and present the 
possibility of furthering our understanding of what constitutes a deleterious variant and 
how these variants function in disease.  
 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  239 
References 
ADIE, E. A., ADAMS, R. R., EVANS, K. L., PORTEOUS, D. J. & PICKARD, B. 
S. 2005. Speeding disease gene discovery by sequence based candidate 
prioritization. BMC Bioinformatics, 6, 55. 
ADORI, C., GLUCK, L., BARDE, S., YOSHITAKE, T., KOVACS, G. G., 
MULDER, J., MAGLOCZKY, Z., HAVAS, L., BOLCSKEI, K., MITSIOS, 
N., UHLEN, M., SZOLCSANYI, J., KEHR, J., RONNBACK, A., 
SCHWARTZ, T., REHFELD, J. F., HARKANY, T., PALKOVITS, M., 
SCHULZ, S. & HOKFELT, T. 2015. Critical role of somatostatin receptor 2 
in the vulnerability of the central noradrenergic system: new aspects on 
Alzheimer's disease. Acta Neuropathol, 129, 541-63. 
ADZHUBEI, I. A., SCHMIDT, S., PESHKIN, L., RAMENSKY, V. E., 
GERASIMOVA, A., BORK, P., KONDRASHOV, A. S. & SUNYAEV, S. 
R. 2010. A method and server for predicting damaging missense mutations. 
Nat Methods, 7, 248-9. 
AGOPIAN, A. J., EASTCOTT, L. M. & MITCHELL, L. E. 2012. Age of onset and 
effect size in genome-wide association studies. Birth Defects Res A Clin Mol 
Teratol, 94, 908-11. 
ALBERT, F. W. & KRUGLYAK, L. 2015. The role of regulatory variation in 
complex traits and disease. Nat Rev Genet, 16, 197-212. 
AMBERGER, J. S., BOCCHINI, C. A., SCHIETTECATTE, F., SCOTT, A. F. & 
HAMOSH, A. 2015. OMIM.org: Online Mendelian Inheritance in Man 
(OMIM(R)), an online catalog of human genes and genetic disorders. Nucleic 
Acids Res, 43, D789-98. 
AMENT, S. A., SZELINGER, S., GLUSMAN, G., ASHWORTH, J., HOU, L., 
AKULA, N., SHEKHTMAN, T., BADNER, J. A., BRUNKOW, M. E., 
MAULDIN, D. E., STITTRICH, A. B., ROULEAU, K., DETERA-
WADLEIGH, S. D., NURNBERGER, J. I., JR., EDENBERG, H. J., 
GERSHON, E. S., SCHORK, N., BIPOLAR GENOME, S., PRICE, N. D., 
GELINAS, R., HOOD, L., CRAIG, D., MCMAHON, F. J., KELSOE, J. R. & 
ROACH, J. C. 2015. Rare variants in neuronal excitability genes influence 
risk for bipolar disorder. Proc Natl Acad Sci U S A, 112, 3576-81. 
AMIRY-MOGHADDAM, M., FRYDENLUND, D. S. & OTTERSEN, O. P. 2004. 
Anchoring of aquaporin-4 in brain: molecular mechanisms and implications 
for the physiology and pathophysiology of water transport. Neuroscience, 
129, 999-1010. 
ANDERSEN, M. C., ENGSTROM, P. G., LITHWICK, S., ARENILLAS, D., 
ERIKSSON, P., LENHARD, B., WASSERMAN, W. W. & ODEBERG, J. 
2008. In silico detection of sequence variations modifying transcriptional 
regulation. PLoS Comput Biol, 4, e5. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  240 
ANDERSON, C. A., MACLEAN, A., DUNNIGAN, M. G., PELOSI, A. J., 
MURRAY, V., MCKEE, I., MCDONALD, G., BURT, D. W., MORRICE, 
D. R., MUIR, W. J., VISSCHER, P. M. & BLACKWOOD, D. H. 2008. A 
genome-wide linkage study in families with major depression and co-morbid 
unexplained swelling. Am J Med Genet B Neuropsychiatr Genet, 147, 356-
62. 
ANDERSSON, R., GEBHARD, C., MIGUEL-ESCALADA, I., HOOF, I., 
BORNHOLDT, J., BOYD, M., CHEN, Y., ZHAO, X., SCHMIDL, C., 
SUZUKI, T., NTINI, E., ARNER, E., VALEN, E., LI, K., 
SCHWARZFISCHER, L., GLATZ, D., RAITHEL, J., LILJE, B., RAPIN, N., 
BAGGER, F. O., JORGENSEN, M., ANDERSEN, P. R., BERTIN, N., 
RACKHAM, O., BURROUGHS, A. M., BAILLIE, J. K., ISHIZU, Y., 
SHIMIZU, Y., FURUHATA, E., MAEDA, S., NEGISHI, Y., MUNGALL, 
C. J., MEEHAN, T. F., LASSMANN, T., ITOH, M., KAWAJI, H., KONDO, 
N., KAWAI, J., LENNARTSSON, A., DAUB, C. O., HEUTINK, P., HUME, 
D. A., JENSEN, T. H., SUZUKI, H., HAYASHIZAKI, Y., MULLER, F., 
CONSORTIUM, F., FORREST, A. R., CARNINCI, P., REHLI, M. & 
SANDELIN, A. 2014. An atlas of active enhancers across human cell types 
and tissues. Nature, 507, 455-61. 
ANNEY, R., KLEI, L., PINTO, D., REGAN, R., CONROY, J., MAGALHAES, T. 
R., CORREIA, C., ABRAHAMS, B. S., SYKES, N., PAGNAMENTA, A. 
T., ALMEIDA, J., BACCHELLI, E., BAILEY, A. J., BAIRD, G., 
BATTAGLIA, A., BERNEY, T., BOLSHAKOVA, N., BOLTE, S., 
BOLTON, P. F., BOURGERON, T., BRENNAN, S., BRIAN, J., CARSON, 
A. R., CASALLO, G., CASEY, J., CHU, S. H., COCHRANE, L., 
CORSELLO, C., CRAWFORD, E. L., CROSSETT, A., DAWSON, G., DE 
JONGE, M., DELORME, R., DRMIC, I., DUKETIS, E., DUQUE, F., 
ESTES, A., FARRAR, P., FERNANDEZ, B. A., FOLSTEIN, S. E., 
FOMBONNE, E., FREITAG, C. M., GILBERT, J., GILLBERG, C., 
GLESSNER, J. T., GOLDBERG, J., GREEN, J., GUTER, S. J., 
HAKONARSON, H., HERON, E. A., HILL, M., HOLT, R., HOWE, J. L., 
HUGHES, G., HUS, V., IGLIOZZI, R., KIM, C., KLAUCK, S. M., 
KOLEVZON, A., KORVATSKA, O., KUSTANOVICH, V., 
LAJONCHERE, C. M., LAMB, J. A., LASKAWIEC, M., LEBOYER, M., 
LE COUTEUR, A., LEVENTHAL, B. L., LIONEL, A. C., LIU, X. Q., 
LORD, C., LOTSPEICH, L., LUND, S. C., MAESTRINI, E., MAHONEY, 
W., MANTOULAN, C., MARSHALL, C. R., MCCONACHIE, H., 
MCDOUGLE, C. J., MCGRATH, J., MCMAHON, W. M., MELHEM, N. 
M., MERIKANGAS, A., MIGITA, O., MINSHEW, N. J., MIRZA, G. K., 
MUNSON, J., NELSON, S. F., NOAKES, C., NOOR, A., NYGREN, G., 
OLIVEIRA, G., PAPANIKOLAOU, K., PARR, J. R., PARRINI, B., 
PATON, T., PICKLES, A., PIVEN, J., POSEY, D. J., POUSTKA, A., 
POUSTKA, F., et al. 2010. A genome-wide scan for common alleles 
affecting risk for autism. Hum Mol Genet, 19, 4072-82. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  241 
ARLOT, C. 2010. A survey of cross-validation procedures for model selection. 
Statist. Surv, 4. 
ARVAN, P., PIETROPAOLO, M., OSTROV, D. & RHODES, C. J. 2012. Islet 
autoantigens: structure, function, localization, and regulation. Cold Spring 
Harb Perspect Med, 2. 
BABU, S. & NUTMAN, T. B. 2014. Immunology of lymphatic filariasis. Parasite 
Immunol, 36, 338-46. 
BACHMANN-GAGESCU, R., ISHAK, G. E., DEMPSEY, J. C., ADKINS, J., 
O'DAY, D., PHELPS, I. G., GUNAY-AYGUN, M., KLINE, A. D., 
SZCZALUBA, K., MARTORELL, L., ALSWAID, A., ALRASHEED, S., 
PAI, S., IZATT, L., RONAN, A., PARISI, M. A., MEFFORD, H., GLASS, I. 
& DOHERTY, D. 2012. Genotype-phenotype correlation in CC2D2A-related 
Joubert syndrome reveals an association with ventriculomegaly and seizures. 
J Med Genet, 49, 126-37. 
BAKER, L. A. 2014. Do our "big data" in genetic analysis need to get bigger? 
Psychophysiology, 51, 1321-2. 
BARENBOIM, M. & MANKE, T. 2013. ChroMoS: an integrated web tool for SNP 
classification, prioritization and functional interpretation. Bioinformatics, 29, 
2197-8. 
BARNETT, J. H. & SMOLLER, J. W. 2009. The genetics of bipolar disorder. 
Neuroscience, 164, 331-43. 
BARRETT, J. C., FRY, B., MALLER, J. & DALY, M. J. 2005. Haploview: analysis 
and visualization of LD and haplotype maps. Bioinformatics, 21, 263-5. 
BASSETT, A. S. & CHOW, E. W. 2008. Schizophrenia and 22q11.2 deletion 
syndrome. Curr Psychiatry Rep, 10, 148-57. 
BAUER, D. E., KAMRAN, S. C., LESSARD, S., XU, J., FUJIWARA, Y., LIN, C., 
SHAO, Z., CANVER, M. C., SMITH, E. C., PINELLO, L., SABO, P. J., 
VIERSTRA, J., VOIT, R. A., YUAN, G. C., PORTEUS, M. H., 
STAMATOYANNOPOULOS, J. A., LETTRE, G. & ORKIN, S. H. 2013. 
An erythroid enhancer of BCL11A subject to genetic variation determines 
fetal hemoglobin level. Science, 342, 253-7. 
BAUM, A. E., AKULA, N., CABANERO, M., CARDONA, I., CORONA, W., 
KLEMENS, B., SCHULZE, T. G., CICHON, S., RIETSCHEL, M., 
NOTHEN, M. M., GEORGI, A., SCHUMACHER, J., SCHWARZ, M., 
ABOU JAMRA, R., HOFELS, S., PROPPING, P., SATAGOPAN, J., 
DETERA-WADLEIGH, S. D., HARDY, J. & MCMAHON, F. J. 2008. A 
genome-wide association study implicates diacylglycerol kinase eta (DGKH) 
and several other genes in the etiology of bipolar disorder. Mol Psychiatry, 
13, 197-207. 
BELL, R. D. & ZLOKOVIC, B. V. 2009. Neurovascular mechanisms and blood-
brain barrier disorder in Alzheimer's disease. Acta Neuropathol, 118, 103-13. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  242 
BERGSTRA, B. 2012. Random Search for Hyper-Parameter Optimization. Journal 
of Machine Learning Research, 13, 281-305. 
BERNDT, S. I., GUSTAFSSON, S., MAGI, R., GANNA, A., WHEELER, E., 
FEITOSA, M. F., JUSTICE, A. E., MONDA, K. L., CROTEAU-CHONKA, 
D. C., DAY, F. R., ESKO, T., FALL, T., FERREIRA, T., GENTILINI, D., 
JACKSON, A. U., LUAN, J., RANDALL, J. C., VEDANTAM, S., WILLER, 
C. J., WINKLER, T. W., WOOD, A. R., WORKALEMAHU, T., HU, Y. J., 
LEE, S. H., LIANG, L., LIN, D. Y., MIN, J. L., NEALE, B. M., 
THORLEIFSSON, G., YANG, J., ALBRECHT, E., AMIN, N., BRAGG-
GRESHAM, J. L., CADBY, G., DEN HEIJER, M., EKLUND, N., 
FISCHER, K., GOEL, A., HOTTENGA, J. J., HUFFMAN, J. E., JARICK, I., 
JOHANSSON, A., JOHNSON, T., KANONI, S., KLEBER, M. E., KONIG, 
I. R., KRISTIANSSON, K., KUTALIK, Z., LAMINA, C., LECOEUR, C., 
LI, G., MANGINO, M., MCARDLE, W. L., MEDINA-GOMEZ, C., 
MULLER-NURASYID, M., NGWA, J. S., NOLTE, I. M., PATERNOSTER, 
L., PECHLIVANIS, S., PEROLA, M., PETERS, M. J., PREUSS, M., ROSE, 
L. M., SHI, J., SHUNGIN, D., SMITH, A. V., STRAWBRIDGE, R. J., 
SURAKKA, I., TEUMER, A., TRIP, M. D., TYRER, J., VAN VLIET-
OSTAPTCHOUK, J. V., VANDENPUT, L., WAITE, L. L., ZHAO, J. H., 
ABSHER, D., ASSELBERGS, F. W., ATALAY, M., ATTWOOD, A. P., 
BALMFORTH, A. J., BASART, H., BEILBY, J., BONNYCASTLE, L. L., 
BRAMBILLA, P., BRUINENBERG, M., CAMPBELL, H., CHASMAN, D. 
I., CHINES, P. S., COLLINS, F. S., CONNELL, J. M., COOKSON, W. O., 
DE FAIRE, U., DE VEGT, F., DEI, M., DIMITRIOU, M., EDKINS, S., 
ESTRADA, K., EVANS, D. M., FARRALL, M., FERRARIO, M. M., et al. 
2013. Genome-wide meta-analysis identifies 11 new loci for anthropometric 
traits and provides insights into genetic architecture. Nat Genet, 45, 501-12. 
BERNSTEIN, B. E., STAMATOYANNOPOULOS, J. A., COSTELLO, J. F., REN, 
B., MILOSAVLJEVIC, A., MEISSNER, A., KELLIS, M., MARRA, M. A., 
BEAUDET, A. L., ECKER, J. R., FARNHAM, P. J., HIRST, M., LANDER, 
E. S., MIKKELSEN, T. S. & THOMSON, J. A. 2010. The NIH Roadmap 
Epigenomics Mapping Consortium. Nat Biotechnol, 28, 1045-8. 
BERTLER, A., FALCK, B., OWMAN, C. & ROSENGRENN, E. 1966. The 
localization of monoaminergic blood-brain barrier mechanisms. Pharmacol 
Rev, 18, 369-85. 
BERTRAM, L., MCQUEEN, M. B., MULLIN, K., BLACKER, D. & TANZI, R. E. 
2007. Systematic meta-analyses of Alzheimer disease genetic association 
studies: the AlzGene database. Nat Genet, 39, 17-23. 
BERTRAM, L. & TANZI, R. E. 2008. Thirty years of Alzheimer's disease genetics: 
the implications of systematic meta-analyses. Nat Rev Neurosci, 9, 768-78. 
BETANCUR, C. 2011. Etiological heterogeneity in autism spectrum disorders: more 
than 100 genetic and genomic disorders and still counting. Brain Res, 1380, 
42-77. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  243 
BHATTACHARYA, M. R., GERDTS, J., NAYLOR, S. A., ROYSE, E. X., 
EBSTEIN, S. Y., SASAKI, Y., MILBRANDT, J. & DIANTONIO, A. 2012. 
A model of toxic neuropathy in Drosophila reveals a role for MORN4 in 
promoting axonal degeneration. J Neurosci, 32, 5054-61. 
BLACKWOOD, D. H., HE, L., MORRIS, S. W., MCLEAN, A., WHITTON, C., 
THOMSON, M., WALKER, M. T., WOODBURN, K., SHARP, C. M., 
WRIGHT, A. F., SHIBASAKI, Y., ST CLAIR, D. M., PORTEOUS, D. J. & 
MUIR, W. J. 1996. A locus for bipolar affective disorder on chromosome 4p. 
Nat Genet, 12, 427-30. 
BLAUSTEIN, M. P. 1977. Sodium ions, calcium ions, blood pressure regulation, and 
hypertension: a reassessment and a hypothesis. Am J Physiol, 232, C165-73. 
BLENNOW, K., DE LEON, M. J. & ZETTERBERG, H. 2006. Alzheimer's disease. 
Lancet, 368, 387-403. 
BOFFELLI, D., MCAULIFFE, J., OVCHARENKO, D., LEWIS, K. D., 
OVCHARENKO, I., PACHTER, L. & RUBIN, E. M. 2003. Phylogenetic 
shadowing of primate sequences to find functional regions of the human 
genome. Science, 299, 1391-4. 
BOYAJYAN, A., ZAKHARYAN, R., ATSHEMYAN, S., CHAVUSHYAN, A. & 
MKRTCHYAN, G. 2015. Schizophrenia-associated Risk and Protective 
Variants of c-Fos Encoding Gene. Recent Adv DNA Gene Seq. 
BOYCOTT, K. M., VANSTONE, M. R., BULMAN, D. E. & MACKENZIE, A. E. 
2013. Rare-disease genetics in the era of next-generation sequencing: 
discovery to translation. Nat Rev Genet, 14, 681-91. 
BOYLE, A. P., HONG, E. L., HARIHARAN, M., CHENG, Y., SCHAUB, M. A., 
KASOWSKI, M., KARCZEWSKI, K. J., PARK, J., HITZ, B. C., WENG, S., 
CHERRY, J. M. & SNYDER, M. 2012. Annotation of functional variation in 
personal genomes using RegulomeDB. Genome Res, 22, 1790-7. 
BRADSHAW, N. J. & PORTEOUS, D. J. 2012. DISC1-binding proteins in neural 
development, signalling and schizophrenia. Neuropharmacology, 62, 1230-
41. 
BRANDON, N. J. & SAWA, A. 2011. Linking neurodevelopmental and synaptic 
theories of mental illness through DISC1. Nat Rev Neurosci, 12, 707-22. 
BREST, P., LAPAQUETTE, P., SOUIDI, M., LEBRIGAND, K., CESARO, A., 
VOURET-CRAVIARI, V., MARI, B., BARBRY, P., MOSNIER, J. F., 
HEBUTERNE, X., HAREL-BELLAN, A., MOGRABI, B., DARFEUILLE-
MICHAUD, A. & HOFMAN, P. 2011. A synonymous variant in IRGM 
alters a binding site for miR-196 and causes deregulation of IRGM-dependent 
xenophagy in Crohn's disease. Nat Genet, 43, 242-5. 
BRISCH, R., SANIOTIS, A., WOLF, R., BIELAU, H., BERNSTEIN, H. G., 
STEINER, J., BOGERTS, B., BRAUN, K., JANKOWSKI, Z., 
KUMARATILAKE, J., HENNEBERG, M. & GOS, T. 2014. The role of 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  244 
dopamine in schizophrenia from a neurobiological and evolutionary 
perspective: old fashioned, but still in vogue. Front Psychiatry, 5, 47. 
BROMBERG, Y. & ROST, B. 2007. SNAP: predict effect of non-synonymous 
polymorphisms on function. Nucleic Acids Res, 35, 3823-35. 
BRUGGER, S. M., MERRILL, A. E., TORRES-VAZQUEZ, J., WU, N., TING, M. 
C., CHO, J. Y., DOBIAS, S. L., YI, S. E., LYONS, K., BELL, J. R., 
ARORA, K., WARRIOR, R. & MAXSON, R. 2004. A phylogenetically 
conserved cis-regulatory module in the Msx2 promoter is sufficient for BMP-
dependent transcription in murine and Drosophila embryos. Development, 
131, 5153-65. 
BRUN, L., NGU, L. H., KENG, W. T., CH'NG, G. S., CHOY, Y. S., HWU, W. L., 
LEE, W. T., WILLEMSEN, M. A., VERBEEK, M. M., WASSENBERG, T., 
REGAL, L., ORCESI, S., TONDUTI, D., ACCORSI, P., TESTARD, H., 
ABDENUR, J. E., TAY, S., ALLEN, G. F., HEALES, S., KERN, I., KATO, 
M., BURLINA, A., MANEGOLD, C., HOFFMANN, G. F. & BLAU, N. 
2010. Clinical and biochemical features of aromatic L-amino acid 
decarboxylase deficiency. Neurology, 75, 64-71. 
CALABRIA, A., MOSCA, E., VITI, F., MERELLI, I. & MILANESI, L. 2010. 
SNPRanker: a tool for identification and scoring of SNPs associated to target 
genes. J Integr Bioinform, 7. 
CAMILLERI, M., BUSCIGLIO, I., ACOSTA, A., SHIN, A., CARLSON, P., 
BURTON, D., RYKS, M., RHOTEN, D., LAMSAM, J., LUEKE, A., 
DONATO, L. J. & ZINSMEISTER, A. R. 2014. Effect of increased bile acid 
synthesis or fecal excretion in irritable bowel syndrome-diarrhea. Am J 
Gastroenterol, 109, 1621-30. 
CARBONELL, J., ALLOZA, E., ARCE, P., BORREGO, S., SANTOYO, J., RUIZ-
FERRER, M., MEDINA, I., JIMENEZ-ALMAZAN, J., MENDEZ-VIDAL, 
C., GONZALEZ-DEL POZO, M., VELA, A., BHATTACHARYA, S. S., 
ANTINOLO, G. & DOPAZO, J. 2012. A map of human microRNA variation 
uncovers unexpectedly high levels of variability. Genome Med, 4, 62. 
CARDNO, A. G. & OWEN, M. J. 2014. Genetic relationships between 
schizophrenia, bipolar disorder, and schizoaffective disorder. Schizophr Bull, 
40, 504-15. 
CARLBORG, O. & HALEY, C. S. 2004. Epistasis: too often neglected in complex 
trait studies? Nat Rev Genet, 5, 618-25. 
CARUANA, N.-M. 2006. An empirical comparison of supervised learning 
algorithms. ICML '06 Proceedings of the 23rd international conference on 
Machine learning, 161-168. 
CENCI, M. A. 2014. Presynaptic Mechanisms of l-DOPA-Induced Dyskinesia: The 
Findings, the Debate, and the Therapeutic Implications. Front Neurol, 5, 242. 
CHEN, D. T., JIANG, X., AKULA, N., SHUGART, Y. Y., WENDLAND, J. R., 
STEELE, C. J., KASSEM, L., PARK, J. H., CHATTERJEE, N., JAMAIN, 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  245 
S., CHENG, A., LEBOYER, M., MUGLIA, P., SCHULZE, T. G., CICHON, 
S., NOTHEN, M. M., RIETSCHEL, M., BIGS, MCMAHON, F. J., 
FARMER, A., MCGUFFIN, P., CRAIG, I., LEWIS, C., HOSANG, G., 
COHEN-WOODS, S., VINCENT, J. B., KENNEDY, J. L. & STRAUSS, J. 
2013. Genome-wide association study meta-analysis of European and Asian-
ancestry samples identifies three novel loci associated with bipolar disorder. 
Mol Psychiatry, 18, 195-205. 
CHILDS, B. & SCRIVER, C. R. 1986. Age at onset and causes of disease. Perspect 
Biol Med, 29, 437-60. 
CHOI, K., LE, T., XING, G., JOHNSON, L. R. & URSANO, R. J. 2011. Analysis of 
kinase gene expression in the frontal cortex of suicide victims: implications 
of fear and stress. Front Behav Neurosci, 5, 46. 
CHRISTOFOROU, A., LE HELLARD, S., THOMSON, P. A., MORRIS, S. W., 
TENESA, A., PICKARD, B. S., WRAY, N. R., MUIR, W. J., 
BLACKWOOD, D. H., PORTEOUS, D. J. & EVANS, K. L. 2007. 
Association analysis of the chromosome 4p15-p16 candidate region for 
bipolar disorder and schizophrenia. Mol Psychiatry, 12, 1011-25. 
CHUN, S. & FAY, J. C. 2009. Identification of deleterious mutations within three 
human genomes. Genome Res, 19, 1553-61. 
CICHON, S., MUHLEISEN, T. W., DEGENHARDT, F. A., MATTHEISEN, M., 
MIRO, X., STROHMAIER, J., STEFFENS, M., MEESTERS, C., HERMS, 
S., WEINGARTEN, M., PRIEBE, L., HAENISCH, B., ALEXANDER, M., 
VOLLMER, J., BREUER, R., SCHMAL, C., TESSMANN, P., MOEBUS, 
S., WICHMANN, H. E., SCHREIBER, S., MULLER-MYHSOK, B., 
LUCAE, S., JAMAIN, S., LEBOYER, M., BELLIVIER, F., ETAIN, B., 
HENRY, C., KAHN, J. P., HEATH, S., BIPOLAR DISORDER GENOME 
STUDY, C., HAMSHERE, M., O'DONOVAN, M. C., OWEN, M. J., 
CRADDOCK, N., SCHWARZ, M., VEDDER, H., KAMMERER-
CIERNIOCH, J., REIF, A., SASSE, J., BAUER, M., HAUTZINGER, M., 
WRIGHT, A., MITCHELL, P. B., SCHOFIELD, P. R., MONTGOMERY, G. 
W., MEDLAND, S. E., GORDON, S. D., MARTIN, N. G., GUSTAFSSON, 
O., ANDREASSEN, O., DJUROVIC, S., SIGURDSSON, E., STEINBERG, 
S., STEFANSSON, H., STEFANSSON, K., KAPUR-POJSKIC, L., ORUC, 
L., RIVAS, F., MAYORAL, F., CHUCHALIN, A., BABADJANOVA, G., 
TIGANOV, A. S., PANTELEJEVA, G., ABRAMOVA, L. I., GRIGOROIU-
SERBANESCU, M., DIACONU, C. C., CZERSKI, P. M., HAUSER, J., 
ZIMMER, A., LATHROP, M., SCHULZE, T. G., WIENKER, T. F., 
SCHUMACHER, J., MAIER, W., PROPPING, P., RIETSCHEL, M. & 
NOTHEN, M. M. 2011. Genome-wide association study identifies genetic 
variation in neurocan as a susceptibility factor for bipolar disorder. Am J Hum 
Genet, 88, 372-81. 
COETZEE, S. G., RHIE, S. K., BERMAN, B. P., COETZEE, G. A. & 
NOUSHMEHR, H. 2012. FunciSNP: an R/bioconductor tool integrating 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  246 
functional non-coding data sets with genetic association studies to identify 
candidate regulatory SNPs. Nucleic Acids Res, 40, e139. 
COHEN, S. & GREENBERG, M. E. 2008. Communication between the synapse and 
the nucleus in neuronal development, plasticity, and disease. Annu Rev Cell 
Dev Biol, 24, 183-209. 
COMBARROS, O., CORTINA-BORJA, M., SMITH, A. D. & LEHMANN, D. J. 
2009. Epistasis in sporadic Alzheimer's disease. Neurobiol Aging, 30, 1333-
49. 
CONDE, L., VAQUERIZAS, J. M., DOPAZO, H., ARBIZA, L., REUMERS, J., 
ROUSSEAU, F., SCHYMKOWITZ, J. & DOPAZO, J. 2006. PupaSuite: 
finding functional single nucleotide polymorphisms for large-scale 
genotyping purposes. Nucleic Acids Res, 34, W621-5. 
CONSORTIUM, C. 2015. Sparse whole-genome sequencing identifies two loci for 
major depressive disorder. Nature, 523, 588-91. 
CONSORTIUM, E. P. 2011. A user's guide to the encyclopedia of DNA elements 
(ENCODE). PLoS Biol, 9, e1001046. 
The ENCODE Project Consortium, E. P. 2012. An integrated encyclopedia of DNA 
elements in the human genome. Nature, 489, 57-74. 
CONSORTIUM, F., THE, R. P., CLST, FORREST, A. R., KAWAJI, H., REHLI, 
M., BAILLIE, J. K., DE HOON, M. J., HABERLE, V., LASSMANN, T., 
KULAKOVSKIY, I. V., LIZIO, M., ITOH, M., ANDERSSON, R., 
MUNGALL, C. J., MEEHAN, T. F., SCHMEIER, S., BERTIN, N., 
JORGENSEN, M., DIMONT, E., ARNER, E., SCHMIDL, C., SCHAEFER, 
U., MEDVEDEVA, Y. A., PLESSY, C., VITEZIC, M., SEVERIN, J., 
SEMPLE, C., ISHIZU, Y., YOUNG, R. S., FRANCESCATTO, M., ALAM, 
I., ALBANESE, D., ALTSCHULER, G. M., ARAKAWA, T., ARCHER, J. 
A., ARNER, P., BABINA, M., RENNIE, S., BALWIERZ, P. J., 
BECKHOUSE, A. G., PRADHAN-BHATT, S., BLAKE, J. A., 
BLUMENTHAL, A., BODEGA, B., BONETTI, A., BRIGGS, J., 
BROMBACHER, F., BURROUGHS, A. M., CALIFANO, A., 
CANNISTRACI, C. V., CARBAJO, D., CHEN, Y., CHIERICI, M., CIANI, 
Y., CLEVERS, H. C., DALLA, E., DAVIS, C. A., DETMAR, M., DIEHL, 
A. D., DOHI, T., DRABLOS, F., EDGE, A. S., EDINGER, M., EKWALL, 
K., ENDOH, M., ENOMOTO, H., FAGIOLINI, M., FAIRBAIRN, L., 
FANG, H., FARACH-CARSON, M. C., FAULKNER, G. J., FAVOROV, A. 
V., FISHER, M. E., FRITH, M. C., FUJITA, R., FUKUDA, S., 
FURLANELLO, C., FURINO, M., FURUSAWA, J., GEIJTENBEEK, T. B., 
GIBSON, A. P., GINGERAS, T., GOLDOWITZ, D., GOUGH, J., GUHL, S., 
GULER, R., GUSTINCICH, S., HA, T. J., HAMAGUCHI, M., HARA, M., 
HARBERS, M., HARSHBARGER, J., HASEGAWA, A., HASEGAWA, Y., 
HASHIMOTO, T., HERLYN, M., HITCHENS, K. J., HO SUI, S. J., 
HOFMANN, O. M., et al. 2014. A promoter-level mammalian expression 
atlas. Nature, 507, 462-70. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  247 
CONSORTIUM, G. T. 2013. The Genotype-Tissue Expression (GTEx) project. Nat 
Genet, 45, 580-5. 
COOPER, G. M. & SHENDURE, J. 2011. Needles in stacks of needles: finding 
disease-causal variants in a wealth of genomic data. Nat Rev Genet, 12, 628-
40. 
COOPER, G. M., STONE, E. A., ASIMENOS, G., PROGRAM, N. C. S., GREEN, 
E. D., BATZOGLOU, S. & SIDOW, A. 2005. Distribution and intensity of 
constraint in mammalian genomic sequence. Genome Res, 15, 901-13. 
COTTON, R. G., AUERBACH, A. D., BECKMANN, J. S., BLUMENFELD, O. O., 
BROOKES, A. J., BROWN, A. F., CARRERA, P., COX, D. W., 
GOTTLIEB, B., GREENBLATT, M. S., HILBERT, P., LEHVASLAIHO, 
H., LIANG, P., MARSH, S., NEBERT, D. W., POVEY, S., ROSSETTI, S., 
SCRIVER, C. R., SUMMAR, M., TOLAN, D. R., VERMA, I. C., VIHINEN, 
M. & DEN DUNNEN, J. T. 2008. Recommendations for locus-specific 
databases and their curation. Hum Mutat, 29, 2-5. 
CRADDOCK, N. & SKLAR, P. 2009. Genetics of bipolar disorder: successful start 
to a long journey. Trends Genet, 25, 99-105. 
CROSS-DISORDER GROUP OF THE PSYCHIATRIC GENOMICS, C. 2013. 
Identification of risk loci with shared effects on five major psychiatric 
disorders: a genome-wide analysis. Lancet, 381, 1371-9. 
CROSS-DISORDER GROUP OF THE PSYCHIATRIC GENOMICS, C., LEE, S. 
H., RIPKE, S., NEALE, B. M., FARAONE, S. V., PURCELL, S. M., 
PERLIS, R. H., MOWRY, B. J., THAPAR, A., GODDARD, M. E., WITTE, 
J. S., ABSHER, D., AGARTZ, I., AKIL, H., AMIN, F., ANDREASSEN, O. 
A., ANJORIN, A., ANNEY, R., ANTTILA, V., ARKING, D. E., 
ASHERSON, P., AZEVEDO, M. H., BACKLUND, L., BADNER, J. A., 
BAILEY, A. J., BANASCHEWSKI, T., BARCHAS, J. D., BARNES, M. R., 
BARRETT, T. B., BASS, N., BATTAGLIA, A., BAUER, M., BAYES, M., 
BELLIVIER, F., BERGEN, S. E., BERRETTINI, W., BETANCUR, C., 
BETTECKEN, T., BIEDERMAN, J., BINDER, E. B., BLACK, D. W., 
BLACKWOOD, D. H., BLOSS, C. S., BOEHNKE, M., BOOMSMA, D. I., 
BREEN, G., BREUER, R., BRUGGEMAN, R., CORMICAN, P., 
BUCCOLA, N. G., BUITELAAR, J. K., BUNNEY, W. E., BUXBAUM, J. 
D., BYERLEY, W. F., BYRNE, E. M., CAESAR, S., CAHN, W., CANTOR, 
R. M., CASAS, M., CHAKRAVARTI, A., CHAMBERT, K., 
CHOUDHURY, K., CICHON, S., CLONINGER, C. R., COLLIER, D. A., 
COOK, E. H., COON, H., CORMAND, B., CORVIN, A., CORYELL, W. 
H., CRAIG, D. W., CRAIG, I. W., CROSBIE, J., CUCCARO, M. L., 
CURTIS, D., CZAMARA, D., DATTA, S., DAWSON, G., DAY, R., DE 
GEUS, E. J., DEGENHARDT, F., DJUROVIC, S., DONOHOE, G. J., 
DOYLE, A. E., DUAN, J., DUDBRIDGE, F., DUKETIS, E., EBSTEIN, R. 
P., EDENBERG, H. J., ELIA, J., ENNIS, S., ETAIN, B., FANOUS, A., 
FARMER, A. E., FERRIER, I. N., FLICKINGER, M., FOMBONNE, E., 
FOROUD, T., FRANK, J., FRANKE, B., et al. 2013. Genetic relationship 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  248 
between five psychiatric disorders estimated from genome-wide SNPs. Nat 
Genet, 45, 984-94. 
CUELLAR-PARTIDA, G., BUSKE, F. A., MCLEAY, R. C., WHITINGTON, T., 
NOBLE, W. S. & BAILEY, T. L. 2012. Epigenetic priors for identifying 
active transcription factor binding sites. Bioinformatics, 28, 56-62. 
CUKIER, H. N., DUEKER, N. D., SLIFER, S. H., LEE, J. M., WHITEHEAD, P. L., 
LALANNE, E., LEYVA, N., KONIDARI, I., GENTRY, R. C., HULME, W. 
F., BOOVEN, D. V., MAYO, V., HOFMANN, N. K., SCHMIDT, M. A., 
MARTIN, E. R., HAINES, J. L., CUCCARO, M. L., GILBERT, J. R. & 
PERICAK-VANCE, M. A. 2014. Exome sequencing of extended families 
with autism reveals genes shared across neurodevelopmental and 
neuropsychiatric disorders. Mol Autism, 5, 1. 
CUNNINGHAM, F., AMODE, M. R., BARRELL, D., BEAL, K., BILLIS, K., 
BRENT, S., CARVALHO-SILVA, D., CLAPHAM, P., COATES, G., 
FITZGERALD, S., GIL, L., GIRON, C. G., GORDON, L., HOURLIER, T., 
HUNT, S. E., JANACEK, S. H., JOHNSON, N., JUETTEMANN, T., 
KAHARI, A. K., KEENAN, S., MARTIN, F. J., MAUREL, T., MCLAREN, 
W., MURPHY, D. N., NAG, R., OVERDUIN, B., PARKER, A., PATRICIO, 
M., PERRY, E., PIGNATELLI, M., RIAT, H. S., SHEPPARD, D., 
TAYLOR, K., THORMANN, A., VULLO, A., WILDER, S. P., ZADISSA, 
A., AKEN, B. L., BIRNEY, E., HARROW, J., KINSELLA, R., MUFFATO, 
M., RUFFIER, M., SEARLE, S. M., SPUDICH, G., TREVANION, S. J., 
YATES, A., ZERBINO, D. R. & FLICEK, P. 2015. Ensembl 2015. Nucleic 
Acids Res, 43, D662-9. 
DAVISON, K. 2012. Autoimmunity in psychiatry. Br J Psychiatry, 200, 353-5. 
DAVYDOV, E. V., GOODE, D. L., SIROTA, M., COOPER, G. M., SIDOW, A. & 
BATZOGLOU, S. 2010. Identifying a high fraction of the human genome to 
be under selective constraint using GERP++. PLoS Comput Biol, 6, 
e1001025. 
DAYEM ULLAH, A. Z., LEMOINE, N. R. & CHELALA, C. 2013. A practical 
guide for the functional annotation of genetic variations using SNPnexus. 
Brief Bioinform, 14, 437-47. 
DE BARTOLOMEIS, A., BUONAGURO, E. F. & IASEVOLI, F. 2013. Serotonin-
glutamate and serotonin-dopamine reciprocal interactions as putative 
molecular targets for novel antipsychotic treatments: from receptor 
heterodimers to postsynaptic scaffolding and effector proteins. 
Psychopharmacology (Berl), 225, 1-19. 
DE BARTOLOMEIS, A. & TOMASETTI, C. 2012. Calcium-dependent networks in 
dopamine-glutamate interaction: the role of postsynaptic scaffolding proteins. 
Mol Neurobiol, 46, 275-96. 
DE GOBBI, M., VIPRAKASIT, V., HUGHES, J. R., FISHER, C., BUCKLE, V. J., 
AYYUB, H., GIBBONS, R. J., VERNIMMEN, D., YOSHINAGA, Y., DE 
JONG, P., CHENG, J. F., RUBIN, E. M., WOOD, W. G., BOWDEN, D. & 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  249 
HIGGS, D. R. 2006. A regulatory SNP causes a human genetic disease by 
creating a new transcriptional promoter. Science, 312, 1215-7. 
DE RUBEIS, S., HE, X., GOLDBERG, A. P., POULTNEY, C. S., SAMOCHA, K., 
CICEK, A. E., KOU, Y., LIU, L., FROMER, M., WALKER, S., SINGH, T., 
KLEI, L., KOSMICKI, J., SHIH-CHEN, F., ALEKSIC, B., BISCALDI, M., 
BOLTON, P. F., BROWNFELD, J. M., CAI, J., CAMPBELL, N. G., 
CARRACEDO, A., CHAHROUR, M. H., CHIOCCHETTI, A. G., COON, 
H., CRAWFORD, E. L., CURRAN, S. R., DAWSON, G., DUKETIS, E., 
FERNANDEZ, B. A., GALLAGHER, L., GELLER, E., GUTER, S. J., 
HILL, R. S., IONITA-LAZA, J., JIMENZ GONZALEZ, P., KILPINEN, H., 
KLAUCK, S. M., KOLEVZON, A., LEE, I., LEI, I., LEI, J., LEHTIMAKI, 
T., LIN, C. F., MA'AYAN, A., MARSHALL, C. R., MCINNES, A. L., 
NEALE, B., OWEN, M. J., OZAKI, N., PARELLADA, M., PARR, J. R., 
PURCELL, S., PUURA, K., RAJAGOPALAN, D., REHNSTROM, K., 
REICHENBERG, A., SABO, A., SACHSE, M., SANDERS, S. J., 
SCHAFER, C., SCHULTE-RUTHER, M., SKUSE, D., STEVENS, C., 
SZATMARI, P., TAMMIMIES, K., VALLADARES, O., VORAN, A., LI-
SAN, W., WEISS, L. A., WILLSEY, A. J., YU, T. W., YUEN, R. K., 
STUDY, D. D. D., HOMOZYGOSITY MAPPING COLLABORATIVE 
FOR, A., CONSORTIUM, U. K., COOK, E. H., FREITAG, C. M., GILL, 
M., HULTMAN, C. M., LEHNER, T., PALOTIE, A., SCHELLENBERG, G. 
D., SKLAR, P., STATE, M. W., SUTCLIFFE, J. S., WALSH, C. A., 
SCHERER, S. W., ZWICK, M. E., BARETT, J. C., CUTLER, D. J., 
ROEDER, K., DEVLIN, B., DALY, M. J. & BUXBAUM, J. D. 2014. 
Synaptic, transcriptional and chromatin genes disrupted in autism. Nature, 
515, 209-15. 
DECIPHERING DEVELOPMENTAL DISORDERS, S. 2015. Large-scale 
discovery of novel genetic causes of developmental disorders. Nature, 519, 
223-8. 
DEGNER, J. F., PAI, A. A., PIQUE-REGI, R., VEYRIERAS, J. B., GAFFNEY, D. 
J., PICKRELL, J. K., DE LEON, S., MICHELINI, K., LEWELLEN, N., 
CRAWFORD, G. E., STEPHENS, M., GILAD, Y. & PRITCHARD, J. K. 
2012. DNase I sensitivity QTLs are a major determinant of human expression 
variation. Nature, 482, 390-4. 
DENERIS, E. S. & WYLER, S. C. 2012. Serotonergic transcriptional networks and 
potential importance to mental health. Nat Neurosci, 15, 519-27. 
DENNING, D. W., DUNNIGAN, M. G., TILLMAN, J., DAVIS, J. A. & FORREST, 
C. A. 1990. The relationship between 'normal' fluid retention in women and 
idiopathic oedema. Postgrad Med J, 66, 363-6. 
DEVUYST, O. & NI, J. 2006. Aquaporin-1 in the peritoneal membrane: Implications 
for water transport across capillaries and peritoneal dialysis. Biochim Biophys 
Acta, 1758, 1078-84. 
DICK, D. M., ALIEV, F., KRUEGER, R. F., EDWARDS, A., AGRAWAL, A., 
LYNSKEY, M., LIN, P., SCHUCKIT, M., HESSELBROCK, V., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  250 
NURNBERGER, J., JR., ALMASY, L., PORJESZ, B., EDENBERG, H. J., 
BUCHOLZ, K., KRAMER, J., KUPERMAN, S. & BIERUT, L. 2011. 
Genome-wide association study of conduct disorder symptomatology. Mol 
Psychiatry, 16, 800-8. 
DONG, C., WEI, P., JIAN, X., GIBBS, R., BOERWINKLE, E., WANG, K. & LIU, 
X. 2015. Comparison and integration of deleteriousness prediction methods 
for nonsynonymous SNVs in whole exome sequencing studies. Hum Mol 
Genet, 24, 2125-37. 
DRUMM, M. L., ZIADY, A. G. & DAVIS, P. B. 2012. Genetic variation and 
clinical heterogeneity in cystic fibrosis. Annu Rev Pathol, 7, 267-82. 
DU, J., JOHNSON, L. M., JACOBSEN, S. E. & PATEL, D. J. 2015. DNA 
methylation pathways and their crosstalk with histone methylation. Nat Rev 
Mol Cell Biol, 16, 519-32. 
DUDBRIDGE, F. 2013. Power and predictive accuracy of polygenic risk scores. 
PLoS Genet, 9, e1003348. 
DUNNIGAN, M. G., HENDERSON, J. B., HOLE, D. & PELOSI, A. J. 2004. 
Unexplained swelling symptoms in women (idiopathic oedema) comprise one 
component of a common polysymptomatic syndrome. QJM, 97, 755-64. 
DUNNIGAN, M. G. & PELOSI, A. J. 1993. Familial idiopathic oedema in 
prepubertal children: a new syndrome. Q J Med, 86, 301-13. 
DUPUY, A. & SIMON, R. M. 2007. Critical review of published microarray studies 
for cancer outcome and guidelines on statistical analysis and reporting. J Natl 
Cancer Inst, 99, 147-57. 
EATON, W. W., MARTINS, S. S., NESTADT, G., BIENVENU, O. J., CLARKE, 
D. & ALEXANDRE, P. 2008. The burden of mental disorders. Epidemiol 
Rev, 30, 1-14. 
EGEROD, K. L., ENGELSTOFT, M. S., LUND, M. L., GRUNDDAL, K. V., 
ZHAO, M., BARIR-JENSEN, D., NYGAARD, E. B., PETERSEN, N., 
HOLST, J. J. & SCHWARTZ, T. W. 2015. Transcriptional and Functional 
Characterization of the G Protein-Coupled Receptor Repertoire of Gastric 
Somatostatin Cells. Endocrinology, EN20151388. 
ELGAR, G. & VAVOURI, T. 2008. Tuning in to the signals: noncoding sequence 
conservation in vertebrate genomes. Trends Genet, 24, 344-52. 
ERNST, J. & KELLIS, M. 2010. Discovery and characterization of chromatin states 
for systematic annotation of the human genome. Nat Biotechnol, 28, 817-25. 
ERNST, J., KHERADPOUR, P., MIKKELSEN, T. S., SHORESH, N., WARD, L. 
D., EPSTEIN, C. B., ZHANG, X., WANG, L., ISSNER, R., COYNE, M., 
KU, M., DURHAM, T., KELLIS, M. & BERNSTEIN, B. E. 2011. Mapping 
and analysis of chromatin state dynamics in nine human cell types. Nature, 
473, 43-9. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  251 
FERREIRA, M. A., O'DONOVAN, M. C., MENG, Y. A., JONES, I. R., 
RUDERFER, D. M., JONES, L., FAN, J., KIROV, G., PERLIS, R. H., 
GREEN, E. K., SMOLLER, J. W., GROZEVA, D., STONE, J., NIKOLOV, 
I., CHAMBERT, K., HAMSHERE, M. L., NIMGAONKAR, V. L., 
MOSKVINA, V., THASE, M. E., CAESAR, S., SACHS, G. S., FRANKLIN, 
J., GORDON-SMITH, K., ARDLIE, K. G., GABRIEL, S. B., FRASER, C., 
BLUMENSTIEL, B., DEFELICE, M., BREEN, G., GILL, M., MORRIS, D. 
W., ELKIN, A., MUIR, W. J., MCGHEE, K. A., WILLIAMSON, R., 
MACINTYRE, D. J., MACLEAN, A. W., ST, C. D., ROBINSON, M., VAN 
BECK, M., PEREIRA, A. C., KANDASWAMY, R., MCQUILLIN, A., 
COLLIER, D. A., BASS, N. J., YOUNG, A. H., LAWRENCE, J., FERRIER, 
I. N., ANJORIN, A., FARMER, A., CURTIS, D., SCOLNICK, E. M., 
MCGUFFIN, P., DALY, M. J., CORVIN, A. P., HOLMANS, P. A., 
BLACKWOOD, D. H., GURLING, H. M., OWEN, M. J., PURCELL, S. M., 
SKLAR, P., CRADDOCK, N. & WELLCOME TRUST CASE CONTROL, 
C. 2008. Collaborative genome-wide association analysis supports a role for 
ANK3 and CACNA1C in bipolar disorder. Nat Genet, 40, 1056-8. 
FLINT, J. & KENDLER, K. S. 2014. The genetics of major depression. Neuron, 81, 
484-503. 
FOLEY, D. L., MACKINNON, A., MORGAN, V. A., WATTS, G. F., CASTLE, D. 
J., WATERREUS, A. & GALLETLY, C. A. 2015. Common familial risk 
factors for schizophrenia and diabetes mellitus. Aust N Z J Psychiatry. 
FROMER, M., POCKLINGTON, A. J., KAVANAGH, D. H., WILLIAMS, H. J., 
DWYER, S., GORMLEY, P., GEORGIEVA, L., REES, E., PALTA, P., 
RUDERFER, D. M., CARRERA, N., HUMPHREYS, I., JOHNSON, J. S., 
ROUSSOS, P., BARKER, D. D., BANKS, E., MILANOVA, V., GRANT, S. 
G., HANNON, E., ROSE, S. A., CHAMBERT, K., MAHAJAN, M., 
SCOLNICK, E. M., MORAN, J. L., KIROV, G., PALOTIE, A., 
MCCARROLL, S. A., HOLMANS, P., SKLAR, P., OWEN, M. J., 
PURCELL, S. M. & O'DONOVAN, M. C. 2014. De novo mutations in 
schizophrenia implicate synaptic networks. Nature, 506, 179-84. 
FU, J., WOLFS, M. G., DEELEN, P., WESTRA, H. J., FEHRMANN, R. S., TE 
MEERMAN, G. J., BUURMAN, W. A., RENSEN, S. S., GROEN, H. J., 
WEERSMA, R. K., VAN DEN BERG, L. H., VELDINK, J., OPHOFF, R. 
A., SNIEDER, H., VAN HEEL, D., JANSEN, R. C., HOFKER, M. H., 
WIJMENGA, C. & FRANKE, L. 2012. Unraveling the regulatory 
mechanisms underlying tissue-dependent genetic variation of gene 
expression. PLoS Genet, 8, e1002431. 
FU, W., O'CONNOR, T. D. & AKEY, J. M. 2013. Genetic architecture of 
quantitative traits and complex diseases. Curr Opin Genet Dev, 23, 678-83. 
GAMAZON, E. R., BADNER, J. A., CHENG, L., ZHANG, C., ZHANG, D., COX, 
N. J., GERSHON, E. S., KELSOE, J. R., GREENWOOD, T. A., 
NIEVERGELT, C. M., CHEN, C., MCKINNEY, R., SHILLING, P. D., 
SCHORK, N. J., SMITH, E. N., BLOSS, C. S., NURNBERGER, J. I., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  252 
EDENBERG, H. J., FOROUD, T., KOLLER, D. L., SCHEFTNER, W. A., 
CORYELL, W., RICE, J., LAWSON, W. B., NWULIA, E. A., HIPOLITO, 
M., BYERLEY, W., MCMAHON, F. J., SCHULZE, T. G., BERRETTINI, 
W. H., POTASH, J. B., ZANDI, P. P., MAHON, P. B., MCINNIS, M. G., 
ZOLLNER, S., ZHANG, P., CRAIG, D. W., SZELINGER, S., BARRETT, 
T. B. & LIU, C. 2013. Enrichment of cis-regulatory gene expression SNPs 
and methylation quantitative trait loci among bipolar disorder susceptibility 
variants. Mol Psychiatry, 18, 340-6. 
GARRIDO, J. J., FERNANDES, F., MOUSSIF, A., FACHE, M. P., GIRAUD, P. & 
DARGENT, B. 2003. Dynamic compartmentalization of the voltage-gated 
sodium channels in axons. Biol Cell, 95, 437-45. 
GAULTON, K. J., NAMMO, T., PASQUALI, L., SIMON, J. M., GIRESI, P. G., 
FOGARTY, M. P., PANHUIS, T. M., MIECZKOWSKI, P., SECCHI, A., 
BOSCO, D., BERNEY, T., MONTANYA, E., MOHLKE, K. L., LIEB, J. D. 
& FERRER, J. 2010. A map of open chromatin in human pancreatic islets. 
Nat Genet, 42, 255-9. 
GENOMES PROJECT, C., ABECASIS, G. R., ALTSHULER, D., AUTON, A., 
BROOKS, L. D., DURBIN, R. M., GIBBS, R. A., HURLES, M. E. & 
MCVEAN, G. A. 2010. A map of human genome variation from population-
scale sequencing. Nature, 467, 1061-73. 
GENOMES PROJECT, C., ABECASIS, G. R., AUTON, A., BROOKS, L. D., 
DEPRISTO, M. A., DURBIN, R. M., HANDSAKER, R. E., KANG, H. M., 
MARTH, G. T. & MCVEAN, G. A. 2012. An integrated map of genetic 
variation from 1,092 human genomes. Nature, 491, 56-65. 
GEORGI, B., CRAIG, D., KEMBER, R. L., LIU, W., LINDQUIST, I., NASSER, S., 
BROWN, C., EGELAND, J. A., PAUL, S. M. & BUCAN, M. 2014. 
Genomic view of bipolar disorder revealed by whole genome sequencing in a 
genetic isolate. PLoS Genet, 10, e1004229. 
GEORGIEVA, L., REES, E., MORAN, J. L., CHAMBERT, K. D., MILANOVA, 
V., CRADDOCK, N., PURCELL, S., SKLAR, P., MCCARROLL, S., 
HOLMANS, P., O'DONOVAN, M. C., OWEN, M. J. & KIROV, G. 2014. 
De novo CNVs in bipolar affective disorder and schizophrenia. Hum Mol 
Genet, 23, 6677-83. 
GERSTEIN, M. B., KUNDAJE, A., HARIHARAN, M., LANDT, S. G., YAN, K. 
K., CHENG, C., MU, X. J., KHURANA, E., ROZOWSKY, J., 
ALEXANDER, R., MIN, R., ALVES, P., ABYZOV, A., ADDLEMAN, N., 
BHARDWAJ, N., BOYLE, A. P., CAYTING, P., CHAROS, A., CHEN, D. 
Z., CHENG, Y., CLARKE, D., EASTMAN, C., EUSKIRCHEN, G., 
FRIETZE, S., FU, Y., GERTZ, J., GRUBERT, F., HARMANCI, A., JAIN, 
P., KASOWSKI, M., LACROUTE, P., LENG, J., LIAN, J., MONAHAN, H., 
O'GEEN, H., OUYANG, Z., PARTRIDGE, E. C., PATACSIL, D., PAULI, 
F., RAHA, D., RAMIREZ, L., REDDY, T. E., REED, B., SHI, M., SLIFER, 
T., WANG, J., WU, L., YANG, X., YIP, K. Y., ZILBERMAN-SCHAPIRA, 
G., BATZOGLOU, S., SIDOW, A., FARNHAM, P. J., MYERS, R. M., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  253 
WEISSMAN, S. M. & SNYDER, M. 2012. Architecture of the human 
regulatory network derived from ENCODE data. Nature, 489, 91-100. 
GHANEM, N., JARINOVA, O., AMORES, A., LONG, Q., HATCH, G., PARK, B. 
K., RUBENSTEIN, J. L. & EKKER, M. 2003. Regulatory roles of conserved 
intergenic domains in vertebrate Dlx bigene clusters. Genome Res, 13, 533-
43. 
GIARDINE, B., VAN BAAL, S., KAIMAKIS, P., RIEMER, C., MILLER, W., 
SAMARA, M., KOLLIA, P., ANAGNOU, N. P., CHUI, D. H., WAJCMAN, 
H., HARDISON, R. C. & PATRINOS, G. P. 2007. HbVar database of human 
hemoglobin variants and thalassemia mutations: 2007 update. Hum Mutat, 
28, 206. 
GIORDANO, S., AMATO, F., ELCE, A., MONTI, M., IANNONE, C., PUCCI, P., 
SEIA, M., ANGIONI, A., ZARRILLI, F., CASTALDO, G. & 
TOMAIUOLO, R. 2013. Molecular and functional analysis of the large 5' 
promoter region of CFTR gene revealed pathogenic mutations in CF and 
CFTR-related disorders. J Mol Diagn, 15, 331-40. 
GOGTAY, N., VYAS, N. S., TESTA, R., WOOD, S. J. & PANTELIS, C. 2011. Age 
of onset of schizophrenia: perspectives from structural neuroimaging studies. 
Schizophr Bull, 37, 504-13. 
GOODSWEN, S. J., GONDRO, C., WATSON-HAIGH, N. S. & KADARMIDEEN, 
H. N. 2010. FunctSNP: an R package to link SNPs to functional knowledge 
and dbAutoMaker: a suite of Perl scripts to build SNP databases. BMC 
Bioinformatics, 11, 311. 
GORDEN, N. T., ARTS, H. H., PARISI, M. A., COENE, K. L., LETTEBOER, S. J., 
VAN BEERSUM, S. E., MANS, D. A., HIKIDA, A., ECKERT, M., 
KNUTZEN, D., ALSWAID, A. F., OZYUREK, H., DIBOOGLU, S., OTTO, 
E. A., LIU, Y., DAVIS, E. E., HUTTER, C. M., BAMMLER, T. K., FARIN, 
F. M., DORSCHNER, M., TOPCU, M., ZACKAI, E. H., ROSENTHAL, P., 
OWENS, K. N., KATSANIS, N., VINCENT, J. B., HILDEBRANDT, F., 
RUBEL, E. W., RAIBLE, D. W., KNOERS, N. V., CHANCE, P. F., 
ROEPMAN, R., MOENS, C. B., GLASS, I. A. & DOHERTY, D. 2008. 
CC2D2A is mutated in Joubert syndrome and interacts with the ciliopathy-
associated basal body protein CEP290. Am J Hum Genet, 83, 559-71. 
GOTTGENS, B., BARTON, L. M., CHAPMAN, M. A., SINCLAIR, A. M., 
KNUDSEN, B., GRAFHAM, D., GILBERT, J. G., ROGERS, J., BENTLEY, 
D. R. & GREEN, A. R. 2002. Transcriptional regulation of the stem cell 
leukemia gene (SCL)--comparative analysis of five vertebrate SCL loci. 
Genome Res, 12, 749-59. 
GRACE, A. A. 2012. Dopamine system dysregulation by the hippocampus: 
implications for the pathophysiology and treatment of schizophrenia. 
Neuropharmacology, 62, 1342-8. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  254 
GRATTEN, J., VISSCHER, P. M., MOWRY, B. J. & WRAY, N. R. 2013. 
Interpreting the role of de novo protein-coding mutations in neuropsychiatric 
disease. Nat Genet, 45, 234-8. 
GREENFIELD, A. D. 1966. Survey of the evidence for active neurogenic 
vasodilatation in man. Fed Proc, 25, 1607-10. 
GREENWOOD, T. A., AKISKAL, H. S., AKISKAL, K. K., BIPOLAR GENOME, 
S. & KELSOE, J. R. 2012. Genome-wide association study of temperament 
in bipolar disorder reveals significant associations with three novel Loci. Biol 
Psychiatry, 72, 303-10. 
GRUNDBERG, E., SMALL, K. S., HEDMAN, A. K., NICA, A. C., BUIL, A., 
KEILDSON, S., BELL, J. T., YANG, T. P., MEDURI, E., BARRETT, A., 
NISBETT, J., SEKOWSKA, M., WILK, A., SHIN, S. Y., GLASS, D., 
TRAVERS, M., MIN, J. L., RING, S., HO, K., THORLEIFSSON, G., 
KONG, A., THORSTEINDOTTIR, U., AINALI, C., DIMAS, A. S., 
HASSANALI, N., INGLE, C., KNOWLES, D., KRESTYANINOVA, M., 
LOWE, C. E., DI MEGLIO, P., MONTGOMERY, S. B., PARTS, L., 
POTTER, S., SURDULESCU, G., TSAPROUNI, L., TSOKA, S., 
BATAILLE, V., DURBIN, R., NESTLE, F. O., O'RAHILLY, S., 
SORANZO, N., LINDGREN, C. M., ZONDERVAN, K. T., AHMADI, K. 
R., SCHADT, E. E., STEFANSSON, K., SMITH, G. D., MCCARTHY, M. 
I., DELOUKAS, P., DERMITZAKIS, E. T., SPECTOR, T. D. & MULTIPLE 
TISSUE HUMAN EXPRESSION RESOURCE, C. 2012. Mapping cis- and 
trans-regulatory effects across multiple tissues in twins. Nat Genet, 44, 1084-
9. 
GUO, L., DU, Y., CHANG, S., ZHANG, K. & WANG, J. 2014. rSNPBase: a 
database for curated regulatory SNPs. Nucleic Acids Res, 42, D1033-9. 
GUSELLA, J. F., WEXLER, N. S., CONNEALLY, P. M., NAYLOR, S. L., 
ANDERSON, M. A., TANZI, R. E., WATKINS, P. C., OTTINA, K., 
WALLACE, M. R., SAKAGUCHI, A. Y. & ET AL. 1983. A polymorphic 
DNA marker genetically linked to Huntington's disease. Nature, 306, 234-8. 
HAGER, G. 2009. Footprints by deep sequencing. Nat Methods, 6, 254-5. 
HARDY, J. & SINGLETON, A. 2009. Genomewide association studies and human 
disease. N Engl J Med, 360, 1759-68. 
HAROLD, D., ABRAHAM, R., HOLLINGWORTH, P., SIMS, R., GERRISH, A., 
HAMSHERE, M. L., PAHWA, J. S., MOSKVINA, V., DOWZELL, K., 
WILLIAMS, A., JONES, N., THOMAS, C., STRETTON, A., MORGAN, A. 
R., LOVESTONE, S., POWELL, J., PROITSI, P., LUPTON, M. K., 
BRAYNE, C., RUBINSZTEIN, D. C., GILL, M., LAWLOR, B., LYNCH, 
A., MORGAN, K., BROWN, K. S., PASSMORE, P. A., CRAIG, D., 
MCGUINNESS, B., TODD, S., HOLMES, C., MANN, D., SMITH, A. D., 
LOVE, S., KEHOE, P. G., HARDY, J., MEAD, S., FOX, N., ROSSOR, M., 
COLLINGE, J., MAIER, W., JESSEN, F., SCHURMANN, B., HEUN, R., 
VAN DEN BUSSCHE, H., HEUSER, I., KORNHUBER, J., WILTFANG, J., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  255 
DICHGANS, M., FROLICH, L., HAMPEL, H., HULL, M., RUJESCU, D., 
GOATE, A. M., KAUWE, J. S., CRUCHAGA, C., NOWOTNY, P., 
MORRIS, J. C., MAYO, K., SLEEGERS, K., BETTENS, K., 
ENGELBORGHS, S., DE DEYN, P. P., VAN BROECKHOVEN, C., 
LIVINGSTON, G., BASS, N. J., GURLING, H., MCQUILLIN, A., 
GWILLIAM, R., DELOUKAS, P., AL-CHALABI, A., SHAW, C. E., 
TSOLAKI, M., SINGLETON, A. B., GUERREIRO, R., MUHLEISEN, T. 
W., NOTHEN, M. M., MOEBUS, S., JOCKEL, K. H., KLOPP, N., 
WICHMANN, H. E., CARRASQUILLO, M. M., PANKRATZ, V. S., 
YOUNKIN, S. G., HOLMANS, P. A., O'DONOVAN, M., OWEN, M. J. & 
WILLIAMS, J. 2009. Genome-wide association study identifies variants at 
CLU and PICALM associated with Alzheimer's disease. Nat Genet, 41, 1088-
93. 
HASTIE, T., FRIEDMAN 2009. The Elements of Statistical Learning: Data Mining, 
Inference and prediction, Springer. 
HENN, B. M., BOTIGUE, L. R., BUSTAMANTE, C. D., CLARK, A. G. & 
GRAVEL, S. 2015. Estimating the mutation load in human genomes. Nat Rev 
Genet, 16, 333-43. 
HENNAH, W., THOMSON, P., MCQUILLIN, A., BASS, N., LOUKOLA, A., 
ANJORIN, A., BLACKWOOD, D., CURTIS, D., DEARY, I. J., HARRIS, S. 
E., ISOMETSA, E. T., LAWRENCE, J., LONNQVIST, J., MUIR, W., 
PALOTIE, A., PARTONEN, T., PAUNIO, T., PYLKKO, E., ROBINSON, 
M., SORONEN, P., SUOMINEN, K., SUVISAARI, J., THIRUMALAI, S., 
ST CLAIR, D., GURLING, H., PELTONEN, L. & PORTEOUS, D. 2009. 
DISC1 association, heterogeneity and interplay in schizophrenia and bipolar 
disorder. Mol Psychiatry, 14, 865-73. 
HERMEY, G. 2009. The Vps10p-domain receptor family. Cell Mol Life Sci, 66, 
2677-89. 
HERRERA, D. G. & ROBERTSON, H. A. 1996. Activation of c-fos in the brain. 
Prog Neurobiol, 50, 83-107. 
HESSELBERTH, J. R., CHEN, X., ZHANG, Z., SABO, P. J., SANDSTROM, R., 
REYNOLDS, A. P., THURMAN, R. E., NEPH, S., KUEHN, M. S., NOBLE, 
W. S., FIELDS, S. & STAMATOYANNOPOULOS, J. A. 2009. Global 
mapping of protein-DNA interactions in vivo by digital genomic footprinting. 
Nat Methods, 6, 283-9. 
HINDORFF, L. A., SETHUPATHY, P., JUNKINS, H. A., RAMOS, E. M., 
MEHTA, J. P., COLLINS, F. S. & MANOLIO, T. A. 2009. Potential 
etiologic and functional implications of genome-wide association loci for 
human diseases and traits. Proc Natl Acad Sci U S A, 106, 9362-7. 
HOENICKA, J., ARAGUES, M., PONCE, G., RODRIGUEZ-JIMENEZ, R., 
JIMENEZ-ARRIERO, M. A. & PALOMO, T. 2007. From dopaminergic 
genes to psychiatric disorders. Neurotox Res, 11, 61-72. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  256 
HOLLINGWORTH, P., HAROLD, D., SIMS, R., GERRISH, A., LAMBERT, J. C., 
CARRASQUILLO, M. M., ABRAHAM, R., HAMSHERE, M. L., PAHWA, 
J. S., MOSKVINA, V., DOWZELL, K., JONES, N., STRETTON, A., 
THOMAS, C., RICHARDS, A., IVANOV, D., WIDDOWSON, C., 
CHAPMAN, J., LOVESTONE, S., POWELL, J., PROITSI, P., LUPTON, M. 
K., BRAYNE, C., RUBINSZTEIN, D. C., GILL, M., LAWLOR, B., 
LYNCH, A., BROWN, K. S., PASSMORE, P. A., CRAIG, D., 
MCGUINNESS, B., TODD, S., HOLMES, C., MANN, D., SMITH, A. D., 
BEAUMONT, H., WARDEN, D., WILCOCK, G., LOVE, S., KEHOE, P. 
G., HOOPER, N. M., VARDY, E. R., HARDY, J., MEAD, S., FOX, N. C., 
ROSSOR, M., COLLINGE, J., MAIER, W., JESSEN, F., RUTHER, E., 
SCHURMANN, B., HEUN, R., KOLSCH, H., VAN DEN BUSSCHE, H., 
HEUSER, I., KORNHUBER, J., WILTFANG, J., DICHGANS, M., 
FROLICH, L., HAMPEL, H., GALLACHER, J., HULL, M., RUJESCU, D., 
GIEGLING, I., GOATE, A. M., KAUWE, J. S., CRUCHAGA, C., 
NOWOTNY, P., MORRIS, J. C., MAYO, K., SLEEGERS, K., BETTENS, 
K., ENGELBORGHS, S., DE DEYN, P. P., VAN BROECKHOVEN, C., 
LIVINGSTON, G., BASS, N. J., GURLING, H., MCQUILLIN, A., 
GWILLIAM, R., DELOUKAS, P., AL-CHALABI, A., SHAW, C. E., 
TSOLAKI, M., SINGLETON, A. B., GUERREIRO, R., MUHLEISEN, T. 
W., NOTHEN, M. M., MOEBUS, S., JOCKEL, K. H., KLOPP, N., 
WICHMANN, H. E., PANKRATZ, V. S., SANDO, S. B., AASLY, J. O., 
BARCIKOWSKA, M., WSZOLEK, Z. K., DICKSON, D. W., GRAFF-
RADFORD, N. R., PETERSEN, R. C., et al. 2011. Common variants at 
ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with 
Alzheimer's disease. Nat Genet, 43, 429-35. 
HOWRIGAN, D. P., LAIRD, N. M., SMOLLER, J. W., DEVLIN, B. & 
MCQUEEN, M. B. 2011. Using linkage information to weight a genome-
wide association of bipolar disorder. Am J Med Genet B Neuropsychiatr 
Genet, 156B, 462-71. 
HSU, C., LIN. 2010. A Practical Guide to Support Vector Classification [Online]. 
Available: http://www.csie.ntu.edu.tw/~cjlin/papers/guide/guide.pdf 
[Accessed March 2014. 
HUBER, W., CAREY, V. J., GENTLEMAN, R., ANDERS, S., CARLSON, M., 
CARVALHO, B. S., BRAVO, H. C., DAVIS, S., GATTO, L., GIRKE, T., 
GOTTARDO, R., HAHNE, F., HANSEN, K. D., IRIZARRY, R. A., 
LAWRENCE, M., LOVE, M. I., MACDONALD, J., OBENCHAIN, V., 
OLES, A. K., PAGES, H., REYES, A., SHANNON, P., SMYTH, G. K., 
TENENBAUM, D., WALDRON, L. & MORGAN, M. 2015. Orchestrating 
high-throughput genomic analysis with Bioconductor. Nat Methods, 12, 115-
21. 
IHAKA, G. 1996.  
R: A Language for Data Analysis and Graphics. Journal of Computational and 
Graphical Statistics, 5, 299-314. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  257 
INTERNATIONAL SCHIZOPHRENIA, C. 2008. Rare chromosomal deletions and 
duplications increase risk of schizophrenia. Nature, 455, 237-41. 
INTERNATIONAL SCHIZOPHRENIA, C., PURCELL, S. M., WRAY, N. R., 
STONE, J. L., VISSCHER, P. M., O'DONOVAN, M. C., SULLIVAN, P. F. 
& SKLAR, P. 2009. Common polygenic variation contributes to risk of 
schizophrenia and bipolar disorder. Nature, 460, 748-52. 
IOSSIFOV, I., O'ROAK, B. J., SANDERS, S. J., RONEMUS, M., KRUMM, N., 
LEVY, D., STESSMAN, H. A., WITHERSPOON, K. T., VIVES, L., 
PATTERSON, K. E., SMITH, J. D., PAEPER, B., NICKERSON, D. A., 
DEA, J., DONG, S., GONZALEZ, L. E., MANDELL, J. D., MANE, S. M., 
MURTHA, M. T., SULLIVAN, C. A., WALKER, M. F., WAQAR, Z., WEI, 
L., WILLSEY, A. J., YAMROM, B., LEE, Y. H., GRABOWSKA, E., 
DALKIC, E., WANG, Z., MARKS, S., ANDREWS, P., LEOTTA, A., 
KENDALL, J., HAKKER, I., ROSENBAUM, J., MA, B., RODGERS, L., 
TROGE, J., NARZISI, G., YOON, S., SCHATZ, M. C., YE, K., 
MCCOMBIE, W. R., SHENDURE, J., EICHLER, E. E., STATE, M. W. & 
WIGLER, M. 2014. The contribution of de novo coding mutations to autism 
spectrum disorder. Nature, 515, 216-21. 
ITOH, A., MIYABAYASHI, T., OHNO, M. & SAKANO, S. 1998. Cloning and 
expressions of three mammalian homologues of Drosophila slit suggest 
possible roles for Slit in the formation and maintenance of the nervous 
system. Brain Res Mol Brain Res, 62, 175-86. 
JANSEN, P., GIEHL, K., NYENGAARD, J. R., TENG, K., LIOUBINSKI, O., 
SJOEGAARD, S. S., BREIDERHOFF, T., GOTTHARDT, M., LIN, F., 
EILERS, A., PETERSEN, C. M., LEWIN, G. R., HEMPSTEAD, B. L., 
WILLNOW, T. E. & NYKJAER, A. 2007. Roles for the pro-neurotrophin 
receptor sortilin in neuronal development, aging and brain injury. Nat 
Neurosci, 10, 1449-57. 
JOHAR, A. S., MASTRONARDI, C., ROJAS-VILLARRAGA, A., PATEL, H. R., 
CHUAH, A., PENG, K., HIGGINS, A., MILBURN, P., PALMER, S., 
SILVA-LARA, M. F., VELEZ, J. I., ANDREWS, D., FIELD, M., 
HUTTLEY, G., GOODNOW, C., ANAYA, J. M. & ARCOS-BURGOS, M. 
2015. Novel and rare functional genomic variants in multiple autoimmune 
syndrome and Sjogren's syndrome. J Transl Med, 13, 173. 
JONSSON, T., STEFANSSON, H., STEINBERG, S., JONSDOTTIR, I., JONSSON, 
P. V., SNAEDAL, J., BJORNSSON, S., HUTTENLOCHER, J., LEVEY, A. 
I., LAH, J. J., RUJESCU, D., HAMPEL, H., GIEGLING, I., 
ANDREASSEN, O. A., ENGEDAL, K., ULSTEIN, I., DJUROVIC, S., 
IBRAHIM-VERBAAS, C., HOFMAN, A., IKRAM, M. A., VAN DUIJN, C. 
M., THORSTEINSDOTTIR, U., KONG, A. & STEFANSSON, K. 2013. 
Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J 
Med, 368, 107-16. 
JOSHI, G. & WILENS, T. 2009. Comorbidity in pediatric bipolar disorder. Child 
Adolesc Psychiatr Clin N Am, 18, 291-319, vii-viii. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  258 
JUDY, J. T., SEIFUDDIN, F., PIROOZNIA, M., MAHON, P. B., BIPOLAR 
GENOME STUDY, C., JANCIC, D., GOES, F. S., SCHULZE, T., CICHON, 
S., NOETHEN, M., RIETSCHEL, M., DEPAULO, J. R., JR., POTASH, J. B. 
& ZANDI, P. P. 2013. Converging Evidence for Epistasis between ANK3 
and Potassium Channel Gene KCNQ2 in Bipolar Disorder. Front Genet, 4, 
87. 
KAO, W. P., YANG, C. Y., SU, T. W., WANG, Y. T., LO, Y. C. & LIN, S. C. 2015. 
The versatile roles of CARDs in regulating apoptosis, inflammation, and NF-
kappaB signaling. Apoptosis, 20, 174-95. 
KARAYIORGOU, M., MORRIS, M. A., MORROW, B., SHPRINTZEN, R. J., 
GOLDBERG, R., BORROW, J., GOS, A., NESTADT, G., WOLYNIEC, P. 
S., LASSETER, V. K. & ET AL. 1995. Schizophrenia susceptibility 
associated with interstitial deletions of chromosome 22q11. Proc Natl Acad 
Sci U S A, 92, 7612-6. 
KAROLCHIK, D., HINRICHS, A. S. & KENT, W. J. 2011. The UCSC Genome 
Browser. Curr Protoc Hum Genet, Chapter 18, Unit18 6. 
KATHIRESAN, S., WILLER, C. J., PELOSO, G. M., DEMISSIE, S., 
MUSUNURU, K., SCHADT, E. E., KAPLAN, L., BENNETT, D., LI, Y., 
TANAKA, T., VOIGHT, B. F., BONNYCASTLE, L. L., JACKSON, A. U., 
CRAWFORD, G., SURTI, A., GUIDUCCI, C., BURTT, N. P., PARISH, S., 
CLARKE, R., ZELENIKA, D., KUBALANZA, K. A., MORKEN, M. A., 
SCOTT, L. J., STRINGHAM, H. M., GALAN, P., SWIFT, A. J., 
KUUSISTO, J., BERGMAN, R. N., SUNDVALL, J., LAAKSO, M., 
FERRUCCI, L., SCHEET, P., SANNA, S., UDA, M., YANG, Q., 
LUNETTA, K. L., DUPUIS, J., DE BAKKER, P. I., O'DONNELL, C. J., 
CHAMBERS, J. C., KOONER, J. S., HERCBERG, S., MENETON, P., 
LAKATTA, E. G., SCUTERI, A., SCHLESSINGER, D., TUOMILEHTO, J., 
COLLINS, F. S., GROOP, L., ALTSHULER, D., COLLINS, R., LATHROP, 
G. M., MELANDER, O., SALOMAA, V., PELTONEN, L., ORHO-
MELANDER, M., ORDOVAS, J. M., BOEHNKE, M., ABECASIS, G. R., 
MOHLKE, K. L. & CUPPLES, L. A. 2009. Common variants at 30 loci 
contribute to polygenic dyslipidemia. Nat Genet, 41, 56-65. 
KAVANAGH, D. H., TANSEY, K. E., O'DONOVAN, M. C. & OWEN, M. J. 2015. 
Schizophrenia genetics: emerging themes for a complex disorder. Mol 
Psychiatry, 20, 72-6. 
KEINAN, A. & CLARK, A. G. 2012. Recent explosive human population growth 
has resulted in an excess of rare genetic variants. Science, 336, 740-3. 
KELLIS, M., WOLD, B., SNYDER, M. P., BERNSTEIN, B. E., KUNDAJE, A., 
MARINOV, G. K., WARD, L. D., BIRNEY, E., CRAWFORD, G. E., 
DEKKER, J., DUNHAM, I., ELNITSKI, L. L., FARNHAM, P. J., 
FEINGOLD, E. A., GERSTEIN, M., GIDDINGS, M. C., GILBERT, D. M., 
GINGERAS, T. R., GREEN, E. D., GUIGO, R., HUBBARD, T., KENT, J., 
LIEB, J. D., MYERS, R. M., PAZIN, M. J., REN, B., 
STAMATOYANNOPOULOS, J. A., WENG, Z., WHITE, K. P. & 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  259 
HARDISON, R. C. 2014. Defining functional DNA elements in the human 
genome. Proc Natl Acad Sci U S A, 111, 6131-8. 
KENDLER, K. S., GATZ, M., GARDNER, C. O. & PEDERSEN, N. L. 2005. Age 
at onset and familial risk for major depression in a Swedish national twin 
sample. Psychol Med, 35, 1573-9. 
KERNER, B., RAO, A. R., CHRISTENSEN, B., DANDEKAR, S., YOURSHAW, 
M. & NELSON, S. F. 2013. Rare Genomic Variants Link Bipolar Disorder 
with Anxiety Disorders to CREB-Regulated Intracellular Signaling Pathways. 
Front Psychiatry, 4, 154. 
KESSLER, R. C., BERGLUND, P., DEMLER, O., JIN, R., MERIKANGAS, K. R. 
& WALTERS, E. E. 2005. Lifetime prevalence and age-of-onset distributions 
of DSM-IV disorders in the National Comorbidity Survey Replication. Arch 
Gen Psychiatry, 62, 593-602. 
KHURANA, E., FU, Y., COLONNA, V., MU, X. J., KANG, H. M., 
LAPPALAINEN, T., SBONER, A., LOCHOVSKY, L., CHEN, J., 
HARMANCI, A., DAS, J., ABYZOV, A., BALASUBRAMANIAN, S., 
BEAL, K., CHAKRAVARTY, D., CHALLIS, D., CHEN, Y., CLARKE, D., 
CLARKE, L., CUNNINGHAM, F., EVANI, U. S., FLICEK, P., FRAGOZA, 
R., GARRISON, E., GIBBS, R., GUMUS, Z. H., HERRERO, J., 
KITABAYASHI, N., KONG, Y., LAGE, K., LILUASHVILI, V., LIPKIN, S. 
M., MACARTHUR, D. G., MARTH, G., MUZNY, D., PERS, T. H., 
RITCHIE, G. R., ROSENFELD, J. A., SISU, C., WEI, X., WILSON, M., 
XUE, Y., YU, F., GENOMES PROJECT, C., DERMITZAKIS, E. T., YU, 
H., RUBIN, M. A., TYLER-SMITH, C. & GERSTEIN, M. 2013. Integrative 
annotation of variants from 1092 humans: application to cancer genomics. 
Science, 342, 1235587. 
KING, D. C., TAYLOR, J., ELNITSKI, L., CHIAROMONTE, F., MILLER, W. & 
HARDISON, R. C. 2005. Evaluation of regulatory potential and conservation 
scores for detecting cis-regulatory modules in aligned mammalian genome 
sequences. Genome Res, 15, 1051-60. 
KIRCHER, M., WITTEN, D. M., JAIN, P., O'ROAK, B. J., COOPER, G. M. & 
SHENDURE, J. 2014. A general framework for estimating the relative 
pathogenicity of human genetic variants. Nat Genet, 46, 310-5. 
KNIGHT, J. C. 2014. Approaches for establishing the function of regulatory genetic 
variants involved in disease. Genome Med, 6, 92. 
KOHLI, M. A., LUCAE, S., SAEMANN, P. G., SCHMIDT, M. V., DEMIRKAN, 
A., HEK, K., CZAMARA, D., ALEXANDER, M., SALYAKINA, D., 
RIPKE, S., HOEHN, D., SPECHT, M., MENKE, A., HENNINGS, J., 
HECK, A., WOLF, C., ISING, M., SCHREIBER, S., CZISCH, M., 
MULLER, M. B., UHR, M., BETTECKEN, T., BECKER, A., SCHRAMM, 
J., RIETSCHEL, M., MAIER, W., BRADLEY, B., RESSLER, K. J., 
NOTHEN, M. M., CICHON, S., CRAIG, I. W., BREEN, G., LEWIS, C. M., 
HOFMAN, A., TIEMEIER, H., VAN DUIJN, C. M., HOLSBOER, F., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  260 
MULLER-MYHSOK, B. & BINDER, E. B. 2011. The neuronal transporter 
gene SLC6A15 confers risk to major depression. Neuron, 70, 252-65. 
KOLBE, D., TAYLOR, J., ELNITSKI, L., ESWARA, P., LI, J., MILLER, W., 
HARDISON, R. & CHIAROMONTE, F. 2004. Regulatory potential scores 
from genome-wide three-way alignments of human, mouse, and rat. Genome 
Res, 14, 700-7. 
KRZYWINSKI, M. & ALTMAN, N. 2014. Points of significance: two-factor 
designs. Nat Methods, 11, 1187-8. 
KUHN, R. M., HAUSSLER, D. & KENT, W. J. 2013. The UCSC genome browser 
and associated tools. Brief Bioinform, 14, 144-61. 
KUMAR, V., WESTRA, H. J., KARJALAINEN, J., ZHERNAKOVA, D. V., ESKO, 
T., HRDLICKOVA, B., ALMEIDA, R., ZHERNAKOVA, A., REINMAA, 
E., VOSA, U., HOFKER, M. H., FEHRMANN, R. S., FU, J., WITHOFF, S., 
METSPALU, A., FRANKE, L. & WIJMENGA, C. 2013. Human disease-
associated genetic variation impacts large intergenic non-coding RNA 
expression. PLoS Genet, 9, e1003201. 
LAM, H. Y., CLARK, M. J., CHEN, R., CHEN, R., NATSOULIS, G., 
O'HUALLACHAIN, M., DEWEY, F. E., HABEGGER, L., ASHLEY, E. A., 
GERSTEIN, M. B., BUTTE, A. J., JI, H. P. & SNYDER, M. 2012. 
Performance comparison of whole-genome sequencing platforms. Nat 
Biotechnol, 30, 78-82. 
LAMBERT, J. C., HEATH, S., EVEN, G., CAMPION, D., SLEEGERS, K., 
HILTUNEN, M., COMBARROS, O., ZELENIKA, D., BULLIDO, M. J., 
TAVERNIER, B., LETENNEUR, L., BETTENS, K., BERR, C., 
PASQUIER, F., FIEVET, N., BARBERGER-GATEAU, P., 
ENGELBORGHS, S., DE DEYN, P., MATEO, I., FRANCK, A., 
HELISALMI, S., PORCELLINI, E., HANON, O., EUROPEAN 
ALZHEIMER'S DISEASE INITIATIVE, I., DE PANCORBO, M. M., 
LENDON, C., DUFOUIL, C., JAILLARD, C., LEVEILLARD, T., 
ALVAREZ, V., BOSCO, P., MANCUSO, M., PANZA, F., NACMIAS, B., 
BOSSU, P., PICCARDI, P., ANNONI, G., SERIPA, D., GALIMBERTI, D., 
HANNEQUIN, D., LICASTRO, F., SOININEN, H., RITCHIE, K., 
BLANCHE, H., DARTIGUES, J. F., TZOURIO, C., GUT, I., VAN 
BROECKHOVEN, C., ALPEROVITCH, A., LATHROP, M. & AMOUYEL, 
P. 2009. Genome-wide association study identifies variants at CLU and CR1 
associated with Alzheimer's disease. Nat Genet, 41, 1094-9. 
LANDER, E. & KRUGLYAK, L. 1995. Genetic dissection of complex traits: 
guidelines for interpreting and reporting linkage results. Nat Genet, 11, 241-
7. 
LANDRUM, M. J., LEE, J. M., RILEY, G. R., JANG, W., RUBINSTEIN, W. S., 
CHURCH, D. M. & MAGLOTT, D. R. 2014. ClinVar: public archive of 
relationships among sequence variation and human phenotype. Nucleic Acids 
Res, 42, D980-5. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  261 
LANDSBERG, L. & YOUNG, J. B. 1985. Insulin-mediated glucose metabolism in 
the relationship between dietary intake and sympathetic nervous system 
activity. Int J Obes, 9 Suppl 2, 63-8. 
LANE, R. F., ST GEORGE-HYSLOP, P., HEMPSTEAD, B. L., SMALL, S. A., 
STRITTMATTER, S. M. & GANDY, S. 2012. Vps10 family proteins and the 
retromer complex in aging-related neurodegeneration and diabetes. J 
Neurosci, 32, 14080-6. 
LANGO ALLEN, H., ESTRADA, K., LETTRE, G., BERNDT, S. I., WEEDON, M. 
N., RIVADENEIRA, F., WILLER, C. J., JACKSON, A. U., VEDANTAM, 
S., RAYCHAUDHURI, S., FERREIRA, T., WOOD, A. R., WEYANT, R. J., 
SEGRE, A. V., SPELIOTES, E. K., WHEELER, E., SORANZO, N., PARK, 
J. H., YANG, J., GUDBJARTSSON, D., HEARD-COSTA, N. L., 
RANDALL, J. C., QI, L., VERNON SMITH, A., MAGI, R., PASTINEN, T., 
LIANG, L., HEID, I. M., LUAN, J., THORLEIFSSON, G., WINKLER, T. 
W., GODDARD, M. E., SIN LO, K., PALMER, C., WORKALEMAHU, T., 
AULCHENKO, Y. S., JOHANSSON, A., ZILLIKENS, M. C., FEITOSA, M. 
F., ESKO, T., JOHNSON, T., KETKAR, S., KRAFT, P., MANGINO, M., 
PROKOPENKO, I., ABSHER, D., ALBRECHT, E., ERNST, F., GLAZER, 
N. L., HAYWARD, C., HOTTENGA, J. J., JACOBS, K. B., KNOWLES, J. 
W., KUTALIK, Z., MONDA, K. L., POLASEK, O., PREUSS, M., 
RAYNER, N. W., ROBERTSON, N. R., STEINTHORSDOTTIR, V., 
TYRER, J. P., VOIGHT, B. F., WIKLUND, F., XU, J., ZHAO, J. H., 
NYHOLT, D. R., PELLIKKA, N., PEROLA, M., PERRY, J. R., 
SURAKKA, I., TAMMESOO, M. L., ALTMAIER, E. L., AMIN, N., 
ASPELUND, T., BHANGALE, T., BOUCHER, G., CHASMAN, D. I., 
CHEN, C., COIN, L., COOPER, M. N., DIXON, A. L., GIBSON, Q., 
GRUNDBERG, E., HAO, K., JUHANI JUNTTILA, M., KAPLAN, L. M., 
KETTUNEN, J., KONIG, I. R., KWAN, T., LAWRENCE, R. W., 
LEVINSON, D. F., LORENTZON, M., MCKNIGHT, B., MORRIS, A. P., 
MULLER, M., SUH NGWA, J., PURCELL, S., RAFELT, S., SALEM, R. 
M., SALVI, E., et al. 2010. Hundreds of variants clustered in genomic loci 
and biological pathways affect human height. Nature, 467, 832-8. 
LARUELLE, M. 2014. Schizophrenia: from dopaminergic to glutamatergic 
interventions. Curr Opin Pharmacol, 14, 97-102. 
LE HELLARD, S., LEE, A. J., UNDERWOOD, S., THOMSON, P. A., MORRIS, S. 
W., TORRANCE, H. S., ANDERSON, S. M., ADAMS, R. R., NAVARRO, 
P., CHRISTOFOROU, A., HOULIHAN, L. M., DETERA-WADLEIGH, S., 
OWEN, M. J., ASHERSON, P., MUIR, W. J., BLACKWOOD, D. H., 
WRAY, N. R., PORTEOUS, D. J. & EVANS, K. L. 2007. Haplotype 
analysis and a novel allele-sharing method refines a chromosome 4p locus 
linked to bipolar affective disorder. Biol Psychiatry, 61, 797-805. 
LEE, D., GORKIN, D. U., BAKER, M., STROBER, B. J., ASONI, A. L., 
MCCALLION, A. S. & BEER, M. A. 2015. A method to predict the impact 
of regulatory variants from DNA sequence. Nat Genet, 47, 955-61. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  262 
LEE, J. A. & LUPSKI, J. R. 2006. Genomic rearrangements and gene copy-number 
alterations as a cause of nervous system disorders. Neuron, 52, 103-21. 
LEE, M. T., CHEN, C. H., LEE, C. S., CHEN, C. C., CHONG, M. Y., OUYANG, 
W. C., CHIU, N. Y., CHUO, L. J., CHEN, C. Y., TAN, H. K., LANE, H. Y., 
CHANG, T. J., LIN, C. H., JOU, S. H., HOU, Y. M., FENG, J., LAI, T. J., 
TUNG, C. L., CHEN, T. J., CHANG, C. J., LUNG, F. W., CHEN, C. K., 
SHIAH, I. S., LIU, C. Y., TENG, P. R., CHEN, K. H., SHEN, L. J., CHENG, 
C. S., CHANG, T. P., LI, C. F., CHOU, C. H., CHEN, C. Y., WANG, K. H., 
FANN, C. S., WU, J. Y., CHEN, Y. T. & CHENG, A. T. 2011. Genome-wide 
association study of bipolar I disorder in the Han Chinese population. Mol 
Psychiatry, 16, 548-56. 
LEE, P. H. & SHATKAY, H. 2008. F-SNP: computationally predicted functional 
SNPs for disease association studies. Nucleic Acids Res, 36, D820-4. 
LEE, S. H., DECANDIA, T. R., RIPKE, S., YANG, J., SCHIZOPHRENIA 
PSYCHIATRIC GENOME-WIDE ASSOCIATION STUDY, C., 
INTERNATIONAL SCHIZOPHRENIA, C., MOLECULAR GENETICS OF 
SCHIZOPHRENIA, C., SULLIVAN, P. F., GODDARD, M. E., KELLER, 
M. C., VISSCHER, P. M. & WRAY, N. R. 2012. Estimating the proportion 
of variation in susceptibility to schizophrenia captured by common SNPs. Nat 
Genet, 44, 247-50. 
LEMIRE, M., ZAIDI, S. H., BAN, M., GE, B., AISSI, D., GERMAIN, M., 
KASSAM, I., WANG, M., ZANKE, B. W., GAGNON, F., MORANGE, P. 
E., TREGOUET, D. A., WELLS, P. S., SAWCER, S., GALLINGER, S., 
PASTINEN, T. & HUDSON, T. J. 2015. Long-range epigenetic regulation is 
conferred by genetic variation located at thousands of independent loci. Nat 
Commun, 6, 6326. 
LEVINSON, D. F., MOSTAFAVI, S., MILANESCHI, Y., RIVERA, M., RIPKE, S., 
WRAY, N. R. & SULLIVAN, P. F. 2014. Genetic studies of major 
depressive disorder: why are there no genome-wide association study 
findings and what can we do about it? Biol Psychiatry, 76, 510-2. 
LEVY, D., RONEMUS, M., YAMROM, B., LEE, Y. H., LEOTTA, A., KENDALL, 
J., MARKS, S., LAKSHMI, B., PAI, D., YE, K., BUJA, A., KRIEGER, A., 
YOON, S., TROGE, J., RODGERS, L., IOSSIFOV, I. & WIGLER, M. 2011. 
Rare de novo and transmitted copy-number variation in autistic spectrum 
disorders. Neuron, 70, 886-97. 
LEWIS, C. M., NG, M. Y., BUTLER, A. W., COHEN-WOODS, S., UHER, R., 
PIRLO, K., WEALE, M. E., SCHOSSER, A., PAREDES, U. M., RIVERA, 
M., CRADDOCK, N., OWEN, M. J., JONES, L., JONES, I., KORSZUN, A., 
AITCHISON, K. J., SHI, J., QUINN, J. P., MACKENZIE, A., 
VOLLENWEIDER, P., WAEBER, G., HEATH, S., LATHROP, M., 
MUGLIA, P., BARNES, M. R., WHITTAKER, J. C., TOZZI, F., 
HOLSBOER, F., PREISIG, M., FARMER, A. E., BREEN, G., CRAIG, I. W. 
& MCGUFFIN, P. 2010. Genome-wide association study of major recurrent 
depression in the U.K. population. Am J Psychiatry, 167, 949-57. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  263 
LI, H. & DURBIN, R. 2009. Fast and accurate short read alignment with Burrows-
Wheeler transform. Bioinformatics, 25, 1754-60. 
LI, M. J., WANG, L. Y., XIA, Z., SHAM, P. C. & WANG, J. 2013. GWAS3D: 
Detecting human regulatory variants by integrative analysis of genome-wide 
associations, chromosome interactions and histone modifications. Nucleic 
Acids Res, 41, W150-8. 
LI, M. J., YAN, B., SHAM, P. C. & WANG, J. 2015. Exploring the function of 
genetic variants in the non-coding genomic regions: approaches for 
identifying human regulatory variants affecting gene expression. Brief 
Bioinform, 16, 393-412. 
LI, M. X., GUI, H. S., KWAN, J. S., BAO, S. Y. & SHAM, P. C. 2012. A 
comprehensive framework for prioritizing variants in exome sequencing 
studies of Mendelian diseases. Nucleic Acids Res, 40, e53. 
LI, X. & MONTGOMERY, S. B. 2013. Detection and impact of rare regulatory 
variants in human disease. Front Genet, 4, 67. 
LIAO, S. & VON DER WEID, P. Y. 2015. Lymphatic system: an active pathway for 
immune protection. Semin Cell Dev Biol, 38, 83-9. 
LICHTENSTEIN, P., YIP, B. H., BJORK, C., PAWITAN, Y., CANNON, T. D., 
SULLIVAN, P. F. & HULTMAN, C. M. 2009. Common genetic 
determinants of schizophrenia and bipolar disorder in Swedish families: a 
population-based study. Lancet, 373, 234-9. 
LIPPERT, C., LISTGARTEN, J., DAVIDSON, R. I., BAXTER, S., POON, H., 
KADIE, C. M. & HECKERMAN, D. 2013. An exhaustive epistatic SNP 
association analysis on expanded Wellcome Trust data. Sci Rep, 3, 1099. 
LIU, D. & ALBERT, P. S. 2014. Combination of longitudinal biomarkers in 
predicting binary events. Biostatistics, 15, 706-18. 
LIU, L., SABO, A., NEALE, B. M., NAGASWAMY, U., STEVENS, C., LIM, E., 
BODEA, C. A., MUZNY, D., REID, J. G., BANKS, E., COON, H., 
DEPRISTO, M., DINH, H., FENNEL, T., FLANNICK, J., GABRIEL, S., 
GARIMELLA, K., GROSS, S., HAWES, A., LEWIS, L., MAKAROV, V., 
MAGUIRE, J., NEWSHAM, I., POPLIN, R., RIPKE, S., SHAKIR, K., 
SAMOCHA, K. E., WU, Y., BOERWINKLE, E., BUXBAUM, J. D., COOK, 
E. H., JR., DEVLIN, B., SCHELLENBERG, G. D., SUTCLIFFE, J. S., 
DALY, M. J., GIBBS, R. A. & ROEDER, K. 2013. Analysis of rare, exonic 
variation amongst subjects with autism spectrum disorders and population 
controls. PLoS Genet, 9, e1003443. 
LIU, Y., XU, H., CHEN, S., CHEN, X., ZHANG, Z., ZHU, Z., QIN, X., HU, L., 
ZHU, J., ZHAO, G. P. & KONG, X. 2011. Genome-wide interaction-based 
association analysis identified multiple new susceptibility Loci for common 
diseases. PLoS Genet, 7, e1001338. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  264 
LODGE, D. J. & GRACE, A. A. 2011. Hippocampal dysregulation of dopamine 
system function and the pathophysiology of schizophrenia. Trends 
Pharmacol Sci, 32, 507-13. 
MA, M., RU, Y., CHUANG, L. S., HSU, N. Y., SHI, L. S., HAKENBERG, J., 
CHENG, W. Y., UZILOV, A., DING, W., GLICKSBERG, B. S. & CHEN, 
R. 2015. Disease-associated variants in different categories of disease located 
in distinct regulatory elements. BMC Genomics, 16 Suppl 8, S3. 
MACARTHUR, D. G., MANOLIO, T. A., DIMMOCK, D. P., REHM, H. L., 
SHENDURE, J., ABECASIS, G. R., ADAMS, D. R., ALTMAN, R. B., 
ANTONARAKIS, S. E., ASHLEY, E. A., BARRETT, J. C., BIESECKER, 
L. G., CONRAD, D. F., COOPER, G. M., COX, N. J., DALY, M. J., 
GERSTEIN, M. B., GOLDSTEIN, D. B., HIRSCHHORN, J. N., LEAL, S. 
M., PENNACCHIO, L. A., STAMATOYANNOPOULOS, J. A., 
SUNYAEV, S. R., VALLE, D., VOIGHT, B. F., WINCKLER, W. & 
GUNTER, C. 2014. Guidelines for investigating causality of sequence 
variants in human disease. Nature, 508, 469-76. 
MACISAAC, K. D., LO, K. A., GORDON, W., MOTOLA, S., MAZOR, T. & 
FRAENKEL, E. 2010. A quantitative model of transcriptional regulation 
reveals the influence of binding location on expression. PLoS Comput Biol, 6, 
e1000773. 
MADRIGAL, P. & KRAJEWSKI, P. 2012. Current bioinformatic approaches to 
identify DNase I hypersensitive sites and genomic footprints from DNase-seq 
data. Front Genet, 3, 230. 
MAES, M., KUBERA, M. & LEUNIS, J. C. 2008. The gut-brain barrier in major 
depression: intestinal mucosal dysfunction with an increased translocation of 
LPS from gram negative enterobacteria (leaky gut) plays a role in the 
inflammatory pathophysiology of depression. Neuro Endocrinol Lett, 29, 
117-24. 
MAIER, R., MOSER, G., CHEN, G. B., RIPKE, S., CROSS-DISORDER 
WORKING GROUP OF THE PSYCHIATRIC GENOMICS, C., 
CORYELL, W., POTASH, J. B., SCHEFTNER, W. A., SHI, J., 
WEISSMAN, M. M., HULTMAN, C. M., LANDEN, M., LEVINSON, D. F., 
KENDLER, K. S., SMOLLER, J. W., WRAY, N. R. & LEE, S. H. 2015. 
Joint analysis of psychiatric disorders increases accuracy of risk prediction 
for schizophrenia, bipolar disorder, and major depressive disorder. Am J Hum 
Genet, 96, 283-94. 
MAJOR DEPRESSIVE DISORDER WORKING GROUP OF THE 
PSYCHIATRIC, G. C., RIPKE, S., WRAY, N. R., LEWIS, C. M., 
HAMILTON, S. P., WEISSMAN, M. M., BREEN, G., BYRNE, E. M., 
BLACKWOOD, D. H., BOOMSMA, D. I., CICHON, S., HEATH, A. C., 
HOLSBOER, F., LUCAE, S., MADDEN, P. A., MARTIN, N. G., 
MCGUFFIN, P., MUGLIA, P., NOETHEN, M. M., PENNINX, B. P., 
PERGADIA, M. L., POTASH, J. B., RIETSCHEL, M., LIN, D., MULLER-
MYHSOK, B., SHI, J., STEINBERG, S., GRABE, H. J., LICHTENSTEIN, 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  265 
P., MAGNUSSON, P., PERLIS, R. H., PREISIG, M., SMOLLER, J. W., 
STEFANSSON, K., UHER, R., KUTALIK, Z., TANSEY, K. E., TEUMER, 
A., VIKTORIN, A., BARNES, M. R., BETTECKEN, T., BINDER, E. B., 
BREUER, R., CASTRO, V. M., CHURCHILL, S. E., CORYELL, W. H., 
CRADDOCK, N., CRAIG, I. W., CZAMARA, D., DE GEUS, E. J., 
DEGENHARDT, F., FARMER, A. E., FAVA, M., FRANK, J., GAINER, V. 
S., GALLAGHER, P. J., GORDON, S. D., GORYACHEV, S., GROSS, M., 
GUIPPONI, M., HENDERS, A. K., HERMS, S., HICKIE, I. B., HOEFELS, 
S., HOOGENDIJK, W., HOTTENGA, J. J., IOSIFESCU, D. V., ISING, M., 
JONES, I., JONES, L., JUNG-YING, T., KNOWLES, J. A., KOHANE, I. S., 
KOHLI, M. A., KORSZUN, A., LANDEN, M., LAWSON, W. B., LEWIS, 
G., MACINTYRE, D., MAIER, W., MATTHEISEN, M., MCGRATH, P. J., 
MCINTOSH, A., MCLEAN, A., MIDDELDORP, C. M., MIDDLETON, L., 
MONTGOMERY, G. M., MURPHY, S. N., NAUCK, M., NOLEN, W. A., 
NYHOLT, D. R., O'DONOVAN, M., OSKARSSON, H., PEDERSEN, N., 
SCHEFTNER, W. A., SCHULZ, A., SCHULZE, T. G., SHYN, S. I., 
SIGURDSSON, E., SLAGER, S. L., et al. 2013. A mega-analysis of genome-
wide association studies for major depressive disorder. Mol Psychiatry, 18, 
497-511. 
MAKAROV, V., O'GRADY, T., CAI, G., LIHM, J., BUXBAUM, J. D. & YOON, 
S. 2012. AnnTools: a comprehensive and versatile annotation toolkit for 
genomic variants. Bioinformatics, 28, 724-5. 
MALHOTRA, D., MCCARTHY, S., MICHAELSON, J. J., VACIC, V., BURDICK, 
K. E., YOON, S., CICHON, S., CORVIN, A., GARY, S., GERSHON, E. S., 
GILL, M., KARAYIORGOU, M., KELSOE, J. R., KRASTOSHEVSKY, O., 
KRAUSE, V., LEIBENLUFT, E., LEVY, D. L., MAKAROV, V., 
BHANDARI, A., MALHOTRA, A. K., MCMAHON, F. J., NOTHEN, M. 
M., POTASH, J. B., RIETSCHEL, M., SCHULZE, T. G. & SEBAT, J. 2011. 
High frequencies of de novo CNVs in bipolar disorder and schizophrenia. 
Neuron, 72, 951-63. 
MANOLIO, T. A., COLLINS, F. S., COX, N. J., GOLDSTEIN, D. B., HINDORFF, 
L. A., HUNTER, D. J., MCCARTHY, M. I., RAMOS, E. M., CARDON, L. 
R., CHAKRAVARTI, A., CHO, J. H., GUTTMACHER, A. E., KONG, A., 
KRUGLYAK, L., MARDIS, E., ROTIMI, C. N., SLATKIN, M., VALLE, 
D., WHITTEMORE, A. S., BOEHNKE, M., CLARK, A. G., EICHLER, E. 
E., GIBSON, G., HAINES, J. L., MACKAY, T. F., MCCARROLL, S. A. & 
VISSCHER, P. M. 2009. Finding the missing heritability of complex 
diseases. Nature, 461, 747-53. 
MARSHALL, C. R., NOOR, A., VINCENT, J. B., LIONEL, A. C., FEUK, L., 
SKAUG, J., SHAGO, M., MOESSNER, R., PINTO, D., REN, Y., 
THIRUVAHINDRAPDURAM, B., FIEBIG, A., SCHREIBER, S., 
FRIEDMAN, J., KETELAARS, C. E., VOS, Y. J., FICICIOGLU, C., 
KIRKPATRICK, S., NICOLSON, R., SLOMAN, L., SUMMERS, A., 
GIBBONS, C. A., TEEBI, A., CHITAYAT, D., WEKSBERG, R., 
THOMPSON, A., VARDY, C., CROSBIE, V., LUSCOMBE, S., BAATJES, 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  266 
R., ZWAIGENBAUM, L., ROBERTS, W., FERNANDEZ, B., SZATMARI, 
P. & SCHERER, S. W. 2008. Structural variation of chromosomes in autism 
spectrum disorder. Am J Hum Genet, 82, 477-88. 
MAURANO, M. T., HUMBERT, R., RYNES, E., THURMAN, R. E., HAUGEN, 
E., WANG, H., REYNOLDS, A. P., SANDSTROM, R., QU, H., BRODY, J., 
SHAFER, A., NERI, F., LEE, K., KUTYAVIN, T., STEHLING-SUN, S., 
JOHNSON, A. K., CANFIELD, T. K., GISTE, E., DIEGEL, M., BATES, D., 
HANSEN, R. S., NEPH, S., SABO, P. J., HEIMFELD, S., RAUBITSCHEK, 
A., ZIEGLER, S., COTSAPAS, C., SOTOODEHNIA, N., GLASS, I., 
SUNYAEV, S. R., KAUL, R. & STAMATOYANNOPOULOS, J. A. 2012. 
Systematic localization of common disease-associated variation in regulatory 
DNA. Science, 337, 1190-5. 
MCCARTHY, M. I., ABECASIS, G. R., CARDON, L. R., GOLDSTEIN, D. B., 
LITTLE, J., IOANNIDIS, J. P. & HIRSCHHORN, J. N. 2008. Genome-wide 
association studies for complex traits: consensus, uncertainty and challenges. 
Nat Rev Genet, 9, 356-69. 
MCCLELLAN, J. & KING, M. C. 2010a. Genetic heterogeneity in human disease. 
Cell, 141, 210-7. 
MCCLELLAN, J. & KING, M. C. 2010b. Genomic analysis of mental illness: a 
changing landscape. JAMA, 303, 2523-4. 
MCCLELLAN, J. M., SUSSER, E. & KING, M. C. 2007. Schizophrenia: a common 
disease caused by multiple rare alleles. Br J Psychiatry, 190, 194-9. 
MCKENNA, A., HANNA, M., BANKS, E., SIVACHENKO, A., CIBULSKIS, K., 
KERNYTSKY, A., GARIMELLA, K., ALTSHULER, D., GABRIEL, S., 
DALY, M. & DEPRISTO, M. A. 2010. The Genome Analysis Toolkit: a 
MapReduce framework for analyzing next-generation DNA sequencing data. 
Genome Res, 20, 1297-303. 
MCKEOWN, L., SWANTON, L., ROBINSON, P. & JONES, O. T. 2008. Surface 
expression and distribution of voltage-gated potassium channels in neurons 
(Review). Mol Membr Biol, 25, 332-43. 
MCLAREN, W., PRITCHARD, B., RIOS, D., CHEN, Y., FLICEK, P. & 
CUNNINGHAM, F. 2010. Deriving the consequences of genomic variants 
with the Ensembl API and SNP Effect Predictor. Bioinformatics, 26, 2069-
70. 
MEADER, S., PONTING, C. P. & LUNTER, G. 2010. Massive turnover of 
functional sequence in human and other mammalian genomes. Genome Res, 
20, 1335-43. 
MERELLI, I., CALABRIA, A., COZZI, P., VITI, F., MOSCA, E. & MILANESI, L. 
2013. SNPranker 2.0: a gene-centric data mining tool for diseases associated 
SNP prioritization in GWAS. BMC Bioinformatics, 14 Suppl 1, S9. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  267 
MEYNERT, A. M., ANSARI, M., FITZPATRICK, D. R. & TAYLOR, M. S. 2014. 
Variant detection sensitivity and biases in whole genome and exome 
sequencing. BMC Bioinformatics, 15, 247. 
MILLAR, J. K., CHRISTIE, S., ANDERSON, S., LAWSON, D., HSIAO-WEI 
LOH, D., DEVON, R. S., ARVEILER, B., MUIR, W. J., BLACKWOOD, D. 
H. & PORTEOUS, D. J. 2001. Genomic structure and localisation within a 
linkage hotspot of Disrupted In Schizophrenia 1, a gene disrupted by a 
translocation segregating with schizophrenia. Mol Psychiatry, 6, 173-8. 
MILLAR, J. K., CHRISTIE, S. & PORTEOUS, D. J. 2003. Yeast two-hybrid screens 
implicate DISC1 in brain development and function. Biochem Biophys Res 
Commun, 311, 1019-25. 
MILLAR, J. K., WILSON-ANNAN, J. C., ANDERSON, S., CHRISTIE, S., 
TAYLOR, M. S., SEMPLE, C. A., DEVON, R. S., ST CLAIR, D. M., 
MUIR, W. J., BLACKWOOD, D. H. & PORTEOUS, D. J. 2000. Disruption 
of two novel genes by a translocation co-segregating with schizophrenia. 
Hum Mol Genet, 9, 1415-23. 
MILLER, A. H. 2010. Depression and immunity: a role for T cells? Brain Behav 
Immun, 24, 1-8. 
MIYATA, Y., FUKUHARA, A., OTSUKI, M. & SHIMOMURA, I. 2013. 
Expression of activating transcription factor 2 in inflammatory macrophages 
in obese adipose tissue. Obesity (Silver Spring), 21, 731-6. 
MONTEN, C., GUDJONSDOTTIR, A. H., BROWALDH, L., ARNELL, H., 
NILSSON, S., AGARDH, D. & NALUAI, A. T. 2015. Genes involved in 
muscle contractility and nutrient signaling pathways within celiac disease risk 
loci show differential mRNA expression. BMC Med Genet, 16, 44. 
MORELLE, J. & DEVUYST, O. 2015. Water and solute transport across the 
peritoneal membrane. Curr Opin Nephrol Hypertens, 24, 434-43. 
MORTIMER, S. A., KIDWELL, M. A. & DOUDNA, J. A. 2014. Insights into RNA 
structure and function from genome-wide studies. Nat Rev Genet, 15, 469-79. 
MUGLIA, P., TOZZI, F., GALWEY, N. W., FRANCKS, C., UPMANYU, R., 
KONG, X. Q., ANTONIADES, A., DOMENICI, E., PERRY, J., ROTHEN, 
S., VANDELEUR, C. L., MOOSER, V., WAEBER, G., VOLLENWEIDER, 
P., PREISIG, M., LUCAE, S., MULLER-MYHSOK, B., HOLSBOER, F., 
MIDDLETON, L. T. & ROSES, A. D. 2010. Genome-wide association study 
of recurrent major depressive disorder in two European case-control cohorts. 
Mol Psychiatry, 15, 589-601. 
MUHLEISEN, T. W., LEBER, M., SCHULZE, T. G., STROHMAIER, J., 
DEGENHARDT, F., TREUTLEIN, J., MATTHEISEN, M., FORSTNER, A. 
J., SCHUMACHER, J., BREUER, R., MEIER, S., HERMS, S., 
HOFFMANN, P., LACOUR, A., WITT, S. H., REIF, A., MULLER-
MYHSOK, B., LUCAE, S., MAIER, W., SCHWARZ, M., VEDDER, H., 
KAMMERER-CIERNIOCH, J., PFENNIG, A., BAUER, M., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  268 
HAUTZINGER, M., MOEBUS, S., PRIEBE, L., CZERSKI, P. M., 
HAUSER, J., LISSOWSKA, J., SZESZENIA-DABROWSKA, N., 
BRENNAN, P., MCKAY, J. D., WRIGHT, A., MITCHELL, P. B., 
FULLERTON, J. M., SCHOFIELD, P. R., MONTGOMERY, G. W., 
MEDLAND, S. E., GORDON, S. D., MARTIN, N. G., KRASNOW, V., 
CHUCHALIN, A., BABADJANOVA, G., PANTELEJEVA, G., 
ABRAMOVA, L. I., TIGANOV, A. S., POLONIKOV, A., 
KHUSNUTDINOVA, E., ALDA, M., GROF, P., ROULEAU, G. A., 
TURECKI, G., LAPRISE, C., RIVAS, F., MAYORAL, F., KOGEVINAS, 
M., GRIGOROIU-SERBANESCU, M., PROPPING, P., BECKER, T., 
RIETSCHEL, M., NOTHEN, M. M. & CICHON, S. 2014. Genome-wide 
association study reveals two new risk loci for bipolar disorder. Nat Commun, 
5, 3339. 
MULLANEY, J. M., MILLS, R. E., PITTARD, W. S. & DEVINE, S. E. 2010. Small 
insertions and deletions (INDELs) in human genomes. Hum Mol Genet, 19, 
R131-6. 
MURRAY, C. J. & LOPEZ, A. D. 1996. Evidence-based health policy--lessons from 
the Global Burden of Disease Study. Science, 274, 740-3. 
MUSUNURU, K., STRONG, A., FRANK-KAMENETSKY, M., LEE, N. E., 
AHFELDT, T., SACHS, K. V., LI, X., LI, H., KUPERWASSER, N., RUDA, 
V. M., PIRRUCCELLO, J. P., MUCHMORE, B., PROKUNINA-OLSSON, 
L., HALL, J. L., SCHADT, E. E., MORALES, C. R., LUND-KATZ, S., 
PHILLIPS, M. C., WONG, J., CANTLEY, W., RACIE, T., EJEBE, K. G., 
ORHO-MELANDER, M., MELANDER, O., KOTELIANSKY, V., 
FITZGERALD, K., KRAUSS, R. M., COWAN, C. A., KATHIRESAN, S. & 
RADER, D. J. 2010. From noncoding variant to phenotype via SORT1 at the 
1p13 cholesterol locus. Nature, 466, 714-9. 
MYOUZEN, K., KOCHI, Y., SHIMANE, K., FUJIO, K., OKAMURA, T., OKADA, 
Y., SUZUKI, A., ATSUMI, T., ITO, S., TAKADA, K., MIMORI, A., 
IKEGAWA, S., YAMADA, R., NAKAMURA, Y. & YAMAMOTO, K. 
2010. Regulatory polymorphisms in EGR2 are associated with susceptibility 
to systemic lupus erythematosus. Hum Mol Genet, 19, 2313-20. 
NAGELHUS, E. A., MATHIISEN, T. M. & OTTERSEN, O. P. 2004. Aquaporin-4 
in the central nervous system: cellular and subcellular distribution and 
coexpression with KIR4.1. Neuroscience, 129, 905-13. 
NAJ, A. C., JUN, G., BEECHAM, G. W., WANG, L. S., VARDARAJAN, B. N., 
BUROS, J., GALLINS, P. J., BUXBAUM, J. D., JARVIK, G. P., CRANE, P. 
K., LARSON, E. B., BIRD, T. D., BOEVE, B. F., GRAFF-RADFORD, N. 
R., DE JAGER, P. L., EVANS, D., SCHNEIDER, J. A., CARRASQUILLO, 
M. M., ERTEKIN-TANER, N., YOUNKIN, S. G., CRUCHAGA, C., 
KAUWE, J. S., NOWOTNY, P., KRAMER, P., HARDY, J., 
HUENTELMAN, M. J., MYERS, A. J., BARMADA, M. M., DEMIRCI, F. 
Y., BALDWIN, C. T., GREEN, R. C., ROGAEVA, E., ST GEORGE-
HYSLOP, P., ARNOLD, S. E., BARBER, R., BEACH, T., BIGIO, E. H., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  269 
BOWEN, J. D., BOXER, A., BURKE, J. R., CAIRNS, N. J., CARLSON, C. 
S., CARNEY, R. M., CARROLL, S. L., CHUI, H. C., CLARK, D. G., 
CORNEVEAUX, J., COTMAN, C. W., CUMMINGS, J. L., DECARLI, C., 
DEKOSKY, S. T., DIAZ-ARRASTIA, R., DICK, M., DICKSON, D. W., 
ELLIS, W. G., FABER, K. M., FALLON, K. B., FARLOW, M. R., FERRIS, 
S., FROSCH, M. P., GALASKO, D. R., GANGULI, M., GEARING, M., 
GESCHWIND, D. H., GHETTI, B., GILBERT, J. R., GILMAN, S., 
GIORDANI, B., GLASS, J. D., GROWDON, J. H., HAMILTON, R. L., 
HARRELL, L. E., HEAD, E., HONIG, L. S., HULETTE, C. M., HYMAN, 
B. T., JICHA, G. A., JIN, L. W., JOHNSON, N., KARLAWISH, J., 
KARYDAS, A., KAYE, J. A., KIM, R., KOO, E. H., KOWALL, N. W., 
LAH, J. J., LEVEY, A. I., LIEBERMAN, A. P., LOPEZ, O. L., MACK, W. 
J., MARSON, D. C., MARTINIUK, F., MASH, D. C., MASLIAH, E., 
MCCORMICK, W. C., MCCURRY, S. M., MCDAVID, A. N., MCKEE, A. 
C., MESULAM, M., MILLER, B. L., et al. 2011. Common variants at 
MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset 
Alzheimer's disease. Nat Genet, 43, 436-41. 
NEED, A. C., MCEVOY, J. P., GENNARELLI, M., HEINZEN, E. L., GE, D., 
MAIA, J. M., SHIANNA, K. V., HE, M., CIRULLI, E. T., GUMBS, C. E., 
ZHAO, Q., CAMPBELL, C. R., HONG, L., ROSENQUIST, P., 
PUTKONEN, A., HALLIKAINEN, T., REPO-TIIHONEN, E., TIIHONEN, 
J., LEVY, D. L., MELTZER, H. Y. & GOLDSTEIN, D. B. 2012. Exome 
sequencing followed by large-scale genotyping suggests a limited role for 
moderately rare risk factors of strong effect in schizophrenia. Am J Hum 
Genet, 91, 303-12. 
NEPH, S., VIERSTRA, J., STERGACHIS, A. B., REYNOLDS, A. P., HAUGEN, 
E., VERNOT, B., THURMAN, R. E., JOHN, S., SANDSTROM, R., 
JOHNSON, A. K., MAURANO, M. T., HUMBERT, R., RYNES, E., 
WANG, H., VONG, S., LEE, K., BATES, D., DIEGEL, M., ROACH, V., 
DUNN, D., NERI, J., SCHAFER, A., HANSEN, R. S., KUTYAVIN, T., 
GISTE, E., WEAVER, M., CANFIELD, T., SABO, P., ZHANG, M., 
BALASUNDARAM, G., BYRON, R., MACCOSS, M. J., AKEY, J. M., 
BENDER, M. A., GROUDINE, M., KAUL, R. & 
STAMATOYANNOPOULOS, J. A. 2012. An expansive human regulatory 
lexicon encoded in transcription factor footprints. Nature, 489, 83-90. 
NETWORK & PATHWAY ANALYSIS SUBGROUP OF PSYCHIATRIC 
GENOMICS, C. 2015. Psychiatric genome-wide association study analyses 
implicate neuronal, immune and histone pathways. Nat Neurosci, 18, 199-
209. 
NG, P. C. & HENIKOFF, S. 2001. Predicting deleterious amino acid substitutions. 
Genome Res, 11, 863-74. 
NICA, A. C., PARTS, L., GLASS, D., NISBET, J., BARRETT, A., SEKOWSKA, 
M., TRAVERS, M., POTTER, S., GRUNDBERG, E., SMALL, K., 
HEDMAN, A. K., BATAILLE, V., TZENOVA BELL, J., SURDULESCU, 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  270 
G., DIMAS, A. S., INGLE, C., NESTLE, F. O., DI MEGLIO, P., MIN, J. L., 
WILK, A., HAMMOND, C. J., HASSANALI, N., YANG, T. P., 
MONTGOMERY, S. B., O'RAHILLY, S., LINDGREN, C. M., 
ZONDERVAN, K. T., SORANZO, N., BARROSO, I., DURBIN, R., 
AHMADI, K., DELOUKAS, P., MCCARTHY, M. I., DERMITZAKIS, E. 
T., SPECTOR, T. D. & MU, T. C. 2011. The architecture of gene regulatory 
variation across multiple human tissues: the MuTHER study. PLoS Genet, 7, 
e1002003. 
NICOLAE, D. L., GAMAZON, E., ZHANG, W., DUAN, S., DOLAN, M. E. & 
COX, N. J. 2010. Trait-associated SNPs are more likely to be eQTLs: 
annotation to enhance discovery from GWAS. PLoS Genet, 6, e1000888. 
NIELSEN, R., PAUL, J. S., ALBRECHTSEN, A. & SONG, Y. S. 2011. Genotype 
and SNP calling from next-generation sequencing data. Nat Rev Genet, 12, 
443-51. 
NOTHEN, M. M., NIERATSCHKER, V., CICHON, S. & RIETSCHEL, M. 2010. 
New findings in the genetics of major psychoses. Dialogues Clin Neurosci, 
12, 85-93. 
NOVAK, G., SEEMAN, P. & TALLERICO, T. 2006. Increased expression of 
calcium/calmodulin-dependent protein kinase IIbeta in frontal cortex in 
schizophrenia and depression. Synapse, 59, 61-8. 
NURNBERGER, J. I., JR., KOLLER, D. L., JUNG, J., EDENBERG, H. J., 
FOROUD, T., GUELLA, I., VAWTER, M. P., KELSOE, J. R. & 
PSYCHIATRIC GENOMICS CONSORTIUM BIPOLAR, G. 2014. 
Identification of pathways for bipolar disorder: a meta-analysis. JAMA 
Psychiatry, 71, 657-64. 
O'LEARY, O. F., FELICE, D., GALIMBERTI, S., SAVIGNAC, H. M., BRAVO, J. 
A., CROWLEY, T., EL YACOUBI, M., VAUGEOIS, J. M., GASSMANN, 
M., BETTLER, B., DINAN, T. G. & CRYAN, J. F. 2014. GABAB(1) 
receptor subunit isoforms differentially regulate stress resilience. Proc Natl 
Acad Sci U S A, 111, 15232-7. 
OLLILA, H. M., SORONEN, P., SILANDER, K., PALO, O. M., KIESEPPA, T., 
KAUNISTO, M. A., LONNQVIST, J., PELTONEN, L., PARTONEN, T. & 
PAUNIO, T. 2009. Findings from bipolar disorder genome-wide association 
studies replicate in a Finnish bipolar family-cohort. Mol Psychiatry, 14, 351-
3. 
OTT, J., WANG, J. & LEAL, S. M. 2015. Genetic linkage analysis in the age of 
whole-genome sequencing. Nat Rev Genet, 16, 275-84. 
PELOSI, A. J., SYKES, R. A., LOUGH, J. R., MUIR, W. J. & DUNNIGAN, M. G. 
1986. A psychiatric study of idiopathic oedema. Lancet, 2, 999-1002. 
PENNACCHIO, L. A. & RUBIN, E. M. 2001. Genomic strategies to identify 
mammalian regulatory sequences. Nat Rev Genet, 2, 100-9. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  271 
PEREZ-PALMA, E., BUSTOS, B. I., VILLAMAN, C. F., ALARCON, M. A., 
AVILA, M. E., UGARTE, G. D., REYES, A. E., OPAZO, C., DE FERRARI, 
G. V., ALZHEIMER'S DISEASE NEUROIMAGING, I. & GROUP, N.-L. 
N. F. S. 2014. Overrepresentation of glutamate signaling in Alzheimer's 
disease: network-based pathway enrichment using meta-analysis of genome-
wide association studies. PLoS One, 9, e95413. 
PETROVSKI, S., WANG, Q., HEINZEN, E. L., ALLEN, A. S. & GOLDSTEIN, D. 
B. 2013. Genic intolerance to functional variation and the interpretation of 
personal genomes. PLoS Genet, 9, e1003709. 
PHILLIPS, P. C. 2008. Epistasis--the essential role of gene interactions in the 
structure and evolution of genetic systems. Nat Rev Genet, 9, 855-67. 
POLLARD, K. S., HUBISZ, M. J., ROSENBLOOM, K. R. & SIEPEL, A. 2010. 
Detection of nonneutral substitution rates on mammalian phylogenies. 
Genome Res, 20, 110-21. 
POMERANTZ, M. M., AHMADIYEH, N., JIA, L., HERMAN, P., VERZI, M. P., 
DODDAPANENI, H., BECKWITH, C. A., CHAN, J. A., HILLS, A., 
DAVIS, M., YAO, K., KEHOE, S. M., LENZ, H. J., HAIMAN, C. A., YAN, 
C., HENDERSON, B. E., FRENKEL, B., BARRETINA, J., BASS, A., 
TABERNERO, J., BASELGA, J., REGAN, M. M., MANAK, J. R., 
SHIVDASANI, R., COETZEE, G. A. & FREEDMAN, M. L. 2009. The 8q24 
cancer risk variant rs6983267 shows long-range interaction with MYC in 
colorectal cancer. Nat Genet, 41, 882-4. 
PRABHU, S. & PE'ER, I. 2012. Ultrafast genome-wide scan for SNP-SNP 
interactions in common complex disease. Genome Res, 22, 2230-40. 
PSYCHIATRIC, G. C. B. D. W. G. 2011. Large-scale genome-wide association 
analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. 
Nat Genet, 43, 977-83. 
PURCELL, S. M., MORAN, J. L., FROMER, M., RUDERFER, D., SOLOVIEFF, 
N., ROUSSOS, P., O'DUSHLAINE, C., CHAMBERT, K., BERGEN, S. E., 
KAHLER, A., DUNCAN, L., STAHL, E., GENOVESE, G., FERNANDEZ, 
E., COLLINS, M. O., KOMIYAMA, N. H., CHOUDHARY, J. S., 
MAGNUSSON, P. K., BANKS, E., SHAKIR, K., GARIMELLA, K., 
FENNELL, T., DEPRISTO, M., GRANT, S. G., HAGGARTY, S. J., 
GABRIEL, S., SCOLNICK, E. M., LANDER, E. S., HULTMAN, C. M., 
SULLIVAN, P. F., MCCARROLL, S. A. & SKLAR, P. 2014. A polygenic 
burden of rare disruptive mutations in schizophrenia. Nature, 506, 185-90. 
QU, H. & FANG, X. 2013. A brief review on the Human Encyclopedia of DNA 
Elements (ENCODE) project. Genomics Proteomics Bioinformatics, 11, 135-
41. 
REHMAN, A. U., SANTOS-CORTEZ, R. L., DRUMMOND, M. C., SHAHZAD, 
M., LEE, K., MORELL, R. J., ANSAR, M., JAN, A., WANG, X., AZIZ, A., 
RIAZUDDIN, S., SMITH, J. D., WANG, G. T., AHMED, Z. M., GUL, K., 
SHEARER, A. E., SMITH, R. J., SHENDURE, J., BAMSHAD, M. J., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  272 
NICKERSON, D. A., UNIVERSITY OF WASHINGTON CENTER FOR 
MENDELIAN, G., HINNANT, J., KHAN, S. N., FISHER, R. A., AHMAD, 
W., FRIDERICI, K. H., RIAZUDDIN, S., FRIEDMAN, T. B., WILCH, E. S. 
& LEAL, S. M. 2015. Challenges and solutions for gene identification in the 
presence of familial locus heterogeneity. Eur J Hum Genet, 23, 1207-15. 
REITZ, C., TOSTO, G., VARDARAJAN, B., ROGAEVA, E., GHANI, M., 
ROGERS, R. S., CONRAD, C., HAINES, J. L., PERICAK-VANCE, M. A., 
FALLIN, M. D., FOROUD, T., FARRER, L. A., SCHELLENBERG, G. D., 
GEORGE-HYSLOP, P. S., MAYEUX, R. & ALZHEIMER'S DISEASE 
GENETICS, C. 2013. Independent and epistatic effects of variants in VPS10-
d receptors on Alzheimer disease risk and processing of the amyloid 
precursor protein (APP). Transl Psychiatry, 3, e256. 
REPLICATION, D. I. G., META-ANALYSIS, C., ASIAN GENETIC 
EPIDEMIOLOGY NETWORK TYPE 2 DIABETES, C., SOUTH ASIAN 
TYPE 2 DIABETES, C., MEXICAN AMERICAN TYPE 2 DIABETES, C., 
TYPE 2 DIABETES GENETIC EXPLORATION BY NEX-GENERATION 
SEQUENCING IN MUYLTI-ETHNIC SAMPLES, C., MAHAJAN, A., GO, 
M. J., ZHANG, W., BELOW, J. E., GAULTON, K. J., FERREIRA, T., 
HORIKOSHI, M., JOHNSON, A. D., NG, M. C., PROKOPENKO, I., 
SALEHEEN, D., WANG, X., ZEGGINI, E., ABECASIS, G. R., ADAIR, L. 
S., ALMGREN, P., ATALAY, M., AUNG, T., BALDASSARRE, D., 
BALKAU, B., BAO, Y., BARNETT, A. H., BARROSO, I., BASIT, A., 
BEEN, L. F., BEILBY, J., BELL, G. I., BENEDIKTSSON, R., BERGMAN, 
R. N., BOEHM, B. O., BOERWINKLE, E., BONNYCASTLE, L. L., 
BURTT, N., CAI, Q., CAMPBELL, H., CAREY, J., CAUCHI, S., 
CAULFIELD, M., CHAN, J. C., CHANG, L. C., CHANG, T. J., CHANG, 
Y. C., CHARPENTIER, G., CHEN, C. H., CHEN, H., CHEN, Y. T., CHIA, 
K. S., CHIDAMBARAM, M., CHINES, P. S., CHO, N. H., CHO, Y. M., 
CHUANG, L. M., COLLINS, F. S., CORNELIS, M. C., COUPER, D. J., 
CRENSHAW, A. T., VAN DAM, R. M., DANESH, J., DAS, D., DE FAIRE, 
U., DEDOUSSIS, G., DELOUKAS, P., DIMAS, A. S., DINA, C., DONEY, 
A. S., DONNELLY, P. J., DORKHAN, M., VAN DUIJN, C., DUPUIS, J., 
EDKINS, S., ELLIOTT, P., EMILSSON, V., ERBEL, R., ERIKSSON, J. G., 
ESCOBEDO, J., ESKO, T., EURY, E., FLOREZ, J. C., FONTANILLAS, P., 
FOROUHI, N. G., FORSEN, T., FOX, C., FRASER, R. M., FRAYLING, T. 
M., FROGUEL, P., FROSSARD, P., GAO, Y., GERTOW, K., GIEGER, C., 
GIGANTE, B., GRALLERT, H., GRANT, G. B., GRROP, L. C., GROVES, 
C. J., et al. 2014. Genome-wide trans-ancestry meta-analysis provides insight 
into the genetic architecture of type 2 diabetes susceptibility. Nat Genet, 46, 
234-44. 
RHINN, H., FUJITA, R., QIANG, L., CHENG, R., LEE, J. H. & ABELIOVICH, A. 
2013. Integrative genomics identifies APOE epsilon4 effectors in Alzheimer's 
disease. Nature, 500, 45-50. 
RICHARDS, A. L., JONES, L., MOSKVINA, V., KIROV, G., GEJMAN, P. V., 
LEVINSON, D. F., SANDERS, A. R., MOLECULAR GENETICS OF 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  273 
SCHIZOPHRENIA, C., INTERNATIONAL SCHIZOPHRENIA, C., 
PURCELL, S., VISSCHER, P. M., CRADDOCK, N., OWEN, M. J., 
HOLMANS, P. & O'DONOVAN, M. C. 2012. Schizophrenia susceptibility 
alleles are enriched for alleles that affect gene expression in adult human 
brain. Mol Psychiatry, 17, 193-201. 
RIETSCHEL, M., MATTHEISEN, M., FRANK, J., TREUTLEIN, J., 
DEGENHARDT, F., BREUER, R., STEFFENS, M., MIER, D., 
ESSLINGER, C., WALTER, H., KIRSCH, P., ERK, S., SCHNELL, K., 
HERMS, S., WICHMANN, H. E., SCHREIBER, S., JOCKEL, K. H., 
STROHMAIER, J., ROESKE, D., HAENISCH, B., GROSS, M., HOEFELS, 
S., LUCAE, S., BINDER, E. B., WIENKER, T. F., SCHULZE, T. G., 
SCHMAL, C., ZIMMER, A., JURAEVA, D., BRORS, B., BETTECKEN, T., 
MEYER-LINDENBERG, A., MULLER-MYHSOK, B., MAIER, W., 
NOTHEN, M. M. & CICHON, S. 2010. Genome-wide association-, 
replication-, and neuroimaging study implicates HOMER1 in the etiology of 
major depression. Biol Psychiatry, 68, 578-85. 
RIPKE, S., O'DUSHLAINE, C., CHAMBERT, K., MORAN, J. L., KAHLER, A. K., 
AKTERIN, S., BERGEN, S. E., COLLINS, A. L., CROWLEY, J. J., 
FROMER, M., KIM, Y., LEE, S. H., MAGNUSSON, P. K., SANCHEZ, N., 
STAHL, E. A., WILLIAMS, S., WRAY, N. R., XIA, K., BETTELLA, F., 
BORGLUM, A. D., BULIK-SULLIVAN, B. K., CORMICAN, P., 
CRADDOCK, N., DE LEEUW, C., DURMISHI, N., GILL, M., 
GOLIMBET, V., HAMSHERE, M. L., HOLMANS, P., HOUGAARD, D. 
M., KENDLER, K. S., LIN, K., MORRIS, D. W., MORS, O., 
MORTENSEN, P. B., NEALE, B. M., O'NEILL, F. A., OWEN, M. J., 
MILOVANCEVIC, M. P., POSTHUMA, D., POWELL, J., RICHARDS, A. 
L., RILEY, B. P., RUDERFER, D., RUJESCU, D., SIGURDSSON, E., 
SILAGADZE, T., SMIT, A. B., STEFANSSON, H., STEINBERG, S., 
SUVISAARI, J., TOSATO, S., VERHAGE, M., WALTERS, J. T., 
MULTICENTER GENETIC STUDIES OF SCHIZOPHRENIA, C., 
LEVINSON, D. F., GEJMAN, P. V., KENDLER, K. S., LAURENT, C., 
MOWRY, B. J., O'DONOVAN, M. C., OWEN, M. J., PULVER, A. E., 
RILEY, B. P., SCHWAB, S. G., WILDENAUER, D. B., DUDBRIDGE, F., 
HOLMANS, P., SHI, J., ALBUS, M., ALEXANDER, M., CAMPION, D., 
COHEN, D., DIKEOS, D., DUAN, J., EICHHAMMER, P., GODARD, S., 
HANSEN, M., LERER, F. B., LIANG, K. Y., MAIER, W., MALLET, J., 
NERTNEY, D. A., NESTADT, G., NORTON, N., O'NEILL, F. A., 
PAPADIMITRIOU, G. N., RIBBLE, R., SANDERS, A. R., SILVERMAN, J. 
M., WALSH, D., WILLIAMS, N. M., WORMLEY, B., PSYCHOSIS 
ENDOPHENOTYPES INTERNATIONAL, C., ARRANZ, M. J., BAKKER, 
S., BENDER, S., BRAMON, E., COLLIER, D., CRESPO-FACORRO, B., et 
al. 2013. Genome-wide association analysis identifies 13 new risk loci for 
schizophrenia. Nat Genet, 45, 1150-9. 
RITCHIE, G. R., DUNHAM, I., ZEGGINI, E. & FLICEK, P. 2014. Functional 
annotation of noncoding sequence variants. Nat Methods, 11, 294-6. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  274 
RONEMUS, M., IOSSIFOV, I., LEVY, D. & WIGLER, M. 2014. The role of de 
novo mutations in the genetics of autism spectrum disorders. Nat Rev Genet, 
15, 133-41. 
ROWE, C. C., BOURGEAT, P., ELLIS, K. A., BROWN, B., LIM, Y. Y., 
MULLIGAN, R., JONES, G., MARUFF, P., WOODWARD, M., PRICE, R., 
ROBINS, P., TOCHON-DANGUY, H., O'KEEFE, G., PIKE, K. E., YATES, 
P., SZOEKE, C., SALVADO, O., MACAULAY, S. L., O'MEARA, T., 
HEAD, R., COBIAC, L., SAVAGE, G., MARTINS, R., MASTERS, C. L., 
AMES, D. & VILLEMAGNE, V. L. 2013. Predicting Alzheimer disease with 
beta-amyloid imaging: results from the Australian imaging, biomarkers, and 
lifestyle study of ageing. Ann Neurol, 74, 905-13. 
RYAN, N. M., MORRIS, S. W., PORTEOUS, D. J., TAYLOR, M. S. & EVANS, K. 
L. 2014. SuRFing the genomics wave: an R package for prioritising SNPs by 
functionality. Genome Med, 6, 79. 
SABO, P. J., HAWRYLYCZ, M., WALLACE, J. C., HUMBERT, R., YU, M., 
SHAFER, A., KAWAMOTO, J., HALL, R., MACK, J., DORSCHNER, M. 
O., MCARTHUR, M. & STAMATOYANNOPOULOS, J. A. 2004. 
Discovery of functional noncoding elements by digital analysis of chromatin 
structure. Proc Natl Acad Sci U S A, 101, 16837-42. 
SACCONE, S. F., BOLZE, R., THOMAS, P., QUAN, J., MEHTA, G., DEELMAN, 
E., TISCHFIELD, J. A. & RICE, J. P. 2010. SPOT: a web-based tool for 
using biological databases to prioritize SNPs after a genome-wide association 
study. Nucleic Acids Res, 38, W201-9. 
SAMUELS, M. E. & ROULEAU, G. A. 2011. The case for locus-specific databases. 
Nat Rev Genet, 12, 378-9. 
SANDERS, S. J., ERCAN-SENCICEK, A. G., HUS, V., LUO, R., MURTHA, M. 
T., MORENO-DE-LUCA, D., CHU, S. H., MOREAU, M. P., GUPTA, A. 
R., THOMSON, S. A., MASON, C. E., BILGUVAR, K., CELESTINO-
SOPER, P. B., CHOI, M., CRAWFORD, E. L., DAVIS, L., WRIGHT, N. R., 
DHODAPKAR, R. M., DICOLA, M., DILULLO, N. M., FERNANDEZ, T. 
V., FIELDING-SINGH, V., FISHMAN, D. O., FRAHM, S., 
GARAGALOYAN, R., GOH, G. S., KAMMELA, S., KLEI, L., LOWE, J. 
K., LUND, S. C., MCGREW, A. D., MEYER, K. A., MOFFAT, W. J., 
MURDOCH, J. D., O'ROAK, B. J., OBER, G. T., POTTENGER, R. S., 
RAUBESON, M. J., SONG, Y., WANG, Q., YASPAN, B. L., YU, T. W., 
YURKIEWICZ, I. R., BEAUDET, A. L., CANTOR, R. M., CURLAND, M., 
GRICE, D. E., GUNEL, M., LIFTON, R. P., MANE, S. M., MARTIN, D. 
M., SHAW, C. A., SHELDON, M., TISCHFIELD, J. A., WALSH, C. A., 
MORROW, E. M., LEDBETTER, D. H., FOMBONNE, E., LORD, C., 
MARTIN, C. L., BROOKS, A. I., SUTCLIFFE, J. S., COOK, E. H., JR., 
GESCHWIND, D., ROEDER, K., DEVLIN, B. & STATE, M. W. 2011. 
Multiple recurrent de novo CNVs, including duplications of the 7q11.23 
Williams syndrome region, are strongly associated with autism. Neuron, 70, 
863-85. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  275 
SCHIZOPHRENIA PSYCHIATRIC GENOME-WIDE ASSOCIATION STUDY, C. 
2011. Genome-wide association study identifies five new schizophrenia loci. 
Nat Genet, 43, 969-76. 
SCHIZOPHRENIA WORKING GROUP OF THE PSYCHIATRIC GENOMICS, C. 
2014. Biological insights from 108 schizophrenia-associated genetic loci. 
Nature, 511, 421-7. 
SCHODEL, J., BARDELLA, C., SCIESIELSKI, L. K., BROWN, J. M., PUGH, C. 
W., BUCKLE, V., TOMLINSON, I. P., RATCLIFFE, P. J. & MOLE, D. R. 
2012. Common genetic variants at the 11q13.3 renal cancer susceptibility 
locus influence binding of HIF to an enhancer of cyclin D1 expression. Nat 
Genet, 44, 420-5, S1-2. 
SCHORK, A. J., THOMPSON, W. K., PHAM, P., TORKAMANI, A., RODDEY, J. 
C., SULLIVAN, P. F., KELSOE, J. R., O'DONOVAN, M. C., FURBERG, 
H., TOBACCO, GENETICS, C., BIPOLAR DISORDER PSYCHIATRIC 
GENOMICS, C., SCHIZOPHRENIA PSYCHIATRIC GENOMICS, C., 
SCHORK, N. J., ANDREASSEN, O. A. & DALE, A. M. 2013. All SNPs are 
not created equal: genome-wide association studies reveal a consistent pattern 
of enrichment among functionally annotated SNPs. PLoS Genet, 9, e1003449. 
SCHULZE, T. G., AKULA, N., BREUER, R., STEELE, J., NALLS, M. A., 
SINGLETON, A. B., DEGENHARDT, F. A., NOTHEN, M. M., CICHON, 
S., RIETSCHEL, M., BIPOLAR GENOME, S. & MCMAHON, F. J. 2014. 
Molecular genetic overlap in bipolar disorder, schizophrenia, and major 
depressive disorder. World J Biol Psychiatry, 15, 200-8. 
SEBAT, J., LAKSHMI, B., MALHOTRA, D., TROGE, J., LESE-MARTIN, C., 
WALSH, T., YAMROM, B., YOON, S., KRASNITZ, A., KENDALL, J., 
LEOTTA, A., PAI, D., ZHANG, R., LEE, Y. H., HICKS, J., SPENCE, S. J., 
LEE, A. T., PUURA, K., LEHTIMAKI, T., LEDBETTER, D., 
GREGERSEN, P. K., BREGMAN, J., SUTCLIFFE, J. S., JOBANPUTRA, 
V., CHUNG, W., WARBURTON, D., KING, M. C., SKUSE, D., 
GESCHWIND, D. H., GILLIAM, T. C., YE, K. & WIGLER, M. 2007. 
Strong association of de novo copy number mutations with autism. Science, 
316, 445-9. 
SERRETTI, A. & FABBRI, C. 2013. Shared genetics among major psychiatric 
disorders. Lancet, 381, 1339-41. 
SHALEV, H., SERLIN, Y. & FRIEDMAN, A. 2009. Breaching the blood-brain 
barrier as a gate to psychiatric disorder. Cardiovasc Psychiatry Neurol, 2009, 
278531. 
SHERRY, S. T., WARD, M. H., KHOLODOV, M., BAKER, J., PHAN, L., 
SMIGIELSKI, E. M. & SIROTKIN, K. 2001. dbSNP: the NCBI database of 
genetic variation. Nucleic Acids Res, 29, 308-11. 
SHI, J., POTASH, J. B., KNOWLES, J. A., WEISSMAN, M. M., CORYELL, W., 
SCHEFTNER, W. A., LAWSON, W. B., DEPAULO, J. R., JR., GEJMAN, 
P. V., SANDERS, A. R., JOHNSON, J. K., ADAMS, P., CHAUDHURY, S., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  276 
JANCIC, D., EVGRAFOV, O., ZVINYATSKOVSKIY, A., ERTMAN, N., 
GLADIS, M., NEIMANAS, K., GOODELL, M., HALE, N., NEY, N., 
VERMA, R., MIREL, D., HOLMANS, P. & LEVINSON, D. F. 2011. 
Genome-wide association study of recurrent early-onset major depressive 
disorder. Mol Psychiatry, 16, 193-201. 
SHIHAB, H. A., GOUGH, J., COOPER, D. N., STENSON, P. D., BARKER, G. L., 
EDWARDS, K. J., DAY, I. N. & GAUNT, T. R. 2013. Predicting the 
functional, molecular, and phenotypic consequences of amino acid 
substitutions using hidden Markov models. Hum Mutat, 34, 57-65. 
SHINOZAKI, G. & POTASH, J. B. 2014. New developments in the genetics of 
bipolar disorder. Curr Psychiatry Rep, 16, 493. 
SHYN, S. I., SHI, J., KRAFT, J. B., POTASH, J. B., KNOWLES, J. A., 
WEISSMAN, M. M., GARRIOCK, H. A., YOKOYAMA, J. S., MCGRATH, 
P. J., PETERS, E. J., SCHEFTNER, W. A., CORYELL, W., LAWSON, W. 
B., JANCIC, D., GEJMAN, P. V., SANDERS, A. R., HOLMANS, P., 
SLAGER, S. L., LEVINSON, D. F. & HAMILTON, S. P. 2011. Novel loci 
for major depression identified by genome-wide association study of 
Sequenced Treatment Alternatives to Relieve Depression and meta-analysis 
of three studies. Mol Psychiatry, 16, 202-15. 
SIEPEL, A., BEJERANO, G., PEDERSEN, J. S., HINRICHS, A. S., HOU, M., 
ROSENBLOOM, K., CLAWSON, H., SPIETH, J., HILLIER, L. W., 
RICHARDS, S., WEINSTOCK, G. M., WILSON, R. K., GIBBS, R. A., 
KENT, W. J., MILLER, W. & HAUSSLER, D. 2005. Evolutionarily 
conserved elements in vertebrate, insect, worm, and yeast genomes. Genome 
Res, 15, 1034-50. 
SIFRIM, A., POPOVIC, D., TRANCHEVENT, L. C., ARDESHIRDAVANI, A., 
SAKAI, R., KONINGS, P., VERMEESCH, J. R., AERTS, J., DE MOOR, B. 
& MOREAU, Y. 2013. eXtasy: variant prioritization by genomic data fusion. 
Nat Methods, 10, 1083-4. 
SILVENTOINEN, K., SAMMALISTO, S., PEROLA, M., BOOMSMA, D. I., 
CORNES, B. K., DAVIS, C., DUNKEL, L., DE LANGE, M., HARRIS, J. 
R., HJELMBORG, J. V., LUCIANO, M., MARTIN, N. G., MORTENSEN, 
J., NISTICO, L., PEDERSEN, N. L., SKYTTHE, A., SPECTOR, T. D., 
STAZI, M. A., WILLEMSEN, G. & KAPRIO, J. 2003. Heritability of adult 
body height: a comparative study of twin cohorts in eight countries. Twin 
Res, 6, 399-408. 
SING, T., SANDER, O., BEERENWINKEL, N. & LENGAUER, T. 2005. ROCR: 
visualizing classifier performance in R. Bioinformatics, 21, 3940-1. 
SKLAR, P., SMOLLER, J. W., FAN, J., FERREIRA, M. A., PERLIS, R. H., 
CHAMBERT, K., NIMGAONKAR, V. L., MCQUEEN, M. B., FARAONE, 
S. V., KIRBY, A., DE BAKKER, P. I., OGDIE, M. N., THASE, M. E., 
SACHS, G. S., TODD-BROWN, K., GABRIEL, S. B., SOUGNEZ, C., 
GATES, C., BLUMENSTIEL, B., DEFELICE, M., ARDLIE, K. G., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  277 
FRANKLIN, J., MUIR, W. J., MCGHEE, K. A., MACINTYRE, D. J., 
MCLEAN, A., VANBECK, M., MCQUILLIN, A., BASS, N. J., 
ROBINSON, M., LAWRENCE, J., ANJORIN, A., CURTIS, D., 
SCOLNICK, E. M., DALY, M. J., BLACKWOOD, D. H., GURLING, H. M. 
& PURCELL, S. M. 2008. Whole-genome association study of bipolar 
disorder. Mol Psychiatry, 13, 558-69. 
SMIALOWSKI, P., FRISHMAN, D. & KRAMER, S. 2010. Pitfalls of supervised 
feature selection. Bioinformatics, 26, 440-3. 
SMITH, E. N., BLOSS, C. S., BADNER, J. A., BARRETT, T., BELMONTE, P. L., 
BERRETTINI, W., BYERLEY, W., CORYELL, W., CRAIG, D., 
EDENBERG, H. J., ESKIN, E., FOROUD, T., GERSHON, E., 
GREENWOOD, T. A., HIPOLITO, M., KOLLER, D. L., LAWSON, W. B., 
LIU, C., LOHOFF, F., MCINNIS, M. G., MCMAHON, F. J., MIREL, D. B., 
MURRAY, S. S., NIEVERGELT, C., NURNBERGER, J., NWULIA, E. A., 
PASCHALL, J., POTASH, J. B., RICE, J., SCHULZE, T. G., SCHEFTNER, 
W., PANGANIBAN, C., ZAITLEN, N., ZANDI, P. P., ZOLLNER, S., 
SCHORK, N. J. & KELSOE, J. R. 2009. Genome-wide association study of 
bipolar disorder in European American and African American individuals. 
Mol Psychiatry, 14, 755-63. 
SMITH, E. N., KOLLER, D. L., PANGANIBAN, C., SZELINGER, S., ZHANG, P., 
BADNER, J. A., BARRETT, T. B., BERRETTINI, W. H., BLOSS, C. S., 
BYERLEY, W., CORYELL, W., EDENBERG, H. J., FOROUD, T., 
GERSHON, E. S., GREENWOOD, T. A., GUO, Y., HIPOLITO, M., 
KEATING, B. J., LAWSON, W. B., LIU, C., MAHON, P. B., MCINNIS, M. 
G., MCMAHON, F. J., MCKINNEY, R., MURRAY, S. S., NIEVERGELT, 
C. M., NURNBERGER, J. I., JR., NWULIA, E. A., POTASH, J. B., RICE, 
J., SCHULZE, T. G., SCHEFTNER, W. A., SHILLING, P. D., ZANDI, P. P., 
ZOLLNER, S., CRAIG, D. W., SCHORK, N. J. & KELSOE, J. R. 2011. 
Genome-wide association of bipolar disorder suggests an enrichment of 
replicable associations in regions near genes. PLoS Genet, 7, e1002134. 
SMOLLER, J. W. & FINN, C. T. 2003. Family, twin, and adoption studies of bipolar 
disorder. Am J Med Genet C Semin Med Genet, 123C, 48-58. 
SOKOLOWSKI, M., WASSERMAN, J. & WASSERMAN, D. 2010. Association of 
polymorphisms in the SLIT2 axonal guidance gene with anger in suicide 
attempters. Mol Psychiatry, 15, 10-1. 
ST CLAIR, D., BLACKWOOD, D., MUIR, W., CAROTHERS, A., WALKER, M., 
SPOWART, G., GOSDEN, C. & EVANS, H. J. 1990. Association within a 
family of a balanced autosomal translocation with major mental illness. 
Lancet, 336, 13-6. 
STEFANSSON, H., RUJESCU, D., CICHON, S., PIETILAINEN, O. P., INGASON, 
A., STEINBERG, S., FOSSDAL, R., SIGURDSSON, E., SIGMUNDSSON, 
T., BUIZER-VOSKAMP, J. E., HANSEN, T., JAKOBSEN, K. D., 
MUGLIA, P., FRANCKS, C., MATTHEWS, P. M., GYLFASON, A., 
HALLDORSSON, B. V., GUDBJARTSSON, D., THORGEIRSSON, T. E., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  278 
SIGURDSSON, A., JONASDOTTIR, A., JONASDOTTIR, A., 
BJORNSSON, A., MATTIASDOTTIR, S., BLONDAL, T., HARALDSSON, 
M., MAGNUSDOTTIR, B. B., GIEGLING, I., MOLLER, H. J., 
HARTMANN, A., SHIANNA, K. V., GE, D., NEED, A. C., CROMBIE, C., 
FRASER, G., WALKER, N., LONNQVIST, J., SUVISAARI, J., TUULIO-
HENRIKSSON, A., PAUNIO, T., TOULOPOULOU, T., BRAMON, E., DI 
FORTI, M., MURRAY, R., RUGGERI, M., VASSOS, E., TOSATO, S., 
WALSHE, M., LI, T., VASILESCU, C., MUHLEISEN, T. W., WANG, A. 
G., ULLUM, H., DJUROVIC, S., MELLE, I., OLESEN, J., KIEMENEY, L. 
A., FRANKE, B., GROUP, SABATTI, C., FREIMER, N. B., GULCHER, J. 
R., THORSTEINSDOTTIR, U., KONG, A., ANDREASSEN, O. A., 
OPHOFF, R. A., GEORGI, A., RIETSCHEL, M., WERGE, T., 
PETURSSON, H., GOLDSTEIN, D. B., NOTHEN, M. M., PELTONEN, L., 
COLLIER, D. A., ST CLAIR, D. & STEFANSSON, K. 2008. Large 
recurrent microdeletions associated with schizophrenia. Nature, 455, 232-6. 
STENSON, P. D., BALL, E. V., MORT, M., PHILLIPS, A. D., SHIEL, J. A., 
THOMAS, N. S., ABEYSINGHE, S., KRAWCZAK, M. & COOPER, D. N. 
2003. Human Gene Mutation Database (HGMD): 2003 update. Hum Mutat, 
21, 577-81. 
STRITTMATTER, W. J., SAUNDERS, A. M., SCHMECHEL, D., PERICAK-
VANCE, M., ENGHILD, J., SALVESEN, G. S. & ROSES, A. D. 1993. 
Apolipoprotein E: high-avidity binding to beta-amyloid and increased 
frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl 
Acad Sci U S A, 90, 1977-81. 
SULLIVAN, P. F. 2010. The psychiatric GWAS consortium: big science comes to 
psychiatry. Neuron, 68, 182-6. 
SULLIVAN, P. F., DALY, M. J. & O'DONOVAN, M. 2012. Genetic architectures 
of psychiatric disorders: the emerging picture and its implications. Nat Rev 
Genet, 13, 537-51. 
SULLIVAN, P. F., DE GEUS, E. J., WILLEMSEN, G., JAMES, M. R., SMIT, J. H., 
ZANDBELT, T., AROLT, V., BAUNE, B. T., BLACKWOOD, D., 
CICHON, S., COVENTRY, W. L., DOMSCHKE, K., FARMER, A., FAVA, 
M., GORDON, S. D., HE, Q., HEATH, A. C., HEUTINK, P., HOLSBOER, 
F., HOOGENDIJK, W. J., HOTTENGA, J. J., HU, Y., KOHLI, M., LIN, D., 
LUCAE, S., MACINTYRE, D. J., MAIER, W., MCGHEE, K. A., 
MCGUFFIN, P., MONTGOMERY, G. W., MUIR, W. J., NOLEN, W. A., 
NOTHEN, M. M., PERLIS, R. H., PIRLO, K., POSTHUMA, D., 
RIETSCHEL, M., RIZZU, P., SCHOSSER, A., SMIT, A. B., SMOLLER, J. 
W., TZENG, J. Y., VAN DYCK, R., VERHAGE, M., ZITMAN, F. G., 
MARTIN, N. G., WRAY, N. R., BOOMSMA, D. I. & PENNINX, B. W. 
2009. Genome-wide association for major depressive disorder: a possible role 
for the presynaptic protein piccolo. Mol Psychiatry, 14, 359-75. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  279 
SULLIVAN, P. F., NEALE, M. C. & KENDLER, K. S. 2000. Genetic epidemiology 
of major depression: review and meta-analysis. Am J Psychiatry, 157, 1552-
62. 
SWOBODA, K. J., SAUL, J. P., MCKENNA, C. E., SPELLER, N. B. & HYLAND, 
K. 2003. Aromatic L-amino acid decarboxylase deficiency: overview of 
clinical features and outcomes. Ann Neurol, 54 Suppl 6, S49-55. 
TAN, A. C. & GILBERT, D. 2003. Ensemble machine learning on gene expression 
data for cancer classification. Appl Bioinformatics, 2, S75-83. 
TAVARÉ 1986. Some Probabilistic and Statistical Problems in the Analysis of DNA 
Sequences. American Mathematical Society: Lectures on Mathematics in the 
Life Sciences, 17, 57-86. 
THOMAS, P. D., CAMPBELL, M. J., KEJARIWAL, A., MI, H., KARLAK, B., 
DAVERMAN, R., DIEMER, K., MURUGANUJAN, A. & NARECHANIA, 
A. 2003. PANTHER: a library of protein families and subfamilies indexed by 
function. Genome Res, 13, 2129-41. 
THORN, G. W. 1968. Approach to the patient with "idiopathic edema" or "periodic 
swelling". JAMA, 206, 333-8. 
THURMAN, R. E., RYNES, E., HUMBERT, R., VIERSTRA, J., MAURANO, M. 
T., HAUGEN, E., SHEFFIELD, N. C., STERGACHIS, A. B., WANG, H., 
VERNOT, B., GARG, K., JOHN, S., SANDSTROM, R., BATES, D., 
BOATMAN, L., CANFIELD, T. K., DIEGEL, M., DUNN, D., EBERSOL, 
A. K., FRUM, T., GISTE, E., JOHNSON, A. K., JOHNSON, E. M., 
KUTYAVIN, T., LAJOIE, B., LEE, B. K., LEE, K., LONDON, D., 
LOTAKIS, D., NEPH, S., NERI, F., NGUYEN, E. D., QU, H., REYNOLDS, 
A. P., ROACH, V., SAFI, A., SANCHEZ, M. E., SANYAL, A., SHAFER, 
A., SIMON, J. M., SONG, L., VONG, S., WEAVER, M., YAN, Y., 
ZHANG, Z., ZHANG, Z., LENHARD, B., TEWARI, M., DORSCHNER, M. 
O., HANSEN, R. S., NAVAS, P. A., STAMATOYANNOPOULOS, G., 
IYER, V. R., LIEB, J. D., SUNYAEV, S. R., AKEY, J. M., SABO, P. J., 
KAUL, R., FUREY, T. S., DEKKER, J., CRAWFORD, G. E. & 
STAMATOYANNOPOULOS, J. A. 2012. The accessible chromatin 
landscape of the human genome. Nature, 489, 75-82. 
TORKAMANI, A. & SCHORK, N. J. 2008. Predicting functional regulatory 
polymorphisms. Bioinformatics, 24, 1787-92. 
TREANGEN, T. J. & SALZBERG, S. L. 2012. Repetitive DNA and next-generation 
sequencing: computational challenges and solutions. Nat Rev Genet, 13, 36-
46. 
UHER, R. 2014. Gene-environment interactions in severe mental illness. Front 
Psychiatry, 5, 48. 
VACIC, V., MCCARTHY, S., MALHOTRA, D., MURRAY, F., CHOU, H. H., 
PEOPLES, A., MAKAROV, V., YOON, S., BHANDARI, A., 
COROMINAS, R., IAKOUCHEVA, L. M., KRASTOSHEVSKY, O., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  280 
KRAUSE, V., LARACH-WALTERS, V., WELSH, D. K., CRAIG, D., 
KELSOE, J. R., GERSHON, E. S., LEAL, S. M., DELL AQUILA, M., 
MORRIS, D. W., GILL, M., CORVIN, A., INSEL, P. A., MCCLELLAN, J., 
KING, M. C., KARAYIORGOU, M., LEVY, D. L., DELISI, L. E. & 
SEBAT, J. 2011. Duplications of the neuropeptide receptor gene VIPR2 
confer significant risk for schizophrenia. Nature, 471, 499-503. 
VANCAMPFORT, D., MITCHELL, A. J., DE HERT, M., SIENAERT, P., 
PROBST, M., BUYS, R. & STUBBS, B. 2015a. Prevalence and predictors of 
type 2 diabetes mellitus in people with bipolar disorder: a systematic review 
and meta-analysis. J Clin Psychiatry. 
VANCAMPFORT, D., MITCHELL, A. J., DE HERT, M., SIENAERT, P., 
PROBST, M., BUYS, R. & STUBBS, B. 2015b. Type 2 Diabetes in Patients 
with Major Depressive Disorder: A Meta-Analysis of Prevalence Estimates 
and Predictors. Depress Anxiety. 
VANNESCHI, L., FARINACCIO, A., MAURI, G., ANTONIOTTI, M., PROVERO, 
P. & GIACOBINI, M. 2011. A comparison of machine learning techniques 
for survival prediction in breast cancer. BioData Min, 4, 12. 
VERBEEK, E. C., BEVOVA, M. R., BOCHDANOVITS, Z., RIZZU, P., BAKKER, 
I. M., UITHUISJE, T., DE GEUS, E. J., SMIT, J. H., PENNINX, B. W., 
BOOMSMA, D. I., HOOGENDIJK, W. J. & HEUTINK, P. 2013. 
Resequencing three candidate genes for major depressive disorder in a Dutch 
cohort. PLoS One, 8, e79921. 
VERNOT, B., STERGACHIS, A. B., MAURANO, M. T., VIERSTRA, J., NEPH, 
S., THURMAN, R. E., STAMATOYANNOPOULOS, J. A. & AKEY, J. M. 
2012. Personal and population genomics of human regulatory variation. 
Genome Res, 22, 1689-97. 
VIHINEN, M. 2012. How to evaluate performance of prediction methods? Measures 
and their interpretation in variation effect analysis. BMC Genomics, 13 Suppl 
4, S2. 
VISSCHER, P. M., GODDARD, M. E., DERKS, E. M. & WRAY, N. R. 2012. 
Evidence-based psychiatric genetics, AKA the false dichotomy between 
common and rare variant hypotheses. Mol Psychiatry, 17, 474-85. 
VISSCHER, P. M., HALEY, C. S., HEATH, S. C., MUIR, W. J. & BLACKWOOD, 
D. H. 1999. Detecting QTLs for uni- and bipolar disorder using a variance 
component method. Psychiatr Genet, 9, 75-84. 
VOIGHT, B. F., SCOTT, L. J., STEINTHORSDOTTIR, V., MORRIS, A. P., DINA, 
C., WELCH, R. P., ZEGGINI, E., HUTH, C., AULCHENKO, Y. S., 
THORLEIFSSON, G., MCCULLOCH, L. J., FERREIRA, T., GRALLERT, 
H., AMIN, N., WU, G., WILLER, C. J., RAYCHAUDHURI, S., 
MCCARROLL, S. A., LANGENBERG, C., HOFMANN, O. M., DUPUIS, 
J., QI, L., SEGRE, A. V., VAN HOEK, M., NAVARRO, P., ARDLIE, K., 
BALKAU, B., BENEDIKTSSON, R., BENNETT, A. J., BLAGIEVA, R., 
BOERWINKLE, E., BONNYCASTLE, L. L., BENGTSSON BOSTROM, 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  281 
K., BRAVENBOER, B., BUMPSTEAD, S., BURTT, N. P., 
CHARPENTIER, G., CHINES, P. S., CORNELIS, M., COUPER, D. J., 
CRAWFORD, G., DONEY, A. S., ELLIOTT, K. S., ELLIOTT, A. L., 
ERDOS, M. R., FOX, C. S., FRANKLIN, C. S., GANSER, M., GIEGER, C., 
GRARUP, N., GREEN, T., GRIFFIN, S., GROVES, C. J., GUIDUCCI, C., 
HADJADJ, S., HASSANALI, N., HERDER, C., ISOMAA, B., JACKSON, 
A. U., JOHNSON, P. R., JORGENSEN, T., KAO, W. H., KLOPP, N., 
KONG, A., KRAFT, P., KUUSISTO, J., LAURITZEN, T., LI, M., 
LIEVERSE, A., LINDGREN, C. M., LYSSENKO, V., MARRE, M., 
MEITINGER, T., MIDTHJELL, K., MORKEN, M. A., NARISU, N., 
NILSSON, P., OWEN, K. R., PAYNE, F., PERRY, J. R., PETERSEN, A. K., 
PLATOU, C., PROENCA, C., PROKOPENKO, I., RATHMANN, W., 
RAYNER, N. W., ROBERTSON, N. R., ROCHELEAU, G., RODEN, M., 
SAMPSON, M. J., SAXENA, R., SHIELDS, B. M., SHRADER, P., 
SIGURDSSON, G., SPARSO, T., STRASSBURGER, K., STRINGHAM, H. 
M., SUN, Q., SWIFT, A. J., THORAND, B., et al. 2010. Twelve type 2 
diabetes susceptibility loci identified through large-scale association analysis. 
Nat Genet, 42, 579-89. 
WALKER, R. M., CHRISTOFOROU, A., THOMSON, P. A., MCGHEE, K. A., 
MACLEAN, A., MUHLEISEN, T. W., STROHMAIER, J., 
NIERATSCHKER, V., NOTHEN, M. M., RIETSCHEL, M., CICHON, S., 
MORRIS, S. W., JILANI, O., STCLAIR, D., BLACKWOOD, D. H., MUIR, 
W. J., PORTEOUS, D. J. & EVANS, K. L. 2010. Association analysis of 
Neuregulin 1 candidate regions in schizophrenia and bipolar disorder. 
Neurosci Lett, 478, 9-13. 
WAN, X., YANG, C., YANG, Q., XUE, H., TANG, N. L. & YU, W. 2010. 
Predictive rule inference for epistatic interaction detection in genome-wide 
association studies. Bioinformatics, 26, 30-7. 
WANG, J., ZHUANG, J., IYER, S., LIN, X., WHITFIELD, T. W., GREVEN, M. C., 
PIERCE, B. G., DONG, X., KUNDAJE, A., CHENG, Y., RANDO, O. J., 
BIRNEY, E., MYERS, R. M., NOBLE, W. S., SNYDER, M. & WENG, Z. 
2012. Sequence features and chromatin structure around the genomic regions 
bound by 119 human transcription factors. Genome Res, 22, 1798-812. 
WANG, J., ZHUANG, J., IYER, S., LIN, X. Y., GREVEN, M. C., KIM, B. H., 
MOORE, J., PIERCE, B. G., DONG, X., VIRGIL, D., BIRNEY, E., HUNG, 
J. H. & WENG, Z. 2013. Factorbook.org: a Wiki-based database for 
transcription factor-binding data generated by the ENCODE consortium. 
Nucleic Acids Res, 41, D171-6. 
WANG, K., ZHANG, H., MA, D., BUCAN, M., GLESSNER, J. T., ABRAHAMS, 
B. S., SALYAKINA, D., IMIELINSKI, M., BRADFIELD, J. P., SLEIMAN, 
P. M., KIM, C. E., HOU, C., FRACKELTON, E., CHIAVACCI, R., 
TAKAHASHI, N., SAKURAI, T., RAPPAPORT, E., LAJONCHERE, C. 
M., MUNSON, J., ESTES, A., KORVATSKA, O., PIVEN, J., 
SONNENBLICK, L. I., ALVAREZ RETUERTO, A. I., HERMAN, E. I., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  282 
DONG, H., HUTMAN, T., SIGMAN, M., OZONOFF, S., KLIN, A., 
OWLEY, T., SWEENEY, J. A., BRUNE, C. W., CANTOR, R. M., 
BERNIER, R., GILBERT, J. R., CUCCARO, M. L., MCMAHON, W. M., 
MILLER, J., STATE, M. W., WASSINK, T. H., COON, H., LEVY, S. E., 
SCHULTZ, R. T., NURNBERGER, J. I., HAINES, J. L., SUTCLIFFE, J. S., 
COOK, E. H., MINSHEW, N. J., BUXBAUM, J. D., DAWSON, G., 
GRANT, S. F., GESCHWIND, D. H., PERICAK-VANCE, M. A., 
SCHELLENBERG, G. D. & HAKONARSON, H. 2009. Common genetic 
variants on 5p14.1 associate with autism spectrum disorders. Nature, 459, 
528-33. 
WANG, K. S., LIU, X. F. & ARAGAM, N. 2010. A genome-wide meta-analysis 
identifies novel loci associated with schizophrenia and bipolar disorder. 
Schizophr Res, 124, 192-9. 
WANG, Q., LU, Q. & ZHAO, H. 2015. A review of study designs and statistical 
methods for genomic epidemiology studies using next generation sequencing. 
Front Genet, 6, 149. 
WARD, A. J. & COOPER, T. A. 2010. The pathobiology of splicing. J Pathol, 220, 
152-63. 
WARD, L. D. & KELLIS, M. 2012. HaploReg: a resource for exploring chromatin 
states, conservation, and regulatory motif alterations within sets of genetically 
linked variants. Nucleic Acids Res, 40, D930-4. 
WEI, W. H., HEMANI, G. & HALEY, C. S. 2014. Detecting epistasis in human 
complex traits. Nat Rev Genet, 15, 722-33. 
WEISSFLOG, L., SCHOLZ, C. J., JACOB, C. P., NGUYEN, T. T., ZAMZOW, K., 
GROSS-LESCH, S., RENNER, T. J., ROMANOS, M., RUJESCU, D., 
WALITZA, S., KNEITZ, S., LESCH, K. P. & REIF, A. 2013. KCNIP4 as a 
candidate gene for personality disorders and adult ADHD. Eur 
Neuropsychopharmacol, 23, 436-47. 
WELLCOME TRUST CASE CONTROL, C. 2007. Genome-wide association study 
of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 
447, 661-78. 
WELTER, D., MACARTHUR, J., MORALES, J., BURDETT, T., HALL, P., 
JUNKINS, H., KLEMM, A., FLICEK, P., MANOLIO, T., HINDORFF, L. & 
PARKINSON, H. 2014. The NHGRI GWAS Catalog, a curated resource of 
SNP-trait associations. Nucleic Acids Res, 42, D1001-6. 
WESTRA, H. J., PETERS, M. J., ESKO, T., YAGHOOTKAR, H., SCHURMANN, 
C., KETTUNEN, J., CHRISTIANSEN, M. W., FAIRFAX, B. P., 
SCHRAMM, K., POWELL, J. E., ZHERNAKOVA, A., ZHERNAKOVA, D. 
V., VELDINK, J. H., VAN DEN BERG, L. H., KARJALAINEN, J., 
WITHOFF, S., UITTERLINDEN, A. G., HOFMAN, A., RIVADENEIRA, 
F., T HOEN, P. A., REINMAA, E., FISCHER, K., NELIS, M., MILANI, L., 
MELZER, D., FERRUCCI, L., SINGLETON, A. B., HERNANDEZ, D. G., 
NALLS, M. A., HOMUTH, G., NAUCK, M., RADKE, D., VOLKER, U., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  283 
PEROLA, M., SALOMAA, V., BRODY, J., SUCHY-DICEY, A., GHARIB, 
S. A., ENQUOBAHRIE, D. A., LUMLEY, T., MONTGOMERY, G. W., 
MAKINO, S., PROKISCH, H., HERDER, C., RODEN, M., GRALLERT, 
H., MEITINGER, T., STRAUCH, K., LI, Y., JANSEN, R. C., VISSCHER, 
P. M., KNIGHT, J. C., PSATY, B. M., RIPATTI, S., TEUMER, A., 
FRAYLING, T. M., METSPALU, A., VAN MEURS, J. B. & FRANKE, L. 
2013. Systematic identification of trans eQTLs as putative drivers of known 
disease associations. Nat Genet, 45, 1238-43. 
WHO. 2015. http://www.who.int/mental_health/management/en/ [Online].  2015]. 
WILHELM, K., MITCHELL, P., SLADE, T., BROWNHILL, S. & ANDREWS, G. 
2003. Prevalence and correlates of DSM-IV major depression in an 
Australian national survey. J Affect Disord, 75, 155-62. 
WILLNOW, T. E., PETERSEN, C. M. & NYKJAER, A. 2008. VPS10P-domain 
receptors - regulators of neuronal viability and function. Nat Rev Neurosci, 9, 
899-909. 
WILSON, H. S. & SKODOL, A. 1994. Special report: DSM-IV: overview and 
examination of major changes. Arch Psychiatr Nurs, 8, 340-7. 
WINGENDER, E. 2008. The TRANSFAC project as an example of framework 
technology that supports the analysis of genomic regulation. Brief Bioinform, 
9, 326-32. 
WISTE, A., ROBINSON, E. B., MILANESCHI, Y., MEIER, S., RIPKE, S., 
CLEMENTS, C. C., FITZMAURICE, G. M., RIETSCHEL, M., PENNINX, 
B. W., SMOLLER, J. W. & PERLIS, R. H. 2014. Bipolar polygenic loading 
and bipolar spectrum features in major depressive disorder. Bipolar Disord, 
16, 608-16. 
WONG, B. S., CAMILLERI, M., CARLSON, P. J., GUICCIARDI, M. E., 
BURTON, D., MCKINZIE, S., RAO, A. S., ZINSMEISTER, A. R. & 
GORES, G. J. 2011. A Klothobeta variant mediates protein stability and 
associates with colon transit in irritable bowel syndrome with diarrhea. 
Gastroenterology, 140, 1934-42. 
WRAY, N. R., GODDARD, M. E. & VISSCHER, P. M. 2007. Prediction of 
individual genetic risk to disease from genome-wide association studies. 
Genome Res, 17, 1520-8. 
WRAY, N. R. & GOTTESMAN, II 2012. Using summary data from the danish 
national registers to estimate heritabilities for schizophrenia, bipolar disorder, 
and major depressive disorder. Front Genet, 3, 118. 
WRAY, N. R., PERGADIA, M. L., BLACKWOOD, D. H., PENNINX, B. W., 
GORDON, S. D., NYHOLT, D. R., RIPKE, S., MACINTYRE, D. J., 
MCGHEE, K. A., MACLEAN, A. W., SMIT, J. H., HOTTENGA, J. J., 
WILLEMSEN, G., MIDDELDORP, C. M., DE GEUS, E. J., LEWIS, C. M., 
MCGUFFIN, P., HICKIE, I. B., VAN DEN OORD, E. J., LIU, J. Z., 
MACGREGOR, S., MCEVOY, B. P., BYRNE, E. M., MEDLAND, S. E., 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  284 
STATHAM, D. J., HENDERS, A. K., HEATH, A. C., MONTGOMERY, G. 
W., MARTIN, N. G., BOOMSMA, D. I., MADDEN, P. A. & SULLIVAN, 
P. F. 2012. Genome-wide association study of major depressive disorder: new 
results, meta-analysis, and lessons learned. Mol Psychiatry, 17, 36-48. 
WRAY, N. R., YANG, J., HAYES, B. J., PRICE, A. L., GODDARD, M. E. & 
VISSCHER, P. M. 2013. Pitfalls of predicting complex traits from SNPs. Nat 
Rev Genet, 14, 507-15. 
XIA, K., GUO, H., HU, Z., XUN, G., ZUO, L., PENG, Y., WANG, K., HE, Y., 
XIONG, Z., SUN, L., PAN, Q., LONG, Z., ZOU, X., LI, X., LI, W., XU, X., 
LU, L., LIU, Y., HU, Y., TIAN, D., LONG, L., OU, J., LIU, Y., LI, X., 
ZHANG, L., PAN, Y., CHEN, J., PENG, H., LIU, Q., LUO, X., SU, W., 
WU, L., LIANG, D., DAI, H., YAN, X., FENG, Y., TANG, B., LI, J., 
MIEDZYBRODZKA, Z., XIA, J., ZHANG, Z., LUO, X., ZHANG, X., ST 
CLAIR, D., ZHAO, J. & ZHANG, F. 2014. Common genetic variants on 
1p13.2 associate with risk of autism. Mol Psychiatry, 19, 1212-9. 
XU, B., ROOS, J. L., LEVY, S., VAN RENSBURG, E. J., GOGOS, J. A. & 
KARAYIORGOU, M. 2008. Strong association of de novo copy number 
mutations with sporadic schizophrenia. Nat Genet, 40, 880-5. 
XU, H., GREGORY, S. G., HAUSER, E. R., STENGER, J. E., PERICAK-VANCE, 
M. A., VANCE, J. M., ZUCHNER, S. & HAUSER, M. A. 2005. 
SNPselector: a web tool for selecting SNPs for genetic association studies. 
Bioinformatics, 21, 4181-6. 
XU, W., COHEN-WOODS, S., CHEN, Q., NOOR, A., KNIGHT, J., HOSANG, G., 
PARIKH, S. V., DE LUCA, V., TOZZI, F., MUGLIA, P., FORTE, J., 
MCQUILLIN, A., HU, P., GURLING, H. M., KENNEDY, J. L., 
MCGUFFIN, P., FARMER, A., STRAUSS, J. & VINCENT, J. B. 2014. 
Genome-wide association study of bipolar disorder in Canadian and UK 
populations corroborates disease loci including SYNE1 and CSMD1. BMC 
Med Genet, 15, 2. 
YANDELL, M., HUFF, C., HU, H., SINGLETON, M., MOORE, B., XING, J., 
JORDE, L. B. & REESE, M. G. 2011. A probabilistic disease-gene finder for 
personal genomes. Genome Res, 21, 1529-42. 
YELLEN, G. 2002. The voltage-gated potassium channels and their relatives. 
Nature, 419, 35-42. 
YIN, C., LI, S., ZHAO, W., GUO, Y., ZHANG, Y. & FENG, J. 2014. The role of 
fibroblast growth factor receptor 4 polymorphisms in the susceptibility and 
clinical features of ischemic stroke. J Clin Neurosci, 21, 246-9. 
YU, T., LI, Y. J., BIAN, A. H., ZUO, H. B., ZHU, T. W., JI, S. X., KONG, F., YIN 
DE, Q., WANG, C. B., WANG, Z. F., WANG, H. Q., YANG, Y., YOO, B. 
C. & CHO, J. Y. 2014. The regulatory role of activating transcription factor 2 
in inflammation. Mediators Inflamm, 2014, 950472. 
The design and application of SuRFR: an R package to prioritise  
candidate functional DNA sequence variants 
References  285 
ZHANG, H. F., ZHAO, K. J., YANG, P. F., FANG, Y. B., ZHANG, Y. H., LIU, J. 
M. & HUANG, Q. H. 2012a. Association between fibroblast growth factor 
receptor 4 Gly388Arg polymorphism and ischaemic stroke. J Int Med Res, 
40, 1708-14. 
ZHANG, X., COWPER-SAL LARI, R., BAILEY, S. D., MOORE, J. H. & LUPIEN, 
M. 2012b. Integrative functional genomics identifies an enhancer looping to 
the SOX9 gene disrupted by the 17q24.3 prostate cancer risk locus. Genome 
Res, 22, 1437-46. 
ZOLLNER, S. & PRITCHARD, J. K. 2007. Overcoming the winner's curse: 
estimating penetrance parameters from case-control data. Am J Hum Genet, 
80, 605-15. 
 
